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Summary 
My PhD program has been focused on the development of multifunctional systems for potential 
applications in theranostic nanomedicine, which aims at simultaneously providing the diagnosis and 
treatment of a disease. For the construction of these tools, different kinds of nanoparticles (NPs) 
have been investigated, selected as optimal nanoplatforms for the in vivo delivery of drugs and 
diagnostic agents thanks to their capacity to incorporate multiple functional units into their coating. 
Main goal of my research has been the derivatization of these scaffolds with both therapeutic and 
diagnostic agents, as well as with active targeting ligands. In detail, the compounds here studied are: 
- new ruthenium(III)-based complexes, as anticancer agents. 
- suitable derivatives of the macrocycle NOTA, as chelators of 
68
Ga radioisotope, used in PET 
imaging. 
- oligonucleotide aptamers, as the thrombin binding aptamer (TBA) and the nucleolin-targeting 
AS1411. 
All these decorations have been ad hoc designed and synthesized with suitable tethers so to allow 
their attachment onto specific nanoparticles (i.e., gold NPs, streptavidin-coated silica NPs, 
superparamagnetic NPs, liposomes or niosomes). In consideration of the kind of chosen 
derivatization, different recognition schemes can be exploited (i.e. hydrophobic or electrostatic 
interactions, covalent bonds, selective recognition). 
Following this general strategy, a small library of decorated multifunctional NPs, differing for the 
nature of the NP core, Ru(III)-complex, oligonucleotide sequence and 
68
Ga chelator, has been 
prepared. These systems have been tested in vitro as theranostic agents towards targeted 
pathologies, as cancer and clotting disorders. 
 
Despite many Ru(III)-based compounds, in particular NAMI-A and KP1019 - currently in advanced 
clinical trials - display better antitumor activity and pharmacological profile than other metal-based 
drugs, they are poorly stable in aqueous media. So, new amphiphilic nucleolipids have been 
recently proposed by the research group of prof. D. Montesarchio as innovative carriers to transport 
in cell Ru(III)-compounds. Following this strategy, a novel nucleolipid-based Ru(III)-complex, 
named LipThyRu, has been here prepared. Then, in order to expand the repertoire and chemical 
diversity of the available amphiphilic Ru(III)-complexes, biocompatible scaffolds alternative to 
nucleosides, i.e. trifunctional α-amino acids, have been also exploited to serve as carriers for the 
Ru(III) metal core. Within this approach, two new aminoacyl lipidic Ru(III)-complexes, i.e. 
TUGluRu and TOTyroRu, have been synthesized. 
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As far as the imaging agents are concerned, a mini-library of novel lipophilic derivatives of NOTA, 
designed as 
68
Ga chelators in PET analyses, has been prepared. The synthesized analogs differ for 
their hydrophobic tail, i.e. an oleic acid, a lipoic acid or a biotin residue (NOTA-OL, NOTA-Lip 
and NOTA-Bio, respectively), which ensures the subsequent anchoring of NOTA on differently 
decorated nanoplatforms. 
 
Two active targeting agents have been investigated: the 15-mer thrombin-binding aptamer (TBA) 
- able to inhibit the activity of human thrombin, a protein with key roles in coagulation processes - 
and AS1411, an oligonucleotide targeting nucleolin, which is a ubiquitous, multifunctional protein 
involved in cell survival, growth and proliferation, overexpressed on the outer membrane of cancer 
cells. 
 
In a first study, a new tris-conjugated TBA (named tris-mTBA) has been prepared, characterized in 
solution using UV, CD and fluorescence spectroscopy and then immobilized onto silica NPs 
commercially available as Sicastar
®
. This aptamer has been equipped with a biotin tag at the 5’-end, 
allowing its incorporation onto streptavidin-coated Sicastar
®
 NPs, and further conjugated with a 
dansyl group and a β-cyclodextrin at the 3’- and 5’-end, respectively. This represents an efficient 
host-guest system useful to monitor the NP functionalization and the correct aptamer folding onto 
the nanoparticles, thanks to the fluorescence enhancement of the dansyl probe observed when it is 
inserted in the hydrophobic cavity of β-cyclodextrin. 
Sicastar
®
 NPs have been thus functionalized with the tris-mTBA and characterized using DLS, 
SLS, gel electrophoresis and fluorescence analysis. DLS experiments nicely demonstrated that the 
tris-mTBA inhibited human α-thrombin ca. 10-fold more efficiently than unmodified TBA. 
Notably, under the same experimental conditions, the tris-mTBA/Sicastar
®
 NPs completely blocked 
thrombin activity, which was restored upon addition of the TBA antidote, i.e. its complementary 
sequence. 
 
In a successive study, with the aim of exploiting AS1411 as an active targeting agent for 
multifunctional, theranostic nanoplatforms, a set of AS1411 derivatives have been selected (i.e.: 5’-
stearyl-AS1411, 5’-cholesteryl-C6-AS1411 and 5’-cholesteryl-TEG-AS1411) with lipophilic tails 
at their 5’-end allowing their subsequent insertion into liposomes or lipid coated-NPs. 
The solution behavior of the AS1411 derivatives has been investigated using different techniques, 
in comparison with the unmodified aptamer. In particular, CD, CD-melting, UV-melting, gel 
electrophoresis and size exclusion chromatography analysis have been carried out to get 
information on their secondary structure and the thermal stability of their preferred conformations. 
Summary 
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This study was carried out in two different solutions, mimicking the extracellular and intracellular 
media, and at different oligonucleotide concentrations; special attention was devoted to the 
investigation of possible effects due to the nature of the lipophilic tail, or of the specific linker, on 
the overall structure and conformation of the aptamers. 
All these experiments consistently showed a high polymorphism for AS1411 and its derivatives, 
which are able to form form higher order G4 structures or large aggregates, particularly at high 
concentrations. 
 
These decorations (Ru complexes, aptamers and NOTA chelators) have been then combined on 
suitable platforms, realizing to date mainly two multifunctional systems: DOTAP-based liposomes, 
functionalized with TUGluRu and NOTA-OL, and niosome-based formulations, decorated with 
LipThyRu and AS1411. 
 
DOTAP-based liposomes functionalized with TUGluRu and NOTA-OL represent a good model for 
the realization of theranostic nanoparticles, offering several advantages, such as the possibility of 
monitoring their half-life, distribution, and tissue release. DOTAP/TUGluRu (70:30), 
DOTAP/NOTA-OL (95:5) and DOTAP/TUGluRu/NOTA-OL (65:30:5) systems have been 
prepared and fully characterized. DLS data indicated that these species form stable, monodisperse 
vesicles. In cell bioactivity assays, these formulations showed a good antiproliferative activity on 
MCF-7, C6 and HeLa cancer cell lines, with IC50 values in the low M conc., in turn not evidencing 
any toxicity on normal human cells even at 250 µM concentration. 
 
Niosome formulations including the nucleolipidic Ru(III)-complex LipThyRu and the nucleolin-
selective aptamer AS1411 have been prepared and characterized using several techniques, i.e. gel 
electrophoresis, Zeta potential and DLS measurements. Preliminary cellular experiments on HeLa 
cells showed a small, but detectable cell viability decrease for the niosome_LipThyRu system, and a 
relevant antiproliferative effect for the formulation containing both AS1411 and the nucleolipidic 
Ru(III)-complex, indicating a marked synergic effect for these niosome-based anticancer agents. 
 
Future work, starting from the results obtained in this PhD program, will be directed to 
incorporating the amphiphilic Ru(III)-complexes (i.e., LipThyRu, TUGluRu, TOTyroRu or 
previously developed Ru(III) derivatives), the imaging agents (i.e., NOTA chelators) and the 
targeting agents (i.e., the lipophilic AS1411 derivatives) in combination into various kinds of other 
nanoplatforms, particularly in superparamagnetic NPs, so to obtain a mini-library of multifunctional 
systems to be tested in vitro and in vivo and identify the best anticancer theranostic agents.  
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Chapter 1 
Introduction 
1. Theranostic nanomedicine: a single “package” for personalized treatments 
and diagnosis 
The concept of personalized medicine has recently emerged as a promising approach to overcome 
the limitations of standard diagnostic and therapeutic strategies and obtain tailored treatments, 
taking into account the inter-individual variability in therapeutic response.
[1–5]
 This therapeutic 
approach may reduce the undesirable side effects of standard treatments and potentially produce 
better overall results.
[1–5]
 
Theranostic nanomedicine, which is intended to provide simultaneous diagnosis and treatment of a 
disease, with early detection, easy monitoring, targeted therapy, minimal toxicity and higher 
therapeutic efficiency,
[1,6]
 can be a very useful tool to reach this challenging goal. The term 
theranostics epitomizes the strict interplay of therapy and diagnosis, the pillars of medicine,
[7,8]
 and 
involves the combination of two activities, i.e. the treatment and diagnostic imaging, into a single 
multifunctional system.
[4,5,9–14]
 The main reason behind the huge enthusiasm for theranostics is its 
revolutionary approach that promises improved therapeutic outcomes on the basis of specific 
molecular features of the drug, greater predictive power for possible side effects and new ways to 
reliably monitor the response to a given treatment.
[9,15]
 These properties are key elements for the 
development of personalized medicine.
[6,9]
 Thus, theranostic agents are designed as integrated 
nanosystems allowing both disease detection and drug delivery, which can play major roles in early 
preclinical studies as well as at a clinical stage of drug development.
[2,7,13,15–17]
 
 
Figure 1. The majority of the known multifunctional nanoparticles are aimed at applications for in 
vivo imaging and therapy. Figure reproduced from Choi and Wang.
[18]
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In this frame, multifunctional nanoparticles (NPs) are attracting a growing interest as suitable 
platforms for several biomedical applications - including drug delivery and bio-imaging (Figure 1) - 
thanks to their ability to exert several advanced functions through incorporation of multiple 
functional units into a unique system.
[2,5,9,18–29]
 In order to achieve this multifunctionality, typically 
four components are included: a) a nanoparticle-based platform, b) a diagnostic imaging moiety, c) 
a targeting ligand, and d) a therapeutic agent.
[5]
 The introduction of suitable targeting ligands may 
help to increase the target-to-background contrast in imaging techniques and, above all, the local 
concentration of the drug at the target site, thus reducing or eliminating possible, untoward side 
effects.
[5,7]
 
Nanomaterial Trade Name Application Target 
Adverse 
Effects 
Manufacturer 
Current 
Status 
Metallic 
Iron oxide Feridex MRI contrast Liver 
Back pain, 
vasodilatation 
Bayer Schering 
FDA 
approved 
 Resovist MRI contrast Liver None Bayer Schering 
FDA 
approved 
 Combidex MRI contrast Lymph nodes None 
Advanced 
Magnetics 
In Phase 3 
clinical trials 
 NanoTherm Cancer therapy Various forms 
Acute urinary 
retention 
MagForce 
In Phase 3 
clinical trials 
Gold Verigene 
In vitro 
diagnostics 
Genetic Not applicable Nanosphere 
FDA 
approved 
 Aurimmune Cancer therapy Various forms Fever 
CytImmune 
Sciences 
In Phase 2 
clinical trials 
Nanoshells Auroshell Cancer therapy Head and neck 
Under 
investigation 
Nanospectra 
Biosciences 
In Phase 1 
clinical trials 
Semicondutor 
Quantum dot 
Qdots, EviTags, 
semiconductor 
nanocrystals 
Fluorescent 
contrast, in vitro 
diagnostics 
Tumors, cells, 
tissues and 
molecular 
sensing 
structures 
Not applicable 
Life Technologies, 
eBioscience, 
Nanoco, 
CrystalPlex, 
Cytodiagnostics 
Research use 
only 
Organic 
Protein Abraxane Cancer therapy Breast Cytopenia 
Abraxis 
Bioscience 
FDA 
approved 
Liposome Doxil/Caelyx Cancer therapy Various forms 
Hand-foot 
syndrome, 
stomatitis 
Ortho Biotech 
FDA 
approved 
Polymer Oncaspar Cancer therapy 
Acute 
lymphoblastic 
leukemia 
Urticaria, rash 
Rhône-Poulenc 
Rorer 
FDA 
approved 
 CALAA-01 Cancer therapy Various forms 
Mild renal 
toxicity 
Calando 
In Phase 2 
clinical trials 
Dendrimer Vivagel Microbicide Cervicovaginal 
Abdominal 
pain, dysuria 
Starpharma 
In Phase 2 
clinical trials 
Micelle Genexol-PM Cancer therapy Various forms 
Peripheral 
sensory 
Samyang 
For Phase 4 
clinical trials 
 
Table 1. Examples of nanomaterials in clinical use. Table reproduced from Chan et al.
[30]
 
 
The success of nanoparticles is certainly due to their distinctive features, such as their easy surface 
functionalization and high surface area-to-volume ratios, yielding high loading capacities.
[7,9,25,30–32]
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The nanometric size of these materials precludes their ready clearance through the kidneys, thereby 
extending their blood circulation depending on their surface functionalization characteristics.
[7,33–37]
 
Furthermore, following a precise design, nanoparticles can be engineered to either avoid immune 
system recognition or specifically inhibit or enhance the immune responses.
[38,39]
 For all these 
reasons, they could act as a promising “single-entity” scaffold able to yield meaningful information 
on the pharmacokinetics and biodistribution of a given drug, as well as on the presence of the exact 
molecular target before, during, and after therapy.
[9]
 
A number of nanostructures, including liposome and nanoparticles-based systems, have been 
approved for clinical applications, and even more are currently under preclinical or clinical 
investigations (Table 1).
[2,30,40,41]
 
 
2. PhD project goals 
The studies carried out during my PhD program are fully inserted into the research context focused 
on the development of multifunctional nanoparticle-based systems for theranostic applications. As 
schematically represented in Figure 2, the main goal of this research is the incorporation on the 
same scaffold of both therapeutic and diagnostic agents, as well as of targeting ligands. 
 
Figure 2. Scheme of an ideal multifunctional nanoparticle-based system for molecular imaging, 
drug delivery and targeting, based on NOTA chelators, Ru(III)-complexes, and oligonucleotide 
aptamers, respectively. 
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In detail, the compounds selected as nanoplatform decorations are: 
- new ruthenium(III)-based complexes, as promising alternative to Pt-based anticancer agents, 
inspired to NAMI-A and KP1019 currently in advanced clinical trials
[42–45]
 (see Chapter 2). 
- suitable derivatives of the macrocycle 1,4,7-triazacyclononane-1,4,7-triacetic acid (NOTA), as 
chelators of 
68
Ga radioisotope used in Positron Emission Tomography (PET) imaging, which can 
provide molecular/functional information on the in vivo biodistribution and pharmacokinetics of the 
drugs
[46,47]
 (see Chapter 3). 
- oligonucleotide aptamers with well proven pharmacological or active targeting activity, as TBA 
and AS1411 aptamers (see Chapter 4). 
All these decorations have been ad hoc designed and synthesized for the functionalization of 
specific types of nanoparticles (i.e., gold NPs, streptavidin-coated silica NPs, superparamagnetic 
NPs, liposomes or niosomes). 
 
In consideration of the kind of chosen derivatization, different recognition schemes can be exploited 
(Figure 3). In the case of a lipophilic tail, we can functionalize liposomes or lipid-coated NPs 
through hydrophobic interactions. Introducing a disulfur or a thiol-moiety into the starting core 
scaffold, we can functionalize metal-based NPs as Au-NPs through formation of stable metal-S or 
Au-S covalent bonds.
[48,49]
 With negatively charged molecules (as aptamers and Ru-based 
compounds) we can exploit electrostatic interactions to functionalize niosomes. Finally, the 
exceptionally high affinity of the streptavidin/biotin recognition system (Kd ~ 10
-15
 M)
[50]
 can be 
exploited for the decoration of streptavidin-coated NPs with molecules labeled with a biotin moiety. 
Following this general strategy, a small library of decorated multifunctional NPs, differing for the 
nature of the platform, Ru(III)-complex, ODN sequence and 
68
Ga chelator, has been prepared and 
tested in vitro as theranostic agents towards targeted pathologies, as cancer and clotting disorders. 
Chapter 1 
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Figure 3. Possible functionalization schemes for nanoparticle surface decoration. By labelling a 
ligand with a lipophilic tail, we can incorporate it into lipid-coated NPs or liposome platforms (not 
shown) through hydrophobic interactions. The insertion of a disulfur or of a thiol moiety into a 
ligand allows its immobilization onto gold NPs through the formation of covalent Au-S linkages. 
The presence of negative charges in the ligand allows the functionalization of niosome platforms 
via simple electrostatic interactions. The high affinity of the (strept)avidin/biotin recognition can be 
useful to conjugate (strept)avidin-coated NPs with biotin-labeled ligands. 
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Chapter 2 
Ruthenium(III)-based complexes 
1. Ru(III)-complexes: state of the art 
A major challenge in biomedical research is the discovery of compounds able to selectively inhibit 
cancer cell proliferation without adversely affecting normal cell growth.
[51]
 To this purpose, 
transition metal-based compounds have been proposed as potential drugs to treat several human 
diseases, in particular cancer.
[52,53]
 Based on their wide spectrum of coordination numbers and 
geometries, metal complexes offer different mechanisms of action that are not accessible with small 
organic molecules.
[53,54]
 
The interest for this class of chemotherapeutics started in the 60’s, with the serendipitous discovery 
by Rosenberg and co-workers of cis-diamminedichloro-platinum(II) or cisplatin. A plethora of 
platinum compounds have been prepared thereafter and evaluated as potential chemotherapeutic 
agents, although very few have entered clinical use.
[55–59]
 In fact, the efficacy of treatments based on 
cisplatin-related derivatives suffers from heavy side effects and resistance phenomena. These 
unresolved problems in platinum-based anticancer therapy have stimulated further research efforts 
aimed at the identification of novel antitumoral, non platinum-containing metal species.
[53,54]
 In this 
context, Ru(III)-complexes have particularly emerged for their remarkable anticancer or 
antimetastatic properties, generally associated with low systemic toxicity.
[60–73]
 
 
1.1. Ru(III)-based lead compounds: NAMI-A and KP1019 
The interest in ruthenium complexes rapidly increased when it was discovered that some Ru(III)-
based derivatives are therapeutically active on solid tumours resistant to cisplatin treatments. In 
principle, these compounds offer several advantages over antitumor Pt(II) complexes currently used 
in clinic - i.e. a reduced toxicity, different mechanisms of action, prospect of non-cross-
resistance
[74,75]
 and wide spectrum of activity.
[64,76]
 Among the available Ru(III)-based compounds, 
some heterocyclic complexes proved to be the most promising candidate drugs.
[61,77]
 They have the 
general formula (HB)[Ru(III)B2Cl4] - where B is a heterocyclic base - and typically include axial 
heterocyclic nitrogen donor ligands and equatorial chlorides, with charge compensation provided by 
protonated nitrogen heterocycles - as is the case of KP1019
[43,78–80]
 (Figure 4), developed by 
Keppler et al. - or sodium ions. 
In this context, Alessio, Sava and coworkers analysed the DMSO-containing variants of the above 
mentioned class, discovering a very active Ru(III)-complex, ImH
+
 [trans-RuCl4(DMSO)Im]
-
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(where Im = imidazole), called NAMI-A (Figure 4).
[81,82]
 This compound, together with KP1019, 
has been introduced in advanced clinical trials.
[42–45]
 
Although the mechanism of action and the main target of these Ru(III)-based drugs have not been 
unambiguously determined yet, a large amount of valuable data have been obtained on their in vitro 
and in vivo behaviour,
[83–85]
 summarized in several reviews.
[68,69,71,86,87]
 In spite of their structural 
similarity, these Ru(III) derivatives exhibit markedly different anticancer effects.
[88–90]
 
 
Figure 4. Chemical structures of ImH
+
 [trans-RuCl4(DMSO)Im]
-
 (NAMI-A) and IndH
+
 
[RuCl4(Ind)2]
-
 (KP1019), where Im = imidazole, and Ind = indazole. 
 
NAMI-A shows a remarkable and selective activity against cancer metastases,
[91–103]
 mostly of solid 
lung tumours, but is not effective in the reduction of primary cancers. ImH
+
 [trans-
RuCl4(DMSO)Im]
-
 consists of a pseudo-octahedral complex, in which Ru(III) is coordinated with 
six ligands: one imidazole, one DMSO and four chloride ions. All these ligands can be replaced by 
water or hydroxide ions, resulting in a mixture of aquated species - ultimately responsible for the 
antimetastatic activity.
[99]
 In vitro experiments have shown that NAMI-A readily undergoes 
hydrolysis under physiological conditions;
[104,105]
 in particular, following the mechanism depicted in 
Figure 5, the chloride ions are the ligands most rapidly substituted by water and/or hydroxide 
ions.
[81,106]
 
 
Figure 5. Proposed hydrolysis mechanism for NAMI-A.
[81] 
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The loss of chloride groups is catalysed by the reduction of Ru(III) to Ru(II), which is expected to 
occur under physiological conditions and is enhanced in vitro by traces of biological reductants, 
such as ascorbic acid or cysteine.
[61,107]
 Overall, NAMI-A hydrolysis is complete within 15-20 min, 
with both Cl
-
 and DMSO ligands replaced by water. The nature and rate of the hydrolytic processes 
in aqueous solution are strongly pH-dependent.
[99,108–110]
 Hydrolysis eventually leads to the 
formation of polymeric oxo- or hydroxo-bridged species which can precipitate; this phenomenon, 
which would dramatically limit the therapeutic efficacy of these compounds, is less likely in vivo 
because of the presence of several proteins (including integrins, transferrin and serum albumin) 
which can form stable adducts with the Ru-complexes, inhibiting the precipitation of insoluble 
oligomers.
[110]
 
Notably, NAMI-A increases the capsule thickness around the primary tumours and the extracellular 
matrix around tumour blood vessels, thereby preventing tumour cells from invading surrounding 
tissue and blood vessels.
[61,82,93,111]
 In addition, NAMI-A is able to inhibit matrix metalloproteinases 
and induce antiangiogenic effects.
[66,111] 
In contrast to platinum-based drugs, NAMI-A weakly binds 
to DNA, which suggests that its antimetastatic activity is not primarily related to DNA damage.
[112]
 
Lastly, NAMI-A is much less toxic to healthy tissues than cisplatin.
[113] 
KP1019 is a Ru(III) chlorido-indazole complex showing remarkable antitumor activity at the 
primary tumour site.
[65,114–118]
 IndH
+
 [RuCl4(Ind)2]
-
 (where Ind = indazole) is an octahedral 
complex, in which Ru(III) is coordinated to two indazole ligands and four chloride groups. 
Biological tests
[71,86,119]
 proved that KP1019 is highly active against colorectal cancer cell lines both 
in vitro and in vivo.
[62,65,114–116]
 The efficiency of KP1019 has been associated with its ability to 
interact with DNA and inhibit its synthesis probably involving different modes of action.
[86]
 
Compared with NAMI-A, KP1019 is more readily taken up by cancer cells and is more stable 
toward hydrolysis.
[68,103,110,119,120]
 Unlike NAMI-A, KP1019 does not have relevant effects on 
metastatic cells, still showing cytotoxic activity and reducing the cell population by promoting 
apoptosis
[71,120–122]
 via the mitochondrial pathway.
[53,86,107]
 Analysis of the intracellular distribution 
of Ru in single human cells treated with KP1019 showed that Ru localized in both cytosol and in 
the nuclear region. In marked contrast, Ru could not be well visualized in cells treated with NAMI-
A, indicating that it was not effectively internalized and supporting the hypothesis that its activity is 
exerted through membrane-binding mechanisms.
[123]
 
In summary, in a very simplified scheme, three main events have been hypothesized to determine 
the fate of these ruthenium complexes in vivo: the activation by hydrolysis, the activation by 
reduction and the high affinity binding to blood plasma proteins. An interplay between these 
mechanisms seems to account for the biological effects of these Ru(III)-complexes. For both 
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species, chlorido ligands can be rapidly exchanged with water molecules or hydroxide ions, 
activating the complex; then, in a second substitution event, the bound aqua ligands are replaced by 
the target biomolecules.
[124]
 In addition, both these Ru(III)-complexes readily react with biological 
reductants
[117]
 suggesting that the in situ reduction of Ru(III) to Ru(II)
[64]
 species may be relevant 
for their biological activity,
[68,76,107]
 producing a more reactive form,
[64,118]
 able to interact with 
proteins
[106,112,125–127]
 and/or to bind nucleic acids.
[106,128] 
Finally, both these Ru-complexes can tightly interact with plasma proteins, in particular with human 
serum transferrin (hTf),
[88–90,129–132]
 i.e. the iron transport protein in blood responsible for 
controlling the level of free iron in biological fluids (for a recent review, see for example Harris et 
al.
[133]
). General interference with the iron metabolism has been also invoked to explain the 
anticancer activity of Ru(III)-complexes.
[68,88,89,107,123,129]
 
 
1.2. AziRu, a pyridine analog of NAMI-A 
In 2012, almost simultaneously, two different research groups, Walsby et al.
[134]
 and Paduano et 
al.
[135,136]
 revisited a pyridine analogue of NAMI-A, called NAMI-Pyr by the first group and AziRu 
by the second ones, whose structure had been previously described by Attia et al. in 1993.
[106]
 
Compared to NAMI-A, AziRu has a pyridine molecule replacing one imidazole ligand, and sodium 
replacing imidazolium as the counterion (Figure 6). 
 
Figure 6. Chemical structure of AziRu, along with a picture of a sample of this compound, obtained 
as a solid orange powder. 
 
In vitro biological experiments have shown very low cytotoxicity for AziRu
[135–137]
 on different 
cancer cell lines. Thus, AziRu is not cytotoxic per se – similarly to NAMI-A – against human 
cancer cells; however, its IC50 value is half that of NAMI-A on MCF-7 breast cancer cells (Table 
2), indicating that the structural modifications introduced in NAMI-A allow increasing its 
antiproliferative activity. One possible reason for this difference lies in the presence of a pyridine 
ligand in lieu of imidazole, conferring a higher lipophilicity to AziRu, which could determine 
enhanced non covalent interactions with proteins, particularly with human serum albumin.
[134]
 
Indeed, Walsby and co-workers have synthesized and studied a mini-library of Ru(III)-complexes; 
N
Ru
S
Cl Cl
Cl Cl
O
-
Na+
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their analysis showed that, upon increasing their lipophilicity, reduced solubility has been observed 
in physiological media for the free complexes, however accompanied by enhancement of non-
covalent interactions with the hydrophobic domains of serum proteins, in particular of human serum 
albumin. Formation of these protein adducts basically improves the solubility of the complexes, 
also inhibiting the formation of oligomeric species and leading to higher in vitro cytotoxicity.
[138–140]
 
IC50 (Μm) 
 MCF-7 WiDr C6 HeLa 
NAMI-A
[141]
 620 ± 30 - - - 
AziRu
[135,137]
 305 ± 16 441 ± 20 318 ± 12 382 ± 19 
 
Table 2. IC50 values (µM) relative to the antiproliferative activity of NAMI-A and AziRu in the 
indicated cancer cell lines following 48 h of incubation. IC50 values are reported as mean ± SEM. 
(MCF-7: human breast adenocarcinoma cell line; WiDr: human epithelial colorectal 
adenocarcinoma cell line; C6: tumor rat glioma cells; HeLa: human cervical cancer cells). 
 
Proteins are considered to be the privileged biological targets of Ru(III)-complexes.
[142–144]
 
However, it cannot be excluded that the adducts formed with proteins, and mainly albumin and 
transferrin present in serum, may represent intermediate forms protecting the metal from further 
degradation
[145]
 and allowing its transport to nuclei; under these circumstances, also DNA could be 
considered a possible in vivo target, in analogy with the mechanism hypothesized for cisplatin.
[146]
 
In this frame, the interaction of AziRu with suitable DNA model systems, both single strand and 
duplex oligonucleotides, has been investigated in comparison with its analogue NAMI-A using 
different biophysical methods, including absorption UV-vis spectroscopy, circular dichroism (CD) 
and electrospray mass spectrometry (ESI-MS) techniques.
[147]
 
UV-vis measurements allowed monitoring over time the ligand exchange processes of these Ru 
complexes, in the absence and presence of the examined oligonucleotides. CD experiments 
provided information on the overall conformational changes of the DNA model systems induced by 
the metal complexes. Treatment with AziRu and NAMI-A did not produce any detectable change in 
the CD profile of the model, preformed duplex, indicating that – contrarily to cisplatin and other 
anticancer Pt(II)-complexes – these compounds did not perturb the overall conformation of the 
studied duplex. Interestingly, CD-melting experiments showed that the ruthenated duplex had in all 
cases higher Tm values compared to the untreated system, showing however a lower difference of 
the CD signal intensity at its maximum (264 nm) upon denaturation with respect to the natural 
duplex. These data indicate the formation of stable ruthenium-duplex adducts, with local, partial 
loss of some Watson–Crick H-bonding and/or stacking interactions induced by Ru binding. 
ESI-MS experiments (Figure 7), carried out on several oligonucleotide/ruthenium complex 
mixtures, allowed detecting the formation of stable adducts with guanine-containing oligomers for 
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both NAMI-A and AziRu, while no adduct was observed with guanine-free sequences. The 
obtained results unambiguously demonstrate that both AziRu and NAMI-A are able to selectively 
interact with DNA model systems at the level of guanines, preferentially targeting a “GG” 
dinucleotide box. Remarkably, AziRu proved to be far more reactive than NAMI-A, leading to 
oligonucleotide adducts with a naked Ru
3+
 ion incorporated, while with NAMI-A only Ru(Im)
3+
 
(Im = imidazole) fragments were observed. Although very similar in their structures, the two metal 
compounds thus show a markedly different reactivity with the examined sequences: AziRu reacts 
with guanine-containing oligonucleotides forming stable adducts in which ruthenium loses all its 
original ligands, while NAMI-A keeps imidazole in the oligonucleotide-ruthenium complex adduct 
formation, showing that pyridine is a more labile ligand compared to imidazole. This different 
behavior in the binding mode with nucleic acids is in good agreement with studies on the interaction 
with proteins
[134,143,144]
 underlining that, although structurally similar, NAMI-A and AziRu have a 
quite different reactivity profile towards biologically relevant targets. 
 
Figure 7. ESI-MS spectrum of the selected ODN 2 (50 µM), incubated with 1 eq of NAMI-A 
(right) and 1 eq of AziRu (left) in water at 37 °C for 48 h. The analysis was carried out at final 
concentration of 25 µM in MeOH/H2O, 1:1 (v/v). Figure adapted from Montesarchio et al.
[147]
 
 
1.3. Design of novel Ru(III)-based complexes 
Although in the case of NAMI-A it is generally accepted that the hydrolysis process and formation 
of oligomer species does not really impair its overall antitumor activity
[148]
 - at least for some tumor 
cell lines
[100]
 - the premature aquation can deactivate or activate too early most of the administered 
drug.
[146,149]
 Thus, in order to obtain long-life Ru(III)-based antineoplastic agents, a pro-drug 
approach, involving the decoration of the ruthenium complex with amphiphilic nanovectors, has 
been proposed by Paduano et al. for the in vivo delivery of these compounds.
[73,135–137,150–154] 
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The use of pro-drugs is an established strategy to improve the physico-chemical, biomedical or 
pharmacokinetic properties of therapeutically relevant compounds. A pro-drug is a chemically 
modified version of a pharmacologically active agent that must undergo an in vivo transformation to 
release the effective drug. For example, the use of pro-drugs allows overcoming drawbacks such as 
poor aqueous solubility, chemical instability, insufficient oral absorption, rapid pre-systemic 
metabolism, inadequate brain penetration and toxicity. A very simplified, representative scheme of 
the pro-drug concept is shown in Figure 8, in which the barrier depicted can be any physical 
obstacle (e.g., a cell membrane) that limits the optimal in vivo performance of a parent drug. The 
drug and the carrier are covalently bound via a linker that contains chemically or enzymatically 
cleavable bonds. The ‘ideal’ pro-drug is based on a non-toxic carrier and, once crossed the barrier, 
releases the intact therapeutic agent in an almost quantitative manner. 
 
Figure 8. Simplified representative scheme of the pro-drug concept. 
 
1.4. Nucleolipid nanovectors as molecular carriers for Ru(III)-based drugs 
As biocompatible carriers for the in vivo transport of Ru(III)-based complexes, Paduano and co-
workers have selected amphiphilic molecules and in particular nucleolipidic scaffolds
[150,151,155]
 to 
which the Ru core can be covalently linked. 
As well known, self-assembling amphiphiles allow an efficient bottom-up strategy for the formation 
of aggregates whose size and shape can be easily tuned. Further benefits related to the use of 
nanostructures in metal-based drug delivery include the possibility to: 
 transport higher amount of the metal inside the blood stream; 
 obtain “stealth” aggregates, not detected by the human immune system, thus specifically 
increasing their permanence in the blood; 
 produce aggregates selectively captured by specific cancer cell lines by inserting, within the 
aggregates, targeting molecules, specifically recognized by protein receptors over-expressed in 
tumor cells; 
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 tune the shape and size of the aggregates by modifying either their molecular structure or some 
external physico-chemical parameters, such as pH and ionic strength.
[136,151,156]
 The latter effects 
may be very useful in a stimuli-responsive approach.
[156,157]
 
Nucleolipids - i.e., hybrid molecules carrying lipid moieties covalently attached to nucleoside 
scaffolds - are able to mimic the molecular organization of the biological systems, forming a wide 
variety of supramolecular systems.
[158–161]
 In planning the synthesis of Ru-containing nanovectors, 
our basic idea was to covalently link the ruthenium complex - i.e., AziRu - to a nucleolipid structure 
able to spontaneously self-assemble in aqueous media, thus protecting it from chemo-enzymatic 
degradation in the extracellular environment and prolonging its half-life. To this purpose, several 
different nucleolipidic carriers have been designed,
[151]
 in principle able to favour the transport of 
the Ru(III)-complex in an intact form until it reaches the tumour site. Following this concept, once 
internalized into the cell, the amphiphilic decorations of the nucleolipid scaffold are removed 
exploiting enzymatic hydrolysis mechanisms, thus releasing a low molecular weight Ru-based 
compound, able to fully exert its activity. The general design of the functional nucleolipids is 
schematically described in Figure 9 and involves: 
 a thymidine or uridine moiety selected as the central scaffold, allowing high and easy 
functionalization; 
 a pyridyl-methyl group inserted at the N-3 position on the nucleobase as the ligand for the Ru-
complexation, thus producing an AziRu-like structure; 
 a lipophilic oleoyl or cholesteroxyacetyl group covalently anchored (one in the case of 
thymidine derivatives, or two in the case of the uridine analogue) at the ribose secondary 
hydroxyl group(s). These residues, able to induce self-structuring in aqueous solutions, have 
been chosen due to their structural similarity with lipid membrane constituents and easy 
availability; 
 a hydrophilic oligo(ethylene glycol) chain linked at the 5’-OH ribose moiety; this decoration is 
expected to optimize the “hydrophilic/lipophilic balance” within the molecule and to increase its 
circulation time
[162]
 preventing extracellular chemo-enzymatic degradation. In addition, 
oligoethylene glycols have ‘stealth properties’,[163–165] allowing the attached drug escaping the 
immune system. 
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Figure 9. Schematic representation of the general design exploited for the preparation of 
nucleolipidic nanocarriers of Ru(III)-based drugs. 
 
Based on the design shown in Figure 9, a series of amphiphilic Ru complexes able to form 
supramolecular aggregates have been prepared. These complexes - named ToThyRu, HoThyRu, 
ToThyCholRu and DoHuRu - are depicted in Figure 10. 
As in the case of NAMI-A and AziRu, also these nucleolipidic complexes tend to be unstable when 
left in aqueous solutions and form insoluble precipitates, though at a much slower rate than NAMI-
A and AziRu, i.e. in a period ranging from few hours, in phosphate buffer, to few days, when 
dissolved in pure water. The hydrolysis results in a change of the solution colour from yellow to 
green, followed by precipitation of brown particles.
[135,136]
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In order to sensibly reduce the aquation processes, nucleolipidic Ru(III)-complexes have been 
studied in formulation with biocompatible bi-tailed phospholipids, as the zwitterionic 1-palmitoyl-
2-oleoyl-sn-glycero-3-phosphocholine (POPC) and the cationic 1,2-dioleoyl-3-
trimethylammoniumpropane (DOTAP), depicted in Figure 11. The use of phospholipid 
formulations allows obtaining Ru complexes stable for months in physiological media, as well as 
finely modulating the metal amount to be administered in vivo. Indeed, bi-tailed phospholipids can 
adopt an ordered arrangement in aqueous solutions by forming bilayers in which the nucleolipidic 
Ru complexes can be easily lodged. The various lipid formulations here prepared differ for the lipid 
in use: in the case of POPC, the main driving forces promoting the formation of stable co-
aggregates are hydrophobic interactions, while for DOTAP also electrostatic interactions contribute 
to stabilize the final co-aggregates. POPC and DOTAP have been chosen as stabilizing agents on 
the basis of their proved biocompatibility, being among the main components of cell 
membranes.
[136,166]
 
Effective retardation of the ligand exchange processes in physiological solutions, resulting into 
formulations stable at r.t. for months, has been observed with the Ru(III)-complex present up to a 
maximum of 15% in mol in mixture with POPC,
[135,136]
 and up to 50% in mixture with 
DOTAP.
[137,153]
 
 
Figure 11. Chemical structures of POPC (1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine) and 
DOTAP (1,2-dioleoyl-3-trimethylammoniumpropane). 
 
An in-depth characterization by dynamic light scattering (DLS) and small angle neutron scattering 
(SANS) - in pure water and in a pseudo-physiological buffer solution - has been performed first on 
ToThy,
[151]
 HoThy,
[151]
 DoHu,
[151]
 and ToThyChol
[136]
 i.e., the parent nucleolipids, and then on the 
corresponding nucleolipidic Ru(III)-complexes, as such and in formulation with POPC or DOTAP. 
ToThy, HoThy, DoHu, ToThyChol nucleolipids showed the desired distinctive features of 
nanocarriers, being mainly organized as small aggregates i.e. rod-like micelles in pure water, and as 
bigger aggregates, i.e. multilayer vesicles, in pseudo-physiological solutions.
[136,151] 
Notably, DLS analysis showed that under pseudo-physiological conditions all the complexes in 
POPC formulation (Ru complex/POPC 15:85 molar ratio) form aggregates with a monomodal 
distribution, having a hydrodynamic radii distribution similar to pure POPC. SANS data allowed 
confirming that the aggregation is essentially driven by POPC self-assembly.
[135,136] 
O O
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O
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Compared with POPC co-aggregates, liposomes based on DOTAP can tolerate a higher amount of 
nucleolipidic Ru complex without losing in stability. In fact, stable liposomal DOTAP co-
aggregates can contain up to 30% in moles of ToThyCholRu
[137]
 and 50 % in moles of ToThyRu, 
HoThyRu and DoHuRu.
[153]
 These nanoaggregates form catanionic vesicles which, analysed in a 
pseudo-physiological solution for more than three months, were found to be perfectly stable at r.t., 
showing no degradation. The formation of catanionic nanoaggregates has been confirmed also by 
zeta potential measurements, which proved that the positive surface charge, carried by bare DOTAP 
vesicles, is partially neutralized upon addition of negatively charged nucleolipidic Ru 
complexes.
[137,153]
 
Furthermore, to gain insight into their antiproliferative activity, an in-depth bioactivity investigation 
has been performed first on ToThy,
[151]
 HoThy,
[151]
 DoHu
[151]
 and ToThyChol
[136]
 - i.e., the naked 
nucleolipids, here used as the carriers - and then on the final formulations ToThyRu/POPC,
[135]
 
HoThyRu/POPC,
[135]
 DoHuRu/POPC,
[135]
 and ToThyCholRu/POPC,
[136]
 in comparison with AziRu 
(see Table 3). Focusing on the cells more sensitive to the ruthenium treatment in vitro, i.e. MCF-7 
and WiDr, naked nucleolipids showed the absence of significant cytotoxicity effects on both normal 
and tumor cells;
[136,151]
 while POPC formulations have been found to be at least one order of 
magnitude more active than free AziRu. Particularly interesting results have been obtained on the 
MCF-7 human breast cancer cell line for the formulations ToThyRu/POPC and HoThyRu/POPC 
with IC50 values of 9 and 7 µM, respectively, calculated with respect to the ruthenium 
concentration. To the best of our knowledge, these in vitro data show these molecules as among the 
most promising Ru-based anticancer agents currently described in the literature.
[135,136]
 
IC50 (μM) 
 MCF-7 WiDr C6 
AziRu 305 ± 16 441 ± 20 318 ± 12 
ToThyRu/POPC 9 ± 4 75 ± 4 36 ± 8 
HoThyRu/POPC 7 ± 4 40 ± 5 81 ± 7 
DoHuRu/POPC 71 ± 6 99 ± 5 24 ± 5 
ToThyCholRu/POPC 70 ± 12 165 ± 10 - 
 
Table 3. IC50 values (µM) relative to AziRu and to the effective ruthenium concentration carried by 
ToThyRu/POPC, HoThyRu/POPC, DoHuRu/POPC and ToThyCholRu/POPC liposomes in the 
indicated cell lines following 48 h of incubation. IC50 values are reported as mean ± SEM. (MCF-7: 
human breast adenocarcinoma cell line; WiDr: human epithelial colorectal adenocarcinoma cell 
line; C6: tumor rat glioma cells). 
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The higher in vitro cytotoxicity of Ru-complex/POPC formulations, compared to AziRu, suggests 
that all the nucleolipidic liposomes are able to deliver the active transition metal in a very efficient 
way, enhancing the effectiveness of the transported anti-cancer drug.
[135,136]
 
Similarly, also DOTAP formulations have been evaluated in vitro showing high antiproliferative 
activity against specific human adenocarcinoma cell types. Remarkably, even the Ru-
complex/DOTAP nanoaggregates, tested on a panel of human and non-human cancer cell lines, 
exhibited IC50 values in the low μM range, proving to be 10−20-fold more cytotoxic against MCF-7 
and WiDr cells than free AziRu.
[137,153]
 In some cases DOTAP formulations were also found to be 
more efficient than those in POPC, as shown in Table 4. Indeed, the liposomes formed by the 
cationic lipid DOTAP may closely interact with the negatively charged cell membrane, further 
improving the liposome fusion with the plasma membrane. Interestingly, no significant cytotoxicity 
has been detected on non-cancer cells, as human HaCaT keratinocytes and rat L6 muscle cells. 
 
IC50 (μM) 
 MCF-7 WiDr C6 HeLa L6 HaCaT 
AziRu 305 ± 16 441 ± 20 318 ± 12 382 ± 19 > 500 > 500 
ToThyRu/DOTAP 19 ± 8 50 ± 11 54 ± 8 - - - 
HoThyRu/DOTAP 15 ± 7 65 ± 8 43 ± 11 - - - 
DoHuRu/DOTAP 13 ± 5 41 ± 10 34 ± 9 - - - 
ToThyCholRu/DOTAP 13 ± 2 23 ± 8 - 34 ± 4 187 ± 1 377 ± 2.5 
 
Table 4. IC50 values (µM) relative to AziRu and to the effective ruthenium concentration carried by 
ToThyRu/DOTAP, HoThyRu/DOTAP, DoHuRu/DOTAP and ToThyCholRu/DOTAP liposomes in 
the indicated cell lines, following 48 h of in vitro treatment. IC50 values are reported as mean ± 
SEM. (MCF-7: human breast adenocarcinoma cell line; WiDr: human epithelial colorectal 
adenocarcinoma cell line; C6: tumor rat glioma cells; HeLa: human cervical cancer cells; L6: rat 
muscle cells; HaCaT: keratinocytes cells). 
 
1.5. Interfacing nucleolipidic Ru(III)-complexes with bilayer-coated superparamagnetic 
nanoparticles: a successful marriage for theranostics 
Normally, cancer is diagnosed at a stage of the disease in which some anatomical changes occur in 
the body in the form of well-defined tumors. Generally, these masses are removed by surgery, but 
this approach is not applicable to small or hidden tumors. Nanotechnology offers potential solutions 
for the treatment of various types of cancer, particularly at a very early stage: nanoparticles could 
protect a drug from recognition by the reticulo-endothelial system (RES) - e.g., if highly PEGylated 
- and deliver a therapeutic agent in a controlled manner at a target site, so that rate and duration of 
drug delivery can be therapeutically effective, minimizing the requirement of booster dose.
[38,167–169] 
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The flexibility in obtaining tailor-made nanoparticles with specific features (for example molecular 
weight, number and types of attached drugs, targeting moieties and even bioresponsive 
components)
[170]
 makes them suitable drug delivery systems. In this frame, the incorporation of 
Ru(III)-complexes within nanoparticles can improve their in vivo performance by - in principle - 
increasing their circulation time in the body, decreasing their susceptibility to degradation, limiting 
recognition by the body’s immune system and targeting specific sites. This strategy allows 
increasing the drug amount which can reach the desired area and reducing the side effects due to 
drug accumulation in undesired regions. 
Remarkably, nanoparticles are very attractive platforms due to their capability to load multiple 
systems, as therapeutic and diagnostic compounds, thus affording useful theranostic agents.
[1,2]
 
Superparamagnetic Iron Oxide Nanoparticles (SPIONs) are particularly attractive tools, being able 
to modify the transversal proton relaxation time (T2) of water molecules, resulting into effective 
contrast agents for in vivo Magnetic Resonance Imaging (MRI) analyses.
[171,172]
 
Stable phosphocholine-functionalized SPIONs (18LPC/SPIONs) have been recently prepared 
exploiting hydrophobic interactions between a suitable phosphocholine, i.e. 1-octadecyl-2-hydroxy-
sn-glycero-3-phosphocholine (18LPC), and an inner amphiphilic layer (oleic acid and oleylamine), 
covering the surface of the NPs.
[173,174]
 
 
Figure 12. Schematic representation of the system 18LPC-ToThyCholRu/SPIONs. 
 
In this context, 18LPC-SPIONs have been loaded with ToThyCholRu (18LPC-
ToThyCholRu/SPIONs),
[174]
 lodged in the external coating layer of the nanoparticle surface, to 
which it is reversibly bound through hydrophobic interactions (Figure 12). ToThyCholRu is thus 
easily transported in vivo where it can exert its activity. The evaluation of the bioactivity of the 
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ToThyCholRu-functionalized SPIONs on selected human cancer and non-cancer cells confirmed 
the potential of the system as an effective theranostic device.
[174]
 Indeed, 18LPC/SPIONs were 
devoid of significant biological effects, while 18LPC-ToThyCholRu/SPIONs showed relevant 
selective cytotoxicity against human cancer cells. These results highlighted the possibility to exploit 
the nucleolipidic Ru(III)-complexes also for the functionalization of properly coated nanoparticles: 
indeed, all these compounds present a hydrophobic appendage which can be inserted not only 
within lipid-decorated SPIONs, but also in any other kind of inorganic nanoparticles, provided that 
they are decorated with a lipophilic layer. 
IC50 (μM) 
 MCF-7 Calu-6 A549 HaCaT 3T3-L1 
cDDP 22 ± 4 45 ± 5 36 ± 4 272 ± 7 > 100 
18LPC-ToThyCholRu/SPIONs 17 ± 5 12 ± 4 14 ± 5 205 ± 6 > 100 
 
Table 5. Comparison of the IC50 values (μM) relative to cisplatin (cDDP) - used as a positive 
control for cytotoxic effects - and to the effective ruthenium concentration carried by 18LPC-
ToThyCholRu/SPIONs in the indicated cell lines following 48 h of incubation. 
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2. Synthesis and characterization of novel nucleolipid-based Ru(III)-complex 
LipThyRu 
Following the design of the amphiphilic nucleolipids ToThyRu, HoThyRu, DoHuRu and 
ToThyCholRu (described before in paragraph 1.4),
[135–137,153]
 a novel nucleolipid-based Ru(III)-
complex was prepared (Figure 13). This compound was named LipThyRu, following the acronym 
taken from the main structural motifs present in its molecular skeleton: Lipoic acid-Thymidine-
Ruthenium salt. 
With a general structure similar to the previously described derivatives, LipThyRu is a thymidine 
derivative carrying a pyridine-methyl arm at the N-3 position of the nucleobase, inserted as 
anchoring ligand for the Ru(III)-complex; this nucleoside has been further derivatized with a 
hydrophilic heptaethylene glycol chain at the 5’-position and a lipophilic chain, i.e. a lipoic acid 
residue, at the 3’ position. As already discussed for the previously described nucleolipidic 
compounds, the use of a hydrophilic moiety is intended not only to optimize the 
“hydrophilic/lipophilic balance” within the hybrid molecule, but also - at a functional level - to 
prevent extracellular enzymatic degradation by the reticuloendothelial system. On the other hand, 
the lipophilic component of the nucleolipidic Ru(III)-complex is necessary in our design to ensure 
its self-assembly in aqueous solution but also to establish specific interactions with suitable 
nanoplatforms, as liposome or niosome structures, which can thus incorporate it giving stable 
formulations. If inserted within liposomes, or liposome-coated nanoparticles, the driving force for 
the nucleolipid encapsulation is simply based on hydrophobic interactions. In the case of niosomes, 
since these are positively charged carriers, their functionalization process is based on electrostatic 
attractions with the negatively charged Ru(III)-complex (see chapter 5.2). 
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Figure 13. Structure of the amphiphilic nucleolipidic Ru(III)-complex LipThyRu. 
 
As an additional property, the presence of the lipoic acid disulfide bond in LipThyRu can be 
exploited to allow its easy immobilization onto gold surfaces, as for instance gold nanoparticles, 
thanks to the high affinity of sulfur for gold, forming very stable S-Au covalent bonds. 
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Thus, this nucleolipidic Ru(III)-complex, carrying useful decorations which in principle allow their 
easy functionalization onto different nanoplatforms, appears as a really versatile tool in the 
construction of multifunctional nanosystems. 
The decoration with the lipophilic and hydrophilic chains on the sugar hydroxyl moieties was 
performed through simple ester bonds, which are easily formed by classical DCC/DMAP activation 
of the selected carboxylic acids.
[175,176]
 These chemical linkages are typically stable in neutral 
solutions and in extracellular media, but are rapidly cleaved within the cell by cellular esterases, 
releasing the active portion of the molecule. 
 
2.1. Results and discussion 
2.1.1. Synthesis and characterization of LipThyRu 
The synthesis of target compound LipThyRu was realized by a straightforward and high yielding 
strategy based on a well-established chemistry, involving the use of easy-to-handle, commercially 
available reagents (Scheme 1). 
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Scheme 1. Synthetic procedure for the preparation of the nucleolipidic Ru(III)-complex LipThyRu. 
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Insertion of the pyridine moiety on the thymidine scaffold was achieved by treatment of the 
commercially available 5′-O-(4,4′-dimethoxytriphenylmethyl)thymidine 1 with a slight excess of 4-
(bromomethyl)pyridine in DMF in the presence of K2CO3 as base. In this reaction, the imide N-3 of 
thymidine has a relatively acidic proton (pKa ca. 8) and could be easily deprotonated, thus 
undergoing a nucleophilic substitution and giving alkylated compound 2 in 59 % isolated yields. 
Under the used conditions, the less reactive 3’-hydroxyl of the sugar moiety did not compete in the 
alkylation reaction, remaining available for the next coupling step. This group was then coupled 
with lipoic acid using DMAP and DCC as condensing agents, affording compound 3 in 77 % yields 
after chromatographic purification on a silica gel column. The successive DMT removal realized 
under acidic conditions (1 % TCA in CH2Cl2) gave compound 4 in almost quantitative yields (99 
%). Next, the condensation with the heptaethylene glycol derivative 8 (BnO-HEG acetic acid) 
allowed obtaining target nucleolipid 5. 
BnO-HEG acetic acid 8 was synthesized starting from hexaethylene glycol (HEG), elaborated into 
an acetic acid derivative (Scheme 2), following a straightforward and high yielding procedure. First, 
a benzylation to selectively cap one OH group was required: this nucleophilic substitution reaction 
was realized using benzyl bromide (in 1:1 ratio with respect to the starting material) and NaH in 
THF as solvent, giving alcohol 6 in 65 % yields. The following treatment with tert-butyl 
bromoacetate, in the presence of NaH, provided ester 7 in 86 % isolated yields. After an acid 
treatment with formic acid, ester 7 was converted into target carboxylic acid 8 in almost quantitative 
yields (98 %), and finally coupled at the 5’-OH end of 4 to give the desired nucleolipid 5. The 5’-
functionalization was obtained by ester bond formation using the coupling system DCC/DMAP, 
affording the target compound in 74 % overall yields after silica gel column purification. 
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Scheme 2. Synthetic procedure for the preparation of BnO-HEG acetic acid (Bn = benzyl group). 
 
Chapter 2 
26 
 
The last step was a ligand exchange reaction between nucleolipid 5 and the Na
+
 [trans-
RuCl4(DMSO)2]
-
 salt prepared in our laboratory following a reported procedure.
[106,177]
 The reaction 
was performed at 40 °C using acetone as solvent. After 4 h, TLC monitoring showed the complete 
disappearance of the starting materials and the reaction was quenched removing the solvent under 
vacuum. Then the crude product, filtered and washed several times with AcOEt, allowed the desired 
LipThyRu, recovered in 71 % yields. Following this synthetic procedure, LipThyRu was obtained 
in 24 % overall yields for 5 steps. 
All the synthetic intermediates and the final nucleolipid have been characterized by 
1
H and 
13
C 
NMR spectroscopy, as well as by ESI-MS spectrometry, which in all cases confirmed the identity 
and purity of the target compounds. Signals observed in the 
1
H NMR spectrum of LipThyRu 
(Figure 14) are particularly diagnostic of the effective complex formation.
[81,178]
 Indeed the presence 
of the paramagnetic ruthenium(III) ion produces a dramatic upfield shift and a broadening of the 
protonic signals of pyridine and dimethyl sulfoxide, found at δ = -1.8 and δ =-12.7 ppm, 
respectively. In the ESI-MS spectrum, recorded in the positive ions mode, the molecular ion shows 
the expected mass/charge ratio and the characteristic isotopic pattern of ruthenium (Figure 15). 
 
Figure 14. Upfield region expansion of the 
1
H NMR spectrum of the nucleolipid-based Ru(III)-
complex LipThyRu [400 MHz, (CD3)2CO]. 
 
Figure 15. ESI-MS spectrum (positive ions) of LipThyRu.  
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2.1.2. UV-vis studies: absorbance spectra of LipThyRu 
In analogy with NAMI-A and AziRu, also the nucleolipidic Ru(III)-complexes ToThyRu, 
HoThyRu, DoHuRu and ToThyCholRu showed limited stability in aqueous solutions. In fact, 
formation of green precipitates, in a period going from few hours in phosphate buffers to few days 
in pure water, was observed also for these nucleolipidic Ru(III)-complexes, even if somehow 
retarded compared with the “naked” AziRu or NAMI-A. The degradation process was attributable 
to the replacement of the ligands of the ruthenium complex by water molecules and/or hydroxide 
ions, well known for NAMI-A and related analogs.
[81,104,105,108]
 In this frame, also the hydrolysis of 
LipThyRu complex has been analysed, by monitoring its UV-vis spectra over time. Indeed, UV-vis 
analysis allows detecting the formation of the aqua-complexes, obtained through the exchange of 
the chloride or DMSO ligands with water molecules and postulated to be the species effectively 
reactive with the in vivo targets.
[64,108,112,118,125–128,178]
 
The UV-vis-monitored hydrolysis of the new complex LipThyRu was analysed over time in a saline 
buffered solution mimicking the extracellular physiological conditions (10 mM phosphate 
buffer/100 mM NaCl pH = 7.3). First of all, the UV-vis spectrum of LipThyRu was recorded 
immediately after its dissolution in DMSO at 100 μM final concentration, and compared with those 
of AziRu
[147]
 and Na
+
 [trans-RuCl4(DMSO)2]
-
 (Figure 16). 
 
Figure 16. Overlapped UV-vis absorption spectra of Na
+
 [trans-RuCl4(DMSO)2]
-
, AziRu and 
LipThyRu (from samples freshly dissolved at 100 μM concentration in DMSO). 
 
The UV-vis spectrum of LipThyRu showed the characteristic band centred at 410 nm, relative to the 
ligand-to-metal charge transfer transition (LMCT) for the Ru–Cl bond, in addition to overlapped 
bands in the region 250-350 nm, which can be attributed to the metal, the pyridine portion and the 
thymine base contributions. Comparing the UV-vis spectra of LipThyRu and AziRu, the presence 
of the same band at ca. 400 nm confirmed the same ligands arrangement around the Ru(III) nucleus. 
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Interestingly, this band is slightly blue-shifted with respect to the salt Na
+
 [trans-RuCl4(DMSO)2]
—
precursor of both AziRu and LipThyRu – which presents DMSO as apical ligand in lieu of pyridine. 
 
2.1.3. UV-vis-monitored hydrolysis of LipThyRu in a saline phosphate buffer 
The hydrolysis of LipThyRu was monitored by UV-vis analysis over time in a saline phosphate 
buffered solution (10 mM phosphate buffer/100 mM NaCl pH = 7.3), mimicking the extracellular 
media. The absorption spectra (Figure 17) showed a band centred at 398 nm, attributed to the 
LMCT, which gradually diminished over time disappearing in ca. 7 h; concomitantly, a decrease of 
the absorption bands in the region between 250-300 nm was observed. 
Since the first monitoring hours, an overall raising of the spectrum baseline was observed, 
associated with scattering phenomena, probably due to the formation of aggregates, which reached 
stability after 4 h (Figure 17). 
 
Figure 17. Overlapped UV-vis absorption spectra of LipThyRu at 50 μM concentration in the PBS 
(saline phosphate buffer) solution, recorded at different times after dissolution (0→24 h). The red 
circle indicates the isosbestic point. 
 
In Figure 18 the absorbance evolution over time of AziRu under the same conditions is reported for 
comparison, showing its conversion into a species having a maximum at 349 nm (presumably, by 
analogy with the hydrolysis of NAMI-A, the mono-aquo complex), successively forming a species 
with a maximum at 305 nm (presumably, the di-aquo complex).
[147]
 
In analogy with AziRu, the presence of an isosbestic point is evident in Figure 17 for LipThyRu, 
indicating its transformation into another species within 3.5 h; unlike AziRu, in the saline phosphate 
buffer LipThyRu was transformed only into the monoaquo-complex and not into a diaquo-complex. 
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Figure 18. Overlapped UV-vis absorption spectra of AziRu at 50 μM conc. in the saline buffer 
recorded at different times after dissolution (0→45 h). The red circles indicate the isosbestic points. 
 
Reporting the A398 as a function of time (Figure 19) a half-life time (t1/2) of 2.5 h is obtained, almost 
3.3 times higher than that observed for AziRu (t1/2 for AziRu = 45 min
[147]
). The slower hydrolysis 
rate of LipThyRu is a clear evidence of the higher stability of the Ru complex when inserted into a 
nucleolipidic carrier. In summary, LipThyRu showed a slower hydrolysis kinetics than AziRu when 
analysed in a pseudo-physiological solution, confirming that the presence of the nucleolipid moiety 
decorating the Ru(III)-complex effectively protects it and retards the aquo-species formation. 
 
Figure 19. A398 values of LipThyRu as a function of the hydrolysis time in a saline phosphate 
buffer. 
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3. Synthesis and characterization of novel aminoacyllipidic Ru(III)-
complexes TUGluRu and TOTyroRu 
In order to expand the repertoire and chemical diversity of available amphiphilic Ru(III)-
complexes, we moved to the exploration of biocompatible scaffolds alternative to nucleosides to 
build novel multifunctional compounds. To this purpose we selected trifunctional α-amino acids to 
replace the central core of previously described nucleolipidic Ru(III)-complexes, however 
maintaining the same general design (Figure 9). In fact, these novel aminoacyl derivatives, as their 
nucleolipidic congeners, incorporate the active principle - i.e., the Ru(III)-complex - into 
multifunctional scaffolds carrying both hydrophilic and lipophilic portions, in principle able to self-
assemble in water to give stable aggregates, and thus obtain a suitable nanocarrier for in vivo 
delivery. 
In this optimization process, special attention has been paid to the simplification of the synthetic 
schemes, trying to reduce the number of purification steps and increase the overall yields, so to 
obtain the target Ru(III)-complexes in the large amounts required for future in vivo studies. 
 
Figure 20. Schematic representation of the general design exploited for the preparation of 
aminoacyllipidic Ru(III)-complexes. 
 
These novel molecules, described as aminoacyllipidic Ru(III)-complexes, share the general design 
represented in Figure 20, characterized by: 
 a natural trifunctional -amino acid, selected as the central scaffold; 
 a lipophilic group, to induce self-assembly in aqueous solutions and to improve cell uptake of 
the final compound through the membrane phospholipidic bilayers; 
 a triethylene glycol monomethyl ether residue as hydrophilic group. This decoration – as in the 
case of nucleolipidic Ru(III)-complexes - is expected to optimize the “hydrophilic/lipophilic 
balance” within the molecule and to increase its circulation time,[162] preventing extracellular 
chemo-enzymatic degradations. In addition, it is known to have ‘stealth properties’, masking the 
attached drug from immune system responses;
[163–165]
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 a pyridine-methyl arm, as the active Ru(III)-complex, inserted through formation of an amide 
bond with the aminoacyl core, expectedly stable in vivo. 
 
Following this general design, two aminoacyllipidic Ru(III)-complexes, named TUGluRu and 
TOTyroRu (Figure 21) - following the acronym taken from the main motifs present: Triethylene 
glycol-Undecenyl-Glutammic acid-Ruthenium salt and Triethylene glycol-Oleyl-Tyrosine-
Ruthenium salt, respectively - have been successfully synthesized and characterized using both 
spectroscopic (NMR and UV) and mass spectrometry techniques. 
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Figure 21. Structure of the novel amphiphilic aminoacyllipid Ru(III)-complexes here prepared. 
 
Following a scheme similar to the one exploited for the nucleolipidic Ru(III)-complexes, we have 
functionalized the central scaffold with different lipophilic and hydrophilic residues, inserted 
exploiting ester linkages, in vivo cleavable by cellular esterases. The choice of ester bonds as 
chemical linkages between the aminoacyl core scaffold and the functional appendage has been 
dictated by both synthetic and functional requirements: these groups are typically obtained easily 
and in high yields, are stable at neutral pH, but are susceptible of rapid hydrolysis within cells, due 
to the action of esterases. These cellular enzymes of the class of hydrolases are capable of cleaving 
the ester bonds in a non-specific manner, thus releasing a small molecular weight Ru-complex once 
internalized into the cell. 
The linker ensuring the attachment of the Ru(III)-complex is also in this design a pyridine 
derivative, selected as chelating ligand given the high affinity of ruthenium for nitrogen, introduced 
into the aminoacyl central scaffold through formation of an amide bond, expectedly stable in vivo. 
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For the preparation of the new aminoacyllipidic Ru(III)-complexes, commercially available 
derivatives of glutammic acid and tyrosine having the same set of protective groups have been 
selected as starting materials, so to handle a similar general synthetic procedure. 
In particular, we focused on protective groups selectively removable in an orthogonal manner, i.e. 
9-fluorenylmethoxycarbonyl (Fmoc) for the -NH2 group, and tert-butyl (tBu) for the side chain 
OH or COOH functions. Fmoc/tBu probably is the most popular “orthogonal” combination of 
protecting groups used for trifunctional -aminoacids, relying on the lability to bases of the -
amino protecting group Fmoc, and on the lability to acids of the side chain protecting group tBu 
ethers/esters. In the Fmoc/tBu strategy, 20 % piperidine in DMF is generally used as the basic 
solution to remove the Fmoc group and release the free -amino group, and 90% TFA to remove 
the tert-butyl group in the side chain. 
This orthogonal protecting group strategy is well established for the solid phase synthesis of 
peptides and peptidomimetics, but can be easily extended to our solution syntheses of novel 
aminoacyllipidic derivatives. 
In particular, the -amino acids here selected have a free, unprotected carboxylic acid group, on 
which the first functionalization reaction (with a lipophilic or a hydrophilic moiety, respectively in 
the case of TUGluRu and TOTyroRu) could be directly performed. Next, removal of the acid labile 
protecting group (tBu) in the side chain allowed performing a coupling of the free COOH or OH 
groups with a hydrophilic (for TUGluRu) or lipophilic (for TOTyroRu) moiety, respectively. 
Finally, after deprotection from the base labile Fmoc protecting group, the -NH2 function was 
exploited for the labeling with a pyridine-containing linker, necessary for successive Ru(III) 
complexation. 
In all the investigated cases, the decorations used for the preparation of the new aminoacyllipidic 
Ru(III)-complexes are commercially available compounds, which have been used as such, without 
further synthetic elaboration before use. For both TUGluRu and ToTyroRu triethylene glycol 
monomethyl ether (TEG-OMe) was used as hydrophilic decoration, already employed in ToThyRu 
and ToThyCholRu, for which the ability to self-assemble in water to give stable aggregates has 
been well proved. In particular, the TEG-OMe residue was introduced on the free carboxylic group 
of Fmoc-protected tyrosine in ToTyroRu and on the side chain carboxylic group of Fmoc-protected 
glutamic acid in TUGluRu. As the lipophilic components, we selected oleic acid for ToTyroRu - 
already tested in ToThyRu, HoThyRu and DoHuRu - inserting it on the phenolic OH in the side 
chain. In the case of TUGluRu, we labeled the free carboxylic COOH with 10-undecen-1-ol. This 
alcohol has been selected to investigate if, even using a shorter lipophilic chain than that of oleic 
acid, stable aggregates in water are still obtained. In addition, this functionalization, carrying a 
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terminal alkene, would also allow in principle the coupling with a thiol using a “thiol-ene” click 
chemistry strategy.
[179]
 Therefore, this type of lipid functionalization could be a powerful strategy to 
incorporate aminoacyllipidic Ru-complexes in nanoparticles or lipid-based platforms exposing a 
thiol functionality on their surface. This design - which will be explored in future studies - could 
improve the conveyance and stability of the drug in physiological environments. 
 
3.1. Results and discussion 
3.1.1. Synthesis and characterization of TUGluRu 
For the preparation of TUGluRu, the first step was the esterification of commercially available 
Fmoc-Glu(OtBu)-OH with 10-undecen-1-ol. The reaction was carried out under anhydrous 
conditions using a little excess of the starting amino acid with respect to the alcohol. HATU/DIPEA 
was selected as the best coupling system
[180]
 after several attempts with other activation methods 
(Scheme 3). Desired compound 9, isolated in 81 % yields after chromatographic purification on a 
silica gel column, was then treated with formic acid to remove the tert-butyl group. The mechanism 
of this deprotection is based on the release of the stable tert-butyl cation, which then rearranges 
forming isobutylene, a volatile compound which can be easily removed by coevaporating the 
reaction mixture with dry CH3CN. The reaction went to completion in 2.5 h and, after this simple 
work-up, compound 10 could be recovered as a pure species in almost quantitative yields. 
Successively, the COOH group in the side chain of 10 was coupled with TEG-OMe, previously 
coevaporated several times with dry CH3CN, using HATU/DIPEA as condensing system under 
anhydrous conditions, yielding compound 11 in 66 % yields after chromatographic purification. 
This derivative was then treated with a 10 % piperidine solution in CH3CN to remove the Fmoc 
protecting group and release the free -amino group. Amino diester 12, obtained in almost 
quantitative yields from TLC analysis of the reaction mixture, was directly reacted, as a crude, with 
4-pyridylacetic acid under dry conditions – using HATU/DIPEA as a coupling system – to obtain 
the final aminoacyllipid derivative 13. 
Desired compound 13 was obtained in 50 % yields (calculated for the two steps, i.e. Fmoc removal 
and 4-pyridyl acetic acid coupling) after chromatographic purification on a silica gel column. This 
compound was not stable in solution and decomposed over time, partially losing the TEG-OMe 
residue (probably due to an intramolecular attack of the pyridine ring on the carboxylylate group, 
which promotes the detachment of the TEG-OMe residue forming a stable six-atom cyclic 
intermediate). Therefore, in order to perform the last reaction, 13 was further purified and then 
immediately reacted with the Ru(III) salt to obtain the final target compound TUGluRu. The 
reaction was performed using a stoichiometric amount of Na
+
 [trans-RuCl4(DMSO)2]
-
 salt, 
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synthesized according to reported procedures
[106,177]
 (see paragraph 5). The reaction mixture was 
left under stirring at 40 °C. After 30 h, TLC monitoring showed the formation of a new product, 
attributed to the desired TUGluRu, recovered as a pure compound by solvent removal under 
reduced pressure (Scheme 3). 
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Scheme 3. Synthetic procedure for the preparation of the target aminoacyllipid Ru(III)-based 
complex TUGluRu. 
 
Following this synthetic scheme, the final aminoacyllipidic Ru(III)-complex TUGluRu was 
obtained in 6 steps and 27 % overall yields. The characterization of all the synthetic intermediates 
and of final TUGluRu has been carried out by NMR spectroscopy and MS spectrometry, which in 
all cases confirmed the identity and purity of the target compounds. The signals observed in the 
1
H 
NMR spectrum of TUGluRu (Figure 22) were particularly diagnostic of the effective complex 
formation, with a dramatic upfield shift and a broadening of the protonic signals of pyridine and 
dimethyl sulfoxide, found at  = - 0.90 and  = -9.51 ppm, respectively. 
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Figure 22. Upfield region expansion of the 
1
H NMR spectrum of TUGluRu [400 MHz, (CD3)2CO]. 
 
The ESI-MS spectrum of TUGluRu, recorded in positive ions mode, did not show the m/z signal 
corresponding to the molecular ion, but clusters of signals with the typical isotopic pattern of 
ruthenium were observed. In particular, as shown in Figure 23, the adduct with sodium (M+Na
+
) 
was found together with other m/z values attributable to ligand exchange species, i.e. (M-2Cl
-
+2H2O) and (M-Cl
-
+H2O). 
 
Figure 23. ESI-TOF (positive ions) mass spectrum of TUGluRu. 
 
3.1.2. Synthesis and characterization of TOTyroRu 
The synthetic strategy to obtain the aminoacyllipid Ru(III)-complex TOTyroRu is similar to the one 
previously described to obtain TUGluRu (see paragraph 3.1.1). The only difference resides in the 
functionalization of the phenolic OH group in the side chain, for which the best results were 
obtained using a Mitsunobu reaction.
[181]
 
As starting material, the commercially available Fmoc-Tyr(tBu)-OH was selected. Its coupling with 
the alcohol TEG-OMe using the system HATU/DIPEA as condensing agent gave desired 
compound 14 (Scheme 4), recovered in 96 % yields after column chromatography. The successive 
deprotection of the phenol group in the side chain was obtained treating compound 14 with formic 
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acid, affording desired compound 15 in almost quantitative yields and in pure form simply 
removing the volatile by-product isobutylene through coevaporation with dry CH3CN. 
Successively, the deprotected phenol OH of tyrosine was reacted with oleic acid to obtain the 
corresponding phenyl ester. First experiments were carried out condensing derivative 15 with oleic 
acid in the presence of the system HATU/DIPEA as coupling agent. Nevertheless, this reaction 
proved to be troublesome, providing the desired compound only after a prolonged reaction time (48 
h) under heating, and in low yields. Unfortunately, also testing different conditions, our attempts did 
not result in a significant yield enhancement, due to the low nucleophilicity of phenolic OH groups. 
Thus, we were intrigued by the possible application of the Mitsunobu reaction to construct the 
desired C-O bond and provide phenyl ester 16. Indeed, various protocols based on the Mitsunobu 
reaction
[182]
 have been developed for the coupling of alcohols with phenols, amines or carboxylic 
acids. Hence, we exploited this synthetic strategy, screening a variety of reaction conditions. The 
best results were obtained on reacting pure compound 15, oleic acid (1 eq.) and triphenylphosphine 
(2 eq.) – previously coevaporated three times with dry CH3CN – in dry THF under stirring at r.t. for 
10 min. Then DEAD (2 eq.) was added dropwise and the reaction mixture heated at 65 °C under 
argon atmosphere. After 24 h, TLC analysis showed the appearance of a new product in the mixture 
and the reaction was quenched by solvent removal in vacuo. The resulting white precipitate of 
triphenylphosphine oxide was filtered off and the solution was then purified by column 
chromatography, affording desired compound 16 in 38 % yield. Pure compound 16 was 
successively treated with a 10 % piperidine solution in dry CH3CN under argon atmosphere. The 
obtained free amine 17 was not isolated, but directly treated with 4-pyridylacetic acid in the 
presence of HATU and DIPEA in anhydrous conditions, so to obtain the final aminoacyllipid 18. 
After 17 h, TLC monitoring showed the complete disappearance of the starting materials and the 
reaction was quenched by taking the mixture to dryness. After work-up, the crude product was 
purified by column chromatography. The desired compound 18 was obtained in 54 % yields, 
calculated for two subsequent steps, i.e. Fmoc removal and coupling with 4-pyridylacetic acid. 
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Scheme 4. Synthetic procedure for the preparation of the target aminoacyllipidic Ru(III)-complex 
TOTyroRu. 
 
The last step of this synthesis was a ligand exchange reaction with a precursor ruthenium salt, 
prepared using reported procedures
[106,177]
 (see paragraph 5), in which pure compound 18 was 
treated with stoichiometric amount of Na
+
 [trans-RuCl4(DMSO)2]
-
 at 40 °C for 30 h (Scheme 4). 
After solvent removal in vacuo, TOTyroRu was recovered as a pure compound in almost 
quantitative yields. 
Following this synthetic scheme, the final aminoacyllipid Ru(III)-complex TOTyroRu was obtained 
in 6 steps and 20 % overall yields. All the synthetic intermediates and the final ruthenium complex 
have been characterized by NMR spectroscopy and mass spectrometry. In particular, as already 
observed for TUGluRu, the 
1
H NMR spectrum of TOTyroRu (Figure 24) showed broadened 
signals, attributable to the presence of the paramagnetic Ru(III) ion. In addition, a dramatic upfield 
shift of the protonic signals of pyridine and DMSO, to  = -1.48 ppm, and  = -9.18 ppm, 
respectively, was observed, particularly diagnostic of the effective complex formation.
[81,178]
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Figure 24. Upfield region expansion of the 
1
H NMR spectrum of TOTyroRu [400 MHz, CDCl3]. 
 
The ESI-MS analysis of TOTyroRu, carried out in the positive ions mode, did not show the m/z 
signals corresponding to the target compound. However, a cluster of signals with the typical 
isotopic pattern of ruthenium have been observed having m/z values attributable to the ligand 
exchange species M-Cl
-
+H2O. (Figure 25). This value is attributable to the aquo-complex of the 
desired Ru(III) derivative, obtained after a single hydrolysis event. This undesired process, 
however, can be presumably obtained during the LC-MS experiments, requiring a prolonged 
contact with the elution aq. solutions, and appears therefore as a MS artefact rather than an effective 
degradation of the target compound. 
 
Figure 25. ESI-TOF (positive ions) mass spectrum of TOTyroRu. 
 
3.1.3. UV-vis studies: absorbance spectra of TUGluRu 
The solution behaviour of the new complex TUGluRu was first of all analysed by UV-vis 
absorbance. Thus, the UV-vis spectrum of TUGluRu was recorded at 100 μM concentration in 
DMSO, and compared with those of AziRu[147] and Na+ [trans-RuCl4(DMSO)2]
-
 under the same 
conditions (Figure 26). 
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Figure 26. Overlapped UV-vis absorption spectra of Na
+
 [trans-RuCl4(DMSO)2], TUGluRu and 
AziRu (from samples freshly dissolved at 100 μM concentration in DMSO). 
 
The UV-vis spectrum of TUGluRu showed the characteristic band centred at 411 nm, relative to the 
ligand-to-metal charge transfer transition (LMCT) for the Ru–Cl bond, in addition to overlapped 
bands in the region 250-350 nm, which can be attributed to the metal, pyridine and thymidine 
absorptions. Comparing the UV-vis spectra of TUGluRu and AziRu, the similarity of the band at ca. 
400 nm confirmed the same ligands arrangement around the Ru(III) core. Interestingly, this band is 
slightly blue-shifted with respect to the salt Na
+
 [trans-RuCl4(DMSO)2]
-
 – precursor of both AziRu 
and TUGluRu – having DMSO as apical ligand in lieu of pyridine (Figure 26). 
 
3.1.4. UV-vis-monitored hydrolysis of TUGluRu in a saline phosphate buffer 
The hydrolysis of TUGluRu was monitored by UV-vis analysis over time in a saline phosphate 
solution buffered at pH = 7.3 so to mimic pseudo-physiological conditions. The absorption spectra 
showed a band centred at 392 nm, attributed to the LMCT, which gradually diminished over time 
disappearing in ca. 3.5 h (Figure 27). In Figure 18 (paragraph 2.1.3.) the absorbance evolution with 
time of AziRu under the same conditions showed its conversion into a species having a maximum at 
349 nm (presumably, by analogy with the hydrolysis of NAMI-A, the mono-aquo complex), 
successively forming a species with a maximum at 305 nm (presumably, the di-aquo complex). In 
the case of TUGluRu, the band at 392 nm gradually decreased over time with the concomitant 
emergence of a new band at 347 nm after 1 h, which reached its highest value after 3.5 h and then 
started decreasing (Figure 27). Unlike AziRu, in the saline phosphate buffer TUGluRu was only 
transformed into the monoaquo-complex and did not produce a diaquo-complex. A concomitant 
decrease of the absorbance intensity in the region 250-300 nm was also observed (Figure 27). 
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Figure 27. Overlapped UV-vis absorption spectra of TUGluRu at 50 μM concentration in the saline 
phosphate buffer, recorded at different times after dissolution (0→3.5 h). The red circle indicates 
the isosbestic point. 
 
In analogy with AziRu, the presence of an isosbestic point is evident in Figure 27 for TUGluRu, 
indicating its transformation into another species during the initial 3.5 h monitoring. Reporting the 
A392 as a function of time (Figure 28) a t1/2 = 105 min is obtained, almost twice higher than observed 
for AziRu (t1/2 for AziRu = 45 min). In the time interval 4-72 h an overall raising of the spectrum 
baseline was observed, associated with scattering phenomena due to the probable formation of 
aggregates. In summary, TUGluRu showed a slower hydrolysis kinetics than AziRu when analysed 
in a pseudo-physiological solution, confirming that the presence of the aminoacyllipid moiety 
decorating the Ru(III)-complex effectively protects it and retards aquo-species formation. 
 
Figure 28. A392 values of TUGluRu as a function of the hydrolysis time in a phosphate buffer.  
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4. Synthesis and characterization of a new Ru(III)-complex, PySSRu, 
carrying a disulfide bridge 
In addition to amphiphilic Ru(III)-complexes, also a new AziRu analog was here prepared, named 
PySSRu, characterized by a disulfide bridge. In analogy with the design chosen for LipThyRu, this 
moiety is finalized to anchoring the Ru(III)-based complex onto gold surfaces (e.g., electrodes) in 
order to study the properties and oxidation kinetics of AziRu-like ruthenium derivatives through 
combined techniques, including cyclic voltammetry and Raman spectroscopy. The immobilization 
onto gold platforms can be realized exploiting the high affinity of sulphur for gold, leading to the 
formation of a stable covalent bond. 
The synthetic procedure adopted for the preparation of PySSRu employs simple manipulations and 
easily available starting materials; with the target PySSRu complex obtained in three reaction steps. 
Starting from commercially available 2-(4-pyridinyl)ethanethiol hydrochloride, an acid–base 
reaction was first performed to convert the hydrochloride salt into 2-(4-pyridinyl)ethanethiol. 
Taking into account the pKa values of the pyridinium ion (pKa ca. 5) and the thiol group (pKa ca. 
8-9), addition of a base in stoichiometric amount leads to the deprotonation of the pyridinium ion as 
the exclusive event under the experimental conditions tested. 
N
SH
N
S S
NNH+
SH
NaOH, MeOH
30 min, r.t. 1 h, r.t.
H2O2, KI, MeOH
Cl-
S
Ru
S
Cl Cl
Cl Cl
O
O
-
Na+
Acetone, 2 h, r.t.
PySH PySSPy
PySSRu
N
S S
N
Ru Ru
Cl Cl
Cl Cl
S S
O O
2Na+
2-
Cl Cl
Cl Cl
 
Scheme 5. Synthetic procedure for the preparation of the target compound PySSRu. 
Chapter 2 
42 
 
The conversion to the desired 2-(pyridin-4-yl)ethanethiol (here called PySH) was thus obtained by 
addition of 1 eq. of NaOH in MeOH according to Scheme 5, monitored by pH measurements until 
neutral pH was achieved, indicating that the reaction was complete. Then the solvent was removed 
in vacuo and the crude product extracted with CH2Cl2/H2O. The extraction - necessary to remove 
NaCl formed during the neutralization reaction - provided pure compound 19 as a yellow oil in 82 
% isolated yields.  
PySH could not be used for the complexation reaction with the ruthenium salt. Indeed, first of all 
thiolates are able to strongly coordinate metal ions (including ruthenium) and form stable transition 
metal-thiolate complexes. Then, thiols can reduce Ru(III) to Ru(II): experimental evidences 
indicated that the reaction between PySH and the precursor ruthenium salt cannot be realized 
preserving Ru in its +3 oxidation state. In fact, the reaction mixture immediately turned from dark 
red to green, diagnostic of the reduction of Ru(III) to Ru(II). Therefore, it was necessary to convert 
first the thiol group of PySH to disulfide, using a reported oxidation procedure,
[183]
 involving the 
treatment with hydrogen peroxide (30 wt. % in H2O solution) as co-oxidant agent, and potassium 
iodide as catalyst (Scheme 5). The desired compound 20 (PySSPy) was recovered in almost 
quantitative yields after standard work-up with CH2Cl2/H2O. 
The last step (Scheme 5) is the ligand exchange reaction with the precursor ruthenium salt Na
+
 
[trans-RuCl4(DMSO)2]
-
, prepared using reported procedures.
[106,177]
 After 2 h, TLC analysis showed 
the formation of a new product, corresponding to the desired ruthenium complex, with the 
concomitant complete disappearance of both the starting materials. PySSRu was recovered in 75 % 
yields after solvent removal under reduced pressure and subsequent precipitation/centrifugation 
steps from CH2Cl2 solutions. 
 
Figure 29. 
1
H NMR spectrum of PySSPy (400 MHz, CDCl3). 
 
Chapter 2 
43 
 
 
Figure 30. 
13
C NMR spectrum of PySSPy (100 MHz, CDCl3). 
 
Following this synthetic scheme, the final PySSRu complex was obtained in 3 steps and 62 % 
overall yields. The identity of the target compounds was then confirmed by 
1
H and 
13
C NMR 
spectroscopy and mass spectrometry data (Figures 29-32). 
 
Figure 31. MALDI-TOF spectrum (positive ions) of PySSPy. 
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Figure 32. Upfield region expansion of the 
1
H NMR spectrum of PySSRu (400 MHz, DMSO-d6). 
 
In analogy with AziRu and all the nucleolipidic and aminoacyllipidic Ru(III)-complexes previously 
described, the 
1
H-NMR spectrum of PySSRu was particularly diagnostic of the effective Ru(III)-
complex formation,
[81,178]
 with the protonic signals of pyridine and dimethyl sulfoxide at δ = -2.4 
and δ = -13.0 ppm, respectively (Figure 32). In addition, in the 7-8 ppm region, free protonic signals 
of pyridine were not present, demonstrating that the complexation of both pyridine ligands with the 
ruthenium ion was quantitative. 
As a further spectroscopic characterization, the UV and IR spectra of the synthesized compounds 
were recorded. In particular, UV analysis of PySH, PySSPy and final PySSRu complex (Figure 33) 
was performed on freshly dissolved samples in CH3CN at 100 μM final concentration. Both PySH 
and PySSPy compounds showed a main absorption band centred at 256 nm.  
 
Figure 33. Overlapped UV-vis absorption spectra of the compounds indicated in the legend, from 
samples freshly dissolved at 100 μM concentration in CH3CN. 
 
On the contrary, the UV-vis absorption spectrum of the final PySSRu complex showed the 
characteristic band of Ru(III) ion at 398 nm - attributable to the ligand-to-metal charge transfer 
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transition (LMCT) for the Ru-Cl bond - as well as a band centred at 296 nm, attributed to 
Ru(III)
[106]
 as well as to pyridine portions. Comparing the UV-vis spectra of PySSRu and that 
reported for AziRu,
[147]
 the similarity of their bands at ca. 400 nm confirmed the same ligands 
arrangement around the Ru(III) ion. 
 
Figure 34. IR spectrum of PySSPy. 
 
 
Figure 35. IR spectrum of PySSRu.  
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5. Synthesis and characterization of the precursor ruthenium salts 
The ruthenium complex Na
+
 [trans-RuCl4(DMSO)2]
˗
, or sodium trans-bis(dimethyl sulfoxide) 
tetrachlororuthenate(III), was synthesized using reported procedures
[106,177]
 starting from ruthenium 
trichloride, as follows. 
The commercial hydrated RuCl3 was first partially dissolved in DMSO and then 37 % aqueous HCl 
was added. The mixture was left at 80 °C under vigorous stirring for 20 min, until complete 
dissolution of RuCl3. The dense and deep dark solution was then heated at 100 °C for 10 min, 
gradually turning colour to bright dark red. After cooling, acetone was added and the solution was 
left at 4 °C overnight to favour precipitation. Dark-red crystals were obtained; these were filtered 
off, then washed with cold acetone and diethyl ether, and vacuum-dried (Scheme 6). 
 
Scheme 6. Synthetic procedure for the preparation of [(DMSO)2H]
+
 [trans-[Ru(DMSO)2Cl4]
-
 (21) 
and Na
+
 [trans-RuCl4(DMSO)2]
-
 (22) salts starting from commercially available RuCl3, as reported 
by Attia et al.
[106,177]
 On the right, pictures of samples of the two salts. 
 
Compound 21, i.e. hydrogen trans-bis(dimethylsulfoxide)tetrachlororuthenate(III) or [(DMSO)2H]
+
 
[trans-[Ru(DMSO)2Cl4]
-
, was obtained in 60 % yields. In this complex, the Ru(III) ion is 
coordinated to four chlorides in equatorial positions and two DMSO molecules – through the sulfur 
atom – in apical positions; (DMSO)2H
+
 is the cationic counterion. 
Afterwards, finely ground [(DMSO)2H]
+
 [trans-[Ru(DMSO)2Cl4]
-
 was dissolved in a mixture of 
ethanol and water and then aqueous NaCl solution was added (Scheme 6). 
The desired compound rapidly precipitated as light-orange microcrystals, which were filtered, 
washed with cold ethanol and diethyl ether, and vacuum-dried. In this reaction a change of 
counterion was realized. Compound 22, i.e. Na
+
 [trans-RuCl4(DMSO)2]
˗
, obtained in 86 % yields, 
RuCl3    H2O
DMSO, HCl 37 %
80 °C - 100 °C
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was used in the synthesis of all Ru(III)-complexes described before (paragraphs 2 for LipThyRu, 3 
for TUGluRu and TOTyroRu and 4 for PySSRu). 
Both Ru(III)-salts 21 and 22 were characterized using spectroscopic techniques (NMR, UV-vis and 
IR) and melting point measurements. 
The 
1
H NMR spectra of [(DMSO)2H]
+
 [trans-[Ru(DMSO)2Cl4]
-
 and of Na
+
 [trans-RuCl4(DMSO)2]
-
 
are shown in Figure 36 and 37, respectively. The paramagnetic Ru(III) nucleus severely shifts and 
broadens the NMR signals of coordinated ligands, not allowing a standard assignment procedure. 
 
Figure 36. Upfield region expansion of the 
1
H NMR spectrum of compound 21 [400 MHz, 
(CD3)2CO]. 
 
 
Figure 37. Upfield region expansion of the 
1
H NMR spectrum of compound 22 [400 MHz, 
(CD3)2CO]. 
 
In both 
1
H spectra, a characteristic broad peak of the S-coordinated protonic signals of DMSO is 
observed in the upfield region, diagnostic of a direct binding to the paramagnetic Ru(III) ion, in 
agreement with literature data
[81,106,177,178]
. Furthermore, in Figure 36 the presence of two significant 
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signals at positive δ, related to the cationic counterion (DMSO)2H
+
,
 
is evident; interestingly, these 
signals disappear in the spectrum of compound 22 (Figure 37), in which Na
+
 is the counterion. 
Melting point measurements for 21 and 22 were in good agreement with the values reported in 
literature
[177]
. Indeed, for compound 21 a melting range of 118-121 °C was found. For compound 
22, a slow and gradual thermal decomposition was found at high temperatures (>230 °C), in 
agreement with literature data (235 °C). 
Also FTIR-ATR spectra were performed, obtaining signals in agreement with those reported in 
literature
[106,177]
. Since the FTIR-ATR spectra of ruthenium salts 21 and 22 were very similar, in 
Figure 38 only the spectrum of compound 21 was representatively shown. 
 
Figure 38. FTIR-ATR spectrum: vibrational frequencies (cm
-1
) for the main absorption band of 
compound 21, i.e. [(DMSO)2H]
+
 [trans-[Ru(DMSO)2Cl4]
-
 (δ = deformation; ν = stretching; ρ = 
rocking). 
 
[(DMSO)2H]
+
 [trans-[Ru(DMSO)2Cl4]
-
 and Na
+
 [trans-RuCl4(DMSO)2]
-
 were further characterized 
by UV-vis spectroscopy. These compounds were analysed as freshly dissolved 100 μM solutions in 
DMSO (Figure 39). The UV-vis absorption spectra showed the characteristic band of Ru(III) ion at 
421 nm, attributable to the ligand-to-metal charge transfer transition (LMCT) for the Ru-Cl bond, as 
well as a band centred at 272 nm, which can be attributed to Ru(III).
[106,177]
 The strong similarity of 
these spectra confirmed for both systems the same arrangement and type of ligands around the 
ruthenium atom. 
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Figure 39. Overlapped UV-vis absorption spectra of compounds [(DMSO)2H] 
+
 [trans-
[Ru(DMSO)2Cl4]
-
 (21) and Na
+
 [trans-RuCl4(DMSO)2]
-
 (22), from samples freshly dissolved at 100 
μM concentration in DMSO. 
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6. Experimental section 
 Materials and general methods 
All the reagents and solvents were of the highest commercially available quality and were used as 
received; where anhydrous conditions were required, coevaporations with dry CH3CN were 
performed before use. All the esterification reactions were carried out in the presence of activated 
molecular sieves and under argon atmosphere. TLC analyses were carried out on silica gel plates 
from Macherey-Nagel (60, F254). Reaction products on TLC plates were visualized by UV-light 
and then by treatment with an oxidant acidic solution (acetic acid / water / sulfuric acid, 10:4:5, 
v/v). For the column chromatography purifications, silica gel from Macherey-Nagel (Kieselgel 60, 
0.063-0.200 mm) was used. 
NMR spectra were recorded on Bruker WM-400, Varian Gemini 200 and Varian Inova 500 
spectrometers, as specified. All the chemical shifts (δ) are expressed in ppm with respect to the 
residual solvent signal both for 
1
H NMR [CDCl3 = 7.26 ppm, (CD3)2CO = 2.05 ppm, MeOD = 3.31 
ppm, DMSO-d6= 2.50 ppm] and 
13
C NMR (CDCl3 = 76.9 ppm, MeOD = 49.1 ppm). All the 
coupling constants (J) are quoted in Hertz (Hz). Peaks assignments were carried out based on 
standard 
1
H-
1
H COSY and HSQC experiments. The following abbreviations were used to explain 
the multiplicities: s = singlet; d = doublet; t = triplet; q = quartet; m = multiplet; b = broad. 
In order to easily identify the proton and carbon signals of the compounds, letters and numbers were 
assigned to their structures; in particular, in TUGluRu and TOTyroRu derivatives the Fmoc group 
was identified with the letters “a-h” starting from the oxygen of the carbamic group. The side chain 
of the amino acid was indicated with progressive numbers starting from the CH-α, to which number 
2 was assigned. Then, the lipophilic components (10-undecen-1-ol in TUGluRu and oleic acid in 
TOTyroRu) were indicated with progressive numbers (1’-11’ or 2’-18’, according to the carbon 
chain length) starting from the ester oxygen or carbonyl group, respectively. Finally, the numbers 
1’’-7’’ were assigned to the protons and carbons of the hydrophilic residue of TEG-OMe, starting 
from the ester oxygen. 
For the ESI-MS analyses, a Waters Micromass ZQ instrument - equipped with an Electrospray 
source - was used in the positive and/or negative mode. 
MALDI-TOF mass spectrometric analyses were performed on a TOF/TOF™ 5800 System in the 
positive mode, using 2,5-dihydroxybenzoic acid (DHB) as the matrix. For the deposition on 
MALDI plate, the droplet spotting method was used: the sample - 1 μg/μL in CH3CN/MeOH, 7:3 
(v/v) - was first deposited on the plate followed by DHB deposition - 10 mg/mL in CH3CN/MeOH, 
7:3 (v/v) - and proper mixing before drying the components. The mass spectra were recorded in the 
range 100-1000 m/z values. 
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LC-MS analyses were performed on an Agilent 6230B TOF LC/MS instrument, equipped with a 
1260 Infinity HPLC analytical system with binary pump coupled with a 6230 time of flight mass 
spectrometer as detector and an Electrospray source; an Agilent ZORBAX C18 column (1.8 µm, 50 
x 4.6 mm) for reverse phase liquid chromatography was used. Stock solutions of the samples were 
prepared at 2 mg/mL concentration in CH3CN, HPLC grade. The injections were carried out at the 
final concentration of 4 ng/μL in CH3CN/H2O (1:1, v/v), using a flow rate of 0.4 mL/min. Column 
elution was performed using H2O (A) and CH3CN (B) as eluents; a gradient elution, starting from 5 
% B in A and increasing B to 95 % over 5 min, was followed by an isocratic elution at 95 % B in A 
for 3 min. The ESI/TOF-MS was operated in positive and/or negative ion mode (100-1500 m/z 
values). 
The UV-vis measurements were performed on a JASCO V-530 UV-vis spectrophotometer 
equipped with Peltier Thermostat JASCO ETC-505T, by using 1 cm path length cuvette. The 
spectra were recorded at r.t. in the range 200-600 nm with a medium response, a scanning speed of 
100 nm/min and a 2.0 nm bandwidth with the appropriate baseline subtracted. 
All the spectra were averaged over 3 scans and each experiment performed in triplicate. All the 
target compounds were analysed from samples freshly dissolved at 100 μM concentration in 
CH3CN or DMSO or at 50 μM concentration in a saline buffered solution (10 mM phosphate 
buffer/100 mM NaCl pH = 7.3). 
The analysis of crystals was carried out on Zeiss Axioskop (Optical microscope), equipped with 
FP82HT Melting Point Systems used for melting point measurements. 
For PySSPy and PySSRu, IR spectra were obtained on a Jasco FTIR-4100 spectrometer in the range 
4000-400 cm
-1
. For the ruthenium salts 21 and 22, IR spectra were obtained on a Nicolet 5700 FT-
IR spectrometer. The solid-state spectra were recorded in the range 1500-500 cm
-1
. The following 
abbreviations were used: δ = deformation; ν = stretching; ρ = rocking; m = medium; w = weak; s = 
strong; br = broad. 
 
 Synthesis and characterization of LipThyRu 
Synthesis of 3-(4-pyridylmethyl)-5’-O-(4,4′-dimethoxytriphenylmethyl)-thymidine (2) 
5’-O-(4,4′-dimethoxytriphenylmethyl)thymidine 1 (121 mg, 0.22 mmol) was dissolved in 8 mL of 
dry DMF. K2CO3 (92.0 mg, 0.67 mmol) and 4-(bromomethyl)pyridine hydrobromide (84.2 mg, 
0.33 mmol) were then added to the reaction mixture, left at 60 °C under stirring. After 4 d, TLC 
analysis indicated the presence of the desired product and the reaction was quenched by removing 
the solvent under reduced pressure. First, an extraction CH2Cl2/H2O was performed to remove the 
excess reagents. Then, the crude product was purified by chromatography on a silica gel column 
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using AcOEt/MeOH (97:3, v/v, containing 2 % of TEA), as eluent, giving desired compound 2 in 
59 % yield (82.5 mg, 0.13 mmol). 
2: oil. Rf = 0.7 (AcOEt/MeOH, 95:5, v/v). 
1
H NMR (400 MHz, CDCl3): δ 8.44 (d, J = 5.2, 2H, 2x Hα Py); 7.56 (s, 1H, H-6); 7.34 (d, J = 7.4, 
2H, 2x Hβ Py); 7.35-7.25 (overlapped signals, 9H, aromatic protons of DMT); 6.77 (d, J = 8.7, 4H, 
4 aromatic protons of DMT), 6.35 (t, J = 7.4 and 6.7, 1H, H-1'); 5.05 (s, 2H, -CH2Py); 4.52 (m, 1H, 
H-3'); 4.06 (m, 1H, H-4'); 3.72 [s, 6H, 2x (-OCH3) of DMT group]; 3.52-3.40 (m, 2H, H2-5'); 2.50-
2.29 (m, 2H, H-2'); 1.43 (s, 3H, CH3-Thy). 
13
C NMR (100 MHz, CDCl3): δ 163.0 (C-4 Thy); 158.4, 144.0, 133.8, 127.9, 127.0 and 113.2 
(aromatic carbons of DMT); 150.8 (C-2 Thy); 149.8 (2x Cα Py); 145.3 (Cγ Py); 135.0 (C-6 Thy); 
123.4 (2x Cβ Py); 110.7 (C-5 Thy); 87.0 (quaternary carbon of DMT); 85.0 (C-1'); 84.0 (C-4'); 74.8 
(C-3'); 63.5 (C-5'); 55.1 [2x (OCH3) of DMT]; 43.4 (-CH2Py); 37.9 (C-2'); 12.2 (CH3-Thy). 
 
Synthesis of 3-(4-pyridylmethyl)-3’-O-lipoyl-5’-O-(4,4′-dimethoxytriphenylmethyl)- 
thymidine (3) 
Alkylated compound 2 (70.0 mg, 0.11 mmol) was dissolved in 2 mL of dry CH2Cl2 and then 
DMAP (40.0 mg, 0.33 mmol), lipoic acid (34.0 mg, 0.16 mmol) and DCC (68.0 mg, 0.33 mmol) 
were sequentially added. After stirring for 2 h at r.t., TLC analysis indicated the complete 
disappearance of the starting materials. Thus, the reaction mixture was concentrated under reduced 
pressure; the crude product was purified by chromatography on a silica gel column using 
CHCl3/MeOH (95:5, v/v, containing 2 % of TEA) as eluent, providing desired compound 3 in 77 % 
yield (66.0 mg, 0.08 mmol). 
3: oil. Rf = 0.8 (AcOEt/MeOH, 95:5, v/v). 
1
H NMR (400 MHz, CDCl3): δ 8.53 (d, J = 5.2, 2H, 2x Hα Py); 7.67 (s, 1H, H-6); 7.39-7.28 
(overlapped signals, 11H, 2x Hβ Py and 9 aromatic protons of DMT); 6.85 (d, J = 8.7, 4H, 4 
aromatic protons of DMT); 6.45 (dd, J = 7.4 and 6.7, 1H, H-1'); 5.45 (m, 1H, H-3'); 5.12 (s, 2H, -
CH2Py); 4.11 (m, 1H, H-4'); 3.80 [s, 6H, 2x (-OCH3) of DMT]; 3.58 (m, 1H, CH-S); 3.49 (m, 2H, 
H2-5'); 3.23-3.11 (m, 2H, CH2-S); 2.50-2.46 (m, 3H, H2-2' and CH2a-CH2-S); 2.35 (t, J = 7.4, 2H, -
CH2-C=O lipoic residue); 1.95-1.90 (m, 1H, CH2b-CH2-S); 1.73-1.46 (m, 6H, 3x CH2 lipoic 
residue); 1.42 (s, 3H, CH3-Thy). 
13
C NMR (100 MHz, CDCl3): δ 172.6 (C=O lipoic ester); 163.0 (C-4 Thy); 158.6, 133.8, 129.9, 
127.9, 127.8, 127.0 and 113.2 (aromatic carbons of DMT); 150.8 (C-2 Thy); 149.8 (2x Cα Py); 
145.3 (Cγ Py); 135.1 (C-6 Thy); 123.3 (2x Cβ Py); 110.7 (C-5 Thy); 87.0 (quaternary carbon of 
DMT); 85.0 (C-1'); 83.9 (C-4'); 75.0 (C-3'); 63.5 (C-5'); 56.1 (CH-S); 55.1 [2x (OCH3) of DMT]; 
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43.4 (-CH2Py); 40.0 (CH2-S); 38.3 (CH2-C=O lipoic residue); 37.9 (C-2'); 34.7, 28.5, 26.1, 24.5 
(overlapped signals, 4 aliphatic carbons of lipoic residue); 12.2 (CH3-Thy). 
ESI-MS (positive ions): calculated for C45H49N3O8S2, 823.3; found m/z: 862.49 [M+K
+
]. 
 
Synthesis of 3-(4-pyridylmethyl)-3’-O-lipoyl-thymidine (4) 
Compound 3 (237 mg, 0.29 mmol) was dissolved in 2 mL of a 1 % TCA solution in CH2Cl2. Upon 
addition of the acid, the reaction mixture acquired an intense yellow-orange colour, typical of the 
trityl cation, and was left under stirring at r.t.. After 1 h, TLC monitoring showed the complete 
disappearance of the starting compound. Thus the reaction was quenched by adding few drops of 
MeOH until complete decoloration, and finally TEA was added to neutralize the solution. Then the 
reaction mixture was concentrated in vacuo and purified by chromatography on a silica gel column 
eluted with CHCl3/MeOH (99:1, v/v), giving the desired compound 4 in almost quantitative yields 
(155 mg, 0.29 mmol). 
4: yellow oil. Rf = 0.4 (CHCl3/MeOH, 95:5, v/v). 
1
H NMR (400 MHz, CDCl3,): δ 8.52 (d, J = 5.2, 2H, 2x Hα Py); 7.65 (s, 1H, H-6); 7.35 (d, 2H, 2x 
Hβ Py); 6.34 (dd, J = 7.4 and 6.7, 1H, H-1'); 5.37 (m, 1H, H-3'); 5.12 (s, 2H, -CH2Py); 4.10 (m, 1H, 
H-4'); 3.93 (m, 2H, H2-5'); 3.59 (m, 1H, CH-S); 3.22-3.12 (m, 2H, CH2-S); 2.48 (m, 1H, CH2a-
CH2-S); 2.40-2.32 (m, 4H, H2-2', CH2-C=O lipoic residue); 1.92 (m, 1H, CH2b-CH2-S); 1.68 (m, 
4H, 2x CH2 lipoic residue); 1.49 (m, 2H, CH2-CH-S); 1.42 (s, 3H, CH3-Thy). 
13
C NMR (100 MHz, CDCl3): δ 171.9 (C=O lipoic ester); 164.5.0 (C-4 Thy); 148.7 (2x Cα Py); 
144.5 (C-2 Thy); 133.7 (Cγ Py); 122.3 (2x Cβ Py); 113.7 (C-6 Thy); 109.4 (C-5 Thy); 85.2 (C-1'); 
84.2 (C-4'); 73.7 (C-3'); 61.3 (C-5'); 56.1(CH-S); 43.4 (-CH2Py); 40.1 (CH2-S); 38.3 (CH2-C=O 
lipoic residue); 37.9 (C-2'); 34.7-24.5 (overlapped signals, 4 aliphatic carbons of lipoic residue); 
12.2 (CH3-Thy). 
ESI-MS (positive ions): calculated for C24H31N3O6S2, 521.17; found m/z: 522.34 [M+H
+
]; 972.38 
[M+K
+
]. 
 
Synthesis of 3-(4-pyridylmethyl)-3’-O-lipoyl-5’-O-(benzyloxy)hexaethylene glycol acetyl-
thymidine (5) 
To compound 4 (35.0 mg, 0.07 mmol), dissolved in 1 mL of dry CH2Cl2, DMAP (16.4 mg, 0.13 
mmol), BnO-HEG acetic acid 8 (43.0 mg, 0.10 mmol) and DCC (28.0 mg, 0.14 mmol) were 
sequentially added, and the resulting reaction mixture was left under stirring at r.t.. After 1 h TLC 
analysis indicated the formation of a new product, so the solvent was removed under reduced 
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pressure and the crude product was purified by chromatography on a silica gel column eluted with 
CHCl3/MeOH (95:5, v/v), giving the desired compound 5 in 74 % yield (48.4 mg, 0.05 mmol). 
5: oil. Rf = 0.8 (CHCl3/MeOH, 9:1, v/v). 
1
H NMR (400 MHz, CDCl3): δ 8.51 (d, J = 5.2, 2H, 2x Hα Py); 7.30-7.26 (overlapped signals, 8H, 
H-6, 2x Hβ Py and 5 aromatic protons of Bn); 6.34 (dd, J = 7.4 and 6.7, 1H, H-1'); 5.15 (m, 1H, H-
3'); 5.08 (s, 2H, -CH2Py); 4.48 (s, 2H, -CH2Ph); 4.41 (m, 2H, H2-5’); 4.21-4.12 (overlapped signals, 
3H, H-4' and -OCH2COO-C5’); 3.72-3.57 [overlapped signals, 25H, 6x (-O-CH2-CH2-O-) and CH-
S]; 3.23-3.15 (m, 2H, CH2-S); 2.37-2.32 (overlapped signals, 5H, H2-2', CH2-C=O lipoic residue 
and CH2a-CH2-S); 1.92 (s, 3H, CH3-Thy); 1.90 (m, 1H, CH2b-CH2-S); 1.65 (m, 4H, 2x CH2 lipoic 
residue); 1.45 (m, 2H, CH2-CH-S lipoic residue). 
13
C NMR (100 MHz, CDCl3): δ 171.7 (C=O lipoic ester); 168.7 (C=O HEG ester); 163.0 (C-4 
Thy); 149.7 (C-2 Thy); 148.8 (2x Cα Py); 144.2 (Cγ Py); 137.0 (quaternary carbon of Bn); 132.4 
(C-6 Thy); 127.2, 126.4 (aromatic carbons of Bn); 122.3 (2x Cβ Py); 109.7 (C-5 Thy); 84.4 (C-1'); 
80.9 (C-4'); 73.2 (C-3'); 72.1 (-CH2Ph); 70.0, 69.4 (O-CH2-CH2-OHEG); 68.3 (-OCH2COO-C5’); 
63.0 (C-5'); 55.1(CH-S); 42.5 (-CH2Py); 49.1 (CH2-S); 37.3 (CH2-C=O lipoic residue); 35.9 (C-2'); 
33.4-23.3 (overlapped signals, 4 aliphatic carbons of lipoic residue); 12.1 (CH3-Thy). 
ESI-MS (positive ions): calculated for C45H63N3O14S2, 933.38; found m/z: 935.28 [M+H
+
]; 972.38 
[M+K
+
]. 
 
Synthesis of LipThyRu 
Nucleolipid 5 (46.0 mg, 0.05 mmol) was dissolved in 2.5 mL of acetone and then Na
+
 [trans-
RuCl4(DMSO)2]
-
 (21.0 mg, 0.05 mmol) was added under stirring at 40 °C. After 4 h the reaction, 
monitored via TLC, indicated the complete disappearance of both starting products and the 
concomitant formation of a more polar product. After removing the solvent under reduced pressure, 
the obtained solid was exhaustively washed with AcOEt, able to solubilize only the target complex 
LipThyRu, which was thus recovered in 71 % isolated yields as a pure compound (45.4 mg, 0.03 
mmol). 
LipThyRu: yellow oil. Rf = 0.3 (CHCl3/MeOH, 9:1 v/v). 
1
H NMR [400 MHz, (CD3)2CO]: significant signals at δ -1.75 (very broad signal, Py protons); -12.7 
(very broad signal, CH3 of DMSO). 
ESI-MS (positive ions): calculated for C47H69Cl4N3NaO15RuS3
+
, 1276.16; found m/z: 1255.22 [(M-
Na
+
)+2H
+
]. 
  
Chapter 2 
55 
 
 Synthesis and characterization of BnO-HEG acetic acid 
Synthesis of (monobenzyloxy)hexaethylene glycol (6) 
Hexaethylene glycol (2.0 g, 7.10 mmol) was dissolved in 8 mL of dry THF and NaH 60 % p.p. (170 
mg, 4.25 mmol) and then benzylbromide (3.37 mL, 22.8 mmol) were sequentially added. The 
reaction mixture was stirred at r.t. for 12 h, then MeOH (1 mL) was added and the solvent removed 
in vacuo. The crude product was dissolved in CHCl3, filtered on celite and then purified by 
chromatography on a silica gel column using AcOEt/MeOH (9:1, v/v) as eluent, yielding the 
desired compound 6 in 65 % yields (1.7 g, 4.60 mmol). 
6: oil. Rf = 0.5 (AcOEt/MeOH, 9:1, v/v). 
1
H NMR (200 MHz, CDCl3): δ 7.34-7.33 (overlapped signals, 5H, aromatic protons of Bn); 4.56 (s, 
2H, -CH2Ph); 3.66-3.60 [overlapped signals, 24H, 6x (-O-CH2-CH2-O-)]. 
13
C NMR (50 MHz, CDCl3): δ 138.2, 128.3, 127.7 and 127.6 (aromatic carbons); 73.2 (-CH2Ph); 
72.5, 70.6, 70.2 and 69.4 [5x (-O-CH2-CH2-O-) and (-O-CH2-CH2-OH)]; 61.7 (O-CH2- CH2-OH). 
ESI-MS (positive ions): calculated for C19H32O7, 372.2; found m/z: 373.2 [M+H
+
]; 395.1 [M+Na
+
]. 
 
Synthesis of tert-butyl (monobenzyloxy)hexaethylene glycol acetate (7) 
Alcohol 6 (155 mg, 0.42 mmol) was dissolved in 1 mL of dry THF and NaH 60 % p.p. (33.0 mg, 
0.83 mmol) and tert-butyl bromoacetate (154 μL, 1.01 mmol) were sequentially added. The reaction 
mixture was stirred at r.t. for 12 h, then few drops of MeOH were added and the solvent removed in 
vacuo. The crude product was dissolved in CHCl3, filtered on celite and then purified by 
chromatography on a silica gel column eluted with AcOEt, yielding the desired compound 7 in 86 
% yields (175 mg, 0.36 mmol). 
7: oil. Rf = 0.6 (AcOEt/MeOH, 95:5, v/v). 
1
H NMR (200 MHz, CDCl3): δ 7.34-7.32 (overlapped signals, 5H, aromatic protons); 4.56 [s, 2H, -
CH2Ph]; 4.01 (s, 2H, -CH2COO tert-butyl); 3.69-3.64 [overlapped signals, 24H, 6x (-OCH2-CH2-
O-)]; 1.46 [s, 9H, 3x (CH3 tert-butyl)]. 
13
C NMR (50 MHz, CDCl3): δ 169.6 (C=O); 138.3, 128.3, 127.7 and 127.5 (aromatic carbons of 
Bn); 81.4 (quaternary carbon of tert-butyl); 73.2 (-CH2Ph); 70.6 and 69.4 [6x (-O-CH2-CH2-O-)]; 
69.0 (-CH2COO-t-Bu); 28.1 [3x (CH3 tert-butyl)]. 
ESI-MS (positive ions): calculated for C25H42O9, 486.3; found m/z: 509.2 [M+Na
+
]; 525.2 [M+K
+
]. 
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Synthesis of (monobenzyloxy)hexaethylene glycol acetic acid (8) 
Ester 7 (95.0 mg, 0.19 mmol) was dissolved in 1.5 mL of HCOOH and stirred at r.t. for 2 h. The 
solvent was then removed in vacuo and the residue was coevaporated three times with CHCl3 (3 x 3 
mL), yielding the desired compound 8 in almost quantitative yields (82.0 mg, 0.19 mmol). 
8: oil. Rf = 0.2 (AcOEt/MeOH, 95:5, v/v). 
1
H NMR (200 MHz, MeOD): δ 7.36-7.33 (overlapped signals, 5H, aromatic protons); 4.55 [s, 2H, -
CH2Ph]; 4.12 (s, 2H, -CH2COOH); 3.66-3.62 [overlapped signals, 24H, 6x (-O-CH2-CH2-O-)]. 
13
C NMR (50 MHz, MeOD): δ 174.0 (C=O); 139.7, 129.4, 129.0 and 128.7 (aromatic carbons); 
74.1 (-CH2Ph); 71.7, 71.6 and 70.6 [6x (-O-CH2-CH2-O-)]; 69.1 (-CH2COOH). 
ESI-MS (positive ions): calculated for C21H34O9, 430.2; found m/z: 431.1 [M+H
+
]; 453.1 [M+Na
+
]; 
459.1 [M+K
+
]. 
 
 Synthesis and characterization of TUGluRu 
Synthesis of 2-[(9H-fluoren-9-yl) methoxy] carbonylamino, 5-tert-butyl, 1-undec-10-enyl 
pentanedioate (9) 
Commercially available Fmoc-Glu(OtBu)-OH (300 mg, 0.71 mmol) was dissolved in 2.0 mL of dry 
DMF and then HATU (402 mg, 1.06 mmol), DIPEA (246 μL, 1.41 mmol) and 10-undecen-1-ol (80 
μL, 0.42 mmol) were sequentially added. The reaction mixture was stirred at r.t. under argon 
atmosphere. After 4 h, TLC analysis indicated the presence of one main product in the reaction 
mixture and the complete disappearance of the starting alcohol. The solvent was removed in vacuo 
and the residue filtered and washed with CH2Cl2. The crude product was purified by 
chromatography on a silica gel column eluted with CH2Cl2 containing 2 % of TEA (v/v). The 
desired compound 9 was obtained in 81 % yields (199 mg, 0.34 mmol). 
9: yellow oil. Rf = 0.7 (n-hexane/acetone, 8:2, v/v). 
1
H NMR (400 MHz, CDCl3): δ 7.75 (d, J = 7.5 Hz, 2H, CH-d Fmoc); 7.59 (t, J = 6.4 and 4.0 Hz, 
2H, CH-e Fmoc); 7.38 (t, J = 7.4 Hz, 2H, CH-f Fmoc); 7.30 (t, J = 7.4 Hz, 2H, CH-g Fmoc); 5.85-
5.75 (m, 1H, CH-10’); 5.62 (bd, J = 8.0 Hz, 1H, NH); 4.96-4.91 (m, 2H, CH2-11’); 4.43-4.36 
(overlapped signals, 3H, CH2-a Fmoc and CH ); 4.21 (t, J = 7.0 Hz, 1H, CH-b Fmoc); 4.14 (t, J = 
6.6 Hz, 2H, CH2-1’); 2.36-2.25 (m, 2H, CH2-4); 2.20-2.14 (m, 1H, CH-3a); 2.04-2.00 (m, 2H, CH2-
9’); 1.99-1.93 (m, 1H, CH-3b); 1.63-1.51 (m, 2H, CH2-2’); 1.45 (s, 9H, tBu); 1.28 (overlapped 
signals, 12H, 6x CH2-3’, 4’, 5’, 6’, 7’, 8’). 
13
C NMR (50 MHz, CDCl3): δ 172.0 (overlapped signals, 2x C=O undecenyl ester and COOtBu); 
155.9 (C=ONH); 143.8, 143.7 (CH-c Fmoc); 141.3 (overlapped signals, CH-h Fmoc); 139.2 (CH-
10’); 127.7 (CH-d Fmoc); 127.0 (CH-g Fmoc); 125.1 (CH-e Fmoc); 119.9 (CH-f Fmoc); 114.1 
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(CH2-11’); 80.8 (quaternary carbon of tBu); 67.0 (CH2-a Fmoc); 65.8 (CH2-1’); 53.5 (CH ); 47.1 
(CH-b Fmoc); 33.8 (CH2-9’); 32.4 (CH2-2’); 31.4 (CH2-4); 29.4 (3x CH3 of tBu); 29.1, 28.9, 28.5, 
28.0 (overlapped signals, 5x CH2-4’, 5’, 6’, 7’, 8’); 27.6 (CH2-3); 25.8 (CH2-3’). 
MALDI-MS (positive ions): calculated for C35H47NO6, 577.34; found m/z: 600.25 [M+Na
+
]; 
616.22 [M+K
+
]. 
 
Synthesis of 4-[(9H-fluoren-9-yl) methoxy] carbonylamino-pentandioic acid, 5-(undec-10-enyl) 
mono ester (10) 
Compound 9 (105 mg, 0.18 mmol) was dissolved in 1.0 mL of formic acid and the reaction mixture 
was stirred at r.t. for 2.5 h. Formic acid was then removed in vacuo and the resulting residue was 
coevaporated three times with dry CH3CN (3 x 5 mL), yielding the desired compound 10 in almost 
quantitative yields (95.2 mg, 0.18 mmol). 
10: pale yellow oil. Rf = 0.3 (n-hexane/acetone, 8:2, v/v); 0.4 (CH2Cl2). 
1
H NMR (400 MHz, CDCl3): δ 7.75 (d, J = 7.5 Hz, 2H, CH-d Fmoc); 7.59 (d, J = 7.0, 2H, CH-e 
Fmoc); 7.39 (t, J = 7.4 and 7.5 Hz, 2H, CH-f Fmoc); 7.30 (t, J = 7.4 Hz, 2H, CH-g Fmoc); 5.84-
5.77 (m, 1H, CH-10’); 5.55 (bd, J = 8.0 Hz, 1H, NH);5.02-4.92 (m, 2H, CH2-11’); 4.44-4.37 
overlapped signals, 3H, CH2-a Fmoc and CH ); 4.21 (t, J = 6.8 and 6.9 Hz, 1H, CH-b Fmoc); 4.14 
(t, J = 4.0 and 8.0 Hz, 2H, CH2-1’); 2.50-2.41 (m, 2H, CH2-4); 2.25-2.20 (m, 1H, CH-3a); 2.06-
1.95 (overlapped signals, 3H, CH2-9’ and CH-3b); 1.63-1.61 (m, 2H, CH2-2’); 1.37-1.22 
(overlapped signals, 12H, 6x CH2-3’, 4’, 5’, 6’, 7’, 8’). 
13
C NMR (50 MHz, CDCl3): δ 177.3 (COOH); 171.8 (C=O undecenyl ester); 155.9 (C=ONH); 
143.7, 143.6 (CH-c Fmoc); 141.2 (overlapped signals, CH-h Fmoc); 139.1 (CH-10’); 127.7 (CH-d 
Fmoc); 126.9 (CH-g Fmoc); 124.9 (CH-e Fmoc); 119.9 (CH-f Fmoc); 114.1 (CH2-11’); 67.0 (CH2-
a Fmoc); 65.9 (CH2-1’); 53.1 (CH ); 47.1 (CH-b Fmoc); 33.7 (CH2-9’); 29.7 (CH2-2’); 29.3, 29.0, 
28.9, 28.8 (overlapped signals, 5x CH2-4’, 5’, 6’, 7’, 8’); 28.5 (CH2-4); 27.5 (CH2-3); 25.6 (CH2-
3’). 
MALDI-MS (positive ions): calculated for C31H39NO6, 521.28; found m/z: 544.18 [M+Na
+
]; 
560.15 [M+K
+
]. 
 
Synthesis of 5-{2-[2-(2-methoxyethoxy)ethoxy]ethyl}, 1-undec-10-enyl, 2-(9H-fluoren-9-
yl)methoxycarbonylamino-pentanedioate (11) 
Compound 10 (17.7 mg, 0.03 mmol) was dissolved in 0.7 mL of dry DMF and then HATU (19.4 
mg, 0.05 mmol), DIPEA (11.8 μL, 0.07 mmol) and triethylene glycol monomethyl ether (6.52 μL, 
0.04 mmol) - previously coevaporated three times with dry CH3CN (3 x 5 mL) - were sequentially 
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added. The reaction mixture was left at r.t. under stirring and argon atmosphere. After 18 h, TLC 
analysis indicated the appearance of a new product. The reaction was quenched by removing the 
solvent under reduced pressure; the resulting crude was filtered and washed several times with 
CH2Cl2. Finally, it was purified by chromatography on a silica gel column using n-hexane/acetone 
(8:2, v/v) as eluent, which provided pure compound 11 with 66 % yields (13.8 mg, 0.02 mmol). 
11: oil. Rf = 0.6 (n-hexane/acetone, 7:3, v/v). 
1
H NMR (400 MHz, CDCl3): δ 7.76 (d, J = 8.0 Hz, 2H, CH-d Fmoc); 7.60 (bd, J = 4.0, 2H, CH-e 
Fmoc); 7.40 (t, J = 8.0, 2H, CH-f Fmoc); 7.31 (t, J = 7.3 and 7.1 Hz , 2H, CH-g Fmoc); 5.85-5.75 
(m, 1H, CH-10’); 5.50 (d, J = 8.0 Hz, 1H, NH); 5.01-4.91 (m, 2H, CH2-11’); 4.42-4.37 (overlapped 
signals, 3H, CH2-a Fmoc and CH ); 4.24-4.20 (overlapped signals, 3H, CH-b Fmoc and CH2-1’’); 
4.14 (bt, J = 4.6 and 6.7 Hz, 2H, CH2-1’); 3.68 (t, J = 4.8 and 4.7 Hz, CH2-2’’); 3.64-3.52 
(overlapped signals, 8H, 4x CH2-3’’, 4’’, 5’’,6’’); 3.36 (s, 3H, OCH3); 2.47-2.39 (m, 2H, CH2-4); 
2.23-2.21 (m, 1H, CH-3a); 2.05-2.00 (overlapped signals, 3H, CH2-9’ and CH-3b); 1.65-1.58 (m, 
2H, CH2-2’); 1.36-1.27 (overlapped signals, 12H, 6x CH2-3’, 4’, 5’, 6’, 7’, 8’). 
13
C NMR (100 MHz, CDCl3): δ 172.4 (C=O TEG ester); 171.7 (C=O undecenyl ester); 155.8 
(C=ONH); 143.7, 143.6 (CH-c Fmoc); 141.2 (overlapped signals, CH-h Fmoc); 139.0 (CH-10’); 
127.5 (CH-d Fmoc); 126.9 (CH-g Fmoc); 124.9 (CH-e Fmoc); 119.8 (CH-f Fmoc); 114.0 (CH2-
11’); 71.8, 70.4, 68.9 (overlapped signals, 5x CH2-2’’, 3’’, 4’’, 5’’, 6’’); 67.0 (CH2-a Fmoc); 65.7 
(CH2-1’); 63.6 (CH2-1’’); 58.8 (OCH3); 53.3 (CH ); 47.1 (CH-b Fmoc); 33.6 (CH2-9’); 30.1 (CH2-
4); 29.2, 29.0, 28.9, 28.7, 28.4 (overlapped signals, 6x CH2-2’, 4’, 5’, 6’, 7’, 8’); 27.5 (CH2-3); 25.6 
(CH2-3’). 
MALDI-MS (positive ions): calculated for C38H53NO9, 667.37; found m/z: 690.27 [M+Na
+
]; 
706.24 [M+K
+
]. 
 
Synthesis of 5-{2-[2-(2-methoxyethoxy)ethoxy]ethyl}, 1-undec-10-enyl, 2-aminopentanedioate 
(12) 
Isolated product 11 (42.7 mg, 0.06 mmol) was dissolved in 1.0 mL of a 10 % piperidine solution in 
CH3CN. After 20 min under stirring at r.t., TLC analysis indicated the complete removal of the 
Fmoc group. Then the solvent was removed in vacuo and the residue was coevaporated three times 
with dry CH3CN (3 x 5 mL), obtaining the desired compound in almost quantitative yields (28.5 
mg, 0.06 mmol). Derivative 12 was not isolated, but directly reacted to obtain the final 
aminoacyllipidic scaffold. 
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Synthesis of 5-{2-[2-(2-methoxyethoxy)ethoxy]ethyl}, 1-undec-10-enyl, 2-(2-(pyridin-4-
yl)acetamido)pentanedioate (13) 
Crude product 12 (35.4 mg, 0.08 mmol) was dissolved in 1.0 mL of dry DMF and then HATU (45.0 
mg, 0.12 mmol), DIPEA (27.5 μL, 0.16 mmol) and 4-pyridylacetic acid hydrochloride (13.7 mg, 
0.08 mmol) were sequentially added. The reaction mixture was left under stirring and argon 
atmosphere at r.t.. After 5 h, TLC monitoring indicated the formation of a new compound and the 
reaction was quenched by removing the solvent in vacuo. The resulting crude was filtered, washed 
with CH2Cl2 and purified by chromatography on a silica gel column eluted with n-hexane/acetone 
(3:2, v/v). The desired product 13 was obtained in 50 % yields (20.0 mg, 0.04 mmol), calculated for 
two steps starting from pure 11. 
13: oil. Rf = 0.7 (CH2Cl2/MeOH, 93:7, v/v). 
1
H NMR (400 MHz, CDCl3): δ 8.64 (bd, J = 17.8 Hz, 2H, 2x Hα Py); 7.65 (bd, J = 4.3 Hz, 2H, 2x 
Hβ Py; 7.14 (d, J = 7.5 Hz, 1H, NH); 5.83-5.76 (m, 1H, CH-10’); 5.00-4.90 (m, 2H, CH2-11’); 
4.59-4.54 (m, 1H, CH ); 4.26-4.08 (overlapped signals, 4H, CH2-1’’ and CH2-1’); 3.76 (s, 2H, -
CH2Py 3.69-3.62 (overlapped signals, 10H, 5x CH2-2’’, 3’’, 4’’, 5’’, 6’’); 3.34 (s, 3H, OCH3); 
2.47-2.33 (m, 2H, CH2-4); 2.25-2.17 (m, 1H, CH-3a); 2.08-2.02 (overlapped signals, 3H, CH2-9’ 
and CH-3b); 1.63-1.60 (m, 2H, CH2-2’); 1.36-1.25 (overlapped signals, 12H, 6x CH2-3’, 4’, 5’, 6’, 
7’, 8’). 
13
C NMR (100 MHz, CDCl3): δ 172.7 (C=O TEG ester); 171.4 (C=O undecenyl ester); 168.1 
(C=ONH); 150.3 (Cγ Py); 144.8 (2x Cα Py); 139.0 (CH-10’); 126.4 (2x Cβ Py); 114.0 (CH2-11’); 
71.8, 70.4, 68.9 (overlapped signals, 5x CH2-2’’, 3’’, 4’’, 5’’, 6’’); 65.8 (CH2-1’); 63.6 (CH2-1’’); 
58.8 (OCH3); 52.2 (CH ); 42.2 (-CH2Py); 33.6 (CH2-9’); 30.3 (CH2-4); 29.5, 29.3, 29.0, 28.9, 28.7 
(overlapped signals, 6x CH-2’, 4’, 5’, 6’, 7’, 8’); 26.6 (CH2-3); 25.6 (CH2-3’). 
MALDI-MS (positive ions): calculated for C30H48N2O8, 564.34; found m/z: 587.24 [M+Na
+
]; 
603.21 [M+K
+
]. 
 
Synthesis of TUGluRu 
Aminoacyllipid 13 (2.40 mg, 4.22 μmol) was dissolved in 750 μL of dry CH2Cl2 and then Na
+
 
[trans-RuCl4(DMSO)2]
-
 (1.78 mg, 4.22 μmol) was added. The reaction mixture was stirred at 40 °C. 
After 30 h the reaction, monitored via TLC, indicated the complete disappearance of both starting 
products and the formation of a new product, attributed to the desired ruthenium complex, 
recovered - by simple solvent removal under reduced pressure - in almost quantitative yields (3.82 
mg, 4.22 μmol). 
TUGluRu: orange powder: Rf = 0.3 (CH2Cl2/MeOH, 93:7, v/v). 
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1
H NMR [400 MHz, (CD3)2CO]: significant signals at δ -0.90 (very broad signal, Py protons); -9.51 
(very broad signal, CH3 DMSO). 
LC-MS (positive ions): calculated for C32H54Cl4N2NaO9RuS
+
, 907.12; found m/z (tR = 6.89 min): 
874.15 [M-Cl
-
+H
+
]; 890.12 [M-Cl
-
+H2O]; 931.15 [M+Na
+
]. 
 
 Synthesis and characterization of TOTyroRu 
Synthesis of 2-[2-(2-methoxyethoxy)ethoxy]ethyl, 2-[(9H-fluoren-9-yl)methoxy 
carbonyl]amino-3-(4-(tert-butoxy)phenyl)propanoate (14) 
Commercially available Fmoc-Tyr(tBu)-OH (117 mg, 0.25 mmol) was dissolved in 1.5 mL of dry 
DMF and then HATU (145 mg, 0.38 mmol), DIPEA (88.5 μL, 0.51 mmol) and triethylene glycol 
monomethyl ether (122 μL, 0.76 mmol) - previously coevaporated three times with dry CH3CN (3 x 
5 mL) - were sequentially added. The reaction mixture was left at r.t. under stirring and argon 
atmosphere. After 3 h, TLC monitoring indicated the presence of a new product in the reaction 
mixture and the complete disappearance of the starting amino acid. Then the solvent was removed 
in vacuo and the residue was filtered and washed with CH2Cl2; the crude product was purified by 
chromatography on a silica gel column eluted with CH2Cl2/MeOH (95:5, v/v) containing 2 % of 
TEA (v/v). The desired compound 14 was obtained in 96 % yields (146 mg, 0.24 mmol). 
14: yellow oil. Rf = 0.7 (CH2Cl2/MeOH, 98:2, v/v). 
1
H NMR (400 MHz, CDCl3): δ 7.76 (d, J = 7.4 Hz, 2H, CH-d Fmoc); 7.56 (bd, J = 6.2 Hz, 2H, 
CH-e Fmoc); 7.39 (t, J = 7.3 Hz, 2H, CH-f Fmoc); 7.31 (t, J = 7.3 and 7.1 Hz, 2H, CH-g Fmoc); 
7.01 (d, J = 7.7 Hz, 2H, CH-5 Ph); 6.88 (d, J = 7.6 Hz, 2H, CH-6 Ph); 5.35 (bd, J = 7.8 Hz, 1H, 
NH); 4.66 (m, 1H, CH ); 4.45-4.31 (m, 2H, CH2-a Fmoc); 4.27 (m, 2H, CH2-1’’); 4.20 (t, J = 6.9 
and 6.6 Hz, 1H, CH-b Fmoc); 3.74-3.52 (overlapped signals, 10H, 5x CH2-2’’, 3’’, 4’’, 5’’, 6’’); 
3.34 (s, 3H, OCH3); 3.11-3.07 (m, 2H, CH2-3); 1.31 (s, 9H, tBu). 
13
C NMR (100 MHz, CDCl3): δ 171.3 (C=O TEG ester); 155.4 (C=ONH); 154.3 (quaternary 
carbon 7 of Ph); 143.7, 143.6 (CH-c Fmoc); 141.2 (overlapped signals, CH-h Fmoc); 130.3 
(quaternary carbon 4 of Ph); 129.7 (CH-5 Ph); 127.6 (CH-d Fmoc); 126.9 (CH-g Fmoc); 124.9 
(CH-e Fmoc); 123.9 (CH-6 Ph); 119.8 (CH-f Fmoc); 78.2 (quaternary carbon of tBu); 72.3 (CH2-
2’’); 71.7 (CH2-6’’); 70.5, 70.4, 70.3 (overlapped signals, 3x CH2-3’’, 4’’, 5’’); 68.6 (CH2-a Fmoc); 
64.3 (CH2-1’’); 61.6 (OCH3); 58.8 (CH ); 47.0 (CH-b Fmoc); 38.5 (CH2-3); 28.6 (3x CH3 of tBu). 
LC-MS (positive ions): calculated for C35H43NO8, 605.30; found m/z (tR = 9.37 min, C18 column): 
606.37 [M+H
+
], 628.37 [M+Na
+
]; 644.32 [M+K
+
]. 
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Synthesis of 2-[2-(2-methoxyethoxy)ethoxy]ethyl, 2-[(9H-fluoren-9-yl)methoxy carbonyl] 
amino)-3-(4-hydroxyphenyl)propanoate (15) 
Compound 14 (146 mg, 0.24 mmol) was dissolved in 3.5 mL of formic acid. The reaction mixture 
was stirred at r.t. for 7 h. Formic acid was removed under reduced pressure and the residue 
coevaporated three times with dry CH3CN (3 x 5 mL), yielding the desired compound 15 in almost 
quantitative yields (132 mg, 0.24 mmol). 
15: oil. Rf = 0.2 (n-hexane/acetone, 7:3, v/v) and Rf = 0.2 (CH2Cl2). 
1
H NMR (400 MHz, CDCl3): δ 7.76 (d, J = 7.4 Hz, 2H, CH-d Fmoc); 7.58 (d, J = 6.4 Hz, 2H, CH-
e Fmoc); 7.39 (t, J = 7.2 and 7.3 Hz, 2H, CH-f Fmoc); 7.30 (t, J = 7.2 and 7.1 Hz, 2H, CH-g Fmoc); 
6.96 (d, J = 7.8 Hz, 2H, CH-5 Ph); 6.76 (d, J = 7.9 Hz, 2H, CH-6 Ph); 5.43 (bd, J = 8.2 Hz, 1H, 
NH); 4.62 (m, 1H, CH ); 4.43-4.36 (m, 2H, CH2-a Fmoc); 4.32 (t, 2H, J = 4.5 and 5.7 Hz, CH2-
1’’); 4.20 (m, 1H, CH-b Fmoc); 3.74 -3.40 (overlapped signals, 10H, 5x CH2-2’’, 3’’, 4’’, 5’’, 6’’); 
3.37 (s, 3H, OCH3); 3.09-3.07 (m, 2H, CH2-3). 
13
C NMR (100 MHz, CDCl3): δ 171.6 (C=O TEG ester); 160.9 (quaternary carbon 7 of Ph); 155.4 
(C=ONH); 143.6, 143.5 (CH-c Fmoc); 141.1 (overlapped signals, CH-h Fmoc); 130.3 (CH-5 Ph); 
127.6 (CH-d Fmoc); 126.9 (CH-g Fmoc); 126.6 (quaternary carbon 4 of Ph); 125.0, 124.9 (CH-e 
Fmoc); 119.8 (CH-f Fmoc); 115.5 (CH-6 Ph); 71.8 (CH2-2’’); 71.7 (CH2-6’’); 70.4, 70.3, 70.1 
(overlapped signals, 3x CH2-3’’, 4’’, 5’’); 68.7 (CH2-a Fmoc); 64.5 (CH2-1’’); 58.7 (OCH3); 54.9 
(CH ); 46.9 (CH-b Fmoc); 37.6 (CH2-3). 
LC-MS (positive ions): calculated for C31H35NO8, 549.24; found m/z (tR = 7.67 min, C18 column): 
550.33 [M+H
+
]; 572.24 [M+Na
+
]; 588.30 [M+K
+
]. 
 
Synthesis of 4-{13-[(9H-fluoren-9-yl)methoxy carbonyl]amino}-12-oxo-2,5,8,11-
tetraoxatetradecan-14-yl)phenyl oleate (16) 
Pure compound 15 (76.0 mg, 0.13 mmol), oleic acid (41.6 μL, 0.13 mmol) and triphenylphosphine 
(72.8 mg, 0.28 mmol) - previously coevaporated three times with dry CH3CN (3 x 2 mL) - were 
dissolved in 5.0 mL of dry THF and stirred at r.t. for 10 min. Then DEAD (43.4 μL, 0.28 mmol) 
was added dropwise and the reaction mixture was heated to reflux at 65 °C under argon atmosphere 
overnight. After 24 h, TLC analysis showed the appearance of a new product in the reaction 
mixture, thus the solvent was removed under reduced pressure. The resulting residue was filtered 
and washed several times with CH2Cl2 and then purified by chromatography on a silica gel column 
eluting with n-hexane/AcOEt (7:3, v/v). The desired compound 16 was obtained in 38 % yields 
(36.4 mg, 0.05 mmol). 
15: oil. Rf = 0.4 (n-hexane/AcOEt, 1:1, v/v). 
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1
H NMR (400 MHz, CDCl3): δ 7.79 (d, J = 7.5 and 7.8 Hz, 2H, CH-d Fmoc); 7.60 (bd, J = 6.9 Hz, 
2H, CH-e Fmoc); 7.43 (t, J = 7.4 and 7.5 Hz, 2H, CH-f Fmoc); 7.34 (t, J = 7.4 Hz, 2H, CH-g 
Fmoc); 7.16 (d, J = 8.0 Hz, 2H, CH-5 Ph); 7.02 (d, J = 8.3 Hz, 2H, CH-6 Ph); 5.40-5.36 
(overlapped signals, 3H, NH and CH-9’, 10’); 4.71 (m, 1H, CH ); 4.49-4.38 (m, 2H, CH2-a 
Fmoc); 4.36-4.33 (m, 2H, CH2-1’’); 4.31 (m, 1H, CH-b Fmoc); 3.65-3.40 (overlapped signals, 10H, 
5x CH2-2’’, 3’’, 4’’, 5’’, 6’’); 3.38 (s, 3H, OCH3); 3.15 (m, 2H, CH2-3); 2.56 (t, J = 7.4 and 7.5 Hz, 
2H, CH2-2’); 2.04 (overlapped signals, 4H, 2x CH2-8’, 11’); 1.80-1.72 (m, 2H, CH2-3’); 1.41 
(overlapped signals, 4H, 2x CH2-7’, 12’); 1.29 (overlapped signals, 16H, 8x CH2-4’, 5’, 6’, 13’, 
14’, 15’, 16’, 17’); 0.90 (t, J = 6.6 and 6.9 Hz, 3H, CH3-18’). 
13
C NMR (100 MHz, CDCl3): δ 172.2 (C=O oleic ester); 171.3 (C=O TEG ester); 160.9 
(quaternary carbon 7 of Ph); 155.6 (C=ONH); 143.9, 143.8 (CH-c Fmoc); 141.3 (overlapped 
signals, CH-h Fmoc); 133.2 (quaternary carbon 4 of Ph); 130.4, 130.1 (overlapped signals, 2x CH-
9’, 10’); 129.7 (CH-5 Ph); 127.7 (CH-d Fmoc); 127.1 (CH-g Fmoc); 125.1 (CH-e Fmoc); 121.6 
(CH-6 Ph); 120.0 (CH-f Fmoc); 71.9 (CH2-2’’); 70.6, 70.5, 68.8, 68.7 (overlapped signals, 4x CH2- 
3’’, 4’’, 5’’, 6’’); 67.0 (CH2-a Fmoc); 63.1 (CH2-1’’); 62.2 (OCH3); 59.0 (CH ); 47.2 (CH-b 
Fmoc); 37.5 (CH2-3); 34.4 (CH2-2’); 31.9, 31.8 (overlapped signals, 2x CH2-7’, 12’); 29.7, 29.5, 
29.3, 29.2, 29.1, 29.0, 28.9 (overlapped signals, 7x CH2-4’, 5’, 6’, 13’, 14’, 15’,16’); 27.2, 26.7 
(overlapped signals, 2x CH2-8’, 11’); 24.9 (CH2-3’); 22.6 (CH2-17’); 14.1 (CH3-18’). 
LC-MS (positive ions): calculated for C49H67NO9, 813.48; found m/z (tR = 11.8 min, C18 column): 
812.59 [M
+
]; 852.59 [M+K
+
]. 
 
Synthesis of 4-(13-amino-12-oxo-2,5,8,11-tetraoxatetradecan-14-yl)phenyl oleate (compound 
17) 
Isolated compound 16 (36.4 mg, 0.04 mmol) was dissolved in 1.0 mL of a 10 % piperidine solution 
in dry CH3CN. After 30 min under stirring and argon atmosphere at r.t., TLC analysis showed the 
complete removal of the Fmoc group. Then the solvent was removed under reduced pressure and 
the residue was coevaporated three times with dry CH3CN (3 x 5 mL), obtaining the desired 
compound in almost quantitative yields (26.5 mg, 0.04 mmol). Derivative 17 was not isolated, but 
directly reacted to obtain the final aminoacyllipidic scaffold. 
 
Synthesis of 4-{12-oxo-13-[2-(pyridin-4-yl)acetamido] 2,5,8,11-tetraoxatetradecan-14-
yl}phenyl oleate (18) 
Crude derivative 17 (26.5 mg, 0.04 mmol) was dissolved in 1.0 mL of dry DMF and then HATU 
(25.5 mg, 0.07 mmol), DIPEA (15.5 μL, 0.09 mmol) and 4-pyridylacetic acid hydrochloride (7.76 
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mg, 0.04 mmol) were sequentially added. The reaction mixture was left under stirring and argon 
atmosphere at r.t.. After 17 h, TLC monitoring showed the complete disappearance of the starting 
materials and the reaction was quenched by removing the solvent in vacuo. The crude product was 
filtered, washed several times with CH2Cl2 and purified by chromatography on a silica gel column 
using CH2Cl2 as eluent. The desired product 18 was obtained in 54 % yields (17.1 mg, 0.02 mmol), 
calculated for two subsequent steps starting from 16. 
18: oil. Rf = 0.7 (CH2Cl2/MeOH, 93:7, v/v). 
1
H NMR (400 MHz, CDCl3): δ 8.55 (d, J = 5.5 Hz, 2H, 2x Hα Py); 7.64 (d, J = 5.5 Hz, 2H, 2x Hβ 
Py; 7.15 (d, J = 8.2 Hz, 2H, CH-5 Ph); 6.94 (d, J = 8.2 Hz, 2H, CH-6 Ph); 5.34-5.29 (overlapped 
signals, 3H, NH and CH-9’, 10’); 4.81-4.77 (m, 1H, CH ); 4.34-4.23 (m, 2H, CH2-1’’); 3.73-3.71 
(m, 2H, -CH2Py 3.69-3.53 (overlapped signals, 10H, 5x CH2-2’’, 3’’, 4’’, 5’’, 6’’); 3.36 (s, 3H, 
OCH3); 3.16-3.12 (m, 2H, CH2-3); 2.54 (t, J = 7.4 and 7.5 Hz, 2H, CH2-2’); 2.01-2.00 (overlapped 
signals, 4H, 2x CH2-8’, 11’); 1.48 (m, 2H, CH2-3’); 1.33 (overlapped signals, 4H, 2x CH2-7’, 12’); 
1.29 (overlapped signals, 16H, 8x CH2-4’, 5’, 6’, 13’, 14’, 15’, 16’, 17’); 0.88-0.85 (m, 3H, CH3-
18’). 
13
C NMR (100 MHz, CDCl3): δ 172.5 (C=ONH); 172.2 (C=O oleic ester); 170.9 (C=O TEG ester); 
162.6 (quaternary carbon 7 of Ph); 149.6 (2x Cα Py); 143.1 (quaternary Cγ Py); 133.8 (quaternary 
carbon 4 of Ph); 130.3, 129.9 (overlapped signals, 2x CH-9’, 10’); 122.3 (2x Cβ Py); 121.6 (CH-5 
Ph); 121.4 (CH-6 Ph); 72.2, 71.6, 70.3, 70.1, 68.6 (overlapped signals, 5x CH2-2’’, 3’’, 4’’, 5’’, 
6’’); 64.3 (CH2-1’’); 61.5 (OCH3); 58.7 (CH ); 43.0 (-CH2Py); 36.6 (CH2-3); 34.2 (CH2-2’); 31.7 
(overlapped signals 2x CH2-7’, 12’); 29.6, 29.5, 29.3, 29.2, 29.1, 28.9 (overlapped signals, 7x CH2-
3’, 4’, 5’, 6’, 13’, 14’, 15’, 16’); 27.1, 27.0 (CH2-8’, 11’); 24.8 (CH2-3’); 22.6 (CH2-17’); 14.0 
(CH3-18’). 
LC-MS (positive ions): calculated for C41H62N2O8, 710.45; found m/z (tR = 5.56 min, C18 column): 
711.57 [M+H
+
]; 733.51 [M+Na
+
]. 
 
Synthesis of TOTyroRu 
Aminoacyllipid 18 (16.5 mg, 0.02 mmol) was dissolved in 750 μL of dry CH2Cl2 and then Na
+
 
[trans-RuCl4(DMSO)2]
-
 (8.48 mg, 0.02 mmol) was added. The reaction mixture was stirred at 40 °C 
for 30 h. TLC monitoring showed the complete disappearance of the starting reagents and the 
formation of a new product, attributed to the desired ruthenium complex, recovered in almost 
quantitative yields after solvent removal in vacuo (24.1 mg, 0.02 mmol). 
TOTyroRu: orange powder. Rf = 0.3 (CH2Cl2/MeOH, 93:7, v/v). 
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1
H NMR (400 MHz, CDCl3): significant signals at δ -1.48 (very broad signal, Py-Ru); -9.18 (very 
broad signal, CH3 DMSO). 
LC-MS (positive ions): calculated for C43H68Cl4N2NaO9RuS
+
, 1053.23; found m/z (tR = 7.03 min, 
C18 column): 1036.32 [M-Cl
-
+H2O]. 
 
 Synthesis and characterization of PySSRu 
Synthesis of 2-(pyridin-4-yl)ethanethiol (19, PySH) 
Commercially available 2-(4-pyridinyl)ethanethiol hydrochloride (502 mg, 2.86 mmol) and NaOH 
(114 mg, 2.86 mmol) were dissolved in 13 mL of MeOH, and then left under stirring at r.t.. The 
reaction, monitored by pH measurements, after ca. 30 min was quenched by solvent removal under 
reduced pressure and the crude product was extracted with CHCl3/H2O. The desired compound was 
recovered in the organic phases, which were dried upon addition of anhydrous Na2SO4, filtered and 
concentrated under reduced pressure. The pure compound 19 was obtained in 82 % isolated yields 
(327 mg, 2.35 mmol). 
19: yellow oil. Rf = 0.8 (CH2Cl2/MeOH, 8:2, v/v). 
1
H NMR (500 MHz, CDCl3,): δ 8.52 (d, J = 5.5 Hz, 2H, 2x Hα Py ); 7.12 (d, J = 5.5 Hz, 2H, 2x Hβ 
Py); 2.91 (t, J = 7.5 Hz, 2H, CH2CH2SH); 2.79 (q, 2H, CH2SH); 1.38 (t, J = 8.0 Hz 1H, SH). 
13
C NMR (125 MHz, CDCl3): δ 149.8 (2x Cα Py); 148.3 (Cγ Py); 123.8 (2x Cβ Py); 39.2 
(CH2CH2SH); 24.6 (CH2SH). 
 
Synthesis of 1,2-bis[2-(pyridin-4-yl)ethyl]disulfane (20, PySSPy) 
Pure product 19 (100 mg, 0.72 mmol) was dissolved in 500 μL of MeOH and then H2O2 (90 μL of a 
30 wt. % in H2O solution, 0.80 mmol) and KI (11.6 mg, 0.07 mmol) were sequentially added to the 
reaction mixture, left under stirring at r.t.. After 1 h, TLC analysis indicated the appearance of a 
new product, with concomitant disappearance of the starting material. Thus, the reaction was 
quenched by addition of few drops of H2O, the solvent was removed in vacuo and the crude product 
was extracted with CH2Cl2/H2O. The desired compound was recovered in the organic phases, which 
were dried over anhydrous Na2SO4, filtered and then taken to dryness, giving compound 20 in 
almost quantitative yields (98.0 mg, 0.35 mmol). 
20: yellow oil. Rf = 0.6 (CH2Cl2/MeOH, 95:5, v/v). 
1
H NMR (400 MHz, CDCl3,): δ 8.50 (d, J = 5.5 Hz, 4H, 2x Hα Py); 7.10 (d, J = 5.5 Hz, 4H, 2x Hβ 
Py); 2.99 – 2.89 (m, 8H, 2x CH2CH2S). 
13
C NMR (100 MHz, CDCl3): δ 149.7 (2x Cα Py); 148.3 (2x Cγ Py); 123.8 (2x Cβ Py); 38.4 
(CH2CH2SH); 34.5 (CH2SH). 
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MALDI-MS (positive ions): calculated for C14H16N2S2, 276.08; found m/z: 276.86 [M+H
+
]; 298.89 
[M+Na
+
]; 314.94 [M+K
+
]. 
IR: cm
-1
 1595 (s), 1557 (m) [C=N)]; 1416 (s), 1215 (m) 991 (m), [CH2]; 798 (s) [C-S]; 575 (m), 
500 (m), [S-S]. 
 
Synthesis of PySSRu 
Pure compound 20 (10.0 mg, 0.04 mmol) was dissolved in 10 mL of dry acetone and then [trans-
RuCl4(DMSO)2]
-
 Na
+
 (25.3 mg, 0.06 mmol) was added to the reaction mixture, left under stirring at 
r.t.. After 2 h, TLC monitoring indicated the complete disappearance of both starting materials and 
the formation of a new product. The desired ruthenium complex PySSRu was recovered in 75 % 
isolated yields (28.9 mg, 0.03 mmol) by solvent removal under vacuum followed by 
precipitation/centrifugation in CH2Cl2. 
PySSRu: orange powder: Rf = 0.3 (CH2Cl2/MeOH, 85:15, v/v). 
1
H NMR (400 MHz, DMSO-d6): significant signals at δ -2.40 (very broad signal, Py protons); -13.0 
(very broad signal, CH3 of DMSO). 
IR: cm
-1
 1705 (s), 1610 (m) [C=N)]; 1422 (s), 1363 (m) 1222 (m), [CH2]; 1089 (m), 1022 (m) 
[(S=O) (DMSO)]; 815 (s) [C-S]; 530 (m) [S-S]. 
 
 Synthesis and characterization of the precursor ruthenium salts 
Synthesis of hydrogen trans-bis(dimethylsulfoxide) tetrachlororuthenate(III): 
[(DMSO)2H][trans-Ru(DMSO)2Cl4] (21) 
A 1.5 g amount of hydrated RuCl3 (7.23 mmol) was partially dissolved in 7 mL of DMSO and 1 mL 
of 37 % aqueous HCl was added. The mixture was left at 80 °C under vigorous stirring until 
complete dissolution of RuCl3. The dense, deep dark solution was then heated at 100 °C for 10 min. 
It gradually became more fluid and its color turned to bright dark red. After cooling, 30 mL of 
acetone were added to the solution, then left at 4 °C overnight. Large dark-red crystals were formed 
and were filtered off, washed with cold acetone and diethyl ether and vacuum-dried. The desired 
product 21 was obtained in 60 % yields (2.3 g, 4.34 mmol). 
1
H NMR [400 MHz, (CD3)2CO]: significant signals at δ 9.11 (very broad signal, DMSOH
+
); 2.94 
(very broad signal, CH3 DMSOH
+
); -9.17 (very broad signal, CH3 DMSO). 
M.p.: 118-121 °C. 
FTIR-ATR: cm
-1
 1395.8 (w), 1287.0 (w) [δ (CH3)]; 1108.0 (s), 1096.0 (s) [ν (S=O) (DMSO)]; 
1011.4 (s), 953.9 (m) [ρ (CH3)]; 718.0 (w), 670.0 (w) [ν (C-S)]. 
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Sodium trans-bis(dimethylsulfoxide)tetrachlororuthenate(III): Na
+
 [trans-Ru(DMSO)2Cl4]
- 
(22) 
1.12 g of finely ground [(DMSO)2H] [trans-[Ru(DMSO)2Cl4] (2.02 mmol) were dissolved in a 
mixture of 50 mL of ethanol and 700 µL of water. To the clear solution, NaCl (176 mg, 3.02 
mmol), dissolved in 500 µL of water, was added. The desired product rapidly precipitated from the 
solution as light-orange microcrystals, which were filtered off, washed with cold ethanol and 
diethyl ether, and vacuum-dried. The target compound was obtained in 86 % yields (735 mg, 1.74 
mmol). 
1
H NMR [400 MHz, (CD3)2CO)]: significant signals at δ -9.37 (very broad signal, CH3 DMSO). 
M.p. (slow and gradual thermal decomposition): >230 °C. 
FTIR-ATR: cm
-1
 1395.8 (w), 1287.0 (w) [δ (CH3)]; 1108.0 (s), 1096.0 (s) [ν (S=O) (DMSO)]; 
1011.4 (s), 953.9 (m) [ρ (CH3)]; 718.0 (w), 670.0 (w) [ν (C-S)]. 
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Chapter 3 
NOTA chelators 
1. Molecular imaging: introduction 
In the treatment of diseases and in particular of cancer, it is essential to deliver the therapeutic 
agents to the target site, at the right time, correct concentration and in a minimally invasive 
manner.
[184–188]
 On the other hand, also the early diagnosis of the disease is important to identify 
functional abnormalities which precede morphological changes, and to this aim molecular imaging 
may contribute to the reduction of morbidity and mortality.
[189]
 
The field of molecular imaging, “the visualization, characterization and measurement of biological 
processes at the molecular and cellular levels in humans and other living systems”,[190] has 
expanded tremendously over the last decade. ‘Molecular imaging’ is based on the biomedical 
imaging methods which allow visualizing specific biomarkers or processes in the living body at the 
molecular level, introducing suitable probes able to measure the expression of these markers at 
different stages of the disease.
[191]
 This approach presents several advantages over traditional 
diagnostic methods: it can give whole-body readout in an intact system which is much more 
relevant and reliable than in vitro/ex vivo assays; reduce the workload and speed up the drug 
development process; aid in lesion detection in patients and help in individualized treatment 
monitoring and dose optimization.
[192,193]
 Non-invasive detection of various molecular markers of 
diseases can allow for much earlier diagnosis, earlier treatment, and better prognosis that could 
eventually lead to personalized medicine.
[191,194]
 
 
Figure 40. Main in vivo imaging techniques. Pictures reproduced from Kizek et al.
[195]
 
 
Chapter 3 
68 
 
Imaging techniques are playing an increasingly important role in the investigation of the 
biodistribution and pharmacokinetics of drugs or drug delivery systems in cancer, and  research 
progresses in medical imaging may be beneficial for the complete health and disease management 
process.
[195]
 Medical imaging covers many different imaging modalities: X-ray-based methods such 
as radiography and Computed Tomography (CT), Magnetic Resonance Imaging (MRI), Ultrasound 
(US), nuclear medicine with Positron Emission Tomography (PET) and Single Photon Emission 
Computed Tomography (SPECT), and several optical imaging methods (Figure 40).
[46,186,195–199]
 
The relative advantages and limitations of these imaging modalities have been elaborately discussed 
in several recent review articles.
[186,197–199]
 
Among these methods, PET and optical imaging are considered quantitative or semi-quantitative 
imaging modalities that employ radiotracers or optical tracers to image biodistribution of the 
labeled drugs or probe loaded delivery systems in the body, while CT and MRI are normally used 
for anatomical imaging purposes.
[200]
 
PET and SPECT techniques exploit, respectively, positron and gamma emitting radionuclides for 
the generation of the signal that results in a whole-body scan in a single examination. They provide 
fast and non-invasive evaluation of physiological and pathological processes, and together with 
external and internal radiotherapy can be used for theranostic applications, which is considered as 
the main step towards personalized medicine.
[1,8,201,202]
 
 
1.1. PET imaging 
PET has become an established method for medical research and clinical routine diagnostics 
because of its ability to diagnose a disease in early stages and monitor therapeutic 
responses.
[197,203,204]
 
The major application domain of PET analyses is oncology; however, potential has been 
demonstrated for imaging of myocardial and pulmonary perfusion and ventilation, as well as 
inflammation and infection. Imaging of general biological properties and processes such as 
proliferation, apoptosis, hypoxia, glycolysis, and angiogenesis have also been investigated.
[205]
 
In a typical scenario of PET imaging (Figure 41), a suitable compound is radiolabeled with 
positron-emitting radionuclides such as 
18
F, 
64
Cu, 
68
Ga, or 
89
Zr and administered to a patient.
[197]
 
When the radioactive isotope incorporated into the PET tracer decays, a positron is emitted and 
immediately collides with an electron. The collision results in annihilation of both particles and 
release two γ photons (with an energy of 511 keV), which are approximately 180° apart.[206] 
The photons can be detected by a ring of detectors configured in the coincidence mode in the PET 
camera. When a sufficient number of decays have been detected, a computer converts the signal 
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relative to the decay events into a three-dimensional image, which provides information on the 
spatial distribution of the radioactivity as a function of time in the living subject.
[197]
 In fact, the 
colour of each pixel is correlated with the radioactivity concentration or some derivative thereof.
[206]
 
The major advantage of PET is that it not only enables the in vivo visualization of physiological 
processes at a molecular level in real time, but also quantifies them by measuring the spatial 
concentration of the radiation source.
[205]
 The widespread opinion is that PET is a costly technique, 
but indeed the total cost of the otherwise required examinations, hospitalization and risks associated 
with biopsy - as well as possible false diagnosis leading to futile surgery cost and patient distress - 
is much higher. In particular, the biopsy results might be misleading since the tumour diagnosis and 
staging is conducted ex vivo on invasively collected tissues. The sampled tissue is commonly 
heterogenic and thus might not be representative, while PET may provide non-invasively more 
detailed and accurate information on the heterogeneity of the whole tumour in a single 
examination.
[205]
 
 
Figure 41. Schematic illustration of a general PET acquisition process. 
 
PET also plays an important role in the process of drug development and evaluation, whereby 
understanding the mechanism of action of a drug and establishing its optimal dosage regimens and 
treatment strategies are most crucial.
[207–210]
 
Positron-emitting radionuclides of elements such as C, N, O can replace the stable analogues in 
drugs and biomolecules, and hence it is possible to synthesize PET probes with the same chemical 
structure as the parent unlabeled molecules without altering their biological activity.
[47]
 The most 
common radionuclides relevant for the labelling procedure of radiopharmaceuticals for PET, 
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SPECT, and radiotherapy are presented in Table 6. The majority are metals typically involved in 
coordination chemistry. Only few radionuclides are produced in generator systems. Factors as their 
production mode as well as physical and chemical features determine the choice of a radionuclide. 
Two gallium isotopes, 
66
Ga (t1/2 = 9.5 h) and 
68
Ga (t1/2 = 68 min), decay by β
+
-emission and are 
therefore suitable for PET imaging, 
67
Ga (t1/2 = 78 h) decays by electron capture with concomitant 
γ-emission and is used for SPECT imaging. Examples of clinically used radionuclides include also 
11
C, 
18
F, 
64
Cu, 
89
Zr, 
99m
Tc, 
111
In, 
124
I.
[47,205]
 The propagation of PET techniques is greatly stimulated 
by the widespread use of [
18
F]-fluorodeoxyglucose ([
18
F]-FDG) for many indications in oncology. 
FDG is a non-metabolized glucose analog that is a substrate both for the dedicated glucose 
transporters on the cell membrane and the cytoplasmic enzyme hexokinase responsible for 
phosphorylation. After phosphorylation, FDG is not a substrate for further pathways and is 
effectively trapped in cells.
[191,206]
 
 
Table 6. Selected radionuclides used in clinical PET, SPECT and radiotherapy, their production 
mode and decay properties.
[205]
 
 
Despite [
18
F]FDG is widely used in many cancer forms as a biomarker of the glucose transport, it 
fails in diagnosis of slowly growing tumours and in differentiating tumours from processes as 
inflammation, infection, reactive lymph nodes, tuberculosis and sarcoidosis.
[211,212]
 
Many cancer forms rely on glucose for energy production and growth and tend to have enhanced 
expression of glucose transporters and hexokinase, resulting in an elevated accumulation of FDG 
when studied with PET in vivo. The high uptake in normal organs, particularly in brain and gut, 
results in poor contrast in those areas and potential failure in lesion detection.
[211]
 Thus alternative 
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imaging agents with specific binding capability to e.g. receptors, antigens, enzymes are highly 
desirable and in this context 
68
Ga-complexes have particularly emerged.
[205]
 
68
Ga can be used for the labelling of small organic compounds, biological macromolecules as well 
as nano- and microparticles, thus largely expanding the potential of PET.
[205,213,214]
 
 
1.2. Chemistry of gallium 
Gallium is the third element of Group 13 of the Periodic Table and in aqueous solutions the only 
stable oxidation state of this metal is +3. Its chemistry is largely influenced by pH changes: the 
optimal pH is 3-5, while at pH >5 it tends to precipitate as Ga(OH)3.
[215,216]
 The isotope 
68
Ga is a 
positron emitter with a physical half-life of 67.71 min, which is compatible with the 
pharmacokinetics of most radiopharmaceuticals of low molecular weight as antibody fragments, 
peptides, aptamers and oligonucleotides. It can be produced from a generator system where 
68
Ge is 
absorbed on a chromatographic column with either inorganic or organic matrix.
[213,217,218]
 The 
generators are eluted with HCl solutions of various molarity (from 0.05 to 5.5 M, 5-7 mL) offering 
68
Ga in a cationic form suitable for the subsequent labelling. The generators can be eluted 
repeatedly during the day.
[205]
 The benefits of 
68
Ga, in comparison with the other radionuclides 
mentioned above, can be summarized as follows: it is produced from a long shelf-life and cost-
effective generator;
[218,219]
 the half-life of 
68
Ga permits the production and immediate application of 
the resulting agents, and the labelling synthesis is amenable to automation and kit-type preparation; 
in addition, it provides sufficient levels of radioactivity for high quality images, short scanning time 
(which determines a fast patient examination) and minimized radiation doses for the patient and 
personnel, also allowing fast dischargement of the patient; finally, it allows repetitive examinations 
within the same day.
[220]
 Various 
68
Ga-based imaging agents have already been tested in humans.
[8]
 
The Ga
3+
 ion is classified as a hard Lewis acid, forming thermodynamically stable complexes with 
ligands that are hard Lewis bases. These are ligands containing oxygen, nitrogen and sulfur donor 
atoms, such as carboxylate, phosphonate, hydroxamate and amine, but also softer functional groups 
such as phenolate and thiol groups were found to be appropriate.
[218]
 The hard acid Ga
3+
 can form 
tetra-, penta-, and hexa-coordinated complexes. The latter ones are the most stable species with 
octahedral coordination sphere.
[213,218]
 
The coordination reaction requires buffering, first of all, to ensure the suitable pH for the 
deprotonation of the coordinating positions, and secondly, to maintain Ga
3+
 in solution that might 
otherwise form Ga(OH)3 and precipitate at pH 3-7.
[213]
 Unlike other PET radioisotopes, like 
18
F or 
11
C, ionic Ga
3+
 cannot be directly bound to targeting vectors but must be conjugated to a target 
vector using a bifunctional chelating agent, such as the macrocyclic chelators NOTA (1,4,7-
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triazacyclononane-1,4,7-triacetic acid) and DOTA (1,4,7,10-tetraazacyclododecane-1,4,7,10-
tetraacetic acid), which can form within 10 min very stable complexes with Ga
3+
 at pH 3.5 at r.t. in 
high chelation efficiency (>95%).
[221–224]
 The thermodynamic stability constant of the Ga
3+
 complex 
with the chelator DOTA is much lower (logK = 21.33)
[225]
 than that of the chelator NOTA (logK = 
30.98)
[226]
 due to the larger size of its cavity. 
 
Figure 42. Chemical structures of DOTA (left) and NOTA (right) macrocycles. 
 
DOTA has 8 binding sites available for complexing with metals, and NOTA has only 6 (Figure 42); 
thus, no free binding sites are left on NOTA after gallium complexation, which requires all the 6 
binding sites. However, it has been shown that amide oxygen or nitrogen can bind gallium
[227]
 and 
as a result, various amino acid derivatives conjugated with NOTA have been developed for cancer 
imaging.
[228,229]
 Remarkbly, different syntheses of bifunctional NOTA derivatives have been 
reported recently by several groups
[230,231]
 Their approaches included intra- or intermolecular 
cyclization strategy as key steps, affording NOTA derivatives functionalized on a carbon of the 
macrocyclic ring. Harsh conditions for deprotection and reduction are required in order to use these 
compounds for coupling to biomolecules. A bifunctional NOTA derivative, functionalized on the –
CH2- group of one of the acetic acid arms, was proposed for conjugation to proteins.
[232]
 
 
1.3. Dual-modality imaging with radiolabeled nanoparticles 
As mentioned above, various imaging modalities are successfully employed to investigate the 
anatomic or functional dissemination of tissues in the body. However, no single imaging modality 
allows overall structural, functional, and molecular information, as each imaging modality has its 
own unique strengths and weaknesses.
[196,233]
 For example, MRI has high resolution, yet it suffers 
from low sensitivity; PET imaging has very high sensitivity but relatively poor resolution.
[234]
 The 
combination of multiple molecular imaging modalities offers the prospect of improved diagnostic 
and therapeutic monitoring abilities, with remarkable synergistic advantages over any modality 
DOTA NOTA
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alone, overcoming the shortcomings of the individual modalities and providing complementary 
information, especially in vivo, on cellular and molecular functions.
[195,233]
 
For example, with dual function probes for PET/MRI, the high sensitivity of PET can be used as a 
whole body screen to identify regions of interest, thereby reducing the volume of tissue that needs 
to be scanned; this reduces scan time required for high-resolution imaging by MRI.
[235,236]
 
The idea of combining imaging technologies moved to the mainstream with the advent of the first 
successful commercial fused instruments. The first fused PET/CT instrument, developed in 1998 by 
Townsend and colleagues in collaboration with Siemens Medical, was available commercially in 
2001.
[236]
 The next wave of innovation has been in PET/MRI-fused instruments, which have 
generated much hope for improved patient safety and imaging capability over PET/CT. Although 
research on PET/MRI instruments was initiated at approximately the same time as PET/CT, the 
economic and engineering challenges of merging the two modalities slowed development, and the 
first commercial PET/MRI prototype for a human scale hybrid scanner was not unveiled until 
2007.
[237]
 
Multimodality imaging using a small molecule-based probe is very challenging, but nanoparticles 
(NPs) can be very useful to this purpose.
[238]
 In fact, they can be intrinsically superparamagnetic – 
as in the case of SPIONs (Superparamagnetic Iron Oxide Nanoparticles) - and therefore useful for 
MRI imaging
[171,172]
 or having large surface areas they can be used as platforms for the 
incorporation of multifunctional agents for multimodality molecular imaging.
[239–242]
 
In particular, lipid-based vectors,
[243,244]
 nanoparticles
[245]
 or nanomaterials
[246]
 are being specially 
investigated due to the fact that the mechanical, chemical, electrical, optical, magnetic, electro-
optical and magneto-optical properties of these systems are different from their bulk properties and 
depend on the particle size.
[21,247] Nanoparticle probes can endow imaging techniques with enhanced 
signal sensitivity, better spatial resolution, and the ability to relay information about biological 
systems at the molecular and cellular levels.
[233,248]
 In particular, PET radionuclide-labeled 
nanoparticles have been extensively used in both preclinical and clinical studies as tools to 
explorethe in vivo pharmacokinetics, imaging capability, and theranostic potential of 
nanoparticles.
[31,249–252]
 Recently, the development of a nanoparticle-based dual-modality diagnostic 
instrument for PET/MRI has been demonstrated,
[234,240–242,252–254]
 and for this aim iron oxide NPs 
are considered as favourite platforms.  
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2. Design, synthesis and characterization of a mini-library of NOTA 
derivatives 
Many novel radio-pharmaceuticals have been recently proposed in the literature to improve tumour 
identification and localization.
[242,255]
 In this context, we here describe the synthesis and 
characterization of a mini-library of lipophilic derivatives of NOTA (1,4,7-triazacyclononane-1,4,7-
triacetic acid) to be used as 
68
Ga chelator in PET analyses.
[230–232]
 
 
Figure 43. General design used for the preparation of NOTA derivatives. 
 
The here described NOTA analogs (as shown in the general scheme in Figure 43) share a common 
design, based on a polar NOTA moiety and a flexible linker (1,2-diaminoethane), and differ for the 
lipophilic component, which is a residue of oleic acid, lipoic acid or a biotin moiety (NOTA-OL, 
NOTA-Lip and NOTA-Bio, respectively, Figure 44). The lipophilic tails inserted have been chosen 
for their proven biocompatibility for in vivo applications, and for the possibility of subsequent 
anchoring on differently decorated nanoparticles or nanoplatforms, to be used as PET analysis 
probes. In the specific case of previously described phosphocholine-decorated SPIONs, the 
insertion of NOTA-OL in their coating would allow performing bimodal “two-in-one” imaging 
investigations, i.e. MRI and PET analysis.
[191,233,236,256,257]
 Oleic acid has an 18-carbon atoms chain 
which allows its immobilization onto lipid-functionalized NPs or liposome platforms through 
hydrophobic interactions. The disulfide bond of lipoic acid, thanks to its high affinity for metals, 
provides covalent bonds with the surface of metal or metal-oxide NPs. Finally, biotin is useful to 
functionalize avidin or streptavidin-coated NPs exploiting the exceptionally high affinity of these 
proteins for biotin. As a successive development of this work, in collaboration with specialized 
laboratories, we intend to label the NOTA-conjugated nanoparticles with 
68
Ga in order to obtain the 
effective labelled probes and evaluate their efficiency as diagnostic agents in animal models. 
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Figure 44. Novel NOTA derivatives here realized. 
 
2.1. Results and discussion 
2.1.1. Synthesis and characterization of lipophilic NOTA derivatives 
The assembly of the three parts of the NOTA derivatives has been based on the formation of amide 
bonds between NH2 and COOH groups, which can be easily obtained in high yields using standard 
condensing agents. Notably, these bonds are chemically stable under a wide range of conditions, 
and particularly in the acid conditions used in our synthetic plan for the protective groups removal. 
For the preparation of all the final NOTA analogs, a similar synthetic protocol has been adopted, 
differing only for the kind of carboxylic acid used in the second step. In particular, the key 
intermediate in the preparation of the final derivatives is compound 24, whose synthesis has been 
realized starting from commercially available 1,2-diaminoethane (compound 23). The mono-
protection of compound 23 was performed to simplify the successive condensation step: in fact, in 
all our initial attempts to directly couple 23 with a carboxylic acid (either of the lipophilic 
component or of the protected NOTA derivative) a very complex mixture was always obtained, 
with prevalence of dimeric products. For this reason, a 4-monomethoxytrityl (MMT) protective 
group was introduced at one end of the diamine, so to have a unique reactive amino group available 
at the other end and thus simplify the successive reaction and related purification. In fact, the MMT 
moiety presents a high molar absorption coefficient, which allows an easy UV monitoring of the 
new formed product during the reaction and its chromatographic purification by silica gel column. 
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The tritylation reaction was hence performed using 4-methoxytriphenylmethyl chloride (MMT-Cl), 
an excess of 1,2-diaminoethane (20 eq.) and catalytic amounts of DMAP (0.2 eq.) in dry pyridine 
(Scheme 7). The excess of compound 23 was necessary in order to exclusively obtain the mono-
alkylated product and was then removed from the reaction mixture through a CH2Cl2/H2O 
extraction. Then, desired compound 24 was isolated in 75 % yields via a chromatographic 
purification on a silica gel column. Successively, this was reacted with commercially available 
carboxylic acids (oleic, lipoic or biotinyl-6-aminocaproic acid) in the presence of DCC (3 eq.) and 
DMAP (2 eq.) as condensing agents. Pure compound 25, isolated in a pure form by silica gel 
column chromatography, was then reacted for 1 h at r.t. with an acidic solution of TCA 2 % in 
CH2Cl2 for the MMT removal. Compound 26 was then conjugated with the macrocycle NOTA 
using the commercially available, tert-butyl protected derivative NODA-Ga(tBu)3 {4-[4,7-bis(2-
tert-butoxy-2-oxoethyl)-1,4,7-triazonan-1-yl]-5-tert-butoxy-5-oxopentanoic acid} in the presence of 
the condensing system DCC/DMAP under anhydrous conditions. After chromatographic 
purification on a silica gel column, compound 27 was obtained in a pure form and finally treated 
with an acidic solution of 10 % TFA in CH2Cl2 in order to remove the tert-butyl protecting groups. 
After reaction completion, the solvent was removed under reduced pressure and the crude product 
coevaporated several times with isopropanol in order to remove acid traces. The use of strong acidic 
conditions causes the removal of the tert-butyl cation, which rearranges by -elimination forming 
isobutylene, a volatile compound easily removed by repeated coevaporations with dry solvents. 
The complete tert-butyl removal from NOTA derivatives was checked by 
1
H NMR of the reaction 
mixture, monitoring the disappearance of the typical signal of the tert-butyl protons. The final 
compound was recovered in almost quantitative yields in all cases (95 %). 
Following this synthetic scheme, the final NOTA-OL, NOTA-Lip and NOTA-Bio were obtained in 
5 steps in 29, 19 and 32% overall yields, respectively. All the synthetic intermediates and the final 
NOTA derivatives were characterized using monodimensional (
1
H, 
13
C) and bidimensional (
1
H-
1
H 
COSY) NMR, as well as by ESI-MS data. As a representative example, the MS spectrum of 
NOTA-OL is shown in Figure 45. 
For the subsequent immobilization onto liposomes or nanoparticles, NOTA-OL has been further 
purified by HPLC on C18 analytical column using a linear gradient of B (50 to 100 % in 14 min) in 
A solutions (Solution A: H2O 0.1% TFA; Solution B: CH3OH 0.1 % TFA) and UV detection at  = 
218 nm (tR = 11.6 min). 
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Scheme 7. Synthetic procedure for the preparation of the NOTA derivatives NOTA-OL, NOTA-Lip 
and NOTA-Bio. 
 
 
Figure 45. MALDI-TOF spectrum (positive ions) of NOTA-OL.  
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2.2. Experimental section 
 Materials and general methods 
All the reagents and solvents were of the highest commercially available quality and were used as 
received. TLC analyses were carried out on silica gel plates from Macherey-Nagel (60, F254). 
Reaction products on TLC plates were visualized by UV-light and then by treatment with an 
oxidant acidic solution (acetic acid / water / sulfuric acid, 10:4:5, v/v). For column chromatography, 
silica gel from Macherey-Nagel (Kieselgel 60, 0.063-0.200 mm) was used. 
NMR spectra were recorded on Bruker WM-400, Varian Gemini 200 and Varian Inova 500 
spectrometers, as specified. All the chemical shifts () are expressed in ppm with respect to the 
residual solvent signal both for 
1
H NMR (CDCl3 = 7.26 ppm, MeOD = 3.31 ppm) and 
13
C NMR 
(CDCl3 = 76.9 ppm, MeOD = 49.1 ppm). All the coupling constants (J) are quoted in Hertz (Hz). 
Peaks assignments have been carried out based on standard 
1
H-
1
H COSY and HSQC experiments. 
The following abbreviations were used to explain the multiplicities: s = singlet; d = doublet; t = 
triplet; q = quartet; m = multiplet; b = broad. 
In order to easily identify the proton and carbon signals of the compounds, letters and numbers were 
assigned to the structures. For MMT and NOTA moieties, the used letters and numbers are shown 
in accompanying pictures. The lipophilic components (oleyl and biotinyl-6-aminocaproyl residues) 
were indicated with progressive numbers (1’-18’ or 1’’-14’’, according to the carbon chain length) 
starting from the carbonyl group. 
MALDI-TOF mass spectrometric analyses were performed on a TOF/TOF™ 5800 System in the 
positive mode, using 2,5-dihydroxybenzoic acid (DHB) as the matrix. For the deposition on 
MALDI plate, the droplet spotting method was used: the sample - 1 μg/μL in CH3CN/CH3OH, 7:3 
(v/v) - was first deposited on the plate followed by DHB deposition - 10 mg/mL in CH3CN/CH3OH, 
7:3 (v/v) - and proper mixing before drying the components. The mass spectra were recorded in the 
range 200-1000 m/z values. 
For the ESI-MS analyses, a Waters Micromass ZQ instrument – equipped with an Electrospray 
source – was used in the positive and/or negative mode. 
HPLC chromatographic analyses and purifications were performed using an Agilent HPLC system, 
equipped with a UV/vis detector. A Kinetex C18 column (Phenomenex, 250 x 4.60 mm; flow rate 
0.8 mL min
-1
) and UV detection at 218 nm were used for the purification. 
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 Synthesis of NOTA-OL 
Synthesis of N-1-[(4-methoxyphenyl)diphenylmethyl]ethane-1,2-diamine (24) 
Commercially available 1,2-diaminoethane (1.07 mL, 16 mmol) was dissolved in 3.5 mL of dry 
pyridine and then MMT-Cl (248 mg, 0.80 mmol) and catalytic amounts of DMAP (19.6 mg, 0.16 
mmol) were sequentially added to the reaction mixture, left under stirring at r.t.. After 2 h, TLC 
analysis indicated the formation of the desired product and the reaction was quenched by addition 
of few drops of MeOH. The reaction mixture was concentrated in vacuo, then the crude product was 
extracted with CH2Cl2/H2O. The desired compound was recovered in the organic phases, which 
were dried upon addition of anhydrous Na2SO4, filtered and then concentrated under vacuum. The 
obtained residue was purified by chromatography on a silica gel column eluted with CH2Cl2/MeOH 
(95:5, v/v), containing 2 % of TEA (v/v), necessary to avoid even partial, undesired removal of the 
MMT protecting group promoted by silica. Target compound 24 was obtained in 75 % yields (200 
mg, 0.60 mmol). 
24: pale yellow oil. Rf = 0.6 (CH2Cl2/MeOH, 9:1, v/v). 
1
H NMR (400 MHz, CDCl3): δ 7.48 (d, J = 7.7 Hz, 4H, 4x Hα); 
7.39 (d, J = 8.6 Hz, 2H, 2x Hα’); 7.26 (t, J = 7.4 and 7.6 Hz, 4H, 
4x Hβ); 7.17 (d, J = 7.1 Hz, 2H, 2x Hγ); 6.80 (d, J = 8.6 Hz, 2H, 
2x Hβ’); 3.74 (s, 3H, -OCH3); 2.78 (t, J =5.8 Hz, 2H, -CH2NH2); 
2.22 (t, J =5.8 Hz, 2H, -CH2NH MMT).  
13
C NMR (100 MHz, CDCl3): δ 157.6 (C-8); 146.1 (2x C-1); 
138.0 (C-5); 129.5 (2x C-6); 128.3 (4x C-2); 127.5 (4x C-3); 125.9 
(2x C-4); 112.8 (2x C-7); 69.9 (quaternary carbon of MMT); 54.8 
(-OCH3); 46.0 (-CH2NH2); 42.4 (-CH2NH MMT). 
 
Synthesis of N-2-[(4-methoxyphenyl)diphenylmethylamino]ethyl oleamide (25a) 
Commercially available oleic acid (85 μL, 0.27 mmol) was dissolved in 3 mL of dry CH2Cl2 and 
then treated with DMAP (66.7 mg, 0.55 mmol) and DCC (169 mg, 0.82 mmol). After 1 h, 
compound 24 (99.7 mg, 0.30 mmol) was added to the reaction mixture, which was taken at r.t. 
under stirring. After 15 h, TLC analysis indicated the complete transformation of oleic acid in a 
more apolar compound. Thus, the reaction mixture was quenched by addition of MeOH and the 
solvent was removed under reduced pressure. The crude product was purified by chromatography 
on a silica gel column using n-hexane/AcOEt (8:2, v/v), containing 2 % of TEA as eluent, yielding 
desired compound 25a in 59 % yields (96.7 mg, 0.16 mmol). 
25a: pale yellow oil. Rf = 0.6 (n-hexane/AcOEt 3:2, v/v). 
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1
H NMR (400 MHz, CDCl3): δ 7.44 (d, J = 7.6 Hz, 4H, 4x Hα); 7.35 (d, J = 8.6 Hz, 2H, 2x Hα’); 
7.27 (t, J = 7.4 and 7.5 Hz, 4H, 4x Hβ); 7.19 (d, J = 7.1 Hz, 2H, 2x Hγ); 6.81 (d, J = 8.5 Hz, 2H, 2x 
Hβ’); 5.98 (bs, 1H, NH); 5.35 (s, 2H, CH-9’, 10’); 3.77 (s, 3H, -OCH3); 3.35 (bd, 2H, -CH2NH); 
2.33 (bt, 2H, -CH2NH MMT); 2.18 (t, J = 7.5 and 7.6 Hz, 2H, CH2-2’); 2.01 (overlapped signals, 
4H, 2x CH2-8’, 11’); 1.66-1.63 (m, 2H, CH2-3’); 1.31-1.28 (overlapped signals, 20H, 10x CH2-4’, 
5’, 6’, 7’, 12’, 13’, 14’, 15’, 16’, 17’); 0.89 (t, J = 6.0 and 6.8 Hz, 3H, CH3-18’). 
13
C NMR (100 MHz, CDCl3): δ 173.3 (C=O oleic); 158.0 (C-8); 145.6 (2x C-1); 137.5 (C-5); 129.9 
(overlapped signals, 2x CH-9’, 10’); 129.7 (2x C-6); 128.3 (4x C-2); 127.8 (4x C-3); 126.4 (2x C-
4); 113.1 (2x C-7); 70.5 (quaternary carbon of MMT); 55.1 (-OCH3); 43.7 (-CH2NH); 39.5 (-
CH2NH MMT); 36.8 (CH2-2’); 31.8, 29.6, 29.4, 29.2, 29.0, 22.5 (overlapped signals, 10x CH2-, 4’, 
5’, 6’, 7’, 12’, 13’, 14’, 15’, 16’, 17’); 27.1 (overlapped signals, 2x CH2-8’, 11’); 25.7 (CH2-3’); 
14.0 (CH3-18’). 
ESI-MS (positive ions): calculated for C40H56N2O2, 596.43; found m/z: 597.97 [M+H
+
]; 619.79 
[M+Na
+
]; 635.59 [M+K
+
]. 
MALDI-MS (positive ions): calculated for C40H56N2O2, 596.43; found m/z: 347.23 [M-
MMT+Na
+
]; 363.20 [M-MMT+K
+
]. 
 
Synthesis of N-(2-aminoethyl)oleamide (26a) 
Compound 25a (40.1 mg, 0.07 mmol) was dissolved in 2 mL of a 2 % TCA solution in CH2Cl2. 
Upon addition of TCA, the reaction mixture showed an intense yellow-orange colour, typical of the 
MMT cation. After 1 h, TLC analysis indicated the complete disappearance of the starting material 
and the appearance of a new, more polar compound. To quench the reaction, MeOH was added 
until disappearance of the orange colour, and then TEA until neutralization. The crude product was 
extracted with CH2Cl2/H2O and the residue purified by chromatography on silica gel column using 
CH2Cl2/MeOH (98:2, v/v) as eluent, also containing 2 % of TEA, yielding desired compound 26a 
in 98 % isolated yields (22.3 mg, 0.07 mmol). 
26a: pale yellow oil. Rf = 0.5 (CH2Cl2/MeOH, 8:2, v/v). 
1
H NMR (400 MHz, CDCl3): δ 6.55 (bs, 1H, NHC=O oleic); 5.32 (s, 2H, CH-9’, 10’); 3.27 (bs, 
2H, -CH2NH oleic); 3.06 (bs, 2H, NH2); 2.90 (bt, 2H, -CH2NH2); 2.19 (t, J = 7.4 and 7.3 Hz, 2H, 
CH2-2’); 1.98 (overlapped signals, 4H, 2x CH2-8’, 11’); 1.60 (m, 2H, CH2-3’); 1.28-1.19 
(overlapped signals, 20H, 10x CH2-4’, 5’, 6’, 7’, 12’, 13’, 14’, 15’, 16’, 17’); 0.86 (bt, 3H, CH3-
18’). 
13
C NMR (100 MHz, CDCl3): δ 174.7 (C=O oleic); 129.5, 129.4 (overlapped signals, 2x CH-9’, 
10’); 39.9 (-CH2NH oleic); 36.7 (-CH2NH2); 36.1 (CH2-2’); 31.5, 29.4, 28.9, 22.3 (overlapped 
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signals, 10x CH2-4’, 5’, 6’, 7’, 12’, 13’, 14’, 15’, 16’, 17’); 26.9 (overlapped signals, 2x CH2-8’, 
11’); 25.3 (CH2-3’); 13.8 (CH3-18’). 
MALDI-MS (positive ions): calculated for C20H40N2O, 324.31; found m/z: 347.17 [M+Na
+
]; 
363.19 [M+K
+
]. 
 
Synthesis of (Z)-di-tert-butyl 2,2'-[7-(1-tert-butoxy-5-2-oleamidoethylamino-1,5-dioxopentan-
2-yl)-1,4,7-triazonane-1,4-diyl]diacetate (27a) 
Commercially available NOTA derivative {4-[4,7-bis(2-tert-butoxy-2-oxoethyl)-1,4,7-triazonan-1-
yl]-5-tert-butoxy-5-oxopentanoic acid} – here indicated as NOTA-(COOtBu)3 - (42 mg, 0.08 
mmol) was dissolved in 3 mL of dry CH2Cl2; then DMAP (18.5 mg, 0.15 mmol) and DCC (47 mg, 
0.23 mmol) were added to the resulting solution. The reaction mixture was left under stirring and 
argon flow at r.t. for ca. 1 h. After complete activation of the carboxylic group of NOTA, compound 
26a was added in slight stoichiometric excess (31.2 mg, 0.10 mmol). After 15 h the reaction, 
monitored via TLC, indicated the complete disappearance of both starting products and the 
appearance of a new product. The reaction was quenched by addition of MeOH; the solvent was 
removed under reduced pressure and the crude product was purified by chromatographic column 
eluting with CHCl3/MeOH (95:5, v/v). This purification procedure was not satisfactory to 
completely remove all the impurities and therefore a second chromatographic purification, using a 
column eluted with AcOEt/MeOH (95:5, v/v), was carried out, affording pure compound 27a with 
68% isolated yields (46.3 mg, 0.05 mmol). 
NOTA-(COOtBu)3: 
1
H NMR (400 MHz, CDCl3): δ 3.41 
(overlapped signals, 4H, CH2-d and CH2-e); 3.34 (m, 1H, CH-c); 
3.05-2.91 (overlapped signals, 12H, -NCH2CH2N- of 
macrocycle); 2.51 (m, 2H, CH2-a); 1.96 (m, 2H, CH2-b); 1.44 (s, 
27H, CH3 of -tBu). 
13
C NMR (100 MHz, CDCl3): δ 176.2 (COOH); 171.0, 170.7 
(overlapped signals, 3x COOtBu); 81.6, 81.1 (overlapped signals, 
3x quaternary carbons of tBu); 68.3 (CH-c); 58.5 (overlapped signals, CH2-d and CH2-e); 54.9, 
54.3, 52.3 (overlapped signals, -NCH2CH2N- of the macrocycle); 33.6 (CH2-a); 28.1 (CH3 of -tBu); 
24.9 (CH2-b). 
27a: yellow oil. Rf = 0.9 (CH2Cl2/MeOH, 8:2, v/v). 
1
H NMR (400 MHz, CDCl3): δ 6.48 (s, 1H, NH); 5.33 (s, 2H, CH-9’, 10’); 3.75 (m, 2H, -CH2NH 
oleic); 3.65 (overlapped signals, 4H, CH2-d and CH2-e); 3.38 (overlapped signals, 3H, CH-c, -
CH2NH oleic); 3.23-2.80 (overlapped signals, 14H, -NCH2CH2N- of the macrocycle, CH2NH); 
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2.38 (m, 2H, CH2-a); 2.20 (bt, 2H, CH2-2’); 1.99 (overlapped signals, 6H, 2x CH2-8’, 11’, CH2-b); 
1.59 (m, 2H, CH2-3’); 1.47 (s, 27H, CH3 of -tBu); 1.28-1.26 (overlapped signals, 20H, 10x CH2-4’, 
5’, 6’, 7’, 12’, 13’, 14’, 15’, 16’, 17’); 0.87 (bt, 3H, CH3-18’). 
13
C NMR (100 MHz, CDCl3): δ 174.6 (overlapped signals, C=O NOTA, C=O oleamide); 172.8 
(overlapped signals, 3x COOtBu); 129.8, 129.7 (2x CH-9’, 10’); 82.8 (overlapped signals, 3x 
quaternary carbons of tBu); 63.8 (CH-c); 55.9 (overlapped signals, CH2-d and CH2-e); 54.3, 53.9, 
51.7 (overlapped signals, -NCH2CH2N- of the macrocycle); 39.9 (-CH2NH oleamide); 39.5 (-
CH2NH NOTA); 36.4 (CH2-2’); 32.7 (CH2-a); 31.8, 29.7, 29.5, 29.2, 29.1, 22.6 (overlapped signals, 
10x CH2-4’, 5’, 6’, 7’, 12’, 13’, 14’, 15’, 16’, 17’); 27.9 (CH3 of -tBu); 27.1 (overlapped signals, 2x 
CH2-8’, 11’); 25.6 (CH2-b); 25.3 (CH2-3’); 14.0 (CH3-18’). 
ESI-MS (positive ions): calculated for C47H87N5O8, 849.66; found m/z: 850.59 [M+H
+
]; 883.55 
[M+Na
+
]. 
 
Synthesis of NOTA-OL 
Compound 27a (20.1 mg, 0.02 mmol) was dissolved in dry CH2Cl2 (1 mL) and then 1 mL of a 10 % 
TFA solution in CHCl3 was added. The reaction mixture was left under stirring at r. t. and checked 
by TLC until the disappearance of the starting compound. After 15 h, the crude reaction was 
concentrated in vacuo to remove the solvent. Subsequently, in order to remove even traces of 
trifluoroacetic acid, the resulting product was coevaporated three times with dry n-isopropanol and 
then taken several hours at the oil pump. In this way, without further purification steps, the final 
product NOTA-OL was recovered in a pure form with 95% yields (13.1 mg, 0.02 mmol). 
NOTA-OL: oil. Rf = 0 (CH2Cl2/MeOH, 8:2, v/v). 
1
H NMR (400 MHz, CDCl3): δ 5.33 (s, 2H, CH-9’, 10’); 4.01-3.36 (overlapped signals, 5H, CH2-d, 
CH2-e, CH-c,); 2.97 (overlapped signals, 4H, -CH2NH oleamide, -CH2NH NOTA); 2.85 
(overlapped signals, 14H, -NCH2CH2N- of the macrocycle, CH2-2’); 2.40 (m, 2H, CH2-a); 2.01-
1.83 (overlapped signals, 6H, 2x CH2-8’, 11’, CH2-b); 1.56 (m, 2H, CH2-3’); 1.25-1.23 (overlapped 
signals, 20H, 10 x CH2-4’, 5’, 6’, 7’, 12’, 13’, 14’, 15’, 16’, 17’); 0.87 (bt, 3H, CH3-18’). 
13
C NMR (100 MHz, CDCl3): δ 175.3 (3x COOH); 172.0 (C=O NOTA); 171.4 (C=O oleic); 129.9, 
128.2 (overlapped signals, 2x CH-9’, 10’); 65.6 (CH-c); 56.3 (overlapped signals, CH2-d and CH2-
e); 53.8, 52.2, 49.4 (overlapped signals, -NCH2CH2N- of the macrocycle); 39.2 (-CH2NH 
oleamide); 38.5 (CH2-2’); 36.5 (-CH2NH NOTA); 34.6 (CH2-a); 31.8, 29.7, 29.6, 29.4, 29.2, 22.6 
(overlapped signals, 10x CH2-4’, 5’, 6’, 7’, 12’, 13’, 14’, 15’, 16’, 17’); 27.1 (overlapped signals, 2x 
CH2-8’, 11’); 26.6 (CH2-3’); 24.5 (CH2-b); 14.0 (CH3-18’). 
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MALDI-MS (positive ions): calculated for C35H63N5O8, 681.47; found m/z: 682.39 [M+H
+
]; 704.38 
[M+Na
+
]; 720.35 [M+K
+
]. 
 
 Synthesis of NOTA-Lip 
Synthesis of 5-{1,2-dithiolan-3-yl-N-2-[(4-methoxyphenyl) diphenylmethylaminoethyl]} 
pentanamide (25b) 
Commercially available lipoic acid (101 mg, 0.49 mmol) was dissolved in 4.5 mL of dry CH2Cl2 
and then treated with DMAP (120 mg, 0.98 mmol) and DCC (305 mg, 1.48 mmol). After 1 h 
compound 24 was added to the reaction mixture in a little stoichiometric excess (179.2 mg, 0.54 
mmol). After stirring for 15 h at r. t. TLC analysis indicated the complete transformation of oleic 
acid into a more apolar product. Thus, the reaction mixture was stopped adding MeOH and the 
solvent was removed under reduced pressure. The crude product was purified by chromatography 
on a silica gel column using n-hexane/AcOEt (6:4, v/v) as eluent, containing 2 % of TEA, affording 
desired compound 25b in 80 % yields (204 mg, 0.40 mmol) 
25b: yellow oil. Rf = 0.7 (CH2Cl2/MeOH, 95:5, v/v). 
1
H NMR (400 MHz, CDCl3): δ 7.52 (d, J = 7.6 Hz, 4H, 4x Hα); 7.42 (d, J = 8.5 Hz, 2H, 2x Hα’); 
7.35 (t, J = 7.3 and 7.4 Hz, 4H, 4x Hβ); 7.27 (d, J = 7.1 Hz, 2H, 2x Hγ); 6.89 (d, J = 8.5 Hz, 2H, 2x 
Hβ’); 5.91 (bs, 1H, NH); 3.85 (s, 3H, -OCH3); 3.62 (m, 1H, CH-S); 3.43 (q, 2H, -CH2NH lipoic); 
3.41-3.19 (m, 2H, CH2-S); 2.55-2.49 (m, 1H, CH2a-CH2-S); 2.39 (t, J = 5.7 and 5.6 Hz, 2H, -
CH2NH MMT); 2.28 (t, J = 7.1 and 7.2 Hz, 2H, -CH2-C=O lipoic); 2.01-1.93 (m, 1H, CH2b-CH2-
S); 1.81-1.53 (m, 6H, 3x CH2 lipoic). 
13
C NMR (100 MHz, CDCl3): δ 172.6 (C=O lipoic); 157.8 (C-8); 145.8 (2x C-1); 137.7 (C-5); 
129.6 (2x C-6); 128.3 (4x C-2); 127.8 (4x C-3); 126.3 (2x C-4); 113.0 (2x C-7); 70.1 (quaternary 
carbon of MMT); 56.3 (CH-S); 55.0 (-OCH3); 43.3 (-CH2NH lipoic); 40.1 (CH2-S); 39.9 (-CH2NH 
MMT); 38.3 (CH2-C=O lipoic); 36.5, 34.5, 28.7, 25.3 (overlapped signals, 4 aliphatic carbons of 
lipoic). 
ESI-MS (positive ions): calculated for C30H36N2O2S2, 520.22; found m/z: 543.75 [M+Na
+
]. 
MALDI-MS (positive ions): calculated for C30H36N2O2S2, 520.22; found m/z: 271.60 [M-
MMT+Na
+
]; 287.08 [M-MMT+K
+
]. 
 
Synthesis of N-2-aminoethyl-5-(1,2-dithiolan-3-yl)pentanamide (26b) 
Compound 25b (200 mg, 0.38 mmol) was dissolved in 3 mL of a 2 % TCA solution in CH2Cl2. 
Upon addition of TCA, the reaction mixture showed an intense yellow-orange coloration, typical of 
the MMT cation. After 1 h, TLC analysis indicated the complete disappearance of the starting 
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material and the appearance of a new, more polar compound. To quench the reaction, MeOH was 
added until disappearance of the orange colour, followed by TEA until neutralization. The crude 
product was extracted with CH2Cl2/H2O, recovering the desired compound in the aqueous phases. 
Then the solvent was removed under vacuum and the residue purified by chromatography on a 
silica gel column using CH2Cl2/MeOH (9:1, v/v) as eluent containing 2 % of TEA, giving desired 
compound 26b in 58 % isolated yields (53.8 mg, 0.22 mmol). 
26b: yellow oil. Rf = 0.4 (CH2Cl2/MeOH, 8:2, v/v). 
1
H NMR (400 MHz, CDCl3): δ 5.93 (bs, 1H, NH); 3.57 (m, 1H, CH-S); 3.30 (m, 2H, -CH2NH 
lipoic); 3.20-3.08 (m, 2H, CH2-S); 2.83 (t, J = 5.9 and 5.8 Hz, 2H, -CH2NH2); 2.50-2.42 (m, 1H, 
CH2a-CH2-S); 2.20 (t, J = 7.2 and 7.5 Hz, 2H, -CH2-C=O lipoic); 1.97-1.86 (m, 1H, CH2b-CH2-S); 
1.77-1.41 (m, 6H, 3x CH2 lipoic). 
13
C NMR (100 MHz, CDCl3): δ 172.8 (C=O lipoic); 56.3 (CH-S); 41.8 (-CH2NH lipoic); 41.2 
(CH2-S); 40.1 (-CH2NH MMT); 38.4 (CH2-C=O lipoic); 36.4, 34.5, 28.7, 25.3 (overlapped signals, 
4 aliphatic carbons of lipoic). 
ESI-MS (positive ions): calculated for C10H20N2OS2, 248.10; found m/z: 249.24 [M+H
+
]; 272.16 
[M+Na
+
]. 
 
Synthesis of di-tert-butyl 2,2'-7-5-{2-[5-(1,2-dithiolan-3-yl)pentanamido ethylamino]-1-tert-
butoxy-1,5-dioxopentan-2-yl}-1,4,7-triazonane-1,4-diyl diacetate (27b) 
Commercially available NOTA derivative NODA-Ga(tBu)3 (40.1 mg, 0.07 mmol) was dissolved in 
3 mL of dry CH2Cl2; then DMAP (17.8 mg, 0.15 mmol) and DCC (45.0 mg, 0.22 mmol) were 
added to the resulting solution. The reaction mixture was left under stirring and argon flow at r. t. 
for ca. 1 h. After complete activation of the carboxylic group of NOTA, compound 26b was added 
to the reaction mixture in slight stoichiometric excess (20.9 mg, 0.08 mmol). After 15 h the 
reaction, monitored via TLC, indicated the complete disappearance of both starting products and the 
appearance of a new product. So the reaction was quenched by addition of MeOH; the solvent was 
removed under reduced pressure and the crude product purified by chromatographic column eluting 
with CHCl3/MeOH (98:2, v/v), affording pure compound 27b with 58% isolated yields (31.4 mg, 
0.04 mmol). 
27b: oil. Rf = 0.8 (CHCl3/MeOH, 8:2, v/v). 
1
H NMR (400 MHz, CDCl3): δ 3.65 (m, 1H, CH-S); 3.35-321 (overlapped signals, 9H, -CH2NH 
lipoic, CH-c, CH2-d, CH2-e, CH2-S); 3.04 (overlapped signals, 12H, -NCH2CH2N- of the 
macrocycle); 2.91-2.74 (overlapped signals, 4H, CH2-a, -CH2NH NOTA); 2.57 (m, 1H, CH2a-CH2-
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S); 1.73-1.13 (overlapped signals, 11H, -CH2-C=O lipoic, CH2-b, CH2b-CH2-S, 3x CH2 lipoic); 
1,44 (s, 27H, CH3 of -tBu). 
13
C NMR (100 MHz, CDCl3): δ 172.7 (overlapped signals, C=O NOTA, C=O lipoic); 171.1 
(overlapped signals, 3x COOtBu); 80.9 (overlapped signals, 3x quaternary carbons of tBu); 66.4 
(CH-c); 59.0 (overlapped signals, CH2-d and CH2-e, CH-S); 55.3, 49.9 (overlapped signals, -
NCH2CH2N- of the macrocycle); 41.6 (overlapped signals, -CH2NH lipoic, CH2-S); 39.2 
(overlapped signals, -CH2NH NOTA, CH2-C=O lipoic); 32.5, 30.7, 26.2, 25.5 (overlapped signals, 
4 aliphatic carbons of lipoic, CH2-a); 28.1 (CH3 of -tBu); 24.8 (CH2-b). 
MALDI-MS (positive ions): calculated for C37H67N5O8S2, 773.44; found m/z: 774.41 [M+H
+
]; 
796.39 [M+Na
+
]. 
 
Synthesis of NOTA-LIP 
Compound 27b (18.0 mg, 0.02 mmol) was dissolved in 1 mL of dry CH2Cl2 and then 1 mL of a 10 
% TFA solution in CH2Cl2 was added. The reaction mixture was left under stirring at r. t. and 
checked by TLC until disappearance of the starting compound. After 15 h, the crude product was 
concentrated in vacuo and then coevaporated three times with dry n-isopropanol and successively 
taken at the oil pump for several hours. Without further purification steps, the final product NOTA-
Lip was recovered in a pure form with 95% yields (11.5 mg, 0.02 mmol). 
NOTA-LIP: oil. Rf = 0 (CH2Cl2/MeOH, 8:2, v/v). 
1
H NMR (400 MHz, CDCl3): δ 3.74-3.36 (overlapped signals, 10H, CH-S, -CH2NH lipoic, CH-c, 
CH2-d, CH2-e, CH2-S); 3.07 (overlapped signals, 12H, -NCH2CH2N- of the macrocycle); 2.70-2.63 
(overlapped signals, 4H, CH2-a, -CH2NH NOTA); 2.33-2.16 (overlapped signals, 12H, CH2a-CH2-
S, -CH2-C=O lipoic, CH2-b, CH2b-CH2-S, 3x CH2 lipoic). 
13
C NMR (100 MHz, CDCl3): δ 174.0 (3x COOH); 172.7 (overlapped signals, C=O NOTA, C=O 
lipoic); 66.4 (CH-c); 59.0 (overlapped signals, CH2-d and CH2-e, CH-S); 55.3, 49.9 (overlapped 
signals, -NCH2CH2N- of the macrocycle); 40.7 (overlapped signals, -CH2NH lipoic, CH2-S); 33.7 
(overlapped signals, -CH2NH NOTA, CH2-C=O lipoic); 27.4, 27.0, 26.5 (overlapped signals, 4 
aliphatic carbons of lipoic, CH2-a); 24.8 (CH2-b). 
ESI-MS (positive ions): calculated C25H43N5O8S2, 605.26; found m/z: 606.67 [M+H
+
]. 
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 Synthesis of NOTA-Bio 
Synthesis of N-{2-(4-methoxyphenyldiphenylmethylamino)ethyl-6-[5-(2-oxo-hexahydro-1H-
thieno[3,4-d]imidazol-4-yl]pentanamido}hexanamide (25c) 
Commercially available biotinyl-6-aminocaproic acid (43.4 mg, 0.12 mmol) was dissolved in 6 mL 
of dry DMF and then DMAP (29.7 mg, 0.24 mmol) and DCC (75.1 mg, 0.36 mmol) were added. 
After 1 h compound 24 was added to the reaction mixture in a little stoichiometric excess (43.2 mg, 
0.13 mmol). After stirring for 15 h at r. t. TLC analysis indicated the complete transformation of the 
starting biotinyl-6-aminocaproic acid into a more apolar product. Thus, the reaction mixture was 
quenched by addition of MeOH and the solvent was removed under reduced pressure. The crude 
product was purified by chromatography on a silica gel column using CH2Cl2/MeOH (95:5, v/v) as 
eluent, containing 2 % of TEA, giving desired compound 25c in 83 % yields (69.8 mg, 0.10 mmol). 
25c: pale yellow oil. Rf = 0.4 (CH2Cl2/MeOH, 95:5, v/v). 
1
H NMR (400 MHz, CDCl3): δ 7.35 (d, J = 7.6 Hz, 4H, 4x Hα); 7.25 (d, J = 8.7 Hz, 2H, 2x Hα’); 
7.19 (t, J = 7.4 Hz, 4H, 4x Hβ); 7.08 (d, J = 7.1 Hz, 2H, 2x Hγ); 6.71 (d, J = 8.7 Hz, 2H, 2x Hβ’); 
6.60 (bs, 1H, NHC=O); 6.54 (s, NHC=ONH); 5.63 (s, 1H, NHC=ONH); 4.36 (m, 1H, CH-13’’); 
4.21 (bt, 1H, CH-12’’); 3.68 (s, 3H, -OCH3); 3.36 (m, 1H, CH-11’’); 3.23 (q, 2H, CH2-6’’); 2.91 
(bt, 2H, -CH2NH biotin); 2.75-2.65 (m, 2H, CH2-14’’); 2.18 (bt, 2H, -CH2NH MMT); 2.13-2.10 
(overlapped signals, 4H, CH2-2’’, 7’’); 1.64-1.21 (m, 12H, 6x CH2-3’’, 4’’, 5’’, 8’’, 9’’, 10’’). 
13
C NMR (100 MHz, CDCl3): δ 173.4 (overlapped signals, NHC=O, C=O biotin); 163.7 
(NHC=ONH); 157.7 (C-8); 145.9 (2x C-1); 137.8 (C-5); 129.5 (2x C-6); 128.2 (4x C-2); 127.6 (4x 
C-3); 126.0 (2x C-4); 112.9 (2x C-7); 70.0 (quaternary carbon of MMT); 61.6 (CH-12’’); 59.9 (CH-
13’’); 55.4 (CH-11’’); 54.9 (-OCH3); 43.3 (-CH2NH biotin); 40.2 (-CH2NH MMT); 39.8 (CH2-
14’’); 38.9 (CH2-6’’); 36.1 (CH2-2’’); 35.5 (CH2-7’’); 28.7 (CH2-5’’); 27.7, 26.1, 26.0, 25.4, 25.0 
(overlapped signals, 5x CH2-3’’, 4’’, 6’’, 9’’, 10’’). 
MALDI-MS (positive ions): calculated for C38H49N5O4S, 671.35; found m/z: 670.36 [M+H
+
]; 
694.36 [M+Na
+
]; 400.25 [M-MMT+H
+
]; 422.24 [M-MMT+Na
+
]; 438.20 [M-MMT+K
+
]. 
 
Synthesis of N-(2-aminoethyl)-6-{5-(2-oxo-hexahydro-1H-thieno[3,4-d]imidazol-4-yl) 
pentanamido}hexanamide (26c) 
Compound 25c (85.0 mg, 0.13 mmol) was dissolved in 4 mL of a 2 % TCA solution in CH2Cl2. 
Upon addition of TCA, the reaction mixture showed an intense yellow-orange coloration, typical of 
the MMT cation. After 1 h, TLC analysis indicated the complete disappearance of the starting 
material and the appearance of a new, more polar compound. To quench the reaction, MeOH was 
added until disappearance of the orange colour, followed by TEA until neutralization. The crude 
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product was extracted with CH2Cl2/H2O, recovering the desired compound in the aqueous phases. 
Then, in order to recover the desired compound in a pure form, another extraction was performed 
using MeOH/H2O providing compound 26c in the organic solvent in 77 % isolated yields (40.1 mg, 
0.10 mmol). 
26c: pale yellow oil. Rf = 0.3 (CHCl3/MeOH, 7:3, v/v). 
1
H NMR (400 MHz, MeOD): δ 4.43 (m, 1H, CH-13’’); 4.33 (bt, 1H, CH-14’’); 3.29 (bt, J = 5.6 
and 5.5 Hz, 2H, -CH2NH2); 3.14 (m, 1H, CH-11’’); 3.07 (q, 2H, CH2-6’’); 2.78 (bt, J = 5.7 and 5.5 
Hz, 2H, -CH2NH biotin); 2.75-2.55 (m, 2H, CH2-14’’); 2.11-2.02 (overlapped signals, 4H, CH2-2’’, 
7’’); 1.53-1.25 (m, 12H, 6x CH2-3’’, 4’’, 5’’, 8’’, 9’’, 10’’). 
13
C NMR (100 MHz, MeOD): δ 177.4 (C=O biotin); 176.0 (NHC=O); 166.2 (NHC=ONH); 63.4 
(CH-12’’); 61.7 (CH-13’’); 57.0 (CH-11’’); 41.1 (-CH2NH2); 40.9 (-CH2NH biotin); 40.2 (CH2-
14’’); 38.3 (CH2-6’’); 36.8 (CH2-2’’); 30.2 (CH2-7’’); 29.7 (CH2-5’’); 29.5, 27.6, 26.9, 26.3 
(overlapped signals, 5x CH2-3’’, 4’’, 8’’, 9’’, 10’’). 
MALDI-MS (positive ions): calculated for C18H33N5O3S, 399.23; found m/z: 400.25 [M+H
+
]; 
422.23 [M+Na
+
]; 438.20 [M+K
+
]. 
 
Synthesis of di-tert-butyl 2,2'-{7-[2,2-dimethyl-4,8,13,20-tetraoxo-24-(2-oxo-hexahydro-1H-
thieno[3,4-d]imidazol-4-yl)-3-oxa-9,12,19-triazatetracosan-5-yl]-1,4,7-triazonane-1,4-
diyl}diacetate (27c) 
Commercially available NOTA derivative NODA-Ga(tBu)3 (39.0 mg, 0.07 mmol) was dissolved in 
3 mL of dry DMF; then DMAP (17.1 mg, 0.14 mmol) and DCC (43.3 mg, 0.21 mmol) were added 
to the resulting solution. The reaction mixture was left under stirring and argon flow at r. t. for ca. 1 
h. After activation of the carboxylic group of NOTA, compound 26c was added in slight 
stoichiometric excess (32.0 mg, 0.08 mmol) dissolved in 5 mL of dry DMF. After 15 h the reaction, 
monitored via TLC, indicated the complete disappearance of both starting products and the 
appearance of a new product. So the reaction was quenched by addition of MeOH; the solvent was 
removed under reduced pressure and the crude product was purified by chromatographic column 
eluting with CHCl3/MeOH (95:5, v/v), affording pure compound 27c with 71 % isolated yields 
(46.3 mg, 0.05 mmol). 
27c: yellow oil. Rf = 0.6 (CHCl3/MeOH, 8:2, v/v). 
1
H NMR (400 MHz, MeOD): δ 4.43 (m, 1H, CH-13’’); 4.33 (bt, 1H, CH-12’’); 3.92-3.89 
(overlapped signals, 7H, -CH2NH NOTA, CH2-d, CH2-e, CH-c); 3.54-3.46 (overlapped signals, 
15H, -NCH2CH2N- of macrocycle, CH-11’’, CH2-6’’); 2.96-2.76 (overlapped signals, 4H, -
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CH2NH-biotin, CH2-14’’); 2.43-1.96 (overlapped signals, 8H, CH2-a, CH2-b, CH2-2’’, CH2-7’’); 
1,43 (s, 27H, CH3 of -tBu); 1.46-1.27 (m, 12H, 6x CH2-3’’, 4’’, 5’’, 8’’, 9’’, 10’’). 
13
C NMR (100 MHz, MeOD): δ 171.6 (overlapped signals, C=O biotin, NHC=O, C=O NOTA); 
171.1 (overlapped signals, 3x COOtBu); 164.6 (NHC=ONH); 81.6, 81.1 (overlapped signals, 3x 
quaternary carbons of tBu); 63.5 (overlapped signlas, CH-c, CH-12’’, CH-13’’); 57.0 (CH-11’’); 
55.7 (overlapped signals, CH2-d and CH2-e); 55.6, 49.9, 46.6, 45.7 (overlapped signals, -
NCH2CH2N- of the macrocycle); 41.1 (-CH2NH biotin); 40.9 (-CH2NH NOTA); 40.2 (CH2-14’’); 
38.3 (CH2-6’’); 36.8 (CH2-2’’); 32.4 (CH2-a); 32.3 (CH2-7’’); 31.7 (CH2-5’’); 30.8, 29.6, 28.0, 27.9 
(overlapped signals, 5x CH2-3’’, 4’’, 8’’, 9’’, 10’’), 28.1 (CH3 of -tBu); 25.2 (CH2-b). 
MALDI-MS (positive ions): calculated for C45H80N8O10S, 924.57; found m/z: 925.85 [M+H
+
]. 
 
Synthesis of NOTA-Bio 
Compound 27c (12.1 mg, 0.01 mmol) was dissolved in 2 mL of CH2Cl2 dry and then 1 mL of a 10 
% TFA solution in CH2Cl2 was added. The reaction mixture was left under stirring at r. t. and was 
checked by TLC until the disappearance of the starting compound. After 15 h, the crude reaction 
was concentrated in vacuo to get rid of the solvent. Subsequently, in order to remove even traces of 
trifluoroacetic acid, the crude product was coevaporated three times with dry n-isopropanol and 
then taken at the oil pump for several hours. In this way, without further purification steps, NOTA-
Bio was recovered with 95% yields (7.20 mg, 9.5 µmol). 
NOTA-Bio: oil. Rf = 0 (CH2Cl2/MeOH, 8:2, v/v). 
1
H NMR (400 MHz, MeOD): δ 4.43 (m, 1H, CH-13’’); 4.33 (bt, 1H, CH-12’’); 3.93-3.76 
(overlapped signals, 7H, -CH2NH NOTA, CH2-d, CH2-e, CH-c); 3.63-3.46 (overlapped signals, 
15H, -NCH2CH2N- of macrocycle, CH-11’’, CH2-6’’); 2.92-2.84 (overlapped signals, 4H, -CH2NH 
biotin, CH2-14’’); 2.25-1.96 (overlapped signals, 8H, CH2-a, CH2-b, CH2-2’’, CH2-7’’); 1.52-1.21 
(m, 12H, 6x CH2-3’’, 4’’, 5’’, 8’’, 9’’, 10’’). 
13
C NMR (100 MHz, MeOD): δ 175.5 (3x COOH); 172.5 (overlapped signals, C=O biotin, 
NHC=O, C=O NOTA); 164.6 (NHC=ONH); 64.6 (overlapped signals, CH-c, CH-12’’, CH-13’’); 
55.6 (overlapped signals, CH2-d and CH2-e); 57.0 (CH-11’’); 56.3, 49.9, 46.6, 45.7 (overlapped 
signals, -NCH2CH2N- of the macrocycle); 41.1 (-CH2NH biotin); 40.9 (-CH2NH NOTA); 40.2 
(CH2-14’’); 38.3 (CH2-6’’); 36.8 (CH2-2’’); 33.7 (CH2-a); 33.0 (CH2-7’’); 32.5 (CH2-5’’); 32.1, 
29.6, 27.5, 27.0 (overlapped signals, 5x CH2-3’’, 4’’, 8’’, 9’’, 10’’), 26.5 (CH2-b). 
MALDI-MS (positive ions): calculated for C33H56N8O10S, 756.38; found m/z: 757.65 [M+H
+
]. 
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Chapter 4 
Aptamers as targeting ligands 
1. G-quadruplex-based aptamers: introduction 
Nucleic acid aptamers are single-stranded DNA or RNA molecules, generally 25 to 60 bases in 
length, identified from pools of random- sequence oligonucleotides (ONs) by an in vitro selection 
process called SELEX (Systematic Evolution of Ligands by EXponential enrichment),
[258]
 
introduced in the early 90s independently by the research groups of Gold and Szostak.
[259–261]
 
Thanks to their unique three-dimensional folding, aptamers can recognize a wide range of 
molecular targets including proteins, small molecules, ions, whole cells and even entire organisms, 
such as viruses or bacteria, with affinities, expressed in terms of dissociation constants (Kd), ranging 
from picomolar (pM) to micromolar (μM).[262–264] 
The high affinity and selectivity for the target, as well as the multiplicity of possible target types, 
make aptamers a valid alternative to antibodies in a wide variety of applications, from therapeutics 
(as drugs or drug-delivery systems) to diagnostic and sensing devices.
[265–272]
 
Nucleic acid aptamers exhibit significant advantages over antibodies, such as smaller size, lower 
immunogenicity, remarkable stability in a wide range of pH (≈ 4–9) and temperature; in addition, 
aptamers allow an easy control of their folding processes, which, even after prolonged denaturation, 
are typically reversible upon restoring the native conditions. In addition, once selected, 
oligonucleotide-based aptamers can be easily synthesized. Chemical synthesis allows also easily 
introducing ad hoc tailored chemical modifications that can increase the aptamer stability and bring 
the production costs well below those of antibodies.
[273,274]
 
 
1.1. SELEX technology 
As mentioned before, aptamer development generally exploits the SELEX methodology which 
involves an in vitro iterative selection procedure consisting of three main steps: (i) binding 
(capture), where a random ODN library is incubated with the desired target molecule under defined 
conditions; (ii) partitioning, in which the target-bound ODN aptamers are separated from unbound 
ones; and (iii) amplification, where the enriched pool of selected aptamers is amplified before being 
used in the successive round of selection. During these processes, the best aptamers for the selected 
target are enriched and the initial ODN library complexity is decreased (Figure 46, left side). The 
starting pool, whose appropriate choice represents a crucial point for the success of the SELEX 
method, can contain 10
12
-10
16
 DNA or RNA single strands, each with an internal randomized 
sequence of usually 30-80 nucleotides and terminal fixed sequences, complementary to pre-defined 
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primers used in the amplification step. Aptamer libraries can be derived from chemical synthesis, 
genomic DNA,
[275]
 or transcriptomic sources,
[276]
 and can be realized with deoxyribo-, ribo-, or 
modified nucleotides.
[277–280]
 Modified nucleotides are primarily used to increase the chemical and 
enzymatic stability of aptamers, but can also contribute to broaden their chemical diversity, 
improving their binding affinity and specificity for a selected target. 
 
Figure 46. Schematic representation of the SELEX process. 
 
After incubation of the library with the selected target, partition of bound from unbound sequences 
can be obtained using different strategies (Figure 46, right side), such as filtration, affinity 
chromatography, or (iii) magnetic beads-based separation.
[281]
 Following partitioning, the target-
bound oligonucleotides are eluted from the target and amplified by PCR (DNA SELEX) or reverse 
transcription PCR (RNA SELEX) to give an enriched pool of selected oligonucleotides, which is 
used in the successive SELEX round. With increasingly stringent conditions (shorter incubation 
times, higher temperatures, higher ODN/target ratios) in successive rounds of SELEX, the high-
affinity oligonucleotides are enriched. Traditionally, enriched aptamer pools from the SELEX 
experiments are cloned into a plasmid and a few hundred individual clones, at most, have to be 
sequenced to identify high affinity aptamers. However, the recent applications of next-generation 
sequencing (NGS) combined with bioinformatic analysis of the growing aptamer populations allow 
greatly improving the SELEX procedure.
[282]
 Next steps for obtaining functional aptamers are 
structure- and sequence- guided molecular engineering that include truncations and/or mutations of 
the sequence(s) to develop the shortest aptamer(s) with the highest affinity and specificity.
[258]
 Once 
identified, the putative aptamers can be synthesized and analysed to determine the target affinity 
and specificity of binding vs. other possible targets. 
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Despite the remarkable success of aptamers, their commercial application remains relatively 
undeveloped, probably because of the overwhelming antibody-based market and a certain degree of 
hesitation to move to new products. To date, Macugen (pegaptanib sodium), selected against the 
vascular endothelial growth factor (VEGF), is the only existing aptamer-based drug, approved by 
the US Food and Drug Administration for the treatment of neovascular age-related macular 
degeneration (AMD), also undergoing clinical trials for the treatment of diabetic macular 
oedema.
[283]
 Nevertheless, new aptamer-based candidate drugs are undertaking clinical trials,
[272,284]
 
and plausibly more aptamers will be approved as drugs in the next future. 
 
1.2. G-quadruplex (G4) motifs in oligonucleotide aptamers 
Among the combinatorially selected aptamers endowed with significant bioactivity, many are G-
rich oligomers sharing a common structural feature, i.e. the ability to fold into stable G-quadruplex 
(G4) conformations under physiological conditions and recognize very different protein 
targets.
[285,286]
 This can be easily explained considering the extremely high polymorphism of G4 
structures, non-canonical nucleic acid conformations in which the core unit is the guanine tetrad, a 
cyclic planar arrangement of four guanines linked through Hoogsteen-type hydrogen bonds (Figure 
47). Stacking of two or more guanine tetrads generates a G4 motif, which is further stabilized by 
cations hosted in the central cavity of the G4.
[287,288]
 
The apparently rigid G4 structure is indeed rather plastic and can fit into widely different nucleic 
acid architectures. Multiple elements participate in conferring G4 structures a high level of 
adaptability: 1) the intramolecular or intermolecular character of the system; 2) the parallel or 
antiparallel direction of the guanine-rich tracts in the G4 assembly; 3) the length, sequence and 
direction of the loops; 4) the syn or anti guanine orientation around the N-glycosidic bonds; and 5) 
the number of consecutive G-quartets formed. Furthermore, other individual differentiating 
elements can be additionally present in the G4-based aptamers, such as bulges,
[289]
 mixed G:A:G:A, 
G:T:G:T and G:C:G:C tetrads,
[290,291]
 G-vacancies,
[292]
 A-tetrads sandwiched between G-tetrads
[293]
 
or A:G4 pentads.
[294]
 An additional level of structural diversity is related to the possibility of raising 
both DNA and RNA G4-based aptamers.
[295,296]
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Figure 47. Schematic representations of: a) a G-tetrad stabilized by a metal ion in the central 
cavity; b) some possible topologies for simple tetramolecular, bimolecular and unimolecular G4s 
(strand polarities are indicated by arrows); c) examples of unimolecular G4s that differ in strand 
orientation within the G4 core; and d) types of loops that join G-rich tracts in the G4 structure. 
 
1.3. G4-forming aptamers in therapeutic applications 
In the last two decades, aptamers proved to be very attractive as therapeutic agents mainly for their 
enhanced cellular uptake, non-immunogenicity and lower production costs.
[297]
 Several aptamers 
against different human pathologies, such as neurodegenerative diseases,
[298]
 age-related macular 
degeneration,
[299]
 inflammation,
[300]
 thrombosis,
[301]
 diabetes,
[285]
 cancer,
[302,303]
 human 
immunodeficiency virus (HIV)
[304]
 and coagulation
[305]
 have been discovered and evaluated. Their 
properties, targets of interest and current clinical evaluation have been recently reviewed in 
detail.
[306]
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2. Fluorescent TBA-tagged nanoparticles for an efficient and reversible 
control of thrombin activity 
The 15-mer G-rich oligonucleotide TBA (Thrombin Binding Aptamer or TBA15) is the best 
characterized aptamer of thrombin, a “trypsin-like” serine protease involved in coagulation 
processes able to convert soluble fibrinogen into insoluble strands of fibrin.
[305,307–311]
 TBA has been 
proposed as a valuable alternative to classical thrombin inhibitors used in clinic, such as heparin, 
warfarin and bivalirudin, showing severe side effects or suffering from narrow therapeutic 
windows.
[312–314]
 Upon folding into an antiparallel, chair-like G-quadruplex structure, TBA can 
strongly and selectively recognize the fibrinogen-binding exosite I of human thrombin,
[315–318]
 
inhibiting its key function in the coagulation cascade.
[319]
 
Due to its intrinsic instability to nucleases in physiological media, TBA did not progress to 
advanced clinical trials, being blocked after Phase I studies. To overcome these drawbacks, several 
TBA analogues have been proposed in the literature, carrying either backbone modifications
[320–323]
 
or specific conjugations (with PEG
[324]
 or different kinds of nanoparticles
[325–334]
), aimed at 
improving its pharmacokinetic profile and reducing the enzymatic degradation by nucleases.
[335–340]
 
TBA and its variants are important not only for their therapeutic potential, but also for possible 
applications as biotechnological and bioanalytical tools. Noteworthy is the possibility to label these 
aptamers with fluorescent probes,
[330,334,341–345]
 which in principle allow monitoring their correct 
folding and, following their turn-off/turn-on fluorescence responses, the target recognition 
processes, particularly crucial for sensitive thrombin detection. 
Thus, with the aim of optimizing the in vivo performance of TBA, a new tris-conjugated TBA (here 
named tris-mTBA, Figure 48) containing an environment-sensitive fluorescent probe has been 
prepared, characterized and then incorporated into silica nanoparticles (commercially available as 
Sicastar
®
). Tris-mTBA has been designed to carry a dansyl group at the 3’-, and a β-cyclodextrin 
and a biotin moiety at the 5’-end. The host-guest system dansyl/β-cyclodextrin - based on the well-
known inclusion properties of cyclodextrins,
[344,346–352]
 able to capture the dansyl fluorescent group - 
has been selected to monitor the correct G-quadruplex folding of the aptamer decorating the 
nanoparticle surface via simple fluorescence measurements. In fact, when TBA is unfolded, the 
dansyl probe, very sensitive to external stimuli,
[353–355]
 is exposed to bulk water and only basal 
fluorescence is observed. In turn, when TBA is structured into an antiparallel, unimolecular G-
quadruplex, the 5’ and 3’ ends of the oligonucleotide strand are in close proximity, favouring the 
encapsulation of the dansyl group into the hydrophobic cyclodextrin cavity. Under these conditions 
a marked fluorescence enhancement is observed, as demonstrated in our previous work, 
investigating as a model system the parent bis-modified TBA, derivatized with a dansyl group at the 
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3’- and a β-cyclodextrin at the 5’-end.[344] TBA has been here conjugated with an additional tag, 
inserting a biotin residue to allow its rapid and efficient binding to streptavidin-coated Sicastar
® 
nanoparticles (NPs), exploiting the high affinity and specificity between this ligand and the surface-
bound protein.
[50,356,357]
 Notably, the streptavidin-biotin complex is stable in a broad range of pH, 
ionic strength and temperature,
[358,359]
 and thus ensures a very stable TBA decoration on the 
nanoparticles. 
 
Figure 48. Molecular structure of the tris-mTBA. The TBA oligonucleotide sequence and the 
dansyl moiety are highlighted in yellow and green, respectively. 
 
Among the commercially available streptavidin-coated NPs, streptavidin-coated Sicastar
®
 NPs with 
hydrodynamic diameter of 50 nm have been selected. According to the literature, NPs of this size 
seem to be the best compromise between optimization of the in vivo NP biodistribution and 
preservation of the biotin-streptavidin interactions. 
As far as the NP pharmacokinetic profile is concerned, it is generally accepted that very small NPs 
(hydrodynamic radius < 5 nm) are rapidly excreted from the body through extravasation or renal 
clearance,
[360,361]
 while NPs in the μm range can easily accumulate in the body, especially in liver, 
spleen and bone marrow.
[362,363]
 On the contrary, NPs with hydrodynamic radius in the 50-100 nm 
range, though showing a characteristic biodistribution and cellular uptake behaviour critically 
depending on the specific cell type,
[364,365]
 in most cases are trapped by mechanical filtration 
operated by sinusoids in the spleen and then rapidly removed from the bloodstream by the 
reticuloendothelial system (RES) cells.
[366]
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Concerning the preservation of the biotin-streptavidin interactions on the silica NP surface, a typical 
stability trend has been observed as a function of the NP size: on increasing their hydrodynamic 
radius from 50 to 200 nm, the affinity (in terms of Kd) between biotin and streptavidin is 
progressively reduced.
[367]
 This effect, probably due to steric constraints or diffusion limitations, 
negatively affecting the ligand-receptor interactions, leads to conclude that NPs suitable for 
bioanalytical applications should not exceed the 50-100 nm size. 
Then, as for the kind of NP core here used, we specifically selected silica nanoparticles, rather than 
metal or metal oxide-based platforms, for their low cytotoxicity, high biocompatibility, and, mainly, 
for not causing fluorescence quenching or general interference with the properties of TBA.
[368–375]
 
The synthesis and purification of this modified aptamer has been realized by dr. Francois Morvan 
and his group at Institut des Biomol cules Max Mousseron in Montpellier. Then, we have 
investigated it by means of UV, CD and fluorescence spectroscopy to get information on its 
conformational behaviour under different solution conditions. Finally, tris-mTBA has been 
immobilized onto Sicastar
®
 nanoparticles, obtaining the corresponding functionalized Sicastar
® 
system. These nanoparticles have been characterized – in collaboration with the research group of 
prof. Luigi Paduano at Department of Chemical Sciences of University of Napoli Federico II - using 
a combined approach including dynamic and static light scattering (DLS and SLS), gel 
electrophoresis and fluorescence spectroscopy analyses. The inhibitory activity of the TBA-
conjugated silica nanoparticles towards human α-thrombin has been evaluated by means of light 
scattering experiments, following the conversion of fibrinogen into fibrin promoted by the protein, 
and compared with free tris-mTBA and unmodified TBA. Control experiments with the 
oligonucleotide sequence complementary to TBA (cTBA), carried out on the tris-mTBA both in 
free form and conjugated to the silica nanoparticles, allowed verifying that – exploiting the higher 
thermodynamic stability of a duplex structure vs. the corresponding G-quadruplex + single strand 
system – the anticoagulant activity of these TBA-functionalized NPs can be reversed and blood 
clotting restored, by simply using cTBA as an antidote. 
 
2.1. Results and discussion 
2.1.1. Synthesis of tris-mTBA 
Tris-mTBA 35 was prepared in three main steps, as described in Scheme 8. First, dansyl azide 
derivative 29
[376]
 was immobilized via a Cu(I)-catalyzed azide-alkyne cycloaddition protocol 
(CuAAC)
[377,378]
 on alkyne-functionalized solid support 28
[379]
 using the CuSO4/sodium ascorbate 
catalytic system under microwave irradiation
[380]
 for 1 h at 60 °C. Then, the resulting solid support 
30 was used for the solid phase assembly of the TBA oligonucleotide sequence 
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d(GGTTGGTGTGGTTGG) on a DNA synthesizer using standard phosphoramidite chemistry. 
Once the desired sequence was assembled, two additional couplings were performed: the first one 
with the DMTr-THME propargyl phosphoramidite 31,
[379]
 introducing an alkyne moiety in the 
oligonucleotide, and the second one with the commercially available biotin phosphoramidite 32. 
 
Scheme 8. Synthetic scheme for the preparation of tris-mTBA 35. 
 
After final DMTr removal, followed by standard ammonia deprotection of the functionalized solid 
support, the 5’-biotin, 3'-dansyl TBA 33 was released in solution, purified by reverse-phase HPLC 
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and then characterized by MALDI-TOF MS. Finally, β-cyclodextrin, in the form of mono-azide 
derivative 34,
[381]
 was coupled in solution with the alkyne-containing oligonucleotide 33 through 
Cu(I)-promoted cycloaddition for 1.5 h at r.t., yielding the target tris-mTBA 35. The desired 
oligomer was purified by gel filtration and characterized by MALDI-TOF MS (Figure 49). 
Successively, 35 was converted into the corresponding potassium salt by treatment with a 1 M KCl 
aq. solution and then desalted using size exclusion chromatography. 
 
Figure 49. a) HPLC profile and b) MALDI-TOF MS spectrum of pure tris-mTBA 35. Linear 
gradient: 10 to 30 % B in A for 20 min, 35 tR: 14.6 min. 
 
2.1.2. Spectroscopic properties of tris-mTBA in solution 
The conformational behaviour in solution of tris-mTBA was investigated combining UV, CD and 
fluorescence data. The spectra collected with the different techniques were obtained from a 
phosphate buffered solution containing 80 mM K
+
 ions (10 mM KH2PO4, 70 mM KCl, 0.2 mM 
EDTA, pH 7.0), in analogy with the previous study performed on the bis-conjugated TBA 
derivative
[344]
 (here named bis-mTBA), used as a model to evaluate the host-guest system dansyl/β-
cyclodextrin on this G-quadruplex forming oligonucleotide. 
The CD spectrum of tris-mTBA at 10 °C shows two positive bands with maxima centred at 295 and 
246 nm and a negative band with minimum at 266 nm (Figure 50a). These spectral features are 
consistent with those reported for the unmodified TBA, forming a chair-like antiparallel G-
quadruplex structure;
[320,382–387]
 thus confirming that the conjugation with the three sterically 
hindered reporter groups (i.e., dansyl, β-cyclodextrin and biotin) does not impair the G-quadruplex 
formation of TBA nor affects the topology of its conformation. 
The CD melting profile, monitoring at 295 nm, provided a melting temperature of 39 °C in the 
selected buffer (Figure 50b). No hysteresis was observed on comparing the heating and cooling 
profiles, indicating that, under the studied experimental conditions, the system is at equilibrium. 
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Figure 50. CD spectrum registered at 10 °C (a) and CD melting profile recorded at 295 nm 
(temperature scan rate = 1 °C/min) (b) of a 5 µM tris-mTBA solution in 10 mM KH2PO4, 70 mM 
KCl, 0.2 mM EDTA (pH 7.0). 
 
The CD spectrum of tris-mTBA was also recorded in PBS, the buffer solution here used for the 
successive functionalization of Sicastar
®
 nanoparticles (see below), containing a lower K
+
 
concentration with respect to the previously used buffer (4.5 vs. 80 mM), and a high content of Na
+
 
ions (157 mM). Also under these conditions, tris-mTBA maintains the same CD profile as in the 80 
mM K
+
-buffer, with the positive CD band having the maximum at 295 nm (Figure 51) diagnostic of 
an antiparallel G-quadruplex structure. 
 
Figure 51. Overlapped CD spectra of tris-mTBA at 5 μM concentration in different solution 
conditions: 80 mM K
+
-buffer solution (red line), PBS (green line), pure water (blu line). 
 
In PBS solution tris-mTBA has a lower structuration degree than in the phosphate buffer containing 
only K
+
 as cation, as expected considering that this species can stabilize G-quadruplex structures 
better than Na
+
.
[388–391]
 The CD spectrum of tris-mTBA in pure water proves that in the absence of 
stabilizing cations, this aptamer is very poorly structured. 
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Figure 52. a) UV spectrum and b) UV melting profile (15-85 °C, temperature scan rate = 1 °C/min) 
of tris-mTBA, both recorded in a 10 mM KH2PO4, 70 mM KCl, 0.2 mM EDTA (pH 7.0) solution at 
5 µM concentration. 
 
Next, the UV spectrum of tris-mTBA, registered at 5 µM concentration in the 10 mM KH2PO4, 70 
mM KCl, 0.2 mM EDTA (pH 7.0) buffer solution, revealed the characteristic absorption of TBA, 
with the double-hump band between 230 and 300 nm (Figure 52a). As determined from comparison 
with the unmodified TBA under the same concentration and solution conditions, the contribution of 
the dansyl, β-cyclodextrin and biotin moieties can be considered negligible with respect to the 
oligonucleotide absorbance. From the UV-melting curve recorded at 295 nm,
[386,392,393]
 a Tm of 39 
°C was derived (Figure 52b), in perfect accordance with the Tm from the CD melting registered at 
the same wavelength. Even in this case, no significant hysteresis was observed on comparing the 
heating and cooling processes (data not shown), indicating a fully reversible process. 
The thermal denaturation of tris-mTBA was also analysed by monitoring the changes of the 
fluorescence emission of the dansyl group, upon excitation at 327 nm, as a function of the 
temperature on an annealed aptamer solution. On increasing the temperature, a gradual, marked 
decrease in the fluorescence intensity, as well as an emission maximum shift from 534 to 551 nm, 
were observed (Figure 53a). These fluorescence features clearly indicate that the dansyl group 
experiences dramatically different environments upon temperature-induced unfolding. These 
findings are consistent with the dansyl residue being encapsulated inside the β-cyclodextrin ring in 
the folded state (low temperature) and pointing outside, exposed to the aqueous solution, in the 
unfolded state (high temperature), as already observed in the case of bis-mTBA.
[344]
 
The fluorescence-monitored melting curve was obtained reporting the wavelength at the 
fluorescence emission maximum as a function of the temperature (Figure 53b).
[344]
 The obtained Tm 
value (40 °C) is, within the experimental error, in good accordance with the results obtained from 
CD and UV data, indicating that the dansyl group is thrown out from the cyclodextrin cavity in 
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concomitance with the unfolding of the whole G-quadruplex structure. Also in this case, the heating 
and cooling profiles were essentially superimposable (data not shown). 
 
Figure 53. a) Overlapped emission fluorescence spectra (λex = 327 nm) of tris-mTBA, recorded at 2 
µM concentration in a 10 mM KH2PO4, 70 mM KCl, 0.2 mM EDTA (pH 7.0) buffer solution, on 
increasing the temperature from 20 to 80 °C; b) fluorescence melting profile obtained reporting the 
wavelength at the fluorescence emission maximum as a function of temperature (range 20-80 °C). 
 
In summary, these results show that tris-mTBA qualitatively behaves as bis-mTBA
[344]
 and the 
unmodified TBA.
[320,384,385,387]
 As expected, the presence of three bulky conjugating groups affects 
the apparent Tm of tris-mTBA, which is ca. 10 °C lower than that of TBA and of bis-mTBA (39 vs. 
49 °C), showing a marked loss in thermal stability in the explored conditions. However, these data 
also confirm that, in a pseudo-physiological solution, tris-mTBA is mainly present as a G4 
structure. It can be also speculated that the G4 structuring of tris-mTBA should be further enhanced 
when conjugated to the NPs, if other interfering surface processes do not intervene. In fact, once the 
biotin residue of tris-mTBA is captured by the streptavidin coating of the NPs, any competition is 
prevented between the dansyl and biotin for cyclodextrin recognition (which is however possible in 
tris-mTBA in solution since the binding constants for their complexes with -cyclodextrin are in the 
same order of magnitude (Ka ~10
2 
M
−1
)
[394,395]
 and could disturb the correct G4 folding). 
 
2.1.3. CD experiments with cTBA sequence 
Reversibility of binding between inhibitors and coagulant factors is essential in drug treatments. In 
fact, in case of clinical complications, such as haemorrhage, physicians need rapidly and safely 
reversing coagulation inhibition. The 15-mer d(CCAACCACACCAACC), here indicated as cTBA, 
complementary to the TBA sequence and able to hybridize it forming a duplex structure, can 
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profitably modulate the activity of TBA, reversing its anticoagulation activity.
[301,396]
 Thus TBA and 
cTBA can be considered a very effective drug/antidote pair for thrombin.
[397]
 
In this frame, the ability of tris-mTBA to form a duplex structure with cTBA was investigated by 
CD measurements and compared with the unmodified TBA. The CD experiments were carried out 
using a tandem cell, a quartz cuvette composed of two distinct compartments, which allows 
recording the sum and mix spectra of two components (i.e. the spectrum obtained by maintaining 
the cTBA and TBA as separate systems, and the one obtained after mixing the two solutions). 
 
Figure 54. CD spectra registered as sum (red lines) and mix (blue lines) of tris-mTBA/cTBA (a) 
and unmodified TBA/cTBA (b) systems in a tandem cell. Each oligonucleotide was analysed at 2.5 
μM concentration in PBS solution. 
 
 
Figure 55. CD melting curves for the mix solutions of tris-mTBA/cTBA (a) and unmodified 
TBA/cTBA (b), recorded in a tandem cell in PBS solution at 268 nm (scan rate = 1 °C/min). 
 
In both cases the sum (red lines) and mix (blue lines) spectra were not superimposable, denoting the 
rapid interaction of the two strands (Figure 54). Thus, for tris-mTBA the formation of a duplex 
structure upon cTBA addition efficiently competes with the G-quadruplex, in analogy with the 
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unmodified TBA behaviour. After mixing the solutions and stabilization of the CD signal, a 
denaturation curve was recorded at 268 nm for each duplex (Figure 55), showing similar Tm values 
for the two systems (62 and 60 °C for tris-mTBA/cTBA and TBA/cTBA, respectively). An end-
stacking stabilizing effect produced by the dansyl moiety could account for the slightly higher Tm of 
the duplex structure containing tris-mTBA. The CD melting curves were almost superimposable to 
the corresponding annealing profiles, not evidencing hysteresis phenomena. 
These data clearly indicate that the residues inserted at the ends of tris-mTBA do not perturb its 
ability to bind its complementary strand, forming a stable duplex under pseudo-physiological 
conditions, necessary pre-requisite for using tris-mTBA/cTBA as an anticoagulant/antidote couple. 
 
2.1.4. Preparation of the tris-mTBA-functionalized Sicastar
®
 nanoparticles 
Once having fully characterized the behaviour of tris-mTBA in solution, this aptamer was 
conjugated to Sicastar
®
 NPs as schematically represented in Figure 56. 
 
Figure 56. Schematic representation of the Sicastar
®
 functionalization with the tris-mTBA. 
 
The functionalization of the streptavidin-coated silica nanoparticles with tris-mTBA is based on the 
high affinity of streptavidin/biotin recognition (Kd ~10
-14 
M).
[50]
 Thus, by simply mixing in an 
eppendorf tube the Sicastar
®
 NPs and tris-mTBA both in PBS buffer (using a biotin/streptavidin 1:1 
ratio) under gentle stirring for 1 h, the conjugated tris-mTBA/Sicastar
®
 NPs were obtained. The 
functionalization protocol was optimized on the basis of DLS results. In fact, specific 
= Streptavidin moiety
= Biotin moiety
streptavidin/biotin 
specific recognition
tris-mTBA
Sicastar®
tris-mTBA/Sicastar®
SiO2
SiO2
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functionalization conditions were necessary to obtain a single NP population (see below), which 
was then analysed using different techniques. 
 
2.1.5. Dynamic and Static Light Scattering analysis of functionalized Sicastar
®
 NPs 
In order to characterize the tris-mTBA-functionalized Sicastar
®
 NPs, dynamic light scattering 
analyses were carried out on the nanoparticles before and after the functionalization with the 
aptamer. The streptavidin-coated Sicastar
®
 NPs – analysed as received from the commercial 
supplier - showed a well-defined, single population, with hydrodynamic radius of ca. 50 nm, 
accounting for more than 95% of the scattering intensity, accompanied by a very small population 
of higher size. Analysis of the tris-mTBA-functionalized NPs samples showed that when the 
functionalization was performed mixing Sicastar
®
 NPs and tris-mTBA so to have a 1:1 or 1:0.9 
streptavidin/biotin ratio, with short incubation times, only a single monodispersed NP population 
was obtained. On the contrary, DLS curves of the functionalized NPs obtained using high 
biotin:streptavidin ratios or long incubation times showed, in addition to the main population, also 
detectable amounts of larger species, likely aggregates (data not shown). 
As expected, due to the negligible size of the aptamer with respect to the streptavidin-coated silica 
NPs, no effect on the overall dimensions of the Sicastar
®
 system was detected after 
functionalization with tris-mTBA, as determined by DLS. 
Static light scattering analysis and Zimm plot elaboration were also exploited to characterize the 
tris-mTBA/Sicastar
®
 NPs system, providing the molecular weight of the NPs before and after 
functionalization. Notably, unfunctionalized NPs showed a molecular weight of the same order of 
magnitude as the tris-mTBA-functionalized Sicastar
®
 NPs (5.4x10
6
 vs. 5.3x10
6
 Da before and after 
functionalization, respectively). As in the case of the overall size determined by DLS, also in terms 
of molecular weight the contribution of tris-mTBA, upon conjugation to the Sicastar
®
 NPs, is 
negligible: indeed, the expected increase in molecular weight after the functionalization falls within 
the uncertainty of the method, which allows a molecular weight evaluation with an error of ca. 
±10%. However, a quite unexpected and remarkable finding is the different slope of the Zimm plots 
relative to the NPs before and after the functionalization (Figure 57a and 57b). In the former case a 
positive slope was observed, indicating a good NP system-solvent interaction, while the latter 
system showed a negative slope, indicating that the interactions among the NPs are favoured over 
the NPs-solvent ones, and therefore an intrinsic tendency of the tris-mTBA/Sicastar
®
 NPs to self-
aggregate should be considered. 
Moving from this result, DLS was further employed to check the stability over time of Sicastar
®
 
NPs before and after the tris-mTBA functionalization. Remarkably, no detectable change in the 
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DLS profiles of unfunctionalized Sicastar
®
 NPs in PBS solution was observed over a period of 
several months. In contrast, in the case of functionalized NPs, DLS analysis showed the appearance 
of new, even if very small, populations of bigger aggregates starting from ca. 4 weeks from the 
functionalization procedure, in close agreement with the results of the Zimm plot analysis (Figure 
57c). However, despite their inherent tendency to aggregate with time, these data prove that the 
functionalized tris-mTBA/Sicastar
®
 NPs can be considered stable in pseudo-physiological solutions 
for ca. one month, a time range well beyond that needed for biomedical applications. 
 
Figure 57. Zimm plot of Sicastar
®
 NPs before (a) and after (b) the functionalization with tris-
mTBA. c) Overlapped DLS profiles of the tris-mTBA/Sicastar
®
 NPs in PBS solution, registered at 
t=0, 1 week, 2 weeks, 3 weeks or 4 weeks after their preparation. 
 
2.1.6. Gel electrophoresis analysis 
Gel electrophoresis analysis was used to further characterize the modified aptamer and the Sicastar
®
 
NPs in solution. In Figure 58 the photograph of a representative 1 % agarose gel, run under native 
conditions, is reported. A detectable difference in electrophoretic mobility was observed for the 
unmodified TBA and tris-mTBA, both previously annealed in PBS, proving that the three bulky, 
pendant groups here introduced on tris-mTBA somehow affected the migration ability of TBA. 
Interestingly, upon UV visualization, the tris-mTBA band showed a different colour with respect to 
the unmodified TBA, probably conferred by the dansyl group (cfr. lanes 3 and 4 in Figure 58, 
respectively). As far as the nanoparticles are concerned, both the unfunctionalized and tris-mTBA-
a)
b)
c)
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functionalized Sicastar
®
 NPs loaded on the gel (lanes 1 and 2, respectively) showed retarded bands 
with respect to the free aptamers in solution. They revealed the same mobility under the used 
conditions, clear evidence that the TBA functionalization of the Sicastar
® 
NPs did not alter their 
migration on an agarose gel, i.e. their overall size and shape, as expected considering the relative 
weight of the streptavidin-coated NPs and of tris-mTBA and in accordance with the DLS and SLS 
analyses. Remarkably, the functionalized NPs loaded on the gel (lane 2) did not show detectable 
bands in correspondence of the free tris-mTBA. Taking into account that gel electrophoresis is a 
low resolution technique, these results however provide an indication that, within the detection limit 
of the method, the functionalized NPs do not contain unbound tris-mTBA. 
 
Figure 58. 1% agarose gel electrophoresis under native conditions of the analysed TBA and NP 
systems; Lane 1: Sicastar
®
 NPs (2.5 mg/mL); Lane 2: tris-mTBA/Sicastar
®
 (2.5 mg/mL); Lane 3: 
tris-mTBA (3.3 µM); Lane 4: unmodified TBA (3.3 µM); Lane 5: tris-mTBA (2.0 µM). 
 
2.1.7. Fluorescence spectroscopy analysis of free and NP-conjugated tris-mTBA 
Fluorescence measurements allowed monitoring the fluorescence emission of the dansyl group. 
Since this fluorescent probe is extremely sensitive to its environment, the persistence of substantial 
fluorescence emission, with the same maximum as observed in the G4-structured tris-mTBA 
solution before the NPs functionalization, can provide evidence of complete encapsulation of dansyl 
within the cyclodextrin cavity even in the NP-immobilized aptamer. As demonstrated in solution 
studies, this event is strictly connected with the correct G4-structuring of tris-mTBA and can thus 
provide information on the effective conformation adopted by the aptamer on the NP surface after 
the functionalization procedure. In Figure 59 overlapped fluorescence spectra of tris-mTBA and 
tris-mTBA/Sicastar
®
 in PBS solution at the same aptamer concentration are reported, after 
subtracting the contributions of the buffer and of Sicastar
®
 NPs alone. These spectra are 
1 2 3 4 5
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qualitatively similar, with a fluorescence difference of less than 20%. The perfect coincidence of the 
fluorescence maxima proved that, after immobilization onto Sicastar
®
, tris-mTBA maintained its 
original fluorescence features. It can be thus deduced that the peculiar G4 conformation of tris-
mTBA, essential for thrombin recognition, is overall preserved on the functionalized Sicastar
®
 NPs. 
 
Figure 59. Overlapped fluorescence spectra of tris-mTBA and tris-mTBA/Sicastar
®
 NPs (black and 
red curves, respectively) in PBS solution, with the emission maximum marked for each spectrum. 
 
2.1.8. Anticoagulant activity 
The anticoagulant activity of tris-mTBA and tris-mTBA/Sicastar
®
 NPs was evaluated following the 
conversion of fibrinogen in fibrin induced by thrombin by means of light scattering experiments, 
and compared with the activity of free TBAs. A rapid increase of the scattered intensity with time 
indicated the progression of fibrin formation in samples only containing fibrinogen and thrombin 
(Figure 60). The addition of the aptamers, TBA or tris-mTBA, caused a marked decrease of the 
scattered intensity with respect to the untreated samples, evidencing the inhibition of thrombin 
coagulation activity. The observed anticoagulant effect was significantly influenced by the 
conjugating groups on TBA. Indeed, tris-mTBA was ca. 10 times more effective than TBA itself 
under the same experimental conditions, probably as a result of its higher affinity for thrombin 
imparted by the presence of the pendant groups. Upon treatment with the tris-mTBA/Sicastar
®
 NPs, 
no increase of the scattered intensity over time was detected, indicating that the coagulation process 
was completely blocked by the functionalized NPs, proving to be much more efficient as 
anticoagulant than both the free TBAs. 
Finally, we verified if the anticoagulant activity of tris-mTBA could be controlled by addition of the 
antidote of TBA (i.e., cTBA) even when the aptamer was bound on the NP surface. A 10-fold 
excess of cTBA was added to the tris-mTBA/Sicastar
®
 NPs and the scattered intensity of the 
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resulting mixture monitored over time. A significant increase of the scattered intensity was detected 
about 30 minutes after the cTBA addition, indicating that the antidote is effectively able to reverse 
the tris-mTBA anticoagulant activity even when the aptamer is immobilized on the NP surface 
(Figure 60). 
 
Figure 60. Coagulation curves of fibrinogen in the presence of thrombin and different anticoagulant 
agents (TBA; tris-mTBA, tris-mTBA/Sicastar
®
 NPs and cTBA). 
 
Control experiments performed in the presence of not functionalized Sicastar® show an almost 
sudden increase of the light scattered intensity, which does not change further with time, in apparent 
contrast with the coagulation of fibrinogen. Thus to get a further insight into the process, we also 
analysed the autocorrelation functions obtained for the different systems at different times. Indeed, 
the analysis of the normalized autocorrelation function gives us a direct information on the size of 
the species in the system, a different experimental view of the coagulation process. 
As emerges from Figure 61a, in the presence of thrombin, a shift of the curves with respect to pure 
fibrinogen (fibr t=0) occurs at increasing times because of the formation of fibrin. Remarkably, the 
autocorrelation curves at the end of the coagulation experiment (t=tf) differ depending on the 
anticoagulant agent. When no anticoagulant is present, the curve does not reach zero even at very 
long times, clearly indicating the formation of very big aggregates. In the presence of TBA the 
strong noise at long times also points towards the formation of big species; while, in the case of tris-
mTBA, the position of the curve and the flat region at long times indicate that only soluble, smaller 
species are present. Finally, in the presence of tris-mTBA/Sicastar
®
 NPs no appreciable shift of the 
autocorrelation curve is observed with time. It is interesting to note that in the control system 
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containing not functionalized Sicastar
®
, the initial curve is intermediate between that of the system 
containing fibrinogen and tris-mTBA/Sicastar
®
 NPs and that of coagulated fibrinogen, suggesting 
the presence of some aggregated species formed upon interaction between NPs and fibrinogen. 
However, at the end of the experiment the normalized autocorrelation curve is superimposable with 
that of coagulated fibrinogen. The conversion of fibrinogen coated NPs into coagulated fibrinogen 
does not result in a significant change of intensity. So, although monitoring of the light scattered 
intensity over time is a good method to follow the coagulation of fibrinogen, nonetheless in some 
cases it fails to reveals what actually happens in the system, and only a concomitant analysis of the 
autocorrelation function can give a clear picture of the system. 
Indeed, the normalized autocorrelation function, compared with that of the other systems containing 
Sicastar
®
 NPs (Figure 61b), upon addition of the antidote, at the end of the measurements, proved to 
be superimposable to that of the control experiment with no anticoagulant agent. 
 
Figure 61. a) Normalized autocorrelation function at different times and in the presence of different 
anticoagulant agents (TBA; tris-mTBA and tris-mTBA-NPs) and in the presence of not 
functionalized Sicastar
®
; b) Comparison of the normalized autocorrelation function upon addition 
of the antidote with respect to systems containing not functionalized and functionalized Sicastar
®
. 
 
2.2. Experimental section 
 Materials and general methods 
All the reagents and solvents were of the highest commercially available quality and used as 
received. 
The Sicastar
®
 nanoparticles were purchased from Micromod (Germany) and consisted of a 
suspension of spherical amorphous silica particles with a hydrodynamic radius of 50 nm (10 
mg/mL, 7.6 × 10
12
 particles per mg, density: 2.0 g/cm
3
) in PBS buffer, stabilized with 0.02% 
a) b)
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sodium azide. The particle surface was covered with covalently-bound streptavidin (protein content: 
2500 ng/mg, corresponding to ca. 3 molecules of streptavidin per single particle). 
UV measurements were obtained on a JASCO V-530 UV/vis spectrophotometer equipped with a 
Peltier block JASCO ETC-505T, by using 1-cm quartz cells of 0.5 and 3 mL internal volume 
(Hellma). The spectra were recorded with a response of 1 s, a scanning speed of 100 nm/min and a 
2.0 nm bandwidth, and corrected by subtracting the buffer background scan. 
CD spectra and CD-monitored melting curves were recorded on a Jasco J-715 spectropolarimeter 
equipped with a Peltier-type temperature control system (model PTC-348WI), using a quartz 
cuvette with a path length of 1 cm (3 mL internal volume, Hellma) or a tandem cell (2 × 0.4375 cm, 
Hellma). CD parameters for spectra recording were: spectral window 220-320 nm, data pitch 1 nm, 
band width 2 nm, response 4 s, scanning speed 100 nm/min, 3 accumulations. CD melting was 
performed at 1 °C/min scan rate. 
Fluorescence spectra were collected in a 1 cm path length cuvette with a HORIBA Jobin Yvon Inc. 
FluoroMax®-4 spectrofluorometer equipped with F-3004 Sample Heater/Cooler Peltier. 
 Preparation of oligonucleotide samples 
Purified and lyophilized oligonucleotides tris-mTBA 8, unmodified TBA and cTBA were dissolved 
in a known volume of Milli-Q water and their concentrations determined by UV spectroscopy in 1 
cm path length cuvette measuring the absorbance at 260 nm (85 °C) using the following molar 
extinction coefficients: for unmodified TBA and tris-mTBA, ε260 = 158478 cm
−1
 M
−1
; for cTBA, 
ε260 = 154655 cm
−1
 M
−1
. Then the oligonucleotides from the stock solutions were diluted in the 
selected buffer and annealed by heating each solution for 5 min at 90 °C and then leaving it to 
slowly cool to r.t. overnight. Annealed samples were then kept at 4° C until use. 
 Spectroscopic characterization of tris m-TBA 
CD experiments. The CD spectra were collected at 10 °C in the range 220-320 nm. The 
characterization of tris-mTBA was performed at 5 μM concentration taking a suitable initial aliquot 
from a 335 μM stock solution in H2O. For the CD melting experiments, the CD signal at 295 nm 
was recorded vs. the temperature in the range 10-85 °C. The CD experiments carried out with the 
unmodified TBA or tris-mTBA and the corresponding complementary strand (cTBA) were 
performed in a tandem cell by placing, in one chamber, the TBA sequence, and in the other the 
complementary strand, each at 2.5 μM concentration in PBS solution. Two CD spectra were 
registered for each experiment: the first one was recorded as the sum of the separate components, 
here named as the sum spectrum, and the second one was recorded after mixing the two solutions 
and stabilization of the signal, here named as mix spectrum. After mixing the two solutions, the 
duplex concentration was reduced by a factor of 2 and the solution path length increased from 0.437 
Chapter 4 
110 
 
to 0.875 cm. Thermal denaturation-renaturation curves of the resulting duplex were recorded 
following the CD signal at 268 nm. The error associated with the Tm determination was ± 1 °C. 
UV-vis absorption experiments. The UV-vis measurements were registered in the range 220–380 
nm using 1 cm path length cuvette. The absorbance vs. temperature profiles were recorded by 
following the absorbance changes at 295 nm on increasing the temperature (heating scan rate 1 
°C/min). The tris-mTBA solution used for these experiments was 5 μM in a 10 mM KH2PO4, 70 
mM KCl, 0.2 mM EDTA (pH 7.0) buffer, prepared diluting the original stock solution of the 
oligonucleotide in H2O. The error associated with the Tm determination was ± 1 °C. 
Fluorescence Spectroscopy experiments. The fluorescence emission spectra were recorded from 
440 to 640 nm, exciting at 327 nm and maintaining the excitation and emission slits at 10 nm. The 
oligonucleotide concentration was 2 μM in a 10 mM KH2PO4, 70 mM KCl, 0.2 mM EDTA (pH 
7.0) solution. Fluorescence melting curves were obtained by reporting the wavelength shift of the 
emission maximum as a function of temperature (from 20 to 80 °C). The error associated with the 
Tm determination was ± 1 °C. 
 Sicastar® functionalization and characterization 
750 μL of a 0.4 μM solution of tris-mTBA in PBS were first subjected to annealing, heating the 
sample at 95 °C for 5 min and then leaving it to slowly cool to r.t. The formation of the desired 
antiparallel G-quadruplex structure of tris-mTBA was confirmed in this buffer solution by CD and 
fluorescence spectra. Then 250 μL of a Sicastar® NPs suspension in PBS buffer (10 mg/mL) were 
added to the tris-mTBA reaching a final volume of 1 mL (Sicastar
®
 NPs 2.5 mg/mL; tris-mTBA 0.3 
μM) and the reaction mixture was gently stirred at r.t. for 1 h. 
Gel electrophoresis. Non denaturing agarose (1% w/v) gel electrophoresis was performed loading 
unmodified TBA, tris-mTBA, Sicastar
®
 NPs and tris-mTBA/Sicastar
® 
NPs on the gel with 3% of 
GelRed dye. The samples were then run at 100 V for 30 min at r.t. in Tris-acetate-EDTA (TAE) 
buffer and visualized under UV light. 
Fluorescence analysis. Fluorescence spectra of the tris-mTBA/Sicastar
®
 NP solution were recorded 
in PBS buffer (0.3 μM oligonucleotide concentration) from 400 to 650 nm exciting at 340 nm and 
maintaining the excitation and emission slits at 10 nm. Fluorescence spectra of the free tris-mTBA 
in solution under the same conditions were also registered. 
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3. G-quadruplex oligonucleotide AS1411 as a cancer cell-targeting agent: 
introduction 
In the last decade, AS1411 has been the subject of a high number of publications.
[398]
 This 
escalation of interest is largely driven by the use of AS1411 as a ligand for the tumor-selective 
delivery of therapeutic or imaging agents, especially in fields related to nanotechnology.
[398]
 
AS1411 is a 26-mer G-rich DNA oligonucleotide with sequence 
5′
GGTGGTGGTGGTTGTGGTGGTGGTGG
3’
. It is well established that AS1411 and longer 
versions of this sequence, such as GRO29A, form G-quadruplex-containing structures showing 
cancer-selective antiproliferative activity and efficient cellular internalization.
[399–404]
 No definitive 
crystal or NMR structure of AS1411 is available, but it is known that this sequence displays a high 
degree of structural polymorphism in solution,
[404]
 as also already observed for many other 
biologically relevant G4-forming sequences.
[405–408]
 Trent and coworkers discovered that at least 8 
different forms of AS1411 could be detected by size exclusion chromatography (SEC) analysis.
[404]
 
Using preparative SEC, they isolated and characterized 5 distinct AS1411 fractions, which 
contained either monomolecular quadruplexes or a mixture of monomer and dimer 
quadruplexes.
[404]
 The isolated species were indistinguishable by most biophysical techniques, but 
had significantly different NMR and circular dichroism (CD) spectra. In the presence of K
+
 ions, 4 
of the 5 fractions displayed the classical CD features of a parallel G4 (positive peak at 264 nm), 
whereas one fraction (Fraction 2) had a very unusual CD spectrum with a positive peak at 245 nm 
and a strong negative ellipticity at 277 nm,
[404]
 which can likely contain a left-handed quadruplex 
form (Z-G4) of AS1411.
[409]
 Possible G4 structures for AS1411 are illustrated in Figure 62. 
The type(s) of quadruplex formed by AS1411 in vivo and how the structure of AS1411 relates to its 
biological activities remains an open question and may be influenced by a number of factors, such 
as protein binding and localization in the body (e.g. in the blood there is ca. 140 mM Na
+
/5 mM K
+
 
compared to ca. 150 mM K
+
/10 mM Na
+
 inside cells).
[398]
 However, some early studies of a series 
of G-rich oligonucleotides indicated that G4 formation is necessary, but not sufficient, for 
antiproliferative effects.
[399–401]
 A few studies have explicitly investigated whether the G4 structure 
of AS1411 is affected by attaching it to various particles. Based on CD analyses, AS1411 maintains 
its parallel-type G4 structure when is conjugated to gold nanospheres
[410,411]
 gold nanostars,
[412]
 gold 
nanoclusters,
[413]
 or quantum dots.
[414]
 Only in one study performed by Odom et al., after 
immobilization of the sequence onto gold nanostars, an antiparallel G4 CD signature has been 
observed, probably due to the specific experimental conditions or their use of a modified AS1411 
sequence lacking the final 3′-G base.[415] 
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Figure 62. Structures of AS1411. (A) Size exclusion chromatogram showing a number of distinct 
G4 species formed by AS1411 in a K
+
-containing solution. (B) Possible G4 structures of AS1411. 
For clarity, the single Ts in the loops of the monomer structures are not shown. Picture reproduced 
from Trent et al.
[398]
 
 
3.1. Clinical development of AS1411 
The clinical development of AS1411 has been reviewed in several articles
[398,402,416,417]
 and in a 
book.
[418]
 Aptamera, a Louisville-based start-up company, initiated Phase I clinical trials of AS1411 
(known at that time as AGRO100) in 17 patients with advanced cancers in 2003 and British 
biotechnology company Antisoma acquired Aptamera in 2005 following its promising 
results.
[419,420]
 Antisoma extended the Phase I studies (clinicaltrials.gov identifier: NCT00881244) 
and performed Phase II trials of AS1411 as monotherapy in patients with renal cell carcinoma who 
had failed or were unable to tolerate standard treatment (NCT00740441) and in combination with 
cytarabine in patients with refractory or relapsed acute myeloid leukemia (NCT00512083). In 2011, 
Antisoma stopped drug development operations after its lead drug candidate (a small molecule 
named AS1413, which is unrelated to AS1411) failed in pivotal Phase III trials and consequently 
the ongoing Phase IIb trial of AS1411 (NCT01034410) was terminated.
[421]
 Advanced Cancer 
Therapeutics have since acquired the rights to AS1411 and the drug has been renamed ACT-GRO-
777. To our knowledge, there are no clinical studies of AS1411 being carried out at present. 
Based on published articles and meeting reports,
[402,419,420,422–425]
 the clinical results for AS1411 can 
be thus summarized: (i) AS1411, tested in over 100 patients, is well tolerated with no evidence of 
severe side effects with continuous infusion dosing of up to 40 mg/kg/day for 7 days, (ii) the overall 
response rate is low but at least 7 patients - 3 with renal cell carcinoma and 4 with acute myeloid 
leukemia - had long-lasting clinical responses where their cancers disappeared or shrank 
substantially, and (iii) steady-state plasma concentrations of AS1411 have been in the range of 1–6 
μM or less during clinical trials. 
Thus, AS1411 has still some potential for clinical impact due to its excellent safety profile and 
ability to induce durable responses in some patients with intractable cancers.
[398]
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However, the suboptimal pharmacology and low potency of this unmodified DNA may limit its 
future development in unselected cancer patients. Therefore, a valuable alternative approach would 
be to develop novel formulations of AS1411 with improved pharmacokinetics and higher potency 
compared to the original, such as the gold nanosphere and nanostar-linked versions.
[426–430]
 Other 
possibilities include identifying synergistic combinations of AS1411 with existing drugs, 
developing modified versions of AS1411 with alternative nucleobases or backbones (though this 
has led to only modest improvements so far),
[431–435]
 or using the targeting properties of AS1411 to 
deliver drugs or contrast agents selectively to cancer cells. 
 
3.2. Nanoformulations of AS1411 with improved activity 
Several examples of nanoformulations of AS1411 have been reported in literature. Bates et al. have 
described stable gold nanospheres (GNS) consisting of 6 nm cores coated with ca. 40 strands of 
AS1411.
[430]
 In vivo experiments, using nude mice with breast cancer xenografts, demonstrated that 
the conjugation dramatically increased the cellular accumulation, antiproliferative activity, and 
cytotoxicity of the aptamer, maintaining its selectivity for cancer cells.
[430]
 
On the other hand, also “Apt-AuNS” - consisting of 25-45 nm gold nanostars coated with 110-950 
strands of AS1411
[412,426–428]
, developed by Odom et al. - proved to be able to accumulate around 
and inside the nucleus of cancer cells and to reduce the viability of cancer cells when used alone or 
following laser light irradiation to stimulate the release of AS1411 from the nanostars.
[412,415,426–429]
 
Apt-AuNS have shown high antiproliferative effects against a broad range of cancer cell types with 
no inhibitory effects on non-malignant cells at comparable concentrations,
[412,428]
 even in organs 
with high uptake levels (e.g. liver, spleen).
[429]
 In addition, AS1411-GNS and Apt-AuNS may also 
be useful as cancer-targeted radiosensitizers in radiation therapy, allowing to improve accumulation 
and cell uptake in tumor tissues, i.e. the main limitations of untargeted gold nanoparticles.
[436]
  
 
3.3. AS1411 as a targeting agent for cancer-selective drug delivery and imaging 
Another attractive feature of AS1411 is the possibility of using this aptamer to direct into malignant 
cells attached molecules or particles (Figure 63). Some of the earliest examples have involved 
coating liposomes, quantum dots, or iron oxide nanocrystals with the aptamer for cancer-selective 
delivery of drugs or imaging agents.
[414,437–439]
 
Very recently a resuming overview of the applications of AS1411-linked nanomaterials as 
therapeutic and imaging agents has been reported.
[398]
 
Chapter 4 
114 
 
 
Figure 63. Schematic representation of the uses and advantages of AS1411 as a cancer-targeting 
agent, showing the variety of structures that AS1411 has been conjugated to for cancer targeting. 
The bullet points (red text) indicate potential clinical applications for AS1411-conjugated materials 
and advantages of using AS1411 compared to monoclonal antibodies or alternative targeting agents 
(e.g. other aptamers, small molecules, peptides). Picture reproduced from Trent et al.
[398]
 
 
Several AS1411-linked conjugates or particles - mainly based on nanoparticles or liposomes - for 
the delivery of chemotherapeutic agents (as Paclitaxel,
[440,441]
 Docetaxel,
[442–444]
 Doxorubicin,
[413,445–
452]
 and Epirubicin)
[453]
 small interfering RNA (siRNA)
[454,455]
 and therapeutic protein
[456]
 have been 
tested in vivo and/or in animal models for therapeutic effects. On the other hand, also AS1411-
linked conjugates or particles have been developed and tested in vivo and in animal models as 
imaging agents for PET, SPECT, CT, MRI and fluorescence analysis.
[413,432,457–466]
 
AS1411-linked materials have superior cancer cell uptake and/or tumor accumulation compared to 
untargeted materials or free drugs, though not all include other important controls such as non-
aptamer DNA-linked materials. For small molecule chemotherapy drugs, there is some evidence 
that delivery via AS1411-conjugated particles can circumvent drug-resistance pumps,
[451]
 pass the 
blood-brain barrier,
[442]
 and reduce toxicity to normal tissues.
[448,449,451]
 
 
3.4. Role of nucleolin in the mechanism of AS1411 
Despite the widespread use of AS1411 and the general acceptance that it functions as a nucleolin 
aptamer, its precise mechanism of action is still uncertain. 
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The presence of nucleolin on the cell surface, initially assumed as surprising for a protein 
considered to be predominantly nucleolar, has been then largely demonstrated.
[467–469]
 In addition to 
mediating cellular internalization, nucleolin is also implicated in trafficking molecules throughout 
the cell and mediating their signaling from the plasma membrane. Nucleolin expression is also 
strongly induced in response to various forms of cellular stress.
[470–474]
 Hovanessian and colleagues 
have reported that nucleolin is translocated from the cytoplasm to the cell surface via an 
unconventional secretory pathway in response to mitogenic stimuli, and have proposed that binding 
of ligands to cell surface nucleolin results in clustering that triggers cell entry by an actin- and Ca
2+
-
dependent process.
[470,475]
 Notably, proliferating cancer cells continuously produce nucleolin in 
comparison with non-malignant cells to constitutively express nucleolin on cell surface.
[398,470]
 In 
addition, nucleolin is also involved in the biology of several viral pathologies; in fact AS1411 
recently proved to have potent antiviral activity against HIV-1, RSV, and dengue in model 
systems.
[476–478]
 
Although it is well established that AS1411 is selectively internalized in cancer cells via nucleolin 
and here interferes with certain cancer-associated functions of nucleolin resulting in cancer cell 
death,
[402]
 several different mechanisms have been proposed to explain the antiproliferative activity 
of AS1411
[399,433,479–489]
 and recently other studies have suggested a new mode of action for the 
cancer-targeting mechanism of AS1411 (Figure 64).
[490,491]
 
In 2010, Bates et al. studied the uptake of a fluorescently labeled AS1411 at therapeutic 
concentrations in comparison with a control oligonucleotide (CRO) in several cancer cell lines and 
in non-malignant cells.
[490]
 They observed that the uptake of AS1411 was much higher than that of 
the CRO control in the cancer cells, probably through an active transport mechanism since the 
process was temperature-dependent. Surprisingly, the initial uptake of AS1411 (2 h after addition) 
was slightly higher in the non-malignant cells than in the cancer cells and was independent of 
nucleolin. They also investigated which of the various forms of endocytosis (e.g. clathrin-mediated, 
caveolin-mediated, or macropinocytosis)
[492]
 contributes to AS1411 internalization, finding as main 
mechanism the macropinocytosis, which is an actin-driven, ligand-independent mechanism where 
cells “gulp” the surrounding medium and any macromolecules it contains.[490,491] 
On the contrary, evaluating the uptake of AS1411 at later time points (24–72 h after addition), the 
same group discovered that AS1411 stimulates macropinocytosis in cancer cells but not in non-
malignant cells, leading to additional cancer-selective uptake of the aptamer. This AS1411-
stimulated form of macropinocytosis was found to be dependent on nucleolin.
[490,491]
 These results 
are not unprecedented since macropinocytosis has been reported as a major route of internalization 
for naked DNA, naked RNA, aptamer conjugates, nanoparticles, and many viruses,
[493–497]
 since 
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cancer cells have inherently high levels of macropinocytosis compared to normal cells.
[490,498]
 In the 
final phase, the nucleolin-mediated trafficking is suppressed and the aptamer is trapped inside 
cancer cells.
[491]
 
 
Figure 64. Model for the mechanism of AS1411 selective accumulation in cancer cells. AS1411 is 
efficiently taken up in cancer and normal cells at early time points, but by different endocytic 
pathways. Then, AS1411 induces further macropinocytosis and trafficking arrest in cancer cells but 
not in normal cells. These effects are nucleolin (NCL)-dependent and result in AS1411 being 
selectively retained in cancer cells compared to normal cells.  
 
To explain why AS1411 and AS1411-conjugates have selective accumulation in cancer cells 
compared to normal cells, it has been proposed that, after initial uptake by a non-macropinocytosis 
form of endocytosis, AS1411 is gradually cleared from normal cells - by efflux or exocytosis – or it 
undergoes lysosomal degradation in normal cells. In other words, the selective accumulation of 
AS1411 in cancer cells is due to both enhanced uptake and increased retention.
[398]
 
Although there are several evidences to support this model
[490,491]
 some differences emerged in the 
uptake and trafficking of AS1411-linked particles of malignant vs. non-malignant cells,
[499,500]
 with 
some contradictory findings on the initial nucleolin-dependence and subsequent trafficking.
[495,501]
 
In addition, from Phase II trials an activating mutation in mTOR has been highlighted in patients 
who had a dramatic response to AS1411.
[425]
 This finding is particularly intriguing because mTOR 
is regulated by Rac1 and has roles in macropinocytosis and intracellular trafficking;
[502–510]
 
however, additional research will be needed to confirm the possible role of mTOR in AS1411 
activity. At present, it is unclear how to reconcile the many different proposed mechanisms; most 
likely, AS1411 can induce multiple biological effects and its internalization and trafficking depends 
on a large number of variables (such as concentration, time, cell type, and attached cargo).  
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4. Studies on the conformational behaviour and molecularity of natural and 
modified AS1411 aptamers 
Considering its great potential for the cancer cell-selective recognition, in principle useful also for 
the delivery of drugs and imaging agents, AS1411 can represent a perfect active targeting ligand in 
the construction of multifunctional systems for anticancer applications. Although much attention 
has been paid to AS1411 in vivo functions, its structural features, and particularly its bioactive 
conformation, are still largely unknown. Indeed, some discrepancies on the preferred AS1411 
conformation, in some cases described as a parallel
[404,410–414]
 and in others as antiparallel G-
quadruplex,
[415]
 have been reported. Furthermore, only few studies have been carried out in order to 
get detailed information on the structure, molecularity and thermal stability of this aptamer
[404]
. 
Recently, Azizi and collegues
[511]
 have investigated the optical properties and thermodynamic 
stability of AS1411 in the presence of different concentrations of metal ions (K
+
 and Pb
2+
) and in 
molecular crowding condition, confirming that AS1411 folds into a parallel G4 structure in the 
presence of both metal ions as well as of PEG. 
Therefore, with the aim of exploiting AS1411 as an active targeting agent for multifunctional, 
theranostic nanoplatforms, we here selected some AS1411 derivatives (Figure 65) presenting at 
their 5’-end biocompatible lipophilic tails, useful for their subsequent insertion into liposomes or 
lipid coated-NPs. In detail, we focused on the 5’-stearyl-AS1411, presenting a saturated 18-carbon 
alkyl chain, and other two derivatives, the 5’-cholesteryl-TEG- and the 5’-cholesteryl-C6-AS1411, 
both presenting a cholesterol residue linked to the oligonucleotide sequence through a triethylene 
glycol or a 6-carbon atoms alkyl chain, respectively. In particular, the 5’-stearyl-AS1411 has a 
lipophilic tail of the same length as 18LPC, recently used as coating of superparamagnetic 
nanoparticles (SPIONs) with a core/double shell architecture
[174]
 - developed by the research group 
of prof. Luigi Paduano. Thus, this conjugating agent is in principle able to establish hydrophobic 
interactions with 18LPC and, more in general, with any lipid residue (e.g. liposome-based 
platforms). On the other hand, the cholesterol residue already proved to be effective to ensure the 
insertion of specific agents in a liposome structure
[136,137]
 or into phosphocholine-functionalized 
SPIONs (18LPC/SPIONs).
[174]
 
In this frame, during my PhD thesis, the behavior of these AS1411 derivatives has been investigated 
also in solution using different techniques, in comparison with the unmodified aptamer. In 
particular, CD, CD-melting, UV-melting, gel electrophoresis and size exclusion chromatography 
analysis have been carried out to get information on their conformational behaviour, secondary 
structure and thermal stability of their preferred conformations. This study was carried out in two 
different buffered solutions and at different oligonucleotide concentrations; special attention was 
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devoted to the investigation of possible effects due to the nature of the lipophilic tail, or of the 
specific linker inserted, on the overall structure and conformation of the aptamer. 
 
Figure 65. AS1411 derivatives selected as potential active targeting ligands in the construction of 
liposome or NP-based anticancer multifunctional systems. 
 
4.1. Results and discussion 
4.1.1. Spectroscopic properties and solution behaviour of AS1411 
The conformational behaviour in solution of AS1411 was investigated combining CD, CD-melting 
and UV-melting data. The spectra and melting/annealing profiles were recorded in two different 
phosphate buffered solutions containing a high content of K
+
 (10 mM KH2PO4, 70 mM KCl, 0.2 
mM EDTA, pH 7.0) or of Na
+
 ions (PBS: 137 mM NaCl, 2.7 mM KCl, 10 mM Na2HPO4, 1.8 mM 
KH2PO4, pH 7.4) in order to evaluate the effect of different saline conditions. In addition, we also 
tested three different concentrations of each aptamer (10, 5 and 2.5 μM) to investigate possible 
concentration-dependent effects on its conformation and stability. 
The CD spectra at r.t. of AS1411 at the analysed concentrations, either in K
+
 or Na
+
 buffer 
solutions, in all cases show a negative band with a minimum at ca. 241 nm, and two positive bands 
with maxima centred at 263 nm, the highest one, and at ca. 295 nm, the weakest (Figure 66). In PBS 
solution the aptamer presents a lower degree of structuration than in the phosphate buffer containing 
only K
+
 ions, as expected considering that these cations can better stabilize G4 structures than Na
+
, 
in accordance with literature studies.
[388–391]
 In addition, the weak band at ca. 295 nm is more 
evident in the spectra recorded in Na
+
 buffer. 
5’-cholesteryl-C6-AS1411
5’-cholesteryl-TEG-AS1411
5’-stearyl-AS1411
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Figure 66. Overlapped CD spectra of AS1411 at 10 μM (a), 5 μM (b) and 2.5 μM (c) in different 
saline conditions: potassium buffer (red line) and sodium buffer (blue line) solutions. 
 
These spectral features are consistent with a predominant parallel G-quadruplex structure
[382–387,512]
 
and in agreement with the CD spectrum of AS1411 reported in previous works,
[402,404,434]
 with only 
a very low fraction of an antiparallel conformation, as evidenced by the weak band at ca. 295 nm. 
The CD melting profile, monitored at 263 nm in K
+
 buffer, provided a melting temperature of 66 °C 
at 10 μM (Figure 67) and of 68 °C at 5 and 2.5 μM concentrations (Figure 68a and 68b, 
respectively), indicating the formation of quite stable species. No significant hysteresis emerged on 
comparing the heating and cooling curves (Figure 67), thereby indicating that, under the 
experimental conditions used (scan rate: 1 °C/min), the studied systems are in equilibrium. The 
comparison between heating and cooling profiles is reported only for the 10 μM conc. sample as a 
representative example. 
 
Figure 67. a) CD melting and b) CD annealing profiles of AS1411 in the selected K
+
 buffer 
solution at 10 µM concentration, recorded at 263 nm (scan rate: 1 °C/min). 
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Figure 68. CD melting profiles of AS1411 in the selected K
+
 buffer solution at 5 µM (a) and 2.5 
µM (b) concentrations, recorded at 263 nm (scan rate: 1 °C/min). 
 
Lower melting temperatures were observed in the Na
+
 buffer solution with respect to the K
+
 buffer, 
monitoring the CD signal at 263 nm on increasing the temperature: melting temperatures of 38 °C 
at 5 μM concentration (Figure 70a) and of 37 °C at 10 and 2.5 μM concentration (Figure 69a and 
70b, respectively) were found. Also for these systems, no significant hysteresis emerged on 
analysing the heating and cooling profiles; as a representative example, this comparison is reported 
for the 10 μM concentration sample (Figure 69). 
 
Figure 69. a) CD melting and b) CD annealing profiles of AS1411 in the selected Na
+
 buffer 
solution at 10 µM concentration, recorded at 263 nm (scan rate: 1 °C/min). 
 
a) b)
K+ buffer
5 μM 2.5 μM
C
D
[m
d
e
g
]
Temperature [ C]
Tm= 68  C ± 1
25
0
10
20
10 9020 40 60 80
40
0
10
20
30
10 9020 40 60 80
C
D
[m
d
e
g
]
Temperature [ C]
Tm= 68  C ± 1
a) b)
60
0
20
40
90 1020406080
C
D
[m
d
e
g
]
Temperature [ C]
Tm= 38  C ± 1
50
0
20
40
10 9020 40 60 80
C
D
[m
d
e
g
]
Temperature [ C]
Tm= 37  C ± 1
10 μM Na+ buffer
Melting Annealing
Chapter 4 
121 
 
 
Figure 70. CD melting profiles of AS1411 in the selected Na
+
 buffer solution at 5 µM (a) and 2.5 
µM (b) concentrations, recorded at 263 nm (scan rate: 1 °C/min). 
 
 
Figure 71. UV-melting profiles of AS1411 in the selected K
+
 buffer solution at 10 µM (a), 5 µM 
(b) and 2.5 µM (c) concentrations, recorded at 295 nm (scan rate: 1 °C/min). 
 
 
Figure 72. UV-melting profiles of AS1411 in the selected Na
+
 buffer solution at 10 µM (a), 5 µM 
(b) and 2.5 µM (c) concentration, recorded at 295 nm (scan rate: 1 °C/min). 
 
In agreement with the CD data, from the UV-melting curve monitored at 295 nm,
[386,392,393]
 a Tm of 
67 °C in K
+
 buffer was obtained at all the tested concentrations, evidence of thermodynamically 
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stable species (Figure 71). In turn, in the Na
+
 buffer solution a Tm of 40 °C at 10 μM concentration 
(Figure 72a) and of 39 °C at 5 and 2.5 μM concentration (Figure 72b and 72c, respectively) was 
found. Also in this case, the melting process was fully reversible, with no significant hysteresis 
observed on comparing the heating and cooling processes (data not shown). 
In summary, a good agreement between the Tm values determined by UV- and CD-melting 
experiments (Table 7), within the experimental error, was always found. As expected, AS1411 
formed G-quadruplex structures with higher stability in the K
+
 buffer solution than in Na
+
. Taking 
into account these experiments, this different thermal stability is mainly dependent on the saline 
conditions and not on the concentration, proving that AS1411 mainly forms a unimolecular G-
quadruplex, at least at the analysed concentrations. 
 K
+
 buffer Na
+
 buffer 
AS1411 conc. 
CD 
Tm (°C) ± 1 
UV 
Tm (°C) ± 1 
CD 
Tm (°C) ± 1 
UV 
Tm (°C) ± 1 
10 μM 66 67 37 40 
5 μM 68 67 38 39 
2.5 μM 68 67 37 39 
 
Table 7. Melting temperature values obtained by UV- and CD-melting experiments for AS1411. 
 
4.1.2. Spectroscopic properties and solution behaviour of lipophilic AS1411 derivatives 
All the here examined AS1411 derivatives have been analysed using the same kind of spectroscopic 
characterization performed to investigate if the presence of a lipophilic tail can influence the 
preferential conformations of AS1411 in solution. Thus, UV and CD experiments were performed 
at three different concentrations and in two different phosphate buffers. 
 
5’-stearyl-AS1411 
The CD spectrum at r.t. of 5’-stearyl-AS1411 shows a positive ellipticity maximum at 263 nm and a 
negative ellipticity minimum at ca. 241 nm (Figure 73), both in K
+
 and Na
+
 buffer solutions, 
characteristic of a prevalent parallel G-quadruplex conformation, as in the case of the unmodified 
aptamer. The weak positive band at 295 nm present in the CD spectra of AS1411 was not evident in 
this case at 10 μM concentration both in K+ and Na+ buffer, and in turn appeared as a broad double-
dump band in K
+
 buffer and as a broad shoulder in Na
+
 buffer (both at 5 and 2.5 μM). Again the K+ 
ions show higher structuring effect on G-quadruplex formation. 
The CD melting profile, monitored at 263 nm, provided a melting temperature of 59 °C in K
+
 buffer 
solution at all the tested concentrations (Figures 74 and 75). No significant hysteresis was observed 
between the melting and cooling profiles - reported only at 10 μM concentration as representative 
example - suggesting a reversible process at the scan rate used (1 °C/min). 
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Figure 73. Overlapped CD spectra of 5’-stearyl-AS1411 at 10 μM (a), 5 μM (b) and 2.5 μM (c) in 
different saline conditions: potassium buffer (red line) and sodium buffer (blue line) solutions. 
 
 
Figure 74. a) CD melting and b) CD annealing profiles of 5’-stearyl-AS1411 in the selected K+ 
buffer solution at 10 µM concentration, recorded at 263 nm (scan rate: 1 °C/min). 
 
 
Figure 75. CD melting profiles of 5’-stearyl-AS1411 in the selected K+ buffer solution at 5 μM (a) 
and 2.5 µM (b) concentrations, recorded at 263 nm (scan rate: 1 °C/min). 
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CD melting profiles, monitored at 263 nm, in Na
+
 buffer solution, evidenced lower Tm values, of 40 
and 39 °C, respectively at 5 and 2.5 μM concentrations (Figures 76a and 76c) with small hysteresis 
effects only in the case of the 5 μM conc. sample: at this concentration the annealing profile 
provided a Tm of 37 °C (Figure 76b). 
 
Figure 76. CD melting (a,c) and CD annealing profiles (b) of 5’-stearyl-AS1411 in the selected 
Na
+
 buffer solution at 5 μM (a, b) and 2.5 µM (c) conc., recorded at 263 nm (scan rate: 1 °C/min). 
 
 
Figure 77. a) CD melting profile and b) spectra recorded every 5 °C of 5’-stearyl-AS1411 in the 
selected Na
+
 buffer solution at 10 µM concentration, recorded at 263 nm (scan rate: 1 °C/min). 
 
Notably, at 10 μM concentration in Na+ buffer a peculiar behaviour was found: the melting profile 
did not show the typical sigmoidal shape, but a curve with multiple transitions, with a not complete 
denaturation of the structures in solution at 80 °C (Figure 77). From the analysis of the CD spectra 
at increasing temperatures the appearance of a new, weak band at 285 nm visible starting from 75 
°C was evidenced (light blue and green dashed lines in Figure 77b). In addition, on increasing the 
temperature, a shift in the maximum of the positive band was also observed. Thus, starting from 30 
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°C the positive maximum shifts at 262 nm and then returns at 263 nm at 80 °C. Probably, multiple 
events occur during the thermal denaturation process (e.g. unfolding/refolding of different G4 
species), overlapping with the dissociation of the prevailing G4 structure. 
The UV-melting profiles, monitored at 295 nm, provided at all tested concentrations a melting 
temperature of 59 °C and 40 °C in K
+
 and Na
+
 buffer solutions, respectively (Figures 78 and 79). 
Also in this case, the melting process was fully reversible, with no significant hysteresis observed 
on comparing the heating and cooling processes (data not shown). 
 
Figure 78. UV-melting profiles of 5’-stearyl-AS1411 in the selected K+ buffer solution at 10 μM 
(a), 5 μM (b) and 2.5 µM (c) concentration, recorded at 295 nm (scan rate: 1 °C/min). 
 
Figure 79. UV-melting profiles of 5’-stearyl-AS1411 in the selected Na+ buffer solution at 10 μM 
(a), 5 μM (b) and 2.5 µM (c) concentration, recorded at 295 nm (scan rate: 1 °C/min). 
 
In summary, a good agreement of Tm values determined by UV- and CD-melting experiments was 
found (Table 8) for all the conditions except for the 10 µM concentration in Na
+
 buffer solution. 
Furthermore, the Tm values obtained in Na
+
 buffer solution for this modified aptamer are very 
similar to those obtained for AS1411, while in K
+
 buffer solution the 5’-stearyl derivative showed a 
lower thermal stability than AS1411, still remaining very high. 
 
20 30 40 50 60 70 80 90
0,56
0,60
0,64
0,68
A
b
s
Temperature [°C]
20 30 40 50 60 70 80 90
0,32
0,34
0,36
0,38
0,40
A
b
s
Temperature [°C]
20 30 40 50 60 70 80 90
0,23
0,24
0,25
0,26
A
b
s
Temperature [°C]
a) b) c)
10 μM 5 μM 2.5 μM
K+ buffer
Tm= 59  C ± 1Tm= 59  C ± 1Tm= 59  C ± 1
20 30 40 50 60 70 80
0,42
0,44
0,46
0,48
A
b
s
Temperature [°C]
20 30 40 50 60 70 80
0,27
0,28
0,29
0,30
0,31
A
b
s
Temperature [°C]
20 30 40 50 60 70 80
0,200
0,205
0,210
0,215
0,220
A
b
s
Temperature [°C]
a) b) c)
Na+ buffer
Tm= 40 C ± 1Tm= 40  C ± 1Tm= 40  C ± 1
10 μM 5 μM 2.5 μM
Chapter 4 
126 
 
 
 CD Tm (°C) ± 1 UV Tm (°C) ± 1 
 AS1411 
5’-stearyl-
AS1411 
AS1411 
5’-stearyl-
AS1411 
 K
+
 buffer 
10 μM 66 59 67 59 
5 μM 68 59 67 59 
2.5 μM 68 59 67 59 
 Na
+
 buffer 
10 μM 37 n.d. 40 40 
5 μM 38 40 39 40 
2.5 μM 37 39 39 40 
 
Table 8. Melting temperature values obtained by UV- and CD-melting experiments for 5’-stearyl-
AS1411 (n.d. = not determined). 
 
5’-cholesteryl-TEG-AS1411 
As in the case of AS1411 and of 5’-stearyl-AS1411, the CD spectra of 5’-chol-TEG-AS1411 
suggest the formation of a parallel G4 structure showing a predominant positive band at 263 nm and 
a negative peak at ca. 241 nm (Figure 80), both in K
+
 and Na
+
 buffer solutions. A lower degree of 
structuration was observed in the Na
+
-containing solution and in all cases, analogously to 5’-stearyl-
AS1411, no positive band was present at ca. 295 nm. 
 
Figure 80. Overlapped CD spectra of 5’-chol-TEG-AS1411 at 10 μM (a), 5 μM (b) and 2.5 μM (c) 
in different saline conditions: potassium buffer (red line) and sodium buffer (blue line) solutions. 
 
In K
+
 buffer solution, CD-melting curves at 263 nm provided similar Tm values at 5 and 2.5 μM 
concentrations (Figure 81b and 81c, respectively) indicating conversely a lower stability for the 
system at 10 μM concentration (Figure 81a). In any case, the melting process was fully reversible, 
with no significant hysteresis observed (data not shown). 
Remarkably, in Na
+
 buffer solution at 5 and 2.5 µM concentrations a similar behaviour to 5’-
stearyl-AS1411 (at 10 µM concentration, Figure 77) was found. Also in this case at 80 °C the 
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structures in solution were not completely denatured. In addition, on increasing the temperature 
there was a shift in the maximum of the positive band. In this case, starting from 45 °C the positive 
maximum shifted from 263 nm to 262 nm and remained at this value until 80 °C (Figure 82). This 
event can be attributed to possible G4 rearrangements and will require a deeper investigation, 
combining also other techniques for their genuine elucidation. 
 
Figure 81. CD melting profiles of 5’-chol-TEG-AS1411 in the selected K+ buffer solution at 10 μM 
(a), 5 μM (b) and 2.5 µM (c) concentrations, recorded at 263 nm (scan rate: 1 °C/min). 
 
 
Figure 82. CD melting profiles of 5’-chol-TEG-AS1411 in the selected Na+ buffer solution at 5 μM 
(a) and 2.5 µM (b) concentrations, recorded at 263 nm (scan rate: 1 °C/min). 
 
Next, in the case of melting profile obtained at 10 µM concentration in Na
+
 buffer solution, another 
different behaviour was observed (Figure 83). Initially, the CD signal decreased up to 40 °C, with 
the positive maximum stable at 263 nm. From 45 °C on, the CD signal intensity began increasing 
and at 50 ° C a shift of the maximum to 262 nm was also observed. At 65 °C the maximum positive 
moved back to 263 nm and from 75 °C on a decrease in the CD signal intensity was observed again.  
The overall result of these events is shown in Figure 83, resulting in an apparent melting 
temperature of 57 °C. A similar melting profile was already observed in a Na
+
 buffer solution for 
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of fractions recovered from AS1411, recorded in Na
+
 buffer solution, showed a peculiar behaviour, 
not indicative of a simple two-state melting process.
[404]
 
 
Figure 83. a) CD melting profile and b) spectra recorded every 5 °C of 5’-chol-TEG-AS1411 in the 
selected Na
+
 buffer solution at 10 µM concentration, recorded at 263 nm (scan rate: 1 °C/min). 
 
 
Figure 84. UV-melting profiles of 5’-chol-TEG-AS1411 in the selected K+ buffer solution at 10 
µM (a), 5 µM (b) and 2.5 µM (c) concentration, recorded at 295 nm (scan rate: 1 °C/min). 
 
 
Figure 85. UV-melting profiles of 5’-chol-TEG-AS1411 in the selected Na+ buffer solution at 10 
µM (a), 5 µM (b) and 2.5 µM (c) concentration, recorded at 295 nm (scan rate: 1 °C/min). 
 
a) b)
10 μM Na+ buffer
70
30
40
50
60
8020 40 60
C
D
[m
d
e
g
]
Temperature [ C]
70
0
20
40
60
220 320240 260 280 300
C
D
[m
d
e
g
]
Wavelength [nm]
15 °C
20 °C
25 °C
30 °C
35 °C
40 °C
45 °C
50 °C
55 °C
60 °C
65 °C
70 °C
75 °C
80 °C
Tm= 57  C ± 1
20 30 40 50 60 70 80 90
0,224
0,228
0,232
0,236
0,240
A
b
s
Temperature [°C]
20 30 40 50 60 70 80 90
0,388
0,392
0,396
0,400
0,404
A
b
s
Temperature [°C]
20 30 40 50 60 70 80 90
0,70
0,72
0,74
0,76
A
b
s
Temperature [°C]
a) b) c)
10 μM 5 μM 2.5 μM
K+ buffer
Tm= 64  C ± 1Tm= 66  C ± 1Tm= 66  C ± 1
20 30 40 50 60 70 80
0,494
0,496
0,498
0,500
0,502
A
b
s
Temperature [°C]
20 30 40 50 60 70 80
0,1515
0,1520
0,1525
0,1530
0,1535
A
b
s
Temperature [°C]
20 30 40 50 60 70 80
0,2070
0,2085
0,2100
0,2115
A
b
s
Temperature [°C]
a) b) c)
Na+ buffer
Tm= 44 C ± 1Tm= 45  C ± 1Tm= 44  C ± 1
10 μM 5 μM 2.5 μM
Chapter 4 
129 
 
In K
+
 buffer solution, the UV-melting curves at 295 nm provided a Tm value of 66 °C at 10 and 5 
μM concentrations (Figure 84a and 84b, respectively) and of 64 °C at 2.5 μM concentration (Figure 
84c) with no detectable difference between the melting and annealing profiles (data not shown). 
In the Na
+
 buffer solution the Tm values obtained were very similar, even if in this case a little 
hysteresis (ca 4 °C) emerged on comparing the melting and annealing profiles (data not shown). 
 
 CD Tm (°C) ± 1 UV Tm (°C) ± 1 
 AS1411 
5’-chol-TEG-
AS1411 
AS1411 
5’-chol-TEG-
AS1411 
 K
+
 buffer 
10 μM 66 62 67 66 
5 μM 68 68 67 66 
2.5 μM 68 69 67 64 
 Na
+
 buffer 
10 μM 37 57 40 44 
5 μM 38 n.d. 39 45 
2.5 μM 37 n.d. 39 44 
 
Table 9. Melting temperature values obtained by UV- and CD-melting experiments for 5’-chol-
TEG-AS1411 (n.d. = not determined). 
 
In summary, the Tm values determined by UV- and CD- melting experiments in K
+
 buffer solution 
(Table 9) are in good agreement among them and with those obtained for AS1411, except for the 10 
µM concentration, in which a lower stability was observed. From the UV data in Na
+
 buffer 
solution, 5’-chol-TEG-AS1411 proved to give a slightly more stable superstructure than unmodified 
AS1411. Remarkably, CD results indicated a peculiar behaviour associated also to 
folding/unfolding processes of other G4 structures or of higher order structures. 
 
5’-cholesteryl-C6-AS1411 
Similarly to previous AS1411 derivatives, 5’-chol-C6-AS1411 folds into a parallel G4 structure 
which exhibits a strong positive band at 263 nm and a negative band at 241 nm (Figure 86), both in 
K
+
 and Na
+
 buffer solutions, with a lower degree of structuration in Na
+
 ions solution. 
In K
+
 buffer solution, CD melting curves at 263 nm provided Tm values of 64, 68 and 70 °C at 10, 5 
and 2.5 μM concentrations, respectively (Figure 87), indicating a lower stability at higher 
concentrations, similarly to what observed in the same conditions for 5’-chol-TEG-AS1411. In all 
cases, the melting process was fully reversible, with no significant hysteresis observed between the 
heating and cooling processes (data not shown). 
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Figure 86. Overlapped CD spectra of 5’-chol-C6-AS1411 at 10 μM (a), 5 μM (b) and 2.5 μM (c) in 
different saline conditions: potassium buffer (red line) and sodium buffer (blue line) solutions. 
 
 
Figure 87. CD melting profiles of 5’-chol-C6-AS1411 in the selected K+ buffer solution at 10 μM 
(a), 5 μM (b) and 2.5 µM (c) concentration, recorded at 263 nm (scan rate: 1 °C/min). 
 
Instead, in the case of Na
+
 buffer solution, the melting profile showed at all tested concentrations a 
shift of the positive maximum on increasing the temperature (Figure 88), resulting in an atypical 
melting curve, as already observed for both 5’-stearyl-AS1411 and for 5’-chol-TEG-AS1411. 
 
Figure 88. CD melting profiles of 5’-chol-C6-AS1411 in the selected Na+ buffer solution at 10 μM 
(a), 5 μM (b) and 2.5 µM (c) concentration, recorded at 263 nm (scan rate: 1 °C/min). 
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In K
+
 buffer solution, UV-melting curves at 295 nm provided a Tm value of 67 °C at 5 and 2.5 μM 
concentrations (Figures 89b and 89c, respectively) and of 65 °C at 10 μM concentration (Figure 
89a). In turn, in the Na
+
 buffer solution the Tm values were 44 °C at 10 and 2.5 μM concentrations 
(Figures 90a and 90c, respectively) and of 43 °C at 5 μM concentration (Figure 90b). However, in 
both saline conditions, no hysteresis phenomena emerged comparing melting and annealing profiles 
(data not shown). 
 
Figure 89. UV-melting profiles of 5’-chol-C6-AS1411 in the selected K+ buffer solution at 10 μM 
(a), 5 μM (b) and 2.5 µM (c) concentration, recorded at 295 nm (scan rate: 1 °C/min). 
 
 
Figure 90. UV-melting profiles of 5’-chol-C6-AS1411 in the selected Na+ buffer solution at 10 μM 
(a), 5 μM (b) and 2.5 µM (c) concentration, recorded at 295 nm (scan rate: 1 °C/min). 
 
In summary, Tm values determined by UV- and CD- melting experiments in K
+
 buffer solution 
(Table 10) are in good agreement among them and with those obtained for AS1411, except for the 
10 µM concentration samples, in which the CD melting profile of 5’-chol-C6-AS1411 showed a 
G4v structure with lower stability. UV data in Na
+
 buffer solution indicated for 5’-chol-TEG-
AS1411 formation of G4 structures with slightly higher stability; while CD results indicated a 
peculiar behaviour not directly associated only to folding/unfolding processes of a single G4 
structure. 
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Taken together these results certainly indicated a higher degree of polymorphism of the AS1411 
derivatives in comparison with unmodified AS1411. To better elucidate what happens to G4 
structure on increasing the temperature, the combination with other techniques such as gel 
electrophoresis, size exclusion chromatography and dynamic light scattering (DLS) analyses are 
needed. 
 CD Tm (°C) ± 1 UV Tm (°C) ± 1 
 AS1411 
5’-chol-C6-
AS1411 
AS1411 
5’-chol-C6-
AS1411 
 K
+
 buffer 
10 μM 66 64 67 65 
5 μM 68 68 67 67 
2.5 μM 68 70 67 67 
 Na
+
 buffer 
10 μM 37 n.d. 40 44 
5 μM 38 n.d. 39 43 
2.5 μM 37 n.d. 39 44 
 
Table 10. Melting temperature values obtained by UV- and CD-melting experiments for 5’-chol-
C6-AS1411 (n.d. = not determined). 
 
4.1.3. Gel electrophoresis analysis 
Gel electrophoresis analysis was used to further characterize AS1411 and its derivatives. Also in 
this case, we tested three different concentrations of the oligonucleotides (5, 10 and 50 μM) in K+ 
and Na
+
 phosphate buffered solutions, using tel26 aptamer as reference oligonucleotide, known to 
adopt a unimolecolar G4 structure.
[513,514]
 
In Figure 91-93 the photographs of 7 % polyacrylamide gels, run under native conditions, are 
reported. 
In comparison with tel26, which migrates on a polyacrylamide gel as a single band, AS1411 in the 
same conditions migrates as a double band (at 10 μM concentration, lines 3 and 7) and as poorly 
resolved three bands (at 50 μM concentration, lines 4 and 8), both in K+ and Na+ phosphate buffered 
solutions (Figure 91a). These bands showed however almost the same apparent mobility of tel26 
confirming a similar charge and overall size distribution. 
Instead, in the case of 5’-stearyl-AS1411 (Figure 91b), a detectable difference in electrophoretic 
mobility was observed: the photograph of the gel shows a band with a similar but not identical 
electrophoretic mobility as tel26 (at lower concentrations) and a retarded band, which can be a 
multimeric species or an aggregate form of the aptamer. This retarded band is not clearly visible at 
10 μM concentration (lines 3 and 7) and becomes clearly visible at 50 μM concentration (lines 4 
and 8). 
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Figure 91. 7% polyacrylamide gel electrophoresis under native conditions of the analysed AS1411 
(a) and 5’-stearyl-AS1411 (b) run at 100 V at r.t. for 1 h 15 min. (a) Lane 1: tel26 (5 μM); Lane 2: 
AS1411 (5 μM); Lane 3: AS1411 (10 μM); Lane 4: AS1411 (50 μM), in Na+ buffer solution; Lane 
5: tel26 (5 μM); Lane 6: AS1411 (5 μM); Lane 7: AS1411 (10 μM); Lane 8: AS1411 (50 μM), in K
+
 
buffer solution; (b) Lane 1: tel26 (5 μM); Lane 2: 5’-stearyl-AS1411 (5 μM); Lane 3: 5’-stearyl-
AS1411 (10 μM); Lane 4: 5’-stearyl-AS1411 (50 μM), in Na+ buffer solution; Lane 5: tel26 (5 μM); 
Lane 6: 5’-stearyl-AS1411 (5 μM); Lane 7: 5’-stearyl-AS1411 (10 μM); Lane 8: 5’-stearyl-AS1411 
(50 μM), in K+ buffer solution. 
 
In the case of 5’-chol-TEG-AS1411 the band with the same electrophoretic mobility of tel26 is 
observable only in K+ buffer solution together with more retarded bands, not well distinguishable, 
on the top of the gel (Figure 92, left side). In presence of Na
+
 ions, only the retarded bands are 
clearly visible. In order to better investigate these retarded bands, the gel was run also for 2 h and 
30 min and 3 h and 15 min. respectively (Figure 92, right side). Also in these conditions, the bands 
migrate poorly, indicating the formation of bigger species which are also more numerous in the 
presence of K
+
 ions. 
Concerning 5’-chol-C6-AS1411, the gel showed at all the conditions tested (different 
concentrations and saline solutions) both the presence of a band with the same mobility as tel26 and 
more retarded bands (Figure 93, left side). Also in this case, the gel was run for 2 h and 30 min and 
3 h and 15 min (Figure 93, right side), in an attempt to separate the retarded bands. 
Taking into account that gel electrophoresis is a low resolution technique, however these results 
provide a good indication that all AS1411 oligonucleotides form more species in solution. Probably 
the bands with the same mobility of tel26 are monomolecular forms, but the retarded species should 
AS1411 AS1411
1 2 3 4 5 6 7 8
Na+ buffer K+ buffer
5’-stearyl-
AS1411
5’-stearyl-
AS1411
1 2 3 4 5 6 7 8
Na+ buffer K+ buffer
a) b)
Chapter 4 
134 
 
be bigger or agglomerate forms. These data also confirm some not canonical CD melting profiles 
clearly showing the presence, particularly at high concentrations, of higher order G4 structures. 
 
Figure 92. 7% polyacrylamide gel electrophoresis under native conditions of the 5’-chol-TEG-
AS1411 run at 100 V at r.t. for 1 h 15 min. Lane 1: tel26 (5 μM); Lane 2: 5’-chol-TEG-AS1411 (5 
μM); Lane 3: 5’-chol-TEG-AS1411 (10 μM); Lane 4: 5’-chol-TEG-AS1411 (50 μM), in Na+ buffer 
solution; Lane 5: tel26 (5 μM); Lane 6: 5’-chol-TEG-AS1411 (5 μM); Lane 7: 5’-chol-TEG-AS1411 
(10 μM); Lane 8: 5’-chol-TEG-AS1411 (50 μM), in K+ buffer solution; On the right side the 
magnification of the gel run at 100 V at r.t. for 2 h 30 min (top) and 3 h 15 min (bottom) are shown. 
 
 
Figure 93. 7% polyacrylamide gel electrophoresis under native conditions of 5’-chol-C6-AS1411 
run at 100 V at r.t. for 1 h 15 min. Lane 1: tel26 (5 μM); Lane 2: 5’-chol-C6-AS1411 (5 μM); Lane 
3: 5’-chol-C6-AS1411 (10 μM); Lane 4: 5’-chol-C6-AS1411 (50 μM), in Na+ buffer solution; Lane 
5: tel26 (5 μM); Lane 6: 5’-chol-C6-AS1411 (5 μM); Lane 7: 5’-chol-C6-AS1411 (10 μM); Lane 8: 
5’-chol-C6-AS1411 (50 μM), in K+ buffer solution; On the right side the magnification of the gel 
run at 100 V at r.t. for 2 h 30 min (top) and 3 h 15 min (bottom) are shown.  
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4.1.4. Size exclusion chromatography analyses 
In order to further characterize AS1411 oligonucleotides and better investigate the number of 
species formed in solution, the samples were also analysed via size exclusion chromatography. Also 
in this case, we tested three different concentrations of the oligonucleotides (5, 10 and 50 μM) in K+ 
and Na
+
 phosphate buffered solutions, using tel26 as the reference oligonucleotide. 
For the 26-mer d(
5’
TTAGGG)4TT
3’
 taken from the human telomere, typically indicated as tel26, it is 
well known that the exact folded structure adopted in solution critically depends on the cation 
composition of the solution. Indeed, in the presence of sodium, one main species consisting in an 
antiparallel “basket” structure is observed; instead, in potassium solution, two types of antiparallel 
“hybrid” structures are known.[513,514] 
In Figure 94 the chromatogram of the slowly annealed tel26 is shown: in the presence of Na
+
 ions 
(Figure 94a), only one peak (tR = 6.18) is present, while in the case of K
+
 ions (Figure 94b), besides 
the main peak (tR = 6.62), also another species (corresponding to 12.6 % in area) is detectable. 
These results are in accordance with the possible structures that tel26 can form in solution. 
 
Figure 94. Size exclusion chromatography of tel26 in K
+
 (a) and Na
+
 (b) buffer solution at 5 μM 
concentration. 
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Figure 95. Size exclusion chromatography of AS1411 in K
+
 (a) and Na
+
 (b) buffer solution at 5, 10 
and 50 μM concentration (green, yellow and purple lines, respectively). 
 
In the case of AS1411, a similar trend was found (Figure 95). In the presence of Na
+
 ions (Figure 
95a), only one peak was observed, even if the retention times are slightly different at the tested 
concentrations (tR = 6.49, 6.39, 6.17 at 5, 10 and 50 μM, respectively). However, upon increasing 
the concentration, another peak with shorter elution times appeared, accounting for an area of 3.2 
and 3.6 % at 10 and 50 μM, respectively. 
In K
+
 buffer (Figure 95b), a main peak with tR = 5.90 min was present at all the concentrations 
tested. Similarly to tel26, also another peak was observed with longer elution times (tR = 7.62), 
whose area gradually decreased on increasing the concentration (from 8.1 to 6.5 %, going from 5 to 
10 μM) until it completely disappeared at higher concentrations. At the same time, a little shoulder 
under the main peak was detectable (tR = 5.68), which had an almost constant percentage area at 5 
and 10 μM concentrations (13.1 % in area), but increased at 50 μM up to 22.3 %. 
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Figure 96. Size exclusion chromatography of 5’-stearyl-AS1411 in K+ (a) and Na+ (b) buffer 
solution at 5, 10 and 50 μM concentration (green, yellow and purple lines, respectively). 
 
For 5’-stearyl-AS1411, several peaks were present already at low concentrations, both in Na+ and 
K
+
 buffer. In Na
+
 buffer (Figure 96a), the chromatogram at 5 μM showed a predominant peak (tR = 
6.23) and other three peaks representing 10.6, 19.5 and 4.4 % (at tR = 3.97, 7.74 and 8.70, 
respectively). At 10 μM concentration, the peaks with tR = 7.74 and 8.70 decreased in intensity (8.1 
and 1.2 %, respectively) until disappearance at higher concentration. Instead, the peak with tR = 
3.97 became more evident (25.1 % at 10 μM), finally being the predominant one at 50 μM 
concentration (77.7 %). Species with so short elution times should be very large aggregates, in 
accordance with the retarded bands observed on polyacrylamide gels. In the chromatogram 
recorded using the K
+
 buffer solution as mobile phase (Figure 96b), three peaks are visible at lower 
concentrations with retention times of 4.02, 6.00 and 7.71. Indeed, the prevalent peak was 
accompanied by another species with tR of 6.17 min. On increasing the concentrations, a similar 
behaviour was found: the peak at tR 7.71 min decreased from 14.7 to 7.5 %, finally disappearing at 
50 μM, while the peak at ca 4 increased from 10.5 to 13.9 %, becoming almost the predominant one 
at 50 μM concentration (53.2 % in area). 
Thus, in the case of AS1411 and 5’-stearyl-AS1411, the main peak was always observed at 
retention times of about 6 min and its intensity – upon increasing the concentration - decreased in 
favour of other species with shorter elution times and thus associated with good approximation to 
aggregates with large dimensions.  
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In the case of 5’-chol-TEG-AS1411, already at low concentrations, the predominant peak in 
intensity had a retention time of ca. 4 min in both saline conditions tested (Figure 97). The 
chromatogram in Na
+
 buffer (Figure 97a) indicated the presence of two peaks at 5 μM 
concentration: one predominant (tR = 3.96) and a weaker one (tR = 6.14), which further decreased on 
increasing the concentration (from 24.8 to 15.8 and 5.1 % at 5, 10 and 50 μM concentration, 
respectively). In the case of K
+
 buffer, in addition to the dominant peak (tR = 4.53) also other two 
peaks at 5 μM concentration (tR = 6.77 and 8.77) were observed, representing the 5.5 and 13.7 % in 
area, respectively (Figure 97b). At higher concentrations, the peak with tR = 6.77 kept an almost 
constant intensity, while the other one (tR = 8.77) decreased to 9.9 and 2.5 % at 10 and 50 μM 
concentration, respectively. At the same time, starting from 10 μM concentration a shoulder under 
the main peak (18.1 %) and another visible peak (with tR = 7.55 and 4.2 % in area) appeared in the 
chromatogram, both maintaining an almost constant intensity also at 50 μM concentration. 
 
Figure 97. Size exclusion chromatography of 5’-chol-TEG-AS1411 in K+ (a) and Na+ (b) buffer 
solution at 5, 10 and 50 μM concentration (green, yellow and purple lines, respectively). 
 
Also for 5’-chol-C6-AS1411, already at low concentrations and in both saline conditions tested, the 
peak corresponding at ca. 4 min retention time was clearly visible (Figure 98). 
In the case of Na
+
 buffer (Figure 98a), also a weaker peak (tR = 6.13) was detected, with an almost 
constant area at the lowest concentrations (8.4 %), then decreasing at 50 μM concentration (5.9 %). 
In K
+
 buffer (Figure 98b), at 5 μM concentration three peaks with retention times of 4.45, 6.65 and 
8.67 min were detected. While the peak with tR = 4.45 min increased in intensity at higher 
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concentrations (from 35.2 to 92.3 and 94.1 %, on going from 5 μM to 50 concentration), becoming 
the dominant one at 50 μM concentration, the other two peaks decreased in intensity on increasing 
the concentration. The major effect was clearly evident for the peak with tR = 8.67, going from 56.0 
% at 5 μM concentration to 3.9 % at 10 μM and finally to 2.0 % at 50 μM. Instead, the peak with tR 
= 6.65 represented the 8.9 % at 5 μM, then decreased to 3.9 % at 10 μM and remained constant at 
50 μM. 
 
Figure 98. Size exclusion chromatography of 5’-chol-C6-AS1411 in K+ (a) and Na+ (b) buffer 
solution at 5, 10 and 50 μM concentration (green, yellow and purple lines, respectively). 
 
Summarizing, size exclusion chromatograms showed the presence of more than one species, above 
all in the case of AS1411 lipophilic derivatives, confirming the high polymorphism of this 
oligonucleotide. These species could be different conformations with the same molecularity or can 
represent different molecular structures (e.g. monomolecular and bimolecular/tetramolecular 
structures). The presence of higher order species is validated both from gel electrophoresis (retarded 
bands observed in native PAGE) and SEC analyses data (peaks with short retention times, i.e. 
totally excluded from the column). 
Remarkably, these different species are essentially parallel G4 structures which show a very similar 
thermal behaviour; nice sigmoids were obtained in all the CD melting experiments, with 
comparable Tm values. 
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4.2. Experimental section 
 Materials and general methods 
All the reagents and solvents were of the highest commercially available quality and were used as 
received. AS1411 (
5′
GGTGGTGGTGGTTGTGGTGGTGGTGG
3’), 5’-stearyl-AS1411, 5’-
cholesteryl-TEG-AS1411 and 5’- cholesteryl-C6-AS1411 oligonucleotides were purchased from 
Biomers. Ethidium bromide and 5X Green GoTaq Flexi Buffer were purchased from Sigma Aldrich 
and Fisher Scientific, respectively. 
 Preparation of oligonucleotide samples 
Lyophilized oligonucleotides were dissolved in a known volume of Milli-Q water and their 
concentrations were determined by UV spectroscopy - on a JASCO V-550 spectrophotometer 
equipped with a Peltier Thermostat JASCO ETC-505T - in 1 cm path length cuvette measuring the 
absorbance at 260 nm (85 °C) using the molar extinction coefficient of 281700 cm
−1
 M
−1
. The 
spectra were recorded in the range 220–380 nm with a medium response, a scanning speed of 100 
nm/min and a 2.0 nm bandwidth, and corrected by subtraction of the background scan with a buffer. 
Then the oligonucleotides from the stock solutions (574, 459, 425 and 234 µM for AS1411, 5’-
stearyl-AS1411, 5’-chol-TEG-AS1411 and 5’-chol-C6-AS1411, respectively) were diluted in the 
selected buffer and annealed by heating each solution for 5 min at 90 °C and then leaving it to 
slowly cool to room temperature overnight. Annealed samples were then kept at 4° C until use.  
 Spectroscopic characterization of AS1411 oligonucleotides 
CD experiments. CD spectra and CD-monitored melting curves were recorded on a Jasco J-715 
spectropolarimeter equipped with a Peltier-type temperature control system (model PTC-348WI), 
using a quartz cuvette with a path length of 1 cm (3 mL internal volume, Hellma). CD parameters 
for spectra recording were the following: spectral window 220-320 nm, data pitch 1 nm, band width 
2 nm, response 4 sec, scanning speed 100 nm/min, 3 accumulations. The characterization of 
oligonucleotides sequences was performed at 2.5, 5 and 10 μM concentrations in K+ (10 mM 
KH2PO4, 70 mM KCl, 0.2 mM EDTA, pH 7.0) and Na
+
 (PBS: 137 mM NaCl, 2.7 mM KCl, 10 mM 
Na2HPO4, 1.8 mM KH2PO4, pH 7.4) phosphate buffer solutions, taking a suitable initial aliquot 
from the stock solution in H2O. Thermal denaturation-renaturation curves were recorded following 
the CD signal at 263 nm vs. the temperature (scan rate of 1 °C/min) in a range of temperature 
slightly different depending on saline conditions (generally 15-90 °C for K
+
 buffer solution and 15-
80 °C for Na
+
 buffer solution). Each experiment was performed in duplicate. Tm was estimated from 
the first derivative of the melting/annealing and the error associated with the Tm values 
determination was ± 1 °C. 
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UV-vis absorption experiments. UV-melting curves were obtained on a Cary 5000 UV-Vis-NIR 
spectrophotometer equipped with a temperature controller system, using 1 cm path length cuvette (1 
mL internal volume, Hellma). The absorbance vs. temperature profiles were recorded by following 
the absorbance changes at 295 nm wavelength on increasing the temperature (heating scan rate 1 
°C/min). The characterization of the oligonucleotides sequences was performed at 2.5, 5 and 10 μM 
concentrations in K
+
 (10 mM KH2PO4, 70 mM KCl, 0.2 mM EDTA, pH 7.0) and Na
+
 (PBS: 137 
mM NaCl, 2.7 mM KCl, 10 mM Na2HPO4, 1.8 mM KH2PO4, pH 7.4) phosphate buffer solutions, 
taking a suitable initial aliquot from the stock solution in H2O. Each experiment was performed in 
duplicate. Tm values were calculated as the maxima of the plots of the first derivative of the melting 
curve (associated error: ± 1 °C). 
Gel electrophoresis. Slowly annealed samples of AS1411, 5’-stearyl-AS1411, 5’-chol-TEG-
AS1411 and 5’-chol-C6-AS1411 in 40 % of dye (5X Green GoTaq Flexi Buffer) were loaded on 
7% acrylamide gels in TBE (Tris-Borate-EDTA, 0.5X) buffer at the different concentrations (5, 10 
and 50 μM) and saline conditions analysed (in K+ and Na+  phosphate buffer solutions).  
The samples were then run at 100 V at room temperature for 75 min, stained with ethidium bromide 
and finally visualized with a UV transilluminator (BioRad ChemiDoc XRS). 
In the case of 5’-chol-TEG-AS1411 and 5’-chol-C6-AS1411, additional runs of 2 h 30 min and 3 h 
15 min were performed to better investigate the retarded bands. 
Size exclusion chromatography. SEC analyses were performed using an Agilent HPLC system, 
equipped with a UV/vis detector and a Yarra 3 µm column (300 x 4.60 mm; flow rate 0.5 mL min
-1
, 
Phenomenex). Elution was monitored at  = 254 nm. The mobile phases used consisted of K+ (10 
mM KH2PO4, 70 mM KCl, 0.2 mM EDTA, pH 6.7) and Na
+
 (PBS: 137 mM NaCl, 2.7 mM KCl, 10 
mM Na2HPO4, 1.8 mM KH2PO4, pH 7.0) phosphate buffer solutions. All the oligonucleotides 
tested were injected from stock solutions of the samples annealed at 5, 10 and 50 µM 
concentrations. 
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Chapter 5 
Multifunctional systems 
1. DOTAP-based liposomes loaded with TUGluRu and NOTA-OL 
In the construction of multifunctional systems for both therapy and diagnosis of cancer pathology, 
the use of liposomes is a well established and efficient drug delivery strategy.
[29,515,516]
 This kind of 
platform allows the incorporation of several functional units on the same scaffold and the protection 
of the active principle until it reaches the target site, reducing possible toxic side effects. 
For this reason, TUGluRu and NOTA-OL (previously described in Chapter 2.3 and 3.2, 
respectively) have been co-aggregated with the cationic lipid 1,2-dioleyl-3-
trimethylammoniumpropane chloride (DOTAP) in order to obtain stable formulations. In the case 
of NOTA-OL the formulation has the only aim to carry the diagnostic agent at a known, specific 
concentration, while in the case of TUGluRu, the formulation is aimed at ensuring high stability in 
aqueous environment even at high Ru-complex content. This nanovector, including both the drug 
and the imaging agent, represents a good model for the realization of theranostic nanoparticles. 
DOTAP liposomes were suitably prepared, mixing the active ingredients and the phospholipid 
carrier at selected molar ratios, by using the lipid film method and were then resuspended in water. 
The microstructural characterization of the obtained aggregates was realized using dynamic light 
scattering (DLS) to estimate aggregate dimensions. Then, in vitro bioactivity profile of the Ru-
loaded nanoparticles was investigated on cancer and normal human cell lines, in order to assess the 
efficacy of TUGluRu co-aggregated with DOTAP, and of its formulation with the imaging agent 
NOTA-OL. The ruthenium-free DOTAP/NOTA-OL system was also tested to evaluate the 
biocompatibility of the formulation. 
Small angle neutron scattering (SANS) analysis – for a deeper structural characterization of the 
aggregates - as well as labelling with Ga
68
 radioisotope and evaluation of their efficiency as 
diagnostic agent in animal models are currently in progress at the University Federico II of Naples, 
Department of Chemical Sciences by the research group of prof. Luigi Paduano, and at CNR, 
Institute of Clinical Physiology, Pisa, by dr. Luca Menichetti, respectively. 
 
1.1. Results and dusussion 
1.1.1. DOTAP-based liposomes preparation 
The samples were prepared by mixing appropriate amounts of DOTAP and TUGluRu and/or 
NOTA-OL dissolved in chloroform in order to have the prefixed molar ratio. Subsequently, an 
appropriate amount of this solution was transferred in round-bottom glass tubes. A thin film was 
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obtained through evaporation of the solvent with dry nitrogen and keeping the samples under 
vacuum for at least 24 h. The samples were then hydrated in water, vortexed and sonicated. The 
final sample prepared were: DOTAP/TUGluRu (70:30), DOTAP/NOTA-OL (95:5) and 
DOTAP/TUGluRu/NOTA-OL (65:30:5). 
 
1.1.2. Characterization of DOTAP-based nanoaggregates 
Structural characterization of the mixed DOTAP nanoaggregates was carried out through dynamic 
light scattering (DLS) analyses in water. 
In Figure 99, an example of the hydrodynamic radius distribution functions at 90° for the different 
mixed aggregates formed is reported. For all the investigated systems, a single and monodisperse 
aggregate population was detected. The hydrodynamic radii for all the systems analysed are located 
in the range 110−130 nm, which is the typical range of large vesicles. 
 
Figure 99. Hydrodynamic radius distribution functions obtained through DLS measurements for 
DOTAP/TUGluRu 70:30 (a), DOTAP/NOTA-OL 95:5 (b) and DOTAP/TUGluRu/NOTA-OL 
65:30:5 (c). 
 
1.1.3. Cell viability 
In Figure 100 the cell viability assay data, evaluated by MTT assay procedure, are reported; these 
were performed on a panel of cancer and normal cell lines, treated for 48 h with a range of 
concentration (10→250 µM) of the DOTAP/TUGluRu, DOTAP/NOTA-OL, and 
DOTAP/TUGluRu/NOTA-OL systems. Generally, the dose-response curves showed a quite linear 
decrease of cell viability with increasing the drug doses. In line with previous results on the other 
ruthenium-based nanovectors,
[137,153]
 DOTAP/TUGluRu showed selective antiproliferative activity 
for the cancer cells, with the breast cancer cells found to be the most sensitive ones. However, also 
the effect on cervix carcinoma and glioma cells was remarkable. The inclusion of NOTA-OL 
rendered the Ru-free formulation (DOTAP/NOTA-OL) slightly cytotoxic, probably due to its 
chelating activity; anyhow, such toxicity was negligible, since the cell viability was in all cases 
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higher than 50 % even at 250 µM. Interestingly, this toxic effect was synergic with the ruthenium 
complex DOTAP/TUGluRu, showing an increased efficacy, still selective against the cancer cells. 
 
Figure 100. Cell viability curves resulting by MTT assay on 3T3L-1 (murine fibroblasts), HaCaT 
(human keratinocytes), MCF-7 (breast adenocarcinoma), C6 (glioma), HeLa (human cervical) cell 
lines incubated for 48 h with DOTAP/TUGluRu, DOTAP/NOTA-OL, DOTAP/TUGluRu/NOTA-
OL systems. 
 
1.1.4. IC50 evaluation 
From the analysis of dose-response curves, the IC50 values were calculated, in order to better 
compare the efficacy of the tested nanovectors (Table 11). In bold, the IC50 values relative to the 
effective concentration of ruthenium (30% of total liposome) were reported. This "normalization" 
makes possible the comparison with the bioactivity of the previously studied nucleolipidic Ru(III)-
based liposomes.
[137,153]
 Through the analysis of these values, it is also possible to highlight the 
synergic effect of NOTA-OL on the DOTAP/TUGluRu efficacy, producing a reduction of IC50 
values of about 25 % for MCF-7 and C6, and 50 % for HeLa cells. 
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Table 11. IC50 values reported as mean values ± SEM. In bold, the IC50 values referred to the 
effective ruthenium concentration (30% of total liposome). 
  
Chapter 5 
146 
 
2. LipThyRu and AS1411-decorated niosomes as potential anticancer drugs 
Niosomes, or non-ionic surfactant vesicles, have gained increasing scientific attention as drug 
delivery systems with respect to conventional liposomes, due to the use of surfactants in their 
formulation, which are cheaper and more stable alternatives than phospholipids.
[516,517]
 Niosomes 
are prepared by mixing non-ionic surfactants, such as alkyl ether, alkyl esters or alkyl amides, fatty 
acids and amino acid derivatives, with or without other lipids and then subsequently hydrating the 
mixture.
[518–520]
The formation of these vesicle-like structures depends on the hydrophilic–lipophilic 
balance (HLB) of the surfactant, the chemical structure of the components, their geometry and the 
ratio between the lipid and the surfactant used.
[518,521]
 
The size range of niosomes includes nano and submicron sizes, and the vesicle structure can be 
unilamellar or multilamellar.
[522]
 Owing to the vesicle structure, niosomes are able to entrap both 
hydrophilic and hydrophobic drugs, as liposomes do. Interestingly, surfactants can be easily 
chemically modified, allowing high versatility of vesicular structures. Niosomes are typically very 
stable, at least in the time range of few months, depending on their components and the presence of 
additive agents.
[523,524]
 Moreover, the high chemical stability of surfactants, compared with 
phospholipids, makes niosome purification, handling and storage much easier.
[525]
 Niosome 
formulations have shown good in vitro and in vivo efficacy in delivering both pharmaceuticals and 
biopharmaceuticals.
[519,526–528]
 For example, promising transfection efficiencies have been achieved 
with niosomes loaded with plasmid DNA after subretinal, intravitreal and brain injections in 
rats.
[529]
 
With the aim of exploring different, multifunctional nanoplatforms to obtain novel, efficient 
anticancer drugs, part of this PhD work has been devoted to study niosome formulations - based on 
the cationic lipid 2,3-di(tetradecyloxy)propan-1-aminium chloride (Figure 101) and polysorbate 80 
as surfactant
[530]
 – as suitable carrier system for the nucleolipidic Ru(III)-complex LipThyRu and 
the oligonucleotide AS1411 (discussed in chapters 2.2 and 4.4, respectively). 
O
Cl-
O
NH3
+
 
Figure 101. Chemical structure of the cationic lipid 2,3-di(tetradecyloxy)propan-1-aminium 
chloride used in niosome preparation. 
 
This aminolipid is a bitailed lipid with two saturated alkyl chains and is positively charged as the 
lipid DOTAP, previously proved to efficiently stabilize and deliver in cell nucleolipidic Ru(III)-
complexes.
[137,153]
 LipThyRu has been here selected as the anticancer drug and the nucleolin-
selective aptamer AS1411 as the active targeting agent; these systems have been mixed to 
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expectedly operate in synergy against cancer cells. The resulting formulations were optimized and 
fully characterized using gel electrophoresis, zeta potential and DLS analysis. Finally, the best 
formulations were tested as antiproliferative agents in preliminary in vitro biological evaluations on 
HeLa cancer cells. This study was carried out in the laboratories of the Spanish National Research 
Council (CSIC) of Barcelona (Spain) under the supervision of prof. Ramon Eritja Casadellà, where 
I spent three months of my PhD program. 
 
2.1. Results and Discussion 
2.1.1. Oligonucleotide binding ability measurements 
As a preliminary experiment, a gel electrophoretic assay under native conditions of different 
AS1411-loaded niosomes was carried out in order to determine at which oligomer/lipid ratio the 
oligonucleotides are fully complexed with the niosomes. As shown in Figure 102, free AS1411 and 
AS1411-loaded niosomes migrated as separate bands in a native polyacrylamide gel 
electrophoresis. When the oligonucleotide was incorporated within the cationic vesicles, the 
resulting complexes were retarded on the gel because of their size change. Free AS1411 
oligonucleotide was observed in the formulations containing oligonucleotides/lipid ratios from 0 to 
1:5. Full incorporation of AS1411 in niosome vesicles was observed starting from 1:8 
oligonucleotide/lipid molar ratio. 
 
Figure 102. AS1411-loaded niosomes characterization by electrophoretic mobility shift assays. The 
numbers specify the oligonucleotide/lipid molar ratio, being 1 the amount of oligonucleotide.  
 
2.1.2. Zeta potential measurements 
AS1411-functionalized niosomes were first of all characterized in terms of Zeta potential to 
determine their surface charge. In particular, several formulations have been prepared mixing the 
niosome vesicles (28.9 mM stock solution in HEPES) in different ratios - ranging from 1:2 to 1:16 - 
0 0.5 1 3 5 8 10 12 14 16
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with fixed amounts of AS1411 oligonucleotide (0.5 μM). Their Zeta potential values have been then 
measured so to determine the optimal oligonucleotide/lipid molar ratio for the desired complexes. 
 
Figure 103. Zeta potential distributions of AS1411/niosome mixtures at the indicated molar ratios. 
 
As depicted in Figures 103 and 104, the Zeta potential results displayed negative values for 
AS1411-loaded niosomes at the lowest AS1411/niosome ratios investigated (ca. -9 mV for the 1:2 
mixture) due to the prevalence of the negative charges of the 26-mer oligonucleotide. Clearly, as the 
concentration of cationic vesicles increased, the resulting Zeta potential values also increased, 
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finally obtaining positive values constantly in the range +13 - +26 mV, indicating an essentially 
stable electrostatic level. 
 
Figure 104. Zeta potential values of AS1411-loaded niosomes at several molar ratios. 
 
2.1.3. Particle size measurements 
DLS measurements have been used by Eritja et al.
[531]
 to demonstrate that niosome formulations -
stored at 4 °C for one month - show an average hydrodynamic radius essentially constant for one 
month, thus basically proving their full stability under the studied solution conditions. 
DLS analysis was here used to determine the average size of niosomes and AS1411-loaded niosome 
formulations at 1:6 and 1:12 molar ratios (Table 12). 
Notably, the average particle size of AS1411/niosome at 1:12 ratio and niosome alone at the same 
concentration were almost identical (ca. 60 nm in radius). Upon insertion of AS1411 within the 
niosomes, the system showed a sharper distribution and a lower polydispersity index, indicating the 
formation of a unique population of stable particles. On the contrary, the AS1411/niosome 
formulation at 1:6 ratio had a bigger radius and a higher polydispersity. For this reason, the 
AS1411/niosome formulation with ratio 1:12 was selected for the successive biological evaluations. 
 
 Radius (nm) Polydispersity index 
AS1411/niosome 1:6 130.3 ± 3.55 0.46 
AS1411/niosome 1:12 62.8 ± 0.67 0.27 
niosome 64.5 ± 6.5 0.57 
 
Table 12. Size measurements of niosome and AS1411/niosome at charge ratios of 1:6 and 1:12. 
The results are means ± S.D. for three independent experiments. 
 
2.1.4. Cell culture 
Cell viability and cytotoxicity studies were carried out incubating HeLa cells with AS1411, 
LipThyRu, niosome_LipThyRu and AS1411/niosome_LipThyRu formulations at oligo/vesicles 
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charge ratios of 1:12 and at 6 μM niosome concentration (corresponding to 500 nM of AS1411 and 
250 nM of LipThyRu). The incubation was realized in the presence of DMEM, supplemented with 
serum (10%) and two antibiotics, using a tetrazolium-based (MTT) colorimetric assay. 
In a previous work
[531]
 no significant toxicity was observed in HeLa cells treated with niosomes 
alone, obtaining viabilities around 90%. 
As depicted in Figure 105, no significant toxicity was observed in the cells treated with AS1411 or 
LipThyRu alone, compared with control samples. A limited decrease in cell viability was observed 
for the complex niosome_LipThyRu, but a relevant antiproliferative effect was observed for the 
formulation presenting both the AS1411 oligonucleotide and the Ru(III)-complex, thus nicely 
indicating that these anticancer agents act in a synergic manner. 
 
Figure 105. Normalized cell viability of AS1411 (500 nM), LipThyRu (250 nM), 
niosome_LipThyRu and AS1411/niosome_LipThyRu formulations (at oligo/vesicles 1:12 ratio and 
6 μM niosome concentrations). The here reported results are mean values ± S.D. for three 
independent experiments. 
 
This study requires a deeper characterization and biological evaluation, but preliminary in vitro 
bioscreens results are very promising demonstrating the sinergic effect between the AS1411 
oligonucleotide and the LipThyRu Ru-complex, therefore prompting us to continue into this 
research. 
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2.2. Experimental section 
 Materials and general methods 
All the reagents and solvents were of the highest commercially available quality and were used as 
received. Polysorbate-80 (Tween-80), 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide (MTT reagent) and the AS1411 oligonucleotide (5′-
GGTGGTGGTGGTTGTGGTGGTGGTGG-3’) were purchased from Sigma-Aldrich. The cationic 
lipid 2,3-di(tetradecyloxy)propan-1-aminium chloride was purchased from Sapala Organics 
Privated Ltd (Telengana St., India). PBS buffer and Dulbecco’s Modified Eagle’s Medium 
(DMEM), which was supplemented with a 10% heat-inactive fetal serum bovine (FBS), were 
purchased from Gibco. 
 Preparation of synthetic niosome vesicles 
Niosome vesicles were prepared using a film-hydration method dissolving in 1 mL of chloroform 
equimolecular amounts of the synthetic cationic lipid [2,3-di(tetradecyloxy)propan-1-aminium 
chloride] and the non-ionic surfactant polysorbate 80. Then the solvent was evaporated and the 
resulting crude was kept under vacuum at r.t. overnight. The dried lipid film was hydrated with 1 
mL of the selected buffer, heated at 60 °C for 20 min and filtered through a 0.2 μm membrane filter. 
The dispersion was vortexed and sonicated for 3 min before use. In order to obtain 
niosome_LipThyRu and AS1411/niosome_LipThyRu, the encapsulation of LipThyRu within the 
niosomes was carried out mixing 1 mg of the Ru(III) compound (0.78 nmol) with the aminolipid 
and the surfactant following the previously described procedure and heating the lipid film from 40 
to 45 
o
C for 40 minutes. 
AS1411/niosome and AS1411/niosome_LipThyRu were then obtained by adding the required 
amount of cationic lipid dispersion to aliquots containing fixed amounts of ODN. The resulting 
mixtures were vortexed and sonicated for 2 min and finally incubated at 37 °C for 30 min. 
 Electrophoretic mobility shift assay 
AS1411 oligonucleotide (0.5 μM) was mixed with increasing amounts of the niosome (taken from a 
28.9 mM stock concentration in HEPES, pH 7.4) providing the system AS1411/niosome ranging 
from 0 to 1:16 molar ratios (total volume of 25 µL). The resulting samples were incubated at 37 °C 
for 30 min. These formulations were then analysed using gel electrophoresis carried out on a 20% 
polyacrylamide gel at 150 V for 5 h at 25 ºC in 1XTBE buffer. Pictures of the obtained gel were 
taken using Fujifilm LAS-1000 Intelligent Dark Box II using IRLAS-1000 Lite v1.2. 
 Zeta potential 
Zeta potential measurements were obtained by laser doppler velocimetry on a Zetasizer Nano ZS 
(Malvern Instruments) using AS1411 (from a 0.5 μM stock solution) at a final volume of 50 μL and 
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evaluating different AS1411/niosome molar ratios ranging from 1:2 to 1:16 (using a 28.9 mM 
niosome stock solution in 20 mM HEPES, pH 7.4). All the measurements were performed at 25 °C 
using water as solvent (total volume of 1.0 mL). Data are shown as the average value of three 
independent determinations. 
 Size measurement 
The particle size of niosome vesicles and niosome formulations were determined using a dynamic 
light scattering instrument (LS Instruments, 3D cross correlation multiple-scattering) equipped with 
a He–Ne laser (632.8 nm) with variable intensity. The samples were prepared using AS1411 at 1.0 
μM concentration in a final volume of 200 μL and the AS1411/niosome system evaluated at 1:6 and 
1:12 molar ratios, respectively (using a 28.9 mM niosome stock solution in 20 mM HEPES, pH 
7.4). All the niosome formulations were previously sonicated and the measurements taken at a 
scattering angle of 90° in triplicates, without diluting the samples at a constant temperature of 25 
°C. The particle radius was calculated by fitting of the first cumulant parameter. 
 Cell culture 
HeLa cells were cultured at 37 °C, under a 5% CO2 atmosphere in DMEM partially supplemented 
with 10% fetal bovine serum with two antibiotics. Cells were regularly passaged in order to 
maintain exponential growth. 24 h before the experiments, the cells were trypsinized and diluted 1:5 
with a fresh medium and 1000 cells were transferred to a 96-well plate (100 μL per well). 
 Analysis of cell viability by the MTT colorimetric assay 
HeLa cells viability in the presence of all niosome formulations was tested at 6 μM concentration 
(from a 63.3 mM niosome_LipThyRu stock solutions in PBS, respectively) using the MTT 
colorimetric assay. For each assay, the cells were seeded at 1000 cell/well on a 96-well plate in 100 
μL of DMEM and cultured for 24 h. Then the cells were incubated with the different niosome 
concentrations, after 6 h, the culture medium was discarded, the wells were washed twice with PBS 
and additional (100 μL) DMEM was added after washing and cultured for 72 h. 
After 72 h, MTT was added at a final concentration of 0.5 mg/mL and the resulting system was 
incubated for 2 h at 37 °C. Finally, the medium was removed and DMSO (100 μL) was added to 
dissolve formazan crystals (15 min under stirring at room temperature) and finally the absorbance 
of the solution at λ = 570 nm was measured using a Glomax spectrophotometer. The experiments 
were carried out in triplicate. 
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Chapter 6 
1. General conclusions 
This work is centred on the preparation of multicomponent systems presenting both therapeutic and 
diagnostic agents as well as active targeting ligands. Specifically it has been focused on the 
evaluation of: 
1) novel Ru(III)-based complexes with enhanced antiproliferative activity: in this context, the 
preparation of new ruthenium compounds involving nucleoside- (in the case of LipThyRu) and 
amino acids-lipid (in the case of TUGluRu and TOTyroRu) as central scaffolds has been described. 
These derivatives have been designed as prodrugs of a simple Ru(III)-complex named Aziru, 
showing higher half-lives in comparison with AziRu; 
2) NOTA derivatives as imaging agents: in this frame, three novel lipid analogs of the macrocycle 
NOTA - a well known 
68
Ga chelator used in PET imaging – presenting lipophilic moieties such as 
oleyl (NOTA-OL), lipoyl (NOTA-Lip) or biotin (NOTA-Bio), have been synthesized and fully 
characterized; 
3) DNA aptamers, exploring in particular the TBA, selectively targeting thrombin involved in fibrin 
formation, and the nucleolin-targeting AS1411 aptamer. 
TBA has been conjugated with a dansyl at the 3'-end a β-cyclodextrin at the 5'-end plus a biotin, 
obtaining a tris-modified TBA (tris-mTBA). The couple dansyl/cyclodextrin allows to monitor the 
folding/unfolding of the aptamer by different spectroscopic techniques, while biotin allows to 
immobilize this aptamer on streptavidin-coated silica nanoparticles. It has been demonstrated that 
functionalized nanoparticles with tris-mTBA inhibit the human thrombin activity about 10 times 
more efficiently than the unmodified TBA. In addition the activity of tris-mTBA can be stopped by 
addition of the complementary sequence, forming a duplex with the tris-mTBA. Hence it is possible 
to restore the thrombin ability to convert fibrinogen into fibrin with a tunable control of the 
coagulation process. 
Concerning AS1411, three lipophilic derivatives of this G-quadruplex forming aptamer with 
cholesteryl or stearyl appendages at the 5’-end have been selected and studied in solution by UV, 
CD, gel electrophoresis and size exclusion chromatography techniques. The influence of the nature 
of the cation (Na
+
 or K
+
) and of concentration on the conformational behaviour and thermal stability 
of the corresponding G-quadruplex structures has been also evaluated. This study has demonstrated 
that not only the unmodified AS1411 aptamer but also its 5’-lipophilic conjugates show a high 
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polymorphism forming high order G-quadruplex structures or large aggregates in solution, 
especially at high concentrations. 
In conclusion, my PhD work has put the bases for the preparation of multifunctional nanoparticles 
for theranostic applications. In particular, with this work suitable targeting, imaging and therapeutic 
agents have been modified with different derivatizations and thus rendered available for the 
functionalization of different types of nanoparticle-based systems. 
To date, three multifunctional systems have been prepared and tested in vitro with very promising 
results: tris-mTBA-Sicastar
®
 nanoparticles, DOTAP-based liposomes loaded with TUGluRu and 
NOTA-OL, and niosome-based formulations incorporating LipThyRu and AS1411 oligonuleotide. 
Further studies are in progress to obtain and characterize multifunctional nanoparticles based on 
SPIONs, incorporating the here prepared targeting (AS1411 derivatives), anticancer (amphiphilic 
Ru complexes) and imaging (NOTA derivatives) agents. 
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3. Abbreviations 
18LPC   1-octadecyl-2-hydroxy-sn-glycero-3-phosphocholine 
3T3L-1  murine fibroblasts 
A549   human lung adenocarcinoma cell line 
AcOEt   ethyl acetate 
AMD   neovascular age-related macular degeneration 
Bn   benzyl 
C6   tumor rat glioma cells 
Calu-6   human lung adenocarcinoma cell line 
CD   circular dichroism spectroscopy 
cDDP   cisplatin 
CE   2-cyanoethyl 
COSY   correlation spectroscopy 
CRO   control oligonucleotides 
CT   computed tomography 
DCC   N,N-dicyclohexylcarbodiimide 
DEAD   diethyl azodicarboxylate 
DHB   2,5-dihydroxybenzoic acid 
DIPEA   N,N-diisopropylethylamine 
DLS   dynamic light scattering 
DMAP   4-(N,N-dimethylamino)pyridine 
DMEM  Dulbecco’s Modified Eagle’s Medium 
DMF   N,N-dimethylformamide 
DMSO   dimethyl sulfoxide 
DMT   4,4-dimethoxytriphenylmethyl 
DOTA   1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid 
DOTAP  1,2-dioleoyl-3-trimethylammoniumpropane 
ec   end-capped 
EDTA   ethylenediaminetetraacetic acid 
ESI   electrospray ionization 
EtOH   ethanol 
FBS   fetal serum bovine 
FDG   fluorodeoxyglucose 
Fmoc   9-fluorenylmethoxycarbonyl 
FTIR-ATR  fourier transformed infrared spectroscopy from attenuated total reflectance 
G4   G-quadruplex 
GRO   guanine-rich oligonucleotide 
HaCaT  non cancer human keratinocytes 
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HATU  1-[bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxid 
 hexafluorophosphate 
HEG   hexaethylene glycol 
HeLa   human cervical cancer cells 
HEPES  2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid 
HEWL   hen egg white lysozyme 
HIV   human immunodeficiency virus 
HPLC   high performance liquid chromatography 
HSQC   heteronuclear single quantum correlation 
hTf   human serum transferrin 
IC50   half-maximal inhibitory concentration 
ID   internal diameter 
Im   imidazole 
Ind   indazole 
L6   rat muscle cells 
LC   liquid chromatography 
LMCT   ligand-to-metal charge transfer transition 
m.p.   melting point 
MALDI  matrix-assisted laser desorption ionization 
MCF-7   human breast adenocarcinoma cell line 
MeOH   methanol 
MMT   4-monomethoxytrityl 
MMT-Cl  4-methoxytriphenylmethyl chloride  
MRI   magnetic resonance imaging 
MS   mass spectrometry 
mTOR   mammalian target of rapamycin 
MTT   3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide 
NGS   next-generation sequencing 
NMR   nuclear magnetic resonance 
NOTA   1,4,7-triazacyclononane-1,4,7-triacetic acid 
NPs   nanoparticles 
ODN   oligonucleotide 
PAGE   polyacrylamide gel electrophoresis 
PBS   phosphate-buffered saline 
PCR   polymerase chain reaction 
PEG   polyethylene glycol 
PET   positron emission tomography 
Ph   phenyl 
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POPC   1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine 
ppm   parts per million 
Py   pyridine 
Rac1   Ras-related C3 botulinum toxin substrate 1 
RES   reticulo-endothelial system 
Rf   retention factor 
RNase A  bovine pancreatic ribonuclease 
RSV   respiratory syncytial virus 
SANS   small angle neutron scattering 
SEC   size exclusion chromatography 
SELEX  systematic evolution of ligands by exponential enrichment 
siRNA   small interfering RNA 
SPECT  single photon emission computed tomography 
SPIONs  superparamagnetic iron oxide nanoparicles 
T2   transversal proton relaxation time 
TAE   Tris-acetate-EDTA 
TBA   thrombin binding aptamer 
tBu   tert-butyl 
TCA   trichloroacetic acid 
TEA   triethylamine 
TEAA   triethylammonium acetate 
TEG-OMe  triethylene glycol monomethyl ether 
TFA   trifluoroacetic acid 
THF   tetrahydrofuran 
THME   1,1,1-tris(hydroxymethyl)ethane 
Thy   thymidine 
TLC   thin layer chromatography 
Tm   melting temperature 
TOF   time of flight 
tR   retention time 
US   ultrasound 
UV   ultraviolet spectroscopy 
VEGF   vascular endothelial growth factor 
WiDr   human epithelial colorectal adenocarcinoma cell line 
  
Chapter 6 
159 
 
4. References 
[1] I. Velikyan, Theranostics 2012, 2, 424–426. 
[2] G. Bao, S. Mitragotri, S. Tong, Annu. Rev. Biomed. Eng. 2013, 15, 253–282. 
[3] M. Kalia, Metabolism. 2013, 62, S11–S14. 
[4] J. H. Ryu, S. Lee, S. Son, S. H. Kim, J. F. Leary, K. Choi, I. C. Kwon, J. Control. Release 2014, 190, 
477–484. 
[5] J. T. Cole, N. B. Holland, Drug Deliv. Transl. Res. 2015, 5, 295–309. 
[6] L. S. Wang, M. C. Chuang, J. A. Ho, Int. J. Nanomedicine 2012, 7, 4679–95. 
[7] S. S. Kelkar, T. M. Reineke, Bioconjugate Chem. 2011, 22, 1879–1903. 
[8] R. P. Baum, H. R. Kulkarni, Theranostics 2012, 2, 437–447. 
[9] D. Y. Lee, K. C. P. Li, Am. J. Roentgenol. 2011, 197, 318–324. 
[10] H. Koo, M. S. Huh, I.-C. Sun, S. H. Yuk, K. Choi, K. Kim, I. C. Know, Acc. Chem. Res. 2011, 44, 
1018–1028. 
[11] X. Ma, Y. Zhao, X. J. Liang, Acc. Chem. Res. 2011, 44, 1114–1122. 
[12] K. Y. Choi, G. Liu, S. Lee, X. Chen, Nanoscale 2012, 4, 330–342. 
[13] J. H. Ryu, H. Koo, I. C. Sun, S. H. Yuk, K. Choi, K. Kim, I. C. Kwon, Adv. Drug Deliv. Rev. 2012, 
64, 1447–1458. 
[14] H. T. Kim, S. Lee, X. Chen, Expert Rev. Mol. Diagn. 2013, 13, 257–269. 
[15] K. Öberg, Theranostics 2012, 2, 448–458. 
[16] B. Sumer, J. Gao, Nanomedicine 2008, 3, 137–140. 
[17] T. Lammers, S. Aime, W. E. Hennink, G. Storm, F. Kiessling, Acc. Chem. Res. 2011, 44, 1029–1038. 
[18] J. Choi, N. S. Wang, in Biomed. Eng. - From Theory to Appl., Prof. Reza Fazel (Ed.), 2011, pp. 299 – 
314. 
[19] M. V. Yezhelyev, X. Gao, Y. Xing, A. Al-Hajj, S. Nie, R. M. O’Regan, Lancet Oncol. 2006, 7, 657–
667. 
[20] X. Wang, L. Yang, Z. Chen, D. M. Shin, A Cancer J. Clin. 2008, 58, 97–110. 
[21] N. Sanvicens, M. P. Marco, Trends Biotechnol. 2008, 26, 425–433. 
[22] A. H. Faraji, P. Wipf, Bioorg. Med. Chem. 2009, 17, 2950–2962. 
[23] S. M. Janib, A. S. Moses, J. A. MacKay, Adv. Drug Deliv. Rev. 2010, 62, 1052–1063. 
[24] A. Shapira, Y. D. Livney, H. J. Broxterman, Y. G. Assaraf, Drug Resist. Updat. 2011, 14, 150–163. 
[25] K. H. Bae, H. J. Chung, T. G. Park, Mol. Cells 2011, 31, 295–302. 
[26] M. K. Yu, J. Park, S. Jon, Theranostics 2012, 2, 3–44. 
[27] R. Paliwal, R. J. Babu, S. Palakurthi, AAPS PharmSciTech 2014, 15, 1527–1534. 
[28] A. Radomska, J. Leszczyszyn, M. W. Radomski, Adv. Clin. Exp. Med. 2016, 25, 151–162. 
[29] H. Xing, K. Hwang, Y. Lu, Theranostics 2016, 6, 1336–1352. 
[30] B. Y. S. Kim, J. T. Rutka, W. C. W. Chan, N. Engl. J. Med. 2010, 363, 2434–2443. 
[31] J. D. Heidel, M. E. Davis, Pharm. Res. 2011, 28, 187–199. 
[32] H. C. Huang, S. Barua, G. Sharma, S. K. Dey, K. Rege, J. Control. Release 2011, 155, 344–357. 
[33] H. Maeda, Adv. Enzyme Regul. 2001, 41, 189–207. 
[34] F. Alexis, E. Pridgen, L. K. Molnar, O. C. Farokhzad, Mol. Pharm. 2008, 5, 505–515. 
[35] M. Longmire, P. L. Choyke, H. Kobayashi, Nanomedicine 2008, 3, 703–717. 
[36] S. D. Li, L. Huang, Mol. Pharm. 2008, 5, 496–504. 
[37] V. Mailänder, K. Landfester, Biomacromolecules 2009, 10, 2379–2400. 
[38] B. S. Zolnik,  .  González-Fernández, N. Sadrieh, M. A. Dobrovolskaia, Endocrinology 2010, 151, 
458–465. 
[39] K. Shao, S. Singha, X. Clemente-Casares, S. Tsai, Y. Yang, P. Santamaria, ACS Nano 2015, 9, 16–
30. 
[40] M. E. Davis, Z. G. Chen, D. M. Shin, Nat. Rev. Drug Discov. 2008, 7, 771–782. 
[41] M. Wang, M. Thanou, Pharmacol. Res. 2010, 62, 90–99. 
[42] J. M. Rademaker-Lakhai, D. Van Den Bongard, D. Pluim, J. H. Beijnen, J. H. M. Schellens, Clin. 
Cancer Res. 2004, 10, 3717–3727. 
[43] C. G. Hartinger, M. A. Jakupec, S. Zorbas-Seifried, M. Groessl, A. Egger, W. Berger, H. Zorbas, P. J. 
Dyson, B. K. Keppler, Chem. Biodivers. 2008, 5, 2140–2155. 
[44] F. Lentz, A. Drescher, A. Lindauer, M. Henke, R. A. Hilger, C. G. Hartinger, M. E. Scheulen, C. 
Dittrich, B. K. Keppler, U. Jaehde, Anticancer Drugs 2009, 20, 97–103. 
Chapter 6 
160 
 
[45] S. Leijen, S. A. Burgers, P. Baas, D. Pluim, M. Tibben, E. Van Werkhoven, E. Alessio, G. Sava, J. H. 
Beijnen, J. H. M. Schellens, Invest. New Drugs 2015, 33, 201–214. 
[46] H. Ding, F. Wu, Theranostics 2012, 2, 1040–1053. 
[47] R. Chakravarty, H. Hong, W. Cai, Mol. Pharm. 2014, 11, 3777–3797. 
[48] H. Grönbeck, A. Curioni, W. Andreoni, J. Am. Chem. Soc. 2000, 122, 3839–3842. 
[49] A. H. Pakiari, Z. Jamshidi, J. Phys. Chem. A 2010, 114, 9212–9221. 
[50] N. M. Green, Methods Enzymol. 1990, 184, 51–67. 
[51] C. Blanpain, Nat. Cell Biol. 2013, 15, 126–134. 
[52] S. Rafique, M. Idrees, A. Nasim, H. Akbar, A. Athar, Biotechnol. Mol. Biol. Rev. 2010, 5, 38–45. 
[53] I. Ott, R. Gust, Arch. Pharm. 2007, 340, 117–126. 
[54] G. Gasser, I. Ott, N. Metzler-Nolte, J. Med. Chem. 2011, 54, 3–25. 
[55] B. Rosenberg, L. Vancamp, T. Krigas, Nature 1965, 205, 698–699. 
[56] E. Renshaw, A. J. Thomson, J. Bacteriol. 1967, 94, 1915–1918. 
[57] B. Rosenberg, L. Van Camp, E. B. Grimley, A. J. Thomson, J. Biol. Chem. 1967, 242, 1347–1352. 
[58] B. Rosenberg, E. Renshaw, L. Vancamp, J. Hartwick, J. Drobnik, J. Bacteriol. 1967, 93, 716–721. 
[59] B. Rosenberg, L. van Camp, J. E. Trosko, V. H. Mansour, Nature 1969, 222, 385–386. 
[60] G. Sava, S. Pacor, F. Bregant, V. Ceschia, G. Mestroni, Anticancer Drugs 1990, 1, 99–108. 
[61] M. J. Clarke, F. Zhu, D. R. Frasca, Chem. Rev. 1999, 99, 2511–2533. 
[62] G. Sava, A. Bergamo, Int. J. Oncol. 2000, 17, 353–365. 
[63] M. J. Clarke, Coord. Chem. Rev. 2002, 232, 69–93. 
[64] M. J. Clarke, Coord. Chem. Rev. 2003, 236, 209–233. 
[65] M. Galanski, V. B. Arion, M. A. Jakupec, B. K. Keppler, Curr. Pharm. Des. 2003, 9, 2078–2089. 
[66] E. Alessio, G. Mestroni, A. Bergamo, G. Sava, Curr. Top. Med. Chem. 2004, 4, 1525–1535. 
[67] I. Kostova, Curr. Med. Chem. 2006, 13, 1085–1107. 
[68] A. Levina, A. Mitra, P. A. Lay, Metallomics 2009, 1, 458–470. 
[69] A. Bergamo, G. Sava, Dalton Trans. 2011, 40, 7817–7823. 
[70] G. Sava, A. Bergamo, P. J. Dyson, Dalton Trans. 2011, 40, 9069–9075. 
[71] A. Bergamo, C. Gaiddon, J. H. Schellens, J. H. Beijnen, G. Sava, J. Inorg. Biochem. 2012, 106, 90–
99. 
[72] S. Komeda, A. Casini, Curr. Top. Med. Chem. 2012, 12, 219–235. 
[73] C. Riccardi, D. Musumeci, C. Irace, L. Paduano, D. Montesarchio, Eur. J. Org. Chem. 2017, 1100–
1119. 
[74] W. J. Zeller, S. Frühauf, G. Chen, B. K. Keppler, E. Frei, M. Kaufmann, Eur. J. Cancer 1991, 27, 62–
67. 
[75] M. Coluccia, G. Sava, F. Loseto, A. Nassi, A. Boccarelli, D. Giordano, E. Alessio, G. Mestroni, Eur. 
J. Cancer 1993, 29, 1873–1879. 
[76] E. Alessio, G. Mestroni, A. Bergamo, G. Sava, in Met. Ions Biol. Syst. (Eds.: A. Sigel, H. Sigel), 
Marcel Dekker, New York, 2004, pp. 323–351. 
[77] V. Brabec, O. Novàkovà, Drug Resist. Updat. 2006, 9, 111–122. 
[78] B. K. Keppler, W. Rupp, U. M. Juhl, H. Endres, R. Niebl, W. Balzer, Inorg. Chem. 1987, 26, 4366–
4370. 
[79] E. D. Kreuser, B. K. Keppler, W. E. Berdel, A. Piest, E. Thiel, Semin. Oncol. 1992, 19, 73–81. 
[80] V. Singh, G. K. Azad, P. Mandal, M. A. Reddy, R. S. Tomar, FEBS Lett. 2014, 588, 1044–1052. 
[81] G. Mestroni, E. Alessio, G. Sava, S. Pacor, M. Coluccia, A. Boccarelli, Met. Based Drugs 1994, 1, 
41–63. 
[82] G. Sava, I. Capozzi, K. Clerici, G. Gagliardi, E. Alessio, G. Mestroni, Clin. Exp. Metastasis 1998, 16, 
371–379. 
[83] M. Brindell, D. Piotrowska, A. A. Shoukry, G. Stochel, R. Eldik, J. Biol. Inorg. Chem. 2007, 12, 
809–818. 
[84] M. Brindell, I. Stawoska, J. Supel, A. Skoczowski, G. Stochel, R. Van Eldik, J. Biol. Inorg. Chem. 
2008, 13, 909–918. 
[85] C. Bartel, A. E. Egger, M. A. Jakupec, P. Heffeter, M. Galanski, W. Berger, B. K. Keppler, J. Biol. 
Inorg. Chem. 2011, 16, 1205–1215. 
[86] C. G. Hartinger, S. Zorbas-Seifried, M. A. Jakupec, B. Kynast, H. Zorbas, B. K. Keppler, J. Inorg. 
Biochem. 2006, 100, 891–904. 
[87] E. Alessio, Eur. J. Inorg. Chem. 2016, 55, DOI 10.1002/ejic.201600986. 
Chapter 6 
161 
 
[88] D. Frasca, J. Ciampa, J. Emerson, R. S. Umans, M. J. Clarke, Met. Based Drugs 1996, 3, 197–209. 
[89] M. Pongratz, P. Schluga, M. A. Jakupec, V. B. Arion, C. G. Hartinger, G. Allmaier, B. K. Keppler, J. 
Anal. At. Spectrom. 2004, 19, 46–51. 
[90] O. Mazuryk, K. Kurpiewska, K. Lewinski, G. Stochel, M. Brindell, J. Inorg. Biochem. 2012, 116, 11–
18. 
[91] A. Bergamo, M. Cocchietto, I. Capozzi, G. Mestroni, E. Alessio, G. Sava, Anticancer Drugs 1996, 7, 
697–702. 
[92] G. Sava, K. Cleriri, I. Capozzi, M. Cocchietto, R. Gagliardi, E. Alessio, G. Mestroni, A. Perbellini, 
Anticancer drugs 1999, 10, 129–138. 
[93] S. Zorzet, A. Bergamo, M. Cocchietto, A. Sorc, B. Gava, E. Alessio, E. Iengo, G. Sava, J. 
Pharmacol. Exp. Ther. 2000, 295, 927–933. 
[94] S. Zorzet, A. Sorc, C. Casarsa, M. Cocchietto, G. Sava, Met. Based Drugs 2001, 8, 1–7. 
[95] G. Pintus, B. Tadolini, A. M. Posadino, B. Sanna, M. Debidda, F. Bennardini, G. Sava, C. Ventura, 
Eur. J. Biochem. 2002, 269, 5861–5870. 
[96] A. Bergamo, B. Gava, E. Alessio, G. Mestroni, B. Serli, M. Cocchietto, S. Zorzet, G. Sava, Int. J. 
Oncol. 2002, 21, 1331–1338. 
[97] G. Sava, S. Zorzet, C. Turrin, F. Vita, M. Soranzo, G. Zabucchi, M. Cocchietto, A. Bergamo, S. 
Digiovine, G. Pezzoni, et al., Clin. Cancer Res. 2003, 9, 1898–1905. 
[98] S. Pacor, S. Zorzet, M. Cocchietto, M. Bacac, M. Vadori, C. Turrin, B. Gava, A. Castellarin, G. Sava, 
J. Pharmacol. Exp. Ther. 2004, 310, 737–744. 
[99] M. Bacac, M. Vadori, G. Sava, S. Pacor, Cancer Immunol. Immunother. 2004, 53, 1101–1110. 
[100] M. Bacac, A. C. G. Hotze, K. Van Der Schilden, J. G. Haasnoot, S. Pacor, E. Alessio, G. Sava, J. 
Reedijk, J. Inorg. Biochem. 2004, 98, 402–412. 
[101] B. Gava, S. Zorzet, P. Spessotto, M. Cocchietto, G. Sava, J. Pharmacol. Exp. Ther. 2006, 317, 284–
291. 
[102] A. Bergamo, G. Sava, Dalton Trans. 2007, 36, 1267–1272. 
[103] M. Groessl, E. Reisner, C. G. Hartinger, R. Eichinger, O. Semenova, A. R. Timerbaev, M. A. 
Jakupec, V. B. Arion, B. K. Keppler, J. Med. Chem. 2007, 50, 2185–2193. 
[104] J. Chen, L. Chen, S. Liao, K. Zheng, L. Ji, J. Phys. Chem. B 2007, 111, 7862–7869. 
[105] N. Besker, C. Coletti, A. Marrone, N. Re, J. Phys. Chem. B 2008, 112, 3871–3875. 
[106] E. Alessio, G. Balducci, A. Lutman, G. Mestroni, M. Calligaris, W. M. Attia, Inorg. Chim. Acta 1993, 
203, 205–217. 
[107] B. M. Blunden, M. H. Stenzel, J. Chem. Technol. Biotechnol. 2015, 90, 1177–1195. 
[108] M. Bouma, B. Nuijen, M. T. Jansen, G. Sava, A. Flaibani, A. Bult, J. H. Beijnen, Int. J. Pharmacol. 
2002, 248, 239–246. 
[109] I. Bratsos, S. Jedner, T. Gianferrara, E. Alessio, Chim. Int. J. Chem. 2007, 61, 692–697. 
[110] A. V. Vargiu, A. Robertazzi, A. Magistrato, P. Ruggerone, P. Carloni, J. Phys. Chem. B 2008, 112, 
4401–4409. 
[111] A. Vacca, M. Bruno, A. Boccarelli, M. Coluccia, D. Ribatti, A. Bergamo, S. Garbisa, L. Sartor, G. 
Sava, Br. J. Cancer 2002, 86, 993–998. 
[112] L. Messori, P. Orioli, D. Vullo, E. Alessio, E. Iengo, Eur. J. Biochem. 2000, 267, 1206–1213. 
[113] A. Bergamo, R. Gagliardi, V. Scarcia, A. Furlani, E. Alessio, G. Mestroni, G. Sava, J. Pharmacol. 
Exp. Ther. 1999, 289, 559–564. 
[114] M. R. Berger, F. T. Garzon, B. K. Keppler, D. Schmahl, Anticancer Res. 1989, 9, 761–765. 
[115] A. Galeano, M. R. Berger, B. K. Keppler, Arzneimittelforschung. 1992, 42, 821–824. 
[116] M. H. Seelig, M. R. Berger, B. K. Keppler, J. Cancer Res. Clin. Oncol. 1992, 118, 195–200. 
[117] P. Schluga, C. G. Hartinger, A. Egger, E. Reisner, M. Galanski, M. A. Jakupec, B. K. Keppler, 
Dalton Trans. 2006, 14, 1796–1802. 
[118] E. Reisner, V. B. Arion, B. K. Keppler, A. J. L. Pombeiro, Inorg. Chim. Acta 2008, 361, 1569–1583. 
[119] C. G. Hartinger, B. K. Keppler, Electrophoresis 2007, 28, 3436–3446. 
[120] S. Kapitza, M. Pongratz, M. A. Jakupec, P. Heffeter, W. Berger, L. Lackinger, B. K. Keppler, B. 
Marian, J. Cancer Res. Clin. Oncol. 2005, 131, 101–110. 
[121] E. S. Antonarakis, A. Emadi, Cancer Chemother. Pharmacol. 2010, 66, 1–9. 
[122] P. Heffeter, K. Böck, B. Atil, M. A. Reza Hoda, W. Körner, C. Bartel, U. Jungwirth, B. K. Keppler, 
M. Micksche, W. Berger, et al., J. Biol. Inorg. Chem. 2010, 15, 737–748. 
[123] J. B. Aitken, S. Antony, C. M. Weekley, B. Lai, L. Spiccia, H. H. Harris, Metallomics 2012, 4, 1051. 
Chapter 6 
162 
 
[124] A. M. Pizarro, A. Habtemariam, P. J. Sadler, in Med. Organomet. Chem. (Eds.: G. Jaouen, N. 
Metzler-Nolte), Springer-Verlag, Heidelberg (Germany), 2010, pp. 21–56. 
[125] O. Dömötör, C. G. Hartinger, A. K. Bytzek, T. Kiss, B. K. Keppler, E. A. Enyedy, J. Biol. Inorg. 
Chem. 2013, 18, 9–17. 
[126] A. Bijelic, S. Theiner, B. K. Keppler, A. Rompel, J. Med. Chem. 2016, 59, 5894–5903. 
[127] L. Messori, F. Kratz, E. Alessio, Met. Based Drugs 1996, 3, 1–9. 
[128] A. M. Pizarro, P. J. Sadler, Biochimie 2009, 91, 1198–1211. 
[129] H. Sun, H. Li, P. J. Sadler, Chem. Rev. 1999, 99, 2817–2842. 
[130] M. Groessl, M. Terenghi, A. Casini, L. Elviri, R. Lobinski, P. J. Dyson, J. Anal . At. Spectrom. 2010, 
25, 305–313. 
[131] W. Guo, W. Zheng, Q. Luo, X. Li, Y. Zhao, S. Xiong, F. Wang, Inorg. Chem. 2013, 52, 5328–5338. 
[132] K. Spiewak, M. Brindell, J. Biol. Inorg. Chem. 2015, 20, 695–703. 
[133] W. E. Winter, L. A. L. Bazydlo, N. S. Harris, Lab. Med. 2014, 45, 92–102. 
[134] M. I. Webb, R. A. Chard, Y. M. Al-Jobory, M. R. Jones, E. W. Y. Wong, C. J. Walsby, Inorg. Chem. 
2012, 51, 954–966. 
[135] G. Mangiapia, G. D’Errico, L. Simeone, C. Irace, A. Radulescu, A. Di Pascale, A. Colonna, D. 
Montesarchio, L. Paduano, Biomaterials 2012, 33, 3770–3782. 
[136] L. Simeone, G. Mangiapia, G. Vitiello, C. Irace, A. Colonna, O. Ortona, D. Montesarchio, L. 
Paduano, Bioconjugate Chem. 2012, 23, 758–770. 
[137] G. Vitiello, A. Luchini, G. D’Errico, R. Santamaria, A. Capuozzo, C. Irace, D. Montesarchio, L. 
Paduano, J. Mater. Chem. B 2015, 3, 3011–3023. 
[138] M. I. Webb, B. Wu, T. Jang, R. A. Chard, E. W. Y. Wong, M. Q. Wong, D. T. T. Yapp, C. J. Walsby, 
Chem. Eur. J. 2013, 19, 17031–17042. 
[139] S. W. Chang, A. R. Lewis, K. E. Prosser, J. R. Thompson, M. Gladkikh, M. B. Bally, J. J. Warren, C. 
J. Walsby, Inorg. Chem. 2016, 55, 4850–4863. 
[140] C. Mu, S. W. Chang, K. E. Prosser, A. W. Y. Leung, S. Santacruz, T. Jang, J. R. Thompson, D. T. T. 
Yapp, J. J. Warren, M. B. Bally, et al., Inorg. Chem. 2016, 55, 177–190. 
[141] C. Tan, S. Wu, S. Lai, M. Wang, Y. Chen, L. Zhou, Y. Zhu, W. Lian, W. Peng, L. Ji, et al., Dalton 
Trans. 2011, 40, 8611–8621. 
[142] A. Vergara, I. Russo Krauss, D. Montesarchio, L. Paduano, A. Merlino, Inorg. Chem. 2013, 52, 
10714–10716. 
[143] A. Vergara, G. D’Errico, D. Montesarchio, L. Paduano, A. Merlino, Inorg. Chem. 2013, 52, 4157–
4159. 
[144] L. Messori, A. Merlino, Dalton Trans. 2014, 43, 6128–6131. 
[145] M. I. Webb, C. J. Walsby, Dalton Trans. 2011, 40, 1322–1331. 
[146] L. Kelland, Nat. Rev. Cancer 2007, 7, 573–584. 
[147] D. Musumeci, L. Rozza, A. Merlino, L. Paduano, T. Marzo, L. Massai, L. Messori, D. Montesarchio, 
Dalton Trans. 2015, 44, 13914–13925. 
[148] G. Sava, A. Bergamo, S. Zorzet, B. Gava, C. Casarsa, M. Cocchietto, A. Furlani, V. Scarcia, B. Serli, 
E. Iengo, et al., Eur. J. Cancer 2002, 38, 427–435. 
[149] M. Galanski, B. K. Keppler, Anticancer. Agents Med. Chem. 2007, 7, 55–73. 
[150] M. Vaccaro, R. Del Litto, G. Mangiapia, A. M. Carnerup, G. D’Errico, F. Ruffo, L. Paduano, Chem. 
Commun. 2009, 1404–6. 
[151] L. Simeone, G. Mangiapia, C. Irace, A. Di Pascale, A. Colonna, O. Ortona, L. De Napoli, D. 
Montesarchio, L. Paduano, Mol. Biosyst. 2011, 7, 3075–3086. 
[152] L. Simeone, C. Irace, A. Di Pascale, D. Ciccarelli, G. D’Errico, D. Montesarchio, Eur. J. Med. Chem. 
2012, 57, 429–440. 
[153] G. Mangiapia, G. Vitiello, C. Irace, R. Santamaria, A. Colonna, R. Angelico, A. Radulescu, G. 
D’Errico, D. Montesarchio, L. Paduano, Biomacromolecules 2013, 14, 2549–2560. 
[154] D. Montesarchio, G. Mangiapia, G. Vitiello, D. Musumeci, C. Irace, R. Santamaria, G. D’Errico, L. 
Paduano, Dalton Trans. 2013, 42, 16697–16708. 
[155] G. Mangiapia, M. Vaccaro, G. D’Errico, H. Frielinghaus, A. Radulescu, V. Pipich, A. M. Carnerup, 
L. Paduano, Soft Matter 2011, 7, 10577–10580. 
[156] M. Vaccaro, A. Accardo, D. Tesauro, G. Mangiapia, D. Löf, K. Schillén, O. Söderman, G. Morelli, L. 
Paduano, Langmuir 2006, 22, 6635–6643. 
[157] G. Mangiapia, A. Accardo, F. Lo Celso, D. Tesauro, G. Morelli, A. Radulescu, L. Paduano, J. Phys. 
Chapter 6 
163 
 
Chem. B 2004, 108, 17611–17617. 
[158] H. Rosemeyer, Chem. Biodivers. 2005, 2, 977–1063. 
[159] D. Berti, F. B. Bombelli, M. Fortini, P. Baglioni, J. Phys. Chem. B 2007, 111, 11734–11744. 
[160] P. Barthélemy, Comptes Rendus Chim. 2009, 12, 171–179. 
[161] V. Allain, C. Bourgaux, P. Couvreur, Nucleic Acids Res. 2012, 40, 1891–1903. 
[162] S. Stolnik, L. Illum, S. S. Davis, Adv. Drug Deliv. Rev. 1995, 16, 195–214. 
[163] N. Nishiyama, K. Kataoka, Pharmacol. Ther. 2006, 112, 630–648. 
[164] M. H. Stenzel, Chem. Commun. 2008, 44, 3486–3503. 
[165] A. Rösler, G. W. M. Vandermeulen, H. A. Klok, Adv. Drug Deliv. Rev. 2011, 53, 95–108. 
[166] L. R. Arriaga, I. López-Montero, F. Monroy, G. Orts-Gil, B. Farago, T. Hellweg, Biophys. J. 2009, 
96, 3629–3637. 
[167] N. Larson, H. Ghandehari, Chem. Mater. 2012, 24, 840–853. 
[168] H. Kobayashi, B. Turkbey, R. Watanabe, P. L. Choyke, Bioconjugate Chem. 2014, 25, 2093–2100. 
[169] S. Di-Wen, G. Z. Pan, L. Hao, J. Zhang, Q. Z. Xue, P. Wang, Q. Z. Yuan, Int. J. Pharm. 2016, 500, 
54–61. 
[170] R. Satchi-Fainaro, R. Duncan, C. M. Barnes, Adv. Polym. Sci. 2006, 193, 1–65. 
[171] O. Bomati-Miguel, N. Miguel-Sancho, I. Abasolo, A. P. Candiota, A. G. Roca, M. Acosta, S. 
Schwartz, C. Arus, C. Marquina, G. Martinez, et al., J. Nanoparticle Res. 2014, 16, 1–13. 
[172] F. Dai, M. Du, Y. Liu, G. Liu, Q. Liu, X. Zhang, J. Mater. Chem. B 2014, 2, 2240–2247. 
[173] A. Luchini, G. Vitiello, F. Rossi, O. Ruiz De Ballesteros, A. Radulescu, G. D’Errico, D. 
Montesarchio, C. de Julián Fernández, L. Paduano, Phys. Chem. Chem. Phys. 2015, 17, 6087–6097. 
[174] A. Luchini, C. Irace, R. Santamaria, D. Montesarchio, R. K. Heenan, N. Szekely, A. Flori, L. 
Menichetti, L. Paduano, Nanoscale 2016, 8, 10078–10086. 
[175] B. Neises, W. Steglich, Angew. Chem. - Int. Ed. Eng. 1978, 17, 522–524. 
[176] A. Hassner, V. Alexanian, Tetrahedron Lett. 1978, 19, 4475–4478. 
[177] E. Alessio, G. Balducci, M. Calligaris, G. Costa, W. M. Attia, G. Mestroni, Inorg. Chem. 1991, 30, 
609–618. 
[178] A. H. Velders, A. Bergamo, E. Alessio, E. Zangrando, J. G. Haasnoot, C. Casarsa, M. Cocchietto, S. 
Zorzet, G. Sava, J. Med. Chem. 2004, 47, 1110–1121. 
[179] C. E. Hoyle, C. N. Bowman, Angew. Chem. - Int. Ed. Eng. 2010, 49, 1540–1573. 
[180] L. Carpino, J. Am. Chem. Soc. 1993, 115, 4397–4398. 
[181] V. P. Fitzjarrald, R. Pongdee, Tetrahedron Lett. 2007, 48, 3553–3557. 
[182] O. Mitsunobu, M. Yamada, Bull. Chem. Soc. Jpn. 1967, 40, 2380–2382. 
[183] M. Kirihara, Y. Asai, S. Ogawa, T. Noguchi, A. Hatano, Y. Hirai, J. Synth. Org. Chem. 2007, 21, 
3286–3289. 
[184] A. Hatefi, T. Minko, Drug Deliv. Transl. Res. 2012, 2, 1–2. 
[185] Y. Zhang, H. F. Chan, K. W. Leong, Adv. Drug Deliv. Rev. 2013, 65, 104–120. 
[186] H. R. Herschman, Science. 2003, 302, 605–608. 
[187] R. Weissleder, M. J. Pittet, Nature 2008, 452, 580–589. 
[188] C. R. Berry, P. Garg, Semin. Nucl. Med. 2014, 44, 66–75. 
[189] L. J. Higgins, M. G. Pomper, Semin. Oncol. 2011, 38, 3–15. 
[190] D. A. Mankoff, J. Nucl. Med. 2007, 48, 18N–21N. 
[191] J. Paeng, D. Lee, Open Nucl. Med. J. 2010, 2, 145–152. 
[192] M. Rudin, R. Weissleder, Nat. Rev. Drug Discov. 2003, 2, 123–131. 
[193] W. B. Cai, X. Y. Chen, J. Nucl. Med. 2008, 49, 113S–128S. 
[194] H. Hong, Y. Zhang, J. Sun, W. Cai, Nano Today 2009, 4, 399–413. 
[195] M. Ryvolova, J. Chomoucka, J. Drbohlavova, P. Kopel, P. Babula, D. Hynek, V. Adam, T. 
Eckschlager, J. Hubalek, M. Stiborova, et al., Sensors 2012, 12, 14792–14820. 
[196] T. F. Massoud, T. F. Massoud, S. S. Gambhir, S. S. Gambhir, Genes Dev. 2003, 17, 545–580. 
[197] S. M. Ametamey, M. Honer, P. A. Schubiger, Chem. Rev. 2008, 108, 1501–1516. 
[198] L. E. Jennings, N. J. Long, Chem. Commun. 2009, 3511–3524. 
[199] F. Kiessling, S. Fokong, J. Bzyl, W. Lederle, M. Palmowski, T. Lammers, Adv. Drug Deliv. Rev. 
2014, 72, 15–27. 
[200] B. C. Visser, B. M. Yeh, A. Qayyum, L. W. Way, C. E. McCulloch, F. V. Coakley, Am. J. 
Roentgenol. 2007, 189, 648–656. 
[201] F. Rösch, R. P. Baum, Dalton Trans. 2011, 40, 6104–6111. 
Chapter 6 
164 
 
[202] R. P. Baum, H. R. Kulkarni, C. Carreras, Semin. Nucl. Med. 2012, 42, 190–207. 
[203] S. S. Gambhir, Nat. Rev. Cancer 2002, 2, 683–693. 
[204] R. J. Hicks, M. S. Hofman, Nat. Rev. Clin. Oncol. 2012, 9, 712–720. 
[205] I. Velikyan, Theranostics 2014, 4, 47–80. 
[206] J. Sörensen, Theranostics 2012, 2, 427–436. 
[207] A. A. M. van der Veldt, E. F. Smit, A. A. Lammertsma, Front. Oncol. 2013, 3, 208–214. 
[208] P. Sharma, H. Singh, S. Basu, R. Kumar, South Asian J. cancer 2013, 2, 171–177. 
[209] B. S. Jang, Toxicol. Res. 2013, 29, 1–6. 
[210] L. Cunha, K. Szigeti, D. Mathé, L. F. Metello, Drug Discov. Today 2014, 19, 936–948. 
[211] S. L. Rice, C. A. Roney, P. Daumar, J. S. Lewis, Semin. Nucl. Med. 2011, 41, 265–282. 
[212] R. L. Wahl, J. M. Herman, E. Ford, Semin. Radiat. Oncol. 2011, 21, 88–100. 
[213] I. Velikyan, Med. Chem. 2011, 7, 345–379. 
[214] I. Velikyan, Molecules 2015, 20, 12913–12943. 
[215] S. M. Moerlein, M. J. Welch, Int. J. Nucl. Med. Biol. 1981, 8, 277–287. 
[216] J. Shukla, B. Mittal, J. Postgrad. Med. Educ. Res. 2013, 47, 74–76. 
[217] R. M. Lambrecht, S. Munawwar, Radiochim. Acta 1988, 43, 171–179. 
[218] M. Fani, J. P. André, H. R. Maecke, Contrast Media Mol. Imaging 2008, 3, 67–77. 
[219] W. A. P. Breeman, A. M. Verbruggen, Eur. J. Nucl. Med. Mol. Imaging 2007, 34, 978–981. 
[220] I. Velikyan, A. Sundin, B. Eriksson, H. Lundqvist, J. Sörensen, M. Bergström, B. Långström, Nucl. 
Med. Biol. 2010, 37, 265–275. 
[221] H. S. Chong, K. Garmestani, D. Ma, D. E. Milenic, T. Overstreet, M. W. Brechbiel, J. Med. Chem. 
2002, 45, 3458–3464. 
[222] P. J. Riss, C. Kroll, V. Nagel, F. Rösch, Bioorg. Med. Chem. 2008, 18, 5364–5367. 
[223] I. Velikyan, H. Maecke, B. Langstrom, Bioconjugate Chem. 2008, 19, 569–573. 
[224] J. M. Jeong, M. K. Hong, Y. S. Chang, Y. S. Lee, Y. J. Kim, G. J. Cheon, D. S. Lee, J. K. Chung, M. 
C. Lee, J. Nucl. Med. 2008, 49, 830–836. 
[225] E. T. Clarke, A. E. Martell, Inorg. Chim. Acta 1991, 190, 37–46. 
[226] E. T. Clarke, A. E. Martell, Inorg. Chim. Acta 1991, 181, 273–280. 
[227] L. Hoigebazar, J. M. Jeong, S. Y. Choi, J. Y. Choi, D. Shetty, Y. S. Lee, D. S. Lee, J. K. Chung, M. 
C. Lee, Y. K. Chung, J. Med. Chem. 2010, 53, 6378–6385. 
[228] D. Shetty, J. M. Jeong, C. H. Ju, Y. J. Kim, J. Y. Lee, Y. S. Lee, D. S. Lee, J. K. Chung, M. C. Lee, 
Bioorg. Med. Chem. 2010, 18, 7338–7347. 
[229] D. Shetty, Y. S. Lee, J. M. Jeong, Nucl. Med. Mol. Imaging. 2010, 44, 233–240. 
[230] J. P. L. Cox, A. S. Craig, I. M. Helps, K. J. Jankowski, D. Parker, M. A. W. Eaton, A. T. Millican, K. 
Millar, N. R. A. Beeley, B. A. Boyce, J. Chem. Soc. 1990, 98, 2567–2576. 
[231] M. Studer, C. F. Meares, Bioconjugate Chem. 1992, 3, 337–341. 
[232] M. W. Brechbiel, T. J. McMurry, O. A. Gansow, Tetrahedron Lett. 1993, 34, 3691–3694. 
[233] J. Cheon, J. H. Lee, Acc. Chem. Res. 2008, 41, 1630–1640. 
[234] D. W. Hwang, H. Y. Ko, S. K. Kim, D. Kim, D. S. Lee, S. Kim, Chem. Eur. J. 2009, 15, 9387–9393. 
[235] B. R. Jarrett, D. L. Kukis, A. Y. Louie, Bioconjugate Chem. 2008, 19, 1496–1504. 
[236] A. Louie, Chem. Rev. 2010, 110, 3146–3195. 
[237] H. P. Schlemmer, B. Pichler, K. Wienhard, M. Schmand, C. Nahmias, D. Townsend, W.-D. Heiss, C. 
Claussen, J. Nucl. Med. 2007, 48, 45. 
[238] U. A. Gunasekera, Q. A. Pankhurst, M. Douek, Target. Oncol. 2009, 4, 169–181. 
[239] O. Veiseh, C. Sun, J. Gunn, N. Kohler, P. Gabikian, D. Lee, N. Bhattarai, R. Ellenbogen, R. Sze, A. 
Hallahan, et al., Nano Lett. 2005, 5, 1003–1008. 
[240] S. M. Kim, M. K. Chae, M. S. Yim, I. H. Jeong, J. Cho, C. Lee, E. K. Ryu, Biomaterials 2013, 34, 
8114–8121. 
[241] R. Madru, T. A. Tran, J. Axelsson, C. Ingvar, A. Bibic, F. Ståhlberg, L. Knutsson, S.-E. Strand, Am. 
J. Nucl. Med. Mol. Imaging 2014, 4, 60–69. 
[242] J. Frigell, I. García, V. Gomez-Vallejo, J. Llop, S. Penadés, J. Am. Chem. Soc. 2014, 136, 449–457. 
[243] W. J. M. Mulder, G. J. Strijkers, G. A. F. Van Tilborg, D. P. Cormode, Z. A. Fayad, K. Nicolay, Acc. 
Chem. Res. 2009, 42, 904–914. 
[244] J. D. Glickson, S. Lund-Katz, R. Zhou, H. Choi, I. W. Chen, H. Li, I. Corbin, A. V. Popov, W. Cao, 
L. Song, et al., Adv. Exp. Med. Biol. 2009, 645, 227–239. 
[245] E. A. Neuwelt, C. G. Várallyay, S. Manninger, D. Solymosi, M. Haluska, M. A. Hunt, G. Nesbit, A. 
Chapter 6 
165 
 
Stevens, M. Jerosch-Herold, P. M. Jacobs, et al., Neurosurgery 2007, 60, 601–611. 
[246] V. Clavijo-Jordan, V. D. Kodibagkar, S. C. Beeman, B. D. Hann, K. M. Bennett, Wiley Interdiscip. 
Rev. Nanomedicine Nanobiotechnology 2012, 4, 345–365. 
[247] E. Locatelli, L. Gil, L. L. Israel, L. Passoni, M. Naddaka, A. Pucci, T. Reese, V. Gomez-Vallejo, P. 
Milani, M. Matteoli, et al., Int. J. Nanomedicine 2012, 7, 6021–6033. 
[248] G. Ting, C. H. Chang, H. E. Wang, Anticancer Res. 2009, 29, 4107–4118. 
[249] M. Hamoudeh, M. A. Kamleh, R. Diab, H. Fessi, Adv. Drug Deliv. Rev. 2008, 60, 1329–1346. 
[250] M. Shokeen, N. M. Fetting, R. Rossin, Q J Nucl Med Mol Imaging 2008, 52, 267–277. 
[251] G. Loudos, G. C. Kagadis, D. Psimadas, Eur. J. Radiol. 2011, 78, 287–295. 
[252] Y. Liu, M. J. Welch, Bioconjugate Chem. 2012, 23, 671–682. 
[253] M. S. Judenhofer, H. F. Wehrl, D. F. Newport, C. Catana, S. B. Siegel, M. Becker, A. Thielscher, M. 
Kneilling, M. P. Lichy, M. Eichner, et al., Nat. Med. 2008, 14, 459–465. 
[254] J. Choi, J. C. Park, H. Nah, S. Woo, J. Oh, K. M. Kim, G. J. Cheon, Y. Chang, J. Yoo, J. Cheon, 
Angew. Chem. - Int. Ed. Eng. 2008, 47, 6259–6262. 
[255] H. S. Chong, X. Sun, Y. Chen, I. Sin, C. S. Kang, M. R. Lewis, D. Liu, V. C. Ruthengael, Y. Zhong, 
N. Wu, et al., Bioorg. Med. Chem. 2015, 23, 1169–1178. 
[256] O. Schober, K. Rahbar, B. Riemann, Eur. J. Nucl. Med. Mol. Imaging 2009, 36, 302–314. 
[257] Y. Cohen, S. Y. Shoushan, Curr. Opin. Biotechnol. 2013, 24, 672–681. 
[258] R. Stoltenburg, C. Reinemann, B. Strehlitz, Biomol. Eng. 2007, 24, 381–403. 
[259] C. Tuerk, L. Gold, Science. 1990, 249, 505–510. 
[260] A. D. Ellington, J. W. Szostak, Nature 1990, 346, 818–822. 
[261] A. Ellington, J. Szostak, Nature 1992, 355, 850–852. 
[262] J. Banerjee, M. Nilsen-Hamilton, J. Mol. Med. 2013, 91, 1333–1342. 
[263] L. Hernandez, I. Machado, T. Schafer, F. Hernandez, Curr. Top. Med. Chem. 2015, 15, 1066–1081. 
[264] A. B. Sullenger, Nucleic Acid Ther. 2016, 26, 119. 
[265] E. J. Cho, J. W. Lee, A. D. Ellington, Annu. Rev. Anal. Chem. 2009, 2, 241–64. 
[266] J. Liu, Z. Cao, Y. Lu, Chem. Rev. 2009, 109, 1948–1998. 
[267] A. D. Keefe, S. Pai, A. Ellington, Nat. Rev. Drug Discov. 2010, 9, 537–550. 
[268] W. Tan, H. Wang, Y. Chen, X. Zhang, H. Zhu, C. Yang, R. Yang, C. Liu, Trends Biotechnol. 2011, 
29, 634–640. 
[269] D. Xiang, S. Shigdar, G. Qiao, T. Wang, A. Z. Kouzani, S. F. Zhou, L. Kong, Y. Li, C. Pu, W. Duan, 
Theranostics 2015, 5, 23–42. 
[270] Y. S. Kim, N. H. Ahmad Raston, B. M. Gu, Biosens. Bioelectron. 2016, 76, 2–19. 
[271] H. Sun, W. Tan, Y. Zu, Analyst 2016, 141, 403–415. 
[272] K. E. Maier, M. Levy, Mol. Ther. Methods Clin. Dev. 2016, 5, 16014–16023. 
[273] R. E. Wang, H. Wu, Y. Niu, J. Cai, Curr. Med. Chem. 2011, 18, 4126–4138. 
[274] M. Kuwahara, in Chem. Biol. Nucleic Acids Fundam. Clin. Appl. (Eds.: V.A. Erdmann, A. Volker, 
W.T. Markiewicz, J. Barciszewski), 2014, pp. 243–270. 
[275] M. M. Vu, N. E. Jameson, S. J. Masuda, D. Lin, R. Larralde-Ridaura, A. Lupták, Chem. Biol. 2012, 
19, 1247–1254. 
[276] Y. Fujimoto, Y. Nakamura, S. Ohuchi, Biochimie 2012, 94, 1900–1909. 
[277] A. D. Keefe, S. T. Cload, Curr. Opin. Chem. Biol. 2008, 12, 448–456. 
[278] L. Gold, D. Ayers, J. Bertino, C. Bock, A. Bock, E. N. Brody, J. Carter, A. B. Dalby, B. E. Eaton, T. 
Fitzwater, et al., PLoS One 2010, 5, e15004. 
[279] V. B. Pinheiro, A. I. Taylor, C. Cozens, M. Abramov, M. Renders, S. Zhang, J. C. Chaput, J. Wengel, 
S. Y. Peak-Chew, S. H. McLaughlin, et al., Science. 2012, 336, 341–344. 
[280] F. Tolle, G. M. Brändle, D. Matzner, G. Mayer, Angew. Chem. - Int. Ed. Eng. 2015, 54, 10971–
10974. 
[281] S. C. B. Gopinath, Anal. Bioanal. Chem. 2007, 387, 171–182. 
[282] T. Schütze, B. Wilhelm, N. Greiner, H. Braun, F. Peter, M. Mörl, V. A. Erdmann, H. Lehrach, Z. 
Konthur, M. Menger, et al., PLoS One 2011, 6, e29604. 
[283] E. W. M. Ng, D. T. Shima, P. Calias, E. T. Cunningham, D. R. Guyer, A. P. Adamis, Nat. Rev. Drug 
Discov. 2006, 5, 123–132. 
[284] A. Vater, S. Klussmann, Drug Discov. Today 2015, 20, 147–155. 
[285] B. Gatto, M. Palumbo, C. Sissi, Curr. Med. Chem. 2009, 16, 1248–1265. 
[286] W. O. Tucker, K. T. Shum, J. A. Tanner, Curr. Pharm. Des. 2012, 18, 2014–2026. 
Chapter 6 
166 
 
[287] S. Neidle, S. Balasubramanian, Quadruplex Nucleic Acids, The Royal Society Of Chemistry, 
Cambridge, 2006. 
[288] L. Spindler, W. Fritzsche, Guanine Quartets: Structure and Application, The Royal Society Of 
Chemistry, Cambridge, 2012. 
[289] V. T. Mukundan, A. T. Phan, J. Am. Chem. Soc. 2013, 135, 5017–5028. 
[290] P. L. Tran, A. De Cian, J. Gros, R. Moriyama, J. L. Mergny, Top. Curr. Chem. 2013, 330, 243–273. 
[291] M. Malgowska, D. Gudanis, R. Kierzek, E. Wyszko, V. Gabelica, Z. Gdaniec, Nucleic Acids Res. 
2014, 42, 10196–10207. 
[292] X. M. Li, K. W. Zheng, J. Y. Zhang, H. H. Liu, Y. De He, B. F. Yuan, Y. H. Hao, Z. Tan, Proc. Natl. 
Acad. Sci. U. S. A. 2015, 112, 14581–14586. 
[293] A. Virgilio, V. Esposito, G. Citarella, L. Mayol, A. Galeone, ChemBioChem 2012, 13, 2219–2224. 
[294] A. T. Phan, V. Kuryavyi, J. B. Ma, A. Faure, M. L. Andréola, D. J. Patel, Proc. Natl. Acad. Sci. U. S. 
A. 2005, 102, 634–639. 
[295] G. W. Collie, G. N. Parkinson, Chem. Soc. Rev. 2011, 40, 5867–5892. 
[296] X. Ji, H. Sun, H. Zhou, J. Xiang, Y. Tang, C. Zhao, Nucleic Acid Ther. 2011, 21, 185–200. 
[297] B. Santosh, P. K. Yadava, Biomed Res. Int. 2014, 2014, 50451–50464. 
[298] J. Qu, S. Yu, Y. Zheng, Y. Zheng, H. Yang, J. Zhang, Cell. Mol. Life Sci. 2016, 74, 683–695. 
[299] D. W. Drolet, L. S. Green, L. Gold, N. Janjic, Nucleic Acid Ther. 2016, 26, 127–146. 
[300] Y. Yu, C. Liang, Q. Lv, D. Li, X. Xu, B. Liu, A. Lu, G. Zhang, Int. J. Mol. Sci. 2016, 17, 358–377. 
[301] R. C. Becker, T. Povsic, C. G. Mauricio, C. P. Rusconi, B. Sullenger, Thromb. Haemost. 2010, 103, 
586–595. 
[302] V. Makwana, S. Simmons, S. Missailidis, in Anticancer Ther., 2008, pp. 331–345. 
[303] H. P. Lassalle, S. Marchal, F. Guillemin, A. Reinhard, L. Bezdetnaya, Curr. Drug Metab. 2012, 13, 
1130–1144. 
[304] D. Musumeci, C. Riccardi, D. Montesarchio, Molecules 2015, 20, 17511–17532. 
[305] E. Zavyalova, N. Ustinov, A. Golovin, G. Pavlova, A. Kopylov, Curr. Med. Chem. 2016, 23, 2230–
2244. 
[306] C. Platella, C. Riccardi, D. Montesarchio, G. N. Roviello, D. Musumeci, Biochim. Biophys. Acta - 
Gen. Subj. 2017, http://dx.doi.org/10.1016/j.bbagen.2016.11.027. 
[307] J. A. Huntington, T. P. Baglin, Trends Pharmacol. Sci. 2003, 24, 589–595. 
[308] J. A. Huntington, J. Thromb. Haemost. 2005, 3, 1861–1872. 
[309] A. S. Wolberg, Blood Rev. 2007, 21, 131–142. 
[310] E. Di Cera, Mol. Aspects Med. 2008, 29, 203–254. 
[311] L. G. Licari, J. P. Kovacic, J. Vet. Emerg. Crit. Care 2009, 19, 11–22. 
[312] J. Hirsh, Thromb. Res. 2003, 109, S1–S8. 
[313] T. E. Warkentin, A. Greinacher, Ann. Thorac. Surg. 2003, 76, 2121–31. 
[314] S. Rangarajan, Haemophilia 2011, 17, 90–94. 
[315] L. C. Bock, L. C. Griffin, J. A. Latham, E. H. Vermaas, J. J. Toole, Nature 1992, 355, 564–566. 
[316] K. Padmanabhan, K. P. Padmanabhan, J. D. Ferrara, J. E. Sadler, A. Tulinsky, J. Biol. Chem. 1993, 
268, 17651–17654. 
[317] S. M. Nimjee, C. P. Rusconi, R. A. Harrington, B. A. Sullenger, Trends Cardiovasc. Med. 2005, 15, 
41–45. 
[318] I. Russo Krauss, A. Merlino, A. Randazzo, E. Novellino, L. Mazzarella, F. Sica, Nucleic Acids Res. 
2012, 40, 8119–8128. 
[319] R. F. Macaya, P. Schultze, F. W. Smith, J. A. Roet, J. Feigon, Proc. Natl. Acad. Sci. U. S. A. 1993, 
90, 3745–3749. 
[320] I. Smirnov, R. H. Shafer, Biochemistry 2000, 39, 1462–1468. 
[321] T. Coppola, M. Varra, G. Oliviero, A. Galeone, G. D. Isa, L. Mayol, E. Morelli, M. Bucci, V. 
Vellecco, G. Cirino, et al., Bioorg. Med. Chem. 2008, 16, 8244–8253. 
[322] M. C. R. Buff, F. Schäfer, B. Wulffen, J. Müller, B. Pötzsch, A. Heckel, G. Mayer, Nucleic Acids 
Res. 2010, 38, 2111–2118. 
[323] T. Agarwal, S. Kumar, S. Maiti, Biochimie 2011, 93, 1694–1700. 
[324] H. Dougan, D. M. Lyster, C. V. Vo, A. Stafford, J. I. Weitz, J. B. Hobbs, Nucl. Med. Biol. 2000, 27, 
289–297. 
[325] M. V. Yigit, D. Mazumdar, Y. Lu, Bioconjugate Chem. 2008, 19, 412–417. 
[326] Y. C. Shiang, C. C. Huang, T. H. Wang, C. W. Chien, H. T. Chang, Adv. Funct. Mater. 2010, 20, 
Chapter 6 
167 
 
3175–3182. 
[327] Y. C. Shiang, C. L. Hsu, C. C. Huang, H. T. Chang, Angew. Chem. - Int. Ed. Eng. 2011, 50, 7660–
7665. 
[328] C. L. Hsu, H. T. Chang, C. T. Chen, S. C. Wei, Y. C. Shiang, C. C. Huang, Chem. Eur. J. 2011, 17, 
10994–11000. 
[329] L. Gao, Y. Cui, Q. He, Y. Yang, J. Fei, J. Li, Chem. Eur. J. 2011, 17, 13170–13174. 
[330] D. Musumeci, G. Oliviero, G. N. Roviello, E. M. Bucci, G. Piccialli, Bioconjugate Chem. 2012, 23, 
382–391. 
[331] C. L. Hsu, S. C. Wei, J. W. Jian, H. T. Chang, W. H. Chen, C. C. Huang, RSC Adv. 2012, 2, 1577–
1584. 
[332] E. Babu, P. M. Mareeswaran, S. Rajagopal, J. Fluoresc. 2013, 23, 137–146. 
[333] Q. Yue, T. Shen, L. Wang, S. Xu, H. Li, Q. Xue, Y. Zhang, X. Gu, S. Zhang, J. Liu, Biosens. 
Bioelectron. 2014, 56, 231–236. 
[334] J. M. Yu, L. R. Yang, X. F. Liang, T. T. Dong, H. Z. Liu, Analyst 2015, 140, 4114–4120. 
[335] L. Martino, A. Virno, A. Randazzo, A. Virgilio, V. Esposito, C. Giancola, M. Bucci, G. Cirino, L. 
Mayol, Nucleic Acids Res. 2006, 34, 6653–6662. 
[336] A. Virno, A. Randazzo, C. Giancola, M. Bucci, G. Cirino, L. Mayol, Bioorg. Med. Chem. 2007, 15, 
5710–5718. 
[337] I. Russo Krauss, A. Merlino, C. Giancola, A. Randazzo, L. Mazzarella, F. Sica, Nucleic Acids Res. 
2011, 39, 7858–7867. 
[338] A. Aviñó, C. Fàbrega, M. Tintoré, R. Eritja, Curr. Pharm. Des. 2012, 18, 2036–47. 
[339] N. Borbone, M. Bucci, G. Oliviero, E. Morelli, J. Amato, V. D’Atri, S. D. D’Errico, V. Vellecco, G. 
Cirino, G. Piccialli, et al., J. Med. Chem. 2012, 55, 10716–10728. 
[340] D. Musumeci, D. Montesarchio, Pharmacol. Ther. 2012, 136, 202–215. 
[341] S. Nagatoishi, T. Nojima, B. Juskowiak, S. Takenaka, Angew. Chem. - Int. Ed. Eng. 2005, 44, 5067–
5070. 
[342] T. M. Lerga, C. K. O’Sullivan, Anal. Chim. Acta 2008, 610, 105–111. 
[343] S. Takenaka, B. Juskowiak, Anal. Sci. 2011, 27, 1167–1172. 
[344] S. De Tito, F. Morvan, A. Meyer, J. J. Vasseur, A. Cummaro, L. Petraccone, B. Pagano, E. Novellino, 
A. Randazzo, C. Giancola, et al., Bioconjugate Chem. 2013, 24, 1917–1927. 
[345] J. Johnson, R. Okyere, A. Joseph, K. Musier-Forsyth, B. Kankia, Nucleic Acids Res. 2013, 41, 220–
228. 
[346] J. Szejtli, Chem. Rev. 1998, 98, 1743–1753. 
[347] T. Ikunaga, H. Ikeda, A. Ueno, Chem. Eur. J. 1999, 5, 2698–2704. 
[348] S. Matsumura, S. Sakamoto, A. Ueno, H. Mihara, Chem. Eur. J. 2000, 6, 1781–1788. 
[349] S. Pagliari, R. Corradini, G. Galaverna, S. Sforza, A. Dossena, M. Montalti, L. Prodi, N. Zaccheroni, 
R. Marchelli, Chem. Eur. J. 2004, 10, 2749–2758. 
[350] M. Montalti, L. Prodi, N. Zaccheroni, G. Battistini, S. Marcuz, F. Mancin, E. Rampazzo, U. 
Tonellato, Langmuir 2006, 22, 5877–5881. 
[351] T. Loftsson, D. Duchêne, Int. J. Pharm. 2007, 329, 1–11. 
[352] V. J. Stella, Q. He, Toxicol. Pathol. 2008, 36, 30–42. 
[353] W. M. Leevy, G. M. Donato, R. Ferdani, W. E. Goldman, P. H. Schlesinger, G. W. Gokel, J. Am. 
Chem. Soc. 2002, 124, 9022–9023. 
[354] L. You, G. W. Gokel, Chem. Eur. J. 2008, 14, 5861–5870. 
[355] C. Coppola, A. Paciello, G. Mangiapia, S. Licen, M. Boccalon, L. De Napoli, L. Paduano, P. Tecilla, 
D. Montesarchio, Chem. Eur. J. 2010, 16, 13757–13772. 
[356] P. C. Weber, D. H. Ohlendorf, J. J. Wendoloski, F. R. Salemme, Science. 1989, 243, 85–88. 
[357] W. A. Hendrickson, A. Pähler, J. L. Smith, Y. Satow, E. A. Merritt, R. P. Phizackerley, Proc. Natl. 
Acad. Sci. U. S. A. 1989, 86, 2190–2194. 
[358] E. P. Diamandis, T. K. Christopoulos, Clin. Chem. 1991, 37, 625–636. 
[359] A. Holmberg, A. Blomstergren, O. Nord, M. Lukacs, J. Lundeberg, M. Uhlén, Electrophoresis 2005, 
26, 501–510. 
[360] S. V. Vinogradov, T. K. Bronich, A. V. Kabanov, Adv. Drug Deliv. Rev. 2002, 54, 135–147. 
[361] H. S. Choi, W. Liu, P. Misra, E. Tanaka, J. P. Zimmer, B. Itty Ipe, M. G. Bawendi, J. V Frangioni, 
Nat. Biotechnol. 2007, 25, 1165–1170. 
[362] L. Illum, S. S. Davis, C. G. Wilson, N. W. Thomas, M. Frier, J. G. Hardy, Int. J. Pharm. 1982, 12, 
Chapter 6 
168 
 
135–146. 
[363] C. J. H. Porter, S. M. Moghimi, L. Illum, S. S. Davis, FEBS Lett. 1992, 305, 62–66. 
[364] S. Mitragotri, J. Lahann, Nat. Mater. 2009, 8, 15–23. 
[365] S. Barua, K. Rege, Small 2009, 5, 370–376. 
[366] S. M. Moghimi, A. C. Hunter, J. C. Murray, Pharmacol. Rev. 2001, 53, 283–318. 
[367] E. V. Piletska, S. A. Piletsky, Langmuir 2010, 26, 3783–3785. 
[368] B. Silvestri, D. Guarnieri, G. Luciani, A. Costantini, P. A. Netti, F. Branda, J. Mater. Sci. Mater. 
Med. 2012, 23, 1697–1704. 
[369] J. L. Vivero-Escoto, R. C. Huxford-Phillips, W. Lin, Chem. Soc. Rev. 2012, 41, 2673–2685. 
[370] K. Wang, X. He, X. Yang, H. Shi, Acc. Chem. Res. 2013, 46, 1367–1376. 
[371] C. Caltagirone, A. Bettoschi, A. Garau, R. Montis, Chem. Soc. Rev. 2014, 44, 4645–4671. 
[372] J.-E. Kim, H. Kim, S. S. An, M. Kim, Y.-J. Song, Int. J. Nanomedicine 2014, 9, 235–241. 
[373] M. Montalti, L. Prodi, E. Rampazzo, N. Zaccheroni, Chem. Soc. Rev. 2014, 43, 4243–4268. 
[374] S. Cheng, B. Zheng, M. Wang, X. Ge, Q. Zhao, W. Liu, M. H. W. Lam, Biosens. Bioelectron. 2014, 
53, 479–485. 
[375] W. Q. Lim, S. Z. F. Phua, H. V. Xu, S. Sreejith, Y. Zhao, Nanoscale 2015, 8, 12510–12519. 
[376] W. G. Lewis, F. G. Magallon, V. V. Fokin, M. G. Finn, J. Am. Chem. Soc. 2004, 126, 9152–9153. 
[377] V. V. Rostovtsev, L. G. Green, V. V. Fokin, K. B. Sharpless, Angew. Chem. - Int. Ed. Eng. 2002, 41, 
2596–2599. 
[378] C. W. Tornøe, C. Christensen, M. Meldal, J. Org. Chem. 2002, 67, 3057–3064. 
[379] J. Lietard, A. Meyer, J. J. Vasseur, F. Morvan, J. Org. Chem. 2008, 73, 191–200. 
[380] C. Bouillon, A. Meyer, S. Vidal, A. Jochum, Y. Chevolot, J. Cloarec, J. Praly, J. Vasseur, F. Morvan, 
J. Org. Chem. 2006, 71, 4700–4702. 
[381] W. Tang, S.-C. Ng, Nat. Protoc. 2008, 3, 691–697. 
[382] R. Giraldo, M. Suzuki, L. Chapman, D. Rhodes, Proc. Natl. Acad. Sci. U. S. A. 1994, 91, 7658–7662. 
[383] S. Paramasivan, I. Rujan, P. H. Bolton, Methods 2007, 43, 324–331. 
[384] S. Masiero, R. Trotta, S. Pieraccini, S. De Tito, R. Perone, A. Randazzo, G. P. Spada, Org. Biomol. 
Chem. 2010, 8, 2683–2692. 
[385] A. I. Karsisiotis, N. M. Hessari, E. Novellino, G. P. Spada, A. Randazzo, M. Webba da Silva, Angew. 
Chem. - Int. Ed. Eng. 2011, 50, 10645–10648. 
[386] M. Malgowska, D. Gudanis, A. Teubert, G. Dominiak, Z. Gdaniec, J. Biotechnol. Comput. Biol. 
Bionanotechnol. 2012, 93, 381–390. 
[387] A. Randazzo, G. P. Spada, M. Webba da Silva, Top. Curr. Chem. 2013, 330, 67–86. 
[388] C. C. Hardin, T. Watson, M. Corregan, C. Bailey, Biochemistry 1992, 31, 833–841. 
[389] N. V Hud, F. W. Smith, F. A. L. Anet, J. Feigon, Biochemistry 1996, 35, 15383–15390. 
[390] S. Poniková, M. Antalík, T. Hianik, Gen. Physiol. Biophys. 2008, 27, 271–277. 
[391] M. Vorlíčková, I. Kejnovská, J. Sagi, D. Renčiuk, K. Bednářová, J. Motlová, J. Kypr, Methods 2012, 
57, 64–75. 
[392] J. Mergny, A. Phan, L. Lacroix, FEBS Lett. 1998, 435, 74–78. 
[393] J. Mergny, L. Lacroix, Curr. Protoc. Nucleic Acid Chem. 2009, 37, 17.1.1–17.1.15. 
[394] M. Holzinger, M. Singh, S. Cosnier, Langmuir 2012, 28, 12569–12574. 
[395] J. Tang, Y. Lu, Y. Wang, J. Zhou, W. Tang, Talanta 2014, 128, 460–465. 
[396] C. P. Rusconi, E. Scardino, J. Layzer, G. a Pitoc, T. L. Ortel, D. Monroe, B. a Sullenger, Nature 
2002, 419, 90–94. 
[397] S. M. Nimjee, J. R. Keys, A. G. Pitoc, G. Quick, C. P. Rusconi, A. S. Bruce, Mol. Ther. 2006, 14, 
408–415. 
[398] P. J. Bates, E. M. Reyes-Reyes, M. T. Malik, E. M. Murphy, M. G. O’Toole, J. O. Trent, Biochim. 
Biophys. Acta - Gen. Subj. 2016, http://dx.doi.org/10.1016/j.bbagen.2016.12.015. 
[399] P. J. Bates, J. B. Kahlon, S. D. Thomas, J. O. Trent, D. M. Miller, J. Biol. Chem. 1999, 274, 26369–
26377. 
[400] V. Dapić, P. J. Bates, J. O. Trent, A. Rodger, S. D. Thomas, D. M. Miller, Biochemistry 2002, 41, 
3676–3685. 
[401] V. Dapić, V. Abdomerović, R. Marrington, J. Peberdy, A. Rodger, J. O. Trent, P. J. Bates, Nucleic 
Acids Res. 2003, 31, 2097–2107. 
[402] P. J. Bates, D. A. Laber, D. M. Miller, S. D. Thomas, J. O. Trent, Exp. Mol. Pathol. 2009, 86, 151–
164. 
Chapter 6 
169 
 
[403] E. W. Choi, L. V. Nayak, P. J. Bates, Nucleic Acids Res. 2009, 38, 1623–1635. 
[404] M. M. Dailey, M. Clarke Miller, P. J. Bates, A. N. Lane, J. O. Trent, Nucleic Acids Res. 2010, 38, 
4877–4888. 
[405] M. C. Miller, J. O. Trent, Curr. Protoc. nucleic acid Chem. 2011, Chapter 17, Unit 17.3. 
[406] M. C. Miller, H. T. Le, W. L. Dean, P. A. Holt, J. B. Chaires, J. O. Trent, Org. Biomol. Chem. 2011, 
9, 7633–7637. 
[407] H. T. Le, M. C. Miller, R. Buscaglia, W. L. Dean, P. A. Holt, J. B. Chaires, J. O. Trent, Org. Biomol. 
Chem. 2012, 10, 9393–9404. 
[408] M. C. Miller, C. J. Ohrenberg, A. Kuttan, J. O. Trent, Curr. Protoc. Nucleic Acid Chem. 2015, 61, 
17.7.1–17.7.18. 
[409] W. J. Chung, B. Heddi, E. Schmitt, K. W. Lim, Y. Mechulam, A. T. Phan, Proc. Natl. Acad. Sci. 
2015, 112, 2729–2733. 
[410] J. Ai, Y. Xu, B. Lou, D. Li, E. Wang, Talanta 2014, 118, 54–60. 
[411] A. B. Chinen, C. M. Guan, C. A. Mirkin, Angew. Chem. - Int. Ed. Eng. 2015, 54, 527–531. 
[412] D. H. M. Dam, J. H. Lee, P. N. Sisco, D. T. Co, M. Zhang, M. R. Wasielewski, T. W. Odom, ACS 
Nano 2012, 6, 3318–3326. 
[413] D. Chen, B. Li, S. Cai, P. Wang, S. Peng, Y. Sheng, Y. He, Y. Gu, H. Chen, Biomaterials 2016, 100, 
1–16. 
[414] J. H. Choi, K. H. Chen, J. H. Han, A. M. Chaffee, M. S. Strano, Small 2009, 5, 672–675. 
[415] D. H. M. Dam, H. Lee, R. C. Lee, K. H. Kim, N. L. Kelleher, T. W. Odom, Bioconjugate Chem. 
2015, 26, 279–285. 
[416] C. R. Ireson, L. R. Kelland, Mol. Cancer Ther. 2006, 5, 2957–62. 
[417] F. Mongelard, P. Bouvet, Curr. Opin. Mol. Ther. 2010, 12, 107–114. 
[418] G. Acton, Sympathy for the Devil, Troubador Publishing Ltd., 2013. 
[419] D. Laber, M. Choudry, B. Taft, L. Bhupalam, V. Sharma, F. Hendler, K. Barnhart, ASCO Annu. Meet. 
Proc. 2004, 3112. 
[420] D. Laber, V. Sharma, L. Bhupalam, B. Taft, F. Hendler, K. Barnhart, ASCO Annu. Meet. Proc. 2005, 
3064. 
[421] Antisoma, Annu. Rep. Accounts 2011. 
[422] D. M. Miller, D. A. Laber, P. J. Bates, J. O. Trent, B. S. Taft, G. Kloecker, in Ann. Oncol., Oxford 
Univ Press, Great Clarendon St, Oxford OX2 6DP, England, 2006, pp. 147–148. 
[423] D. Laber, B. Taft, G. Kloecker, G. Acton, D. Miller, Mol. Cancer Ther. 2007, 6, C147. 
[424] D. Rizzieri, K. Stockerl-Goldstein, A. Wei, R. H. Herzig, F. Erlandsson, R. K. Stuart, ASCO Annu. 
Meet. Abstr. 2010, 28, 6557. 
[425] J. E. Rosenberg, R. M. Bambury, E. M. Van Allen, H. A. Drabkin, P. N. Lara, A. L. Harzstark, N. 
Wagle, R. A. Figlin, G. W. Smith, L. A. Garraway, et al., Invest. New Drugs 2014, 32, 178–187. 
[426] D. H. M. Dam, K. S. B. Culver, P. N. Sisco, T. W. Odom, Ther. Deliv. 2012, 3, 1263–1267. 
[427] D. H. M. Dam, R. C. Lee, T. W. Odom, Nano Lett. 2014, 14, 2843–2848. 
[428] D. H. M. Dam, K. S. B. Culver, T. W. Odom, Mol. Pharm. 2014, 11, 580–587. 
[429] D. H. M. Dam, K. S. B. Culver, I. Kandela, R. C. Lee, K. Chandra, H. Lee, C. Mantis, A. Ugolkov, 
A. P. Mazar, T. W. Odom, Nanomedicine Nanotechnology, Biol. Med. 2015, 11, 671–679. 
[430] M. T. Malik, M. G. O’Toole, L. K. Casson, S. D. Thomas, G. T. Bardi, E. M. Reyes-Reyes, C. K. Ng, 
K. A. Kang, P. J. Bates, Oncotarget 2015, 6, 22270–22281. 
[431] K. Y. Lee, H. Kang, S. H. Ryu, D. S. Lee, J. H. Lee, S. Kim, J. Biomed. Biotechnol. 2010, 2010, 
168306. 
[432] Y. Takafuji, J. I. Jo, Y. Tabata, J. Biomater. Sci. Polym. Ed. 2011, 22, 1179–1195. 
[433] Y. Cho, Y. Bin Lee, J. H. Lee, D. H. Lee, E. J. Cho, S. J. Yu, Y. J. Kim, J. I. Kim, J. H. Im, J. H. Lee, 
et al., PLoS One 2016, 11, 1–14. 
[434] X. Fan, L. Sun, Y. Wu, L. Zhang, Z. Yang, Sci. Rep. 2016, 6, 25799. 
[435] O. Gissberg, E. M. Zaghloul, K. E. Lundin, C. H. Nguyen, C. Landras-Guetta, J. Wengel, R. Zain, C. 
I. E. Smith, Nucleic Acid Ther. 2016, 26, 183–189. 
[436] J. Schuemann, R. Berbeco, D. B. Chithrani, S. H. Cho, R. Kumar, S. J. McMahon, S. Sridhar, S. 
Krishnan, Int. J. Radiat. Oncol. Biol. Phys. 2016, 94, 189–205. 
[437] M. H. Ko, S. Kim, W. J. Kang, J. H. Lee, H. Kang, S. H. Moon, D. W. Hwang, H. Y. Ko, D. S. Lee, 
Small 2009, 5, 1207–1212. 
[438] Z. Cao, R. Tong, A. Mishra, W. Xu, G. C. L. Wong, J. Cheng, Y. Lu, Angew. Chem. - Int. Ed. Eng. 
Chapter 6 
170 
 
2009, 48, 6494–6498. 
[439] Y. A. Shieh, S. J. Yang, M. F. Wei, M. J. Shieh, ACS Nano 2010, 4, 1433–1442. 
[440] J. Guo, X. Gao, L. Su, H. Xia, G. Gu, Z. Pang, X. Jiang, L. Yao, J. Chen, H. Chen, Biomaterials 
2011, 32, 8010–8020. 
[441] J. Zhang, R. Chen, F. Chen, M. Chen, Y. Wang, J. Control. Release 2015, 213, e8–e152. 
[442] H. Gao, J. Qian, S. Cao, Z. Yang, Z. Pang, S. Pan, L. Fan, Z. Xi, X. Jiang, Q. Zhang, Biomaterials 
2012, 33, 5115–5123. 
[443] W. Tao, X. Zeng, J. Wu, X. Zhu, X. Yu, X. Zhang, J. Zhang, G. Liu, L. Mei, Theranostics 2016, 6, 
470–484. 
[444] G. Xu, X. Yu, J. Zhang, Y. Sheng, G. Liu, W. Tao, L. Mei, Int. J. Nanomedicine 2016, 11, 2953–
2965. 
[445] H. Xing, L. Tang, X. Yang, K. Hwang, W. Wang, Q. Yin, N. Y. Wong, L. W. Dobrucki, N. Yasui, J. 
A. Katzenellenbogen, et al., J. Mater. Chem. B. Mater. Biol. Med. 2013, 1, 5288–5297. 
[446] H. Zhang, L. Hou, X. Jiao, J. Yandan, X. Zhu, L. Hongji, X. Chen, J. Ren, Y. Xia, Z. Zhang, Curr 
Pharm Biotechnol 2014, 14, 1105–1117. 
[447] B. Zhang, Z. Luo, J. Liu, X. Ding, J. Li, K. Cai, J. Control. Release 2014, 192, 192–201. 
[448] X. Li, Y. Yu, Q. Ji, L. Qiu, Nanomedicine Nanotechnology, Biol. Med. 2015, 11, 175–184. 
[449] L. H. Peng, Y. H. Zhang, L. J. Han, C. Z. Zhang, J. H. Wu, X. R. Wang, J. Q. Gao, Z. W. Mao, ACS 
Appl. Mater. Interfaces 2015, 7, 18628–18637. 
[450] T. Le Trinh, G. Zhu, X. Xiao, W. Puszyk, K. Sefah, Q. Wu, W. Tan, C. Liu, PLoS One 2015, 10, 1–
17. 
[451] Z. X. Liao, E. Y. Chuang, C. C. Lin, Y. C. Ho, K. J. Lin, P. Y. Cheng, K. J. Chen, H. J. Wei, H. W. 
Sung, J. Control. Release 2015, 208, 42–51. 
[452] X. Li, X. Zhu, L. Qiu, Acta Biomater. 2016, 35, 269–279. 
[453] S. M. Taghdisi, N. M. Danesh, M. Ramezani, P. Lavaee, S. H. Jalalian, R. Y. Robati, K. Abnous, Eur. 
J. Pharm. Biopharm. 2016, 102, 152–158. 
[454] W. Y. Lai, W. Y. Wang, Y. C. Chang, C. J. Chang, P. C. Yang, K. Peck, Biomaterials 2014, 35, 
2905–2914. 
[455] L. Li, J. Hou, X. Liu, Y. Guo, Y. Wu, L. Zhang, Z. Yang, Biomaterials 2014, 35, 3840–3850. 
[456] K. Roy, R. K. Kanwar, J. R. Kanwar, Biomaterials 2015, 71, 84–99. 
[457] D. W. Hwang, H. Y. Ko, J. H. Lee, H. Kang, S. H. Ryu, I. C. Song, D. S. Lee, S. Kim, J. Nucl. Med. 
2010, 51, 98–105. 
[458] J. K. Kim, K. J. Choi, M. Lee, M. H. Jo, S. Kim, Biomaterials 2012, 33, 207–217. 
[459] L. Tang, X. Yang, L. W. Dobrucki, I. Chaudhury, Q. Yin, C. Yao, S. Lezmi, W. G. Helferich, T. M. 
Fan, J. Cheng, Angew. Chem. - Int. Ed. Eng. 2012, 51, 12721–12726. 
[460] H. Hu, A. Dai, J. Sun, X. Li, F. Gao, L. Wu, Y. Fang, H. Yang, L. An, H. Wu, et al., Nanoscale 2013, 
5, 10447–10454. 
[461] T. Kuo, W. Lai, C. Li, Y. Wun, H. Chang, J. Chen, P. Yang, C. Chen, Nano Res. 2014, 7, 658–669. 
[462] J. Li, H. Zheng, P. J. Bates, T. Malik, X. F. Li, J. O. Trent, C. K. Ng, Nucl. Med. Biol. 2014, 41, 179–
185. 
[463] H. Ma, Z. Gao, P. Yu, S. Shen, Y. Liu, B. Xu, Biochem. Biophys. Res. Commun. 2014, 449, 44–48. 
[464] C. H. Li, T. R. Kuo, H. J. Su, W. Y. Lai, P. C. Yang, J. S. Chen, D. Y. Wang, Y. C. Wu, C. C. Chen, 
Sci. Rep. 2015, 5, 15675. 
[465] Z. Noaparast, S. J. Hosseinimehr, M. Piramoon, S. M. Abedi, J. Drug Target. 2015, 23, 497–505. 
[466] X. Zhao, L. Xu, M. Sun, W. Ma, X. Wu, H. Kuang, L. Wang, C. Xu, Small 2016, 12, 4662–4668. 
[467] K. Abdelmohsen, M. Gorospe, RNA Biol. 2012, 9, 799–808. 
[468] M. Koutsioumpa, E. Papadimitriou, Recent Pat. Anticancer. Drug Discov. 2014, 9, 137–152. 
[469] H. Fujiki, T. Watanabe, M. Suganuma, J. Cancer Res. Clin. Oncol. 2014, 140, 689–699. 
[470] A. G. Hovanessian, C. Soundaramourty, D. El Khoury, I. Nondier, J. Svab, B. Krust, PLoS One 2010, 
5, e15787. 
[471] T. Konishi, Y. Karasaki, M. Nomoto, H. Ohmori, K. Shibata, T. Abe, K. Shimizu, H. Itoh, K. 
Higashi, J. Biochem. 1995, 117, 1170–1177. 
[472] Y. Wang, J. Guan, H. Wang, Y. Wang, D. Leeper, G. Iliakis, J. Biol. Chem. 2001, 276, 20579–20588. 
[473] C. Yang, D. A. Maiguel, F. Carrier, Nucleic Acids Res. 2002, 30, 2251–2260. 
[474] K. Kim, D. D. Dimitrova, K. M. Carta, M. Daras, J. A. Borowiec, A. Saxena, 2005, 25, 2463–2474. 
[475] A. G. Hovanessian, F. Puvion-Dutilleul, S. Nisole, J. Svab, E. Perret, J. S. Deng, B. Krust, Exp. Cell 
Chapter 6 
171 
 
Res. 2000, 261, 312–328. 
[476] C. A. Balinsky, H. Schmeisser, S. Ganesan, K. Singh, T. C. Pierson, K. C. Zoon, J. Virol. 2013, 87, 
13094–13106. 
[477] M. Métifiot, S. Amrane, J. L. Mergny, M. L. Andreola, Biochimie 2015, 118, 173–175. 
[478] R. Perrone, E. Butovskaya, S. Lago, A. Garzino-Demo, C. Pannecouque, G. Palù, S. N. Richter, Int. 
J. Antimicrob. Agents 2016, 47, 311–316. 
[479] X. Xu, F. Hamhouyia, S. D. Thomas, T. J. Burke, A. C. Girvan, W. G. McGregor, J. O. Trent, D. M. 
Miller, P. J. Bates, J. Biol. Chem. 2001, 276, 43221–43230. 
[480] A. C. Girvan, Y. Teng, L. K. Casson, S. D. Thomas, S. Juliger, M. W. Ball, J. B. Klein, W. M. Pierce, 
S. S. Barve, P. J. Bates, Mol. Cancer Ther. 2006, 5, 1790–1799. 
[481] B. Scaggiante, B. Dapas, G. Grassi, G. Manzini, FEBS J. 2006, 273, 1350–1361. 
[482] Y. Teng, A. C. Girvan, L. K. Casson, W. M. Pierce, M. Qian, S. D. Thomas, P. J. Bates, Cancer Res. 
2007, 67, 10491–10500. 
[483] S. Soundararajan, W. Chen, E. K. Spicer, N. Courtenay-Luck, D. J. Fernandes, Cancer Res. 2008, 68, 
2358–2365. 
[484] K. Farin, S. Schokoroy, R. Haklai, I. Cohen-Or, G. Elad-Sfadia, M. E. Reyes-Reyes, P. J. Bates, A. 
D. Cox, Y. Kloog, R. Pinkas-Kramarski, Cancer Res. 2011, 71, 2140–2151. 
[485] F. Pichiorri, D. Palmieri, L. De Luca, J. Consiglio, J. You, A. Rocci, T. Talabere, C. Piovan, A. 
Lagana, L. Cascione, et al., J. Exp. Med. 2013, 210, 951–968. 
[486] Y. Goldshmit, S. S. Trangle, Y. Kloog, R. Pinkas-Kramarski, Oncotarget 2014, 5, 8602–8613. 
[487] N. Shen, F. Yan, J. Pang, L. C. Wu, A. Al-Kali, M. R. Litzow, S. Liu, Oncotarget 2014, 5, 5494–
5509. 
[488] N. Zhang, T. Bing, X. Liu, C. Qi, L. Shen, L. Wang, D. Shangguan, Chem. Sci. 2015, 6, 3831–3838. 
[489] E. Wolfson, M. Goldenberg, S. Solomon, A. Frishberg, R. Pinkas-Kramarski, Oncotarget 2016, 7, 
65320–65334. 
[490] E. M. Reyes-Reyes, Y. Teng, P. J. Bates, Cancer Res. 2010, 70, 8617–8629. 
[491] E. M. Reyes-Reyes, F. R. Šalipur, M. Shams, M. K. Forsthoefel, P. J. Bates, Mol. Oncol. 2015, 9, 
1392–1405. 
[492] G. J. Doherty, H. T. McMahon, Annu. Rev. Biochem. 2009, 78, 857–902. 
[493] A. Wittrup, S. Sandgren, J. Lilja, C. Bratt, N. Gustavsson, M. Mörgelin, M. Belting, J. Biol. Chem. 
2007, 282, 27897–27904. 
[494] S. Fumoto, J. Nishi, H. Ishii, X. Wang, H. Miyamoto, N. Yoshikawa, M. Nakashima, J. Nakamura, K. 
Nishida, Mol. Pharm. 2009, 6, 1170–1179. 
[495] D. Yu, Y. Zhang, Z. Mao, C. Gao, Macromol. Biosci. 2013, 13, 1413–1421. 
[496] C. Liang, B. Guo, H. Wu, N. Shao, D. Li, J. Liu, L. Dang, C. Wang, H. Li, S. Li, et al., Nat. Med. 
2015, 21, 288–294. 
[497] M. J. Piña, A. Girotti, M. Santos, J. C. Rodríguez-Cabello, F. J. Arias, Mol. Pharm. 2016, 13, 795–
808. 
[498] K. D. Ha, S. M. Bidlingmaier, B. Liu, Front. Physiol. 2016, 7, 381. 
[499] H. Gao, Z. Yang, S. Zhang, Z. Pang, X. Jiang, J. Drug Target. 2014, 22, 450–459. 
[500] E. Kočišová, P. Praus, J. Bok, S. Bonneau, F. Sureau, J. Fluoresc. 2015, 25, 1245–1250. 
[501] J. W. Kotula, E. D. Pratico, X. Ming, O. Nakagawa, R. L. Juliano, B. a. Sullenger, Nucleic Acid Ther. 
2012, 22, 187–195. 
[502] A. Saci, L. C. Cantley, C. L. Carpenter, Mol. Cell 2011, 42, 50–61. 
[503] P. P. Hsu, S. A. Kang, J. Rameseder, Y. Zhang, K. A. Ottina, D. Lim, T. R. Peterson, Y. Choi, N. S. 
Gray, M. B. Yaffe, et al., Science 2011, 332, 1317–1322. 
[504] Y. Yu, S. O. Yoon, G. Poulogiannis, Q. Yang, X. M. Ma, J. Villén, N. Kubica, G. R. Hoffman, L. C. 
Cantley, S. P. Gygi, et al., Science 2011, 332, 1322–1326. 
[505] H. B. Pang, G. B. Braun, T. Friman, P. Aza-Blanc, M. E. Ruidiaz, K. N. Sugahara, T. Teesalu, E. 
Ruoslahti, Nat. Commun. 2014, 5, 4904. 
[506] S. Yoshida, R. Pacitto, Y. Yao, K. Inoki, J. A. Swanson, J. Cell Biol. 2015, 211, 159–172. 
[507] S. Sung, J. Choi, H. Cheong, Oncotarget 2015, 6, 40405–40417. 
[508] W. Palm, Y. Park, K. Wright, N. N. Pavlova, D. A. Tuveson, C. B. Thompson, Cell 2015, 162, 259–
270. 
[509] Y. Kim, C. H. Jung, M. Seo, E. K. Kim, J. M. Park, S. S. Bae, D. H. Kim, Mol Cell. 2015, 57, 207–
218. 
Chapter 6 
172 
 
[510] J. Lin, S. S. Shi, J. Q. Zhang, Y. J. Zhang, L. Zhang, Y. Liu, P. P. Jin, P. F. Wei, R. H. Shi, W. Zhou, 
et al., Small 2016, 12, 5759–5768. 
[511] Z. Bagheri, B. Ranjbar, H. Latifi, M. I. Zibaii, T. T. Moghadam, A. Azizi, Int. J. Biol. Macromol. 
2015, 72, 806–811. 
[512] P. Balagurumoorthy, S. K. Brahmachari, D. Mohanty, M. Bansal, V. Sasisekharan, Nucleic Acids 
Res. 1992, 20, 4061–4067. 
[513] A. Ambrus, D. Chen, J. Dai, T. Bialis, R. A. Jones, D. Yang, Nucleic Acids Res. 2006, 34, 2723–
2735. 
[514] L. Petraccone, C. Spink, J. O. Trent, N. C. Garbett, C. S. Mekmaysy, C. Giancola, J. B. Chaires, J. 
Am. Chem. Soc. 2011, 133, 20951–20961. 
[515] A. N. U. Puri, R. Blumenthal, Acc. Chem. Res. 2011, 44, 1071–1079. 
[516] N. Grimaldi, F. Andrade, N. Segovia, L. Ferrer-Tasies, S. Sala, J. Veciana, N. Ventosa, Chem. Soc. 
Rev. 2016, 45, 6520–6545. 
[517] O. Paecharoenchai, L. Teng, B. C. Yung, L. Teng, P. Opanasopit, R. J. Lee, Nanomedicine 2013, 8, 
1865–1873. 
[518] R. M. Handjani-Vila, A. Ribier, B. Rondot, G. Vanlerberghie, Int. J. Cosmet. Sci. 1979, 1, 303–314. 
[519] G. P. Kumar, P. Rajeshwarrao, Acta Pharm. Sin. B 2011, 1, 208–219. 
[520] C. Marianecci, L. Di Marzio, F. Rinaldi, C. Celia, D. Paolino, F. Alhaique, S. Esposito, M. Carafa, 
Adv. Colloid Interface Sci. 2014, 205, 187–206. 
[521] R. Rajera, K. Nagpal, S. K. Singh, D. N. Mishra, Biol. Pharm. Bull. 2011, 34, 945–953. 
[522] S. Moghassemi, A. Hadjizadeh, J. Control. Release 2014, 185, 22–36. 
[523] V. B. Junyaprasert, V. Teeranachaideekul, T. Supaperm, AAPS PharmSciTech 2008, 9, 851–859. 
[524] S. Moghassemi, E. Parnian, A. Hakamivala, M. Darzianiazizi, M. M. Vardanjani, S. Kashanian, B. 
Larijani, K. Omidfar, Mater. Sci. Eng. C 2015, 46, 333–340. 
[525] L. Redondo-Morata, M. I. Giannotti, F. Sanz, Langmuir 2012, 28, 12851–12860. 
[526] J. Y. Fang, C. T. Hong, W. T. Chiu, Y. Y. Wang, Int. J. Pharm. 2001, 219, 61–72. 
[527] C. Marianecci, D. Paolino, C. Celia, M. Fresta, M. Carafa, F. Alhaique, J. Control. Release 2010, 
147, 127–135. 
[528] S. Hua, Front. Pharmacol. 2015, 6, 1–5. 
[529] E. Ojeda, G. Puras, M. Agirre, J. Zarate, S. Grijalvo, R. Eritja, G. Martinez-Navarrete, C. Soto-
Sánchez, A. Diaz-Tahoces, M. Aviles-Trigueros, et al., Biomaterials 2016, 77, 267–279. 
[530] G. P. Ochoa, J. Z. Sesma, M. A. Díez, A. Díaz-Tahoces, M. Avilés-Trigeros, S. Grijalvo, R. Eritja, E. 
Fernández, J. L. Pedraz, Pharm. Res. 2014, 31, 1665–1675. 
[531] S. Grijalvo, A. Alagia, G. Puras, J. Zárate, J. L. Pedraz, R. Eritja, Colloids Surfaces B Biointerfaces 
2014, 119, 30–37. 
 
